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Abstract
Many biological systems vary rhythmically in response to changes in both the external
and internal environment. Some rhythms, such as the menstrual cycle in women, are
built into the organism and repeat themselves over time without any support from
external factors. It has been acknowledged for a long time that in addition to the
predictable changes in steroid hormones that occur over the menstrual cycle, many
women also experience concomitant changes in their physical and emotional well being.
Most of the literature concentrates on the fact that negative moods and physical changes
seem to occur predominantly before and during menstruation. Given the close temporal
relationship of these changes to the timing of the steroid cycle, causal mechanisms have
traditionally been sought in the hormonal changes themselves. Yet the literature reveals
that no causal role has consistently been found for any of a large number of hormonal
parameters that change over the menstrual cycle. Further, there is good evidence that
variations in well being of a similar magnitude, and with similar timing occur during the
combined oral contraceptive pill cycle.
This thesis is concerned with exploring the aetiology of cycle-related change in
emotional and physical well being during oral contraceptive use. Its two fundamental
objectives are 1) to clarify why women taking the pill have similar experiences to
women with hormonally distinct, menstrual cycles, and 2) to test a novel aetiological
hypothesis with women taking the pill that there exists an endogenous rhythm of well
being that is coupled to, but not caused by cyclical hormones. This knowledge may
help us to understand better the phenomenology of the 'normal' cycle. The role of
social factors in the expression of cycle-related change is just as poorly understood as
the complex influence of biological factors. Thus a third portion of this thesis is
devoted to exploring the nature of women's beliefs about their cycles, and investigating
how they may 'translate' in their experience and reporting.
The first study aimed to relate the degree of residual ovarian function during pill cycles
to subjective state. Two pill types that deliver the same synthetic hormones, but in
different dose regimens, were compared. Volunteers were monitored for ten weeks
with daily twenty-one item, uni-polar visual analogue symptom diaries and daily early
morning urine samples. The primary urinary metabolites of oestrogen and progesterone
were measured in the urine using ELISA techniques. Diary and hormone results were
then subjected to a variety of statistical analyses which revealed that all women showed
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a small degree of ovarian recovery which did not differ according to pill type, and only
related to the severity of certain, physical, symptoms.
This sample of women also took part in an in-depth semi-structured interview of
contraceptive, menstrual and other reproductive attitudes. The content of these
interviews was incorporated into a questionnaire on menstrual health and reproductive
attitudes that was administered to over one thousand consecutive family planning clinic
attenders. Analysis of a random sample of five hundred of the completed questionnaires
showed that while women taking the pill differ from other contraceptive method users
on a number of demographic variables and those questions relating to features of their
method, they generally do not differ on attitudes to vaginal bleeding and the cycle.
This questionnaire served as a recruitment device for the final study reported in the
thesis. Evidence from this thesis and the previous research literature indicates that
cyclical change in subjective state during pill taking cannot be fully accounted for by
levels of endogenous or exogenous steroids. The combined pill cycle was used as a
model in which to test the hypothesis that the variation in well being which some
women experience over their cycle has in-built momentum, independent of the steroid
hormones. In a double-blind controlled study established pill takers were given two
conventional four-week cycles of low dose combined pills followed by four months of
pills in one of three temporal regimens. One group had four-week control cycles
throughout, another group had four months of active pills continuously, and the third
group had one cycle extended with two extra weeks of active pills. Volunteers
completed daily, sixteen-item, ordinal scale symptom diaries and collected early
morning urine samples three times a week.
There was evidence in the diary data of continued circa-monthly oscillation in mood and
physical well being in the two groups that experienced extended pill taking. There was
no consistent relationship between subjective state and the patterns of urinary oestrogen
or vaginal bleeding over time. The results of this exploratory study suggest that there
may be an endogenous pattern of subjective state that is entrained by the hormonal
cycle. Perhaps this will be a more fruitful area for future research into the aetiology of
cycle-related change in well being, than further studies of direct hormonal causes.
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Refers to vaginal bleeding while taking OCs. As this is
hormone withdrawal bleeding, to refer to it as a "period" or
"menstruation" is incorrect and misleading.
Refers to hormonal secretions or biological rhythms which are
spontaneous and inherent to the woman.
Refers to the items used to collect vaginal blood, namely
tampons and pads. Used in preference to value laden terms such
as "sanitary towels".
Refers to hormones or biological rhythms which are introduced
or controlled from the external environment of the woman.
Refers to self-reported emotional and physical state.
The term symptom is used throughout this thesis to refer to the
changes in state/well being which vary in relation to the
hormonal cycle. This term is problematic because it implies a
disease state. Unfortunately there is no obvious alternative,
therefore it is used in a generic way with the caveat that it is not
intended to reinforce an illness model of women's cycle-related
experience.
This term has been used in preference to "subjects" which
implies passivity and objectification. The women who took part
in this research were conscious participants in the research
process, and generously gave up their time as volunteers.
Refers to both emotional and physical state.
Refers to any force in the internal or external environment of the
individual which acts as a timekeeper or timegiver in a rhythmic
biological process.
Chapter 1 Introduction
Societies are built around systems of classification. One of the most basic
classifications is the distinction made by biological sex, or gender. This division into
female and male is made on the basis of dimorphism in reproductive physiology. There
are obvious biological differences. Heaped on top of these and wedded to them are a
whole host of different patterns of social behaviour, training, and expectation. This
nature-nurture interaction makes it extremely difficult to establish what are genuine
biologically determined differences between the sexes. One of the most conspicuous
outward differences, apart from the obvious secondary sexual characteristics, is that
women have menstrual cycles. Given the bold division between male and non-male, it
is not surprising that a good deal of biological and social significance is attached to the
menstrual cycle, to its functional and its symbolic meanings. A primary focus of
menstruation-related scientific discourse, both ancient and modern, is the nature,
meaning, and function of the sensory concomitants of the female reproductive cycle.
The more this phenomenon is researched the more it is evident that there is no simple,
mechanistic relationship between the gross biological features of the steroid cycle and
women's experience of changes in well being over the menstrual cycle. However, it is
certain that there is a marked temporal relationship between the cycle and changes in
well being for a proportion of women. Classically negative moods and uncomfortable
physical sensations are observed to occur before or during menstrual bleeding. These
are pronounced in some women, and the majority of women detect some minor change
in mood or physical state that alerts them to impending menstruation. A greater
understanding of the mechanisms which cause such variation is of theoretical interest,
sociological importance, and clinical significance. The purpose of this research project
has been to explore a number of different, but possibly interrelated, aetiological
mechanisms for cycle-related variation in mood and physical state.
The starting point of these investigations is the fact that many women who experience
cycle-related changes continued to do so to a similar extent when using combined oral
contraceptives, although the pill cycle is physiologically distinct from the menstrual
cycle. The research comprises two experimental investigations, one questionnaire
survey, and a series of clinical case studies. Three causal factors are considered
progressively in this thesis with women using oral contraception, including: 1) the role
of persistent low level ovarian function during pill cycles, 2) the nature of the belief
Chapter 2 Cyclical Change in Well Being:
Characteristics and Possible Aetiologies in the
Oral Contraceptive Pill and Menstrual Cycles
The research reported in this thesis bridges a number of different disciplines in social
and biological science including the menstrual and oral contraceptive pill cycles and
their sequelae, notably cycle-related changes in well being and attitudes, and biological
rhythms. Each of these areas has a large research literature of its own, therefore the
review that follows covers selected material that is of direct theoretical, methodological,
or empirical relevance to the investigations described in this dissertation.
2.1 The Comparative Neuroendocrinology of the Menstrual
and Oral Contraceptive Pill Cycles
The human ovarian/menstrual cycle is a continuous, rhythmic developmental process.
It arises from the coordinated functioning of the ovaries and the central nervous system.
The endpoints of the interplay between these systems are the functional capacity to
reproduce offspring, and menstrual bleeding when pregnancy does not ensue. A brief
description of the complex sequence of endocrine events and morphological changes
which comprise the "normal menstaial cycle" is necessary background to the questions
addressed by this thesis. In particular, one must appreciate the key events of the
normal menstrual cycle in order to understand the mode of action of oral contraceptive
steroids, and how the combined pill cycle differs physiologically from the ovarian
cycle. This section has been placed at the beginning of this chapter because the very
existence of the menstrual cycle is prerequisite for cycle-related change in well being,
however, is not meant in any way to imply that neuroendocrine cycles are necessarily
causal.
2.1.1 The "Normal Menstrual Cycle"
2.1.1.1 Steroid independent follicular growth
The growth and development of the oocyte containing follicles of the ovaries are
primarily responsible for the timing of the menstrual cycle. In effect the endocrine
structures in the brain and the ovary function in parallel, but modulate the activity of
one another via the chemical signals which they emit (Johnson & Everitt, 1988). From
puberty until the menopause the primordial follicles progress through a sequence of
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spontaneous growth phases, the first stage of which is hormone independent. Each
day a few primary follicles begin to grow from the state in which they have been
arrested since birth, into preantral follicles. Once they reach the advanced preantral
phase they have the capacity to respond to the trophic effects of brain hormones and
mature further (Johnson & Everitt, 1988; O'Roirdon, Malan & Gould, 1982).
If the correct endocrine environment does not coincide with their growth pattern these
follicles undergo atresia and die (Johnson & Everitt, 1988). For every one follicle
which reaches ovulation, an estimated 20 others degenerate (Baker, 1982). Evidence
for the fact that the ovary 'keeps time' in this hormone independent fashion comes from
the fact that follicular atresia continues in women using combined oral contraception to
inhibit ovulation, and therefore they experience the menopause at the same time as
women in whom ovulation is not interrupted (Batzer, 1984).
2.1.1.2 Central nervous system involvement in the menstrual cycle
If a follicle is to advance into the antral phase then an exchange of information must
take place between the ovary and the central nervous system via the hypothalamic-
pituitary-ovarian axis. The hypothalamus is a small, but highly complex area at the
base of the brain which surrounds the cerebro-spinal fluid filled third ventricle. It
regulates sexual and ingestive behaviour, body temperature, and integrates autonomic
activity. Each of these functions is controlled by a specific aggregate of neurones
known as the hypothalamic nuclei. The regions involved with reproduction include the
suprachiasmatic, paraventricular, arcuate, ventromedial, and supraoptic nuclei. The
hypothalamus has neuronal links with many other regulatory centres of the brain. It
has axonal projections into the posterior pituitary and median eminence, for example,
and information about light input into the retina is conveyed directly through neural
connections with the suprachiasmatic nuclei. The hypothalamus is therefore susceptible
to sensory cues from the external environment, and is also responsive to variations in
the internal endocrine and nervous system environment (Johnson & Everitt, 1988;
Karsch, 1984).
The other principle neuroendocrine organ involved in reproduction is the pituitary. The
pituitary, also known as the hypophysis, is situated beneath the hypothalamus in the
fossa of the sphenoid bone (Johnson & Everitt, 1988). It is comprised of three
functionally differentiated lobes: the anterior, intermediate, and posterior lobes. These
are functionally and anatomically connected to the hypothalamus by neural and vascular
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links. The hypothalamus projects specialized hormone releasing neurones directly into
the posterior pituitary, which secretes oxytocin and vasopressin. The anterior pituitary
is primarily involved in coordinating the endocrine events of the menstrual cycle. It is
not neurally linked to the brain, but exchanges chemical information with the
hypothalamus via the hypothalamo-hypophyseal portal system. A variety of different
cell types are located here which correspond to specific hormones, viz. prolactin,
growth hormone, ACTH, and TSH. The "gonadatrophs" are not fully specialized, but
have the capacity to synthesize and secrete either luteinizing hormone (LH) or follicle
stimulating hormone (FSH): the gonadotrophins (Johnson & Everitt, 1988; Karsch,
1984). These two substances are integral to the cycle and are under the stimulatory
control of the hypothalamic releasing hormones: gonadotrophin releasing hormone
(GnRH).
2.1.1.3 The trophic and steroid hormones
GnRH is released in a pulsatile fashion from the hypothalamus into the portal system
and acts on the gonadotrophs. Pulsatility is essential for function, and GnRH released
continuously in an experimental situation does not produce functional pulsatile LH or
FSH secretion (Karsch, 1984). The late preantral ovarian follicle has receptors for LH
and FSH, and if binding occurs the follicle proceeds into the antral phase, becoming a
Graffian follicle. The gonadotrophins promote the secretion of steroid hormones
within the cells of the developing follicle. The two main steroid hormones produced by
the ovary are the oestrogens, predominantly oestradiol-1713 (E2), and progesterone
(P4). The precursors in the biosynthesis of oestradiol are the androgens-
androstenedione and testosterone. There are two different cell types in the developing
follicle which are selectively responsive to gonadotrophins: the thecal cells which under
the influence of LH promote androgen secretion, and the granulosa cells which convert,
or aromatize, testosterone to E2 in response to FSH. Progesterone is secreted by the
structure which arises from the follicle after ovulation, the corpus luteum (CL)
(Johnson & Everitt, 1988; Baird, 1984). The ovary produces a number of other non¬
steroidal substances which have hormone-like actions such as prostaglandins, relaxin,
oxytocin, and inhibin. These will not be discussed further here.
2.1.1.4 The timing of the endocrine events of the cycle
Figure 2.01 is a schematic drawing showing the levels of the steroids and
gonadotrophins over the normal menstrual cycle. Being a genuine cycle, the menstrual
cycle has no particular starting point or end, however, the convention is to consider the






























Days of menstrual cycle
Figure 2.01 Schematic graph of steroid and gonadotropin levels during the
normal human menstrual cycle from Short (1972), p.66.
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first day of menstrual bleeding as day one of the cycle (Vollman, 1977). At day one of
the cycle E2 and P4 levels are at their lowest. Pulses of LH and FSH act on the
preantral follicles in the manner described above, and FSH in particular, as its name
suggests, promotes the growth and differentiation of the follicles (Baird, 1984). As the
follicle grows it produces increasing amounts of E2 relative to its size. In the first half
of the follicular phase of the cycle, gonadotrophin levels remain fairly constant, but in
the second half of this phase E2 from the growing follicles exerts negative feedback on
the release of gonadotrophins. Oestrogen acts directly on the hypothalamus to decrease
GnRH secretion, and also alters pituitary sensitivity to GnRH, thereby preventing
further FSH or LH release.
Without the stimulation of FSH to grow, all the follicles but one become atretic. This
follicle, known as the dominant follicle, continues to grow at an exponential rate. It
produces about 90% of ovarian oestrogen during the preovulatory period (Baird, 1970;
Baird & Guevara, 1969). At day one of the cycle the follicle destined for ovulation is
probably only about 2mm in diameter, but by the time it ovulates it will be in the region
of 25mm in size (Baird, 1984; Baker, 1982). Only the dominant follicle grows to more
than about 15mm in diameter (Bomsel-Helmreich, 1985). The process by which the
dominant follicle is recruited from amongst a cohort of follicles is ill understood at
present (Bomsel-Helmreich, 1985; Hodgen, 1982).
Oestrogen reaches its highest level just before mid-cycle. At this time the previously
negative feedback effect of E2 on gonadotrophin release changes to positive feedback,
and LH is induced to surge and FSH to rise. Thus the ovary seems to signal the brain
of its preparedness for ovulation. The gonadotrophins play an important role in the
final pre-ovulatory maturation of the follicle and egg via the absolute level of the LH
surge, and the LH to FSH ratio. Peak E2 precedes the LH surge by approximately 24
hours, and follicular rupture and ovulation follow after about 36 further hours (Baker,
1982).
After ovulation P4 levels rise sharply. The most important effect of P4 in the feedback
relations of the cycle is that in the high concentrations which are seen after ovulation, it
enhances the negative feedback effects of E2 on the release of LH and FSH. Further, it
prevents oestrogen from exerting positive feedback (Johnson & Everitt, 1988).
Progesterone is secreted from the corpus luteum which develops out of the ruptured
and involuted dominant follicle. The CL is responsible for maintaining the
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endometrium and embryo during early pregnancy. P4 levels peak approximately eight
days after the LH surge and remain high for the rest of the menstrual cycle, i.e.
throughout the luteal phase. Oestrogen levels during the luteal phase are almost as high
as they are during the follicular phase, however, the effects of oestrogen are altered in
the presence of progesterone (Johnson & Everitt, 1988).
Without fertilization and implantation the lifespan of the CL is finite, and is usually
considered to be constant at about 14±3 days ( Landgren, 1989; Lenton, Landgren &
Sextom, 1984). Thus, variations in the length of the human menstrual cycle are
generally attributable to variations in the length of the follicular, and not the luteal
phase. At the end of the luteal phase the CL regresses, or undergoes luteolysis, and
there is a precipitous drop in the levels of both E2 and P4. The hypothalamus and
pituitary are thus relieved of the negative feedback control of the steroids and resume
pulsatile release of GnRH, LH and FSH, and another cycle commences. The other
important consequence of falling steroid levels is the onset of vaginal bleeding, the
characteristics of which will be discussed below.
2.1.1.5 Effects of ovarian steroids on target tissues
The steroid hormones also influence the tissues of the uterus, cervix, vagina, fallopian
tube, and breast amongst others. This thesis is primarily concerned with cyclical
changes related to the steroid cycle, and thus the effects of oestrogen and progesterone
on the uterus and breast are of principle interest. The follicular phase of the cycle is
also known as the proliferative phase because of the effects which the oestrogens have
on the uterine endometrium. E2 causes an increase in contractility and excitability of the
uterine myometrium and produces an increase in the size and number of stromal cells in
the endometrium, with a consequent increase in intra-uterine surface area. E2 acts by
binding to the abundant oestrogen receptors and is also responsible for inducing the
development of intracellular progesterone receptors. An endometrium which is not
primed by oestrogen is not able to respond to the presence of progesterone. P4
stimulates the synthesis of secretory material by the glands, accelerates stromal
proliferation, and encourages cell enlargement. Myometrial contractility is reduced but
its size increases. The progestagenic phase is also known as the secretory phase
(Johnson & Everitt, 1988; Baird, 1984).
The effects of steroids on breast tissue are not well understood. However, it is known
that breast changes do not parallel endometrial changes. The small units of resting
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breast tissue which develop into the secretory units are called lobules. The tissue
constantly undergoes concurrent waves of cell growth (mitosis) and cell death
(apotosis) which are out of phase with the endometrium. The peak in cell division
occurs late in the cycle during the progestagenic rather than oestrogenic phase. Many
different substances act on the breast and it is possible that rather than exerting a direct
effect the endocrine stimuli precipitate paracrine or autocrine regulatory systems.
(Anderson, 1989, 1988).
The steroids affect many other body tissues. Oestrogens have a general influence on
the cardiovascular system and metabolism, being generally protective against
cardiovascular accident. Progesterone on the other hand may increase appetite, and
raises body temperature via a direct influence on the hypothalamus. It may also
produce sodium retention by stimulating angiotensinogen production (Johnson &
Everitt, 1988). P4 also has sedative and anticonvulsant effects (McCauley, Lan& Gee,
1992; Backstrom, Baird, Bancroft, Bixo, Hammarback, Sanders & Zelterlund, 1983a;
Silbergeld, Brast & Noble, 1971).
2.1.2 The "Normal Pill Cycle"
This section is concerned with the levels of endogenous steroids and gonadotrophins
which are observed during the conventional combined oral contraceptive (OC) pill
cycle. Before considering the endocrinology of the pill cycle it is important to briefly
summarize the history of steroidal contraception, and to chart the development of new
contraceptive formulations up to those currently in widespread use. Here and
throughout this thesis the emphasis will be placed on low dose combined preparations.
The oral contraceptive pills are probably amongst the most researched substances in
human history (Weijers, 1984). In the short lifetime of OCs an absolutely vast
literature has accrued on their contraceptive and non-contraceptive effects. They have
been the subject of several large, longitudinal, epidemiological investigations including
those undertaken by the Oxford Family Planning Association (OxFPA), and Royal
College of General Practitioners (RCGP) in this country, and the Harvard Nurses
Study, and Cancer and Steroid Hormone (CASH) studies in the United States. Thus,
the review of the literature contained herein will necessarily be highly selective.
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2.1.2.1 The history of the combined "Pill" and formulations in
current use
The term "the pill" to refer to a wonder contraceptive was originally coined by Aldous
Huxley, in The Brave New World Revisited which was published in 1958, just two
years before OCs became a reality (Djerassi, 1981). After working for seven years
deriving synthetic steroids from the soap-like substances contained in the Mexican yam,
Diosgenin, Djerassi and his co-workers at Syntex (from synthesis and Mexico)
synthesized the first orally active synthetic progestagen, norethisterone1, in 1951. This
substance was submitted to Gregory Pincus and John Rock who tested its ovulation
inhibiting effects, along with about 200 other substances in 1953 and 1954.
Norethisterone was effective, as was norethynodrel which was synthesized by Pincus'
own company, Searle, in 1952. Norethynodrel was chosen as the gestagen to use in
the field trials of the first OC (Djerassi, 1981; Mears, 1966). These trials which took
place in Puerto Rico in 1956 were conducted by Edris Rice-Wray, one of the few
women involved in the early development of the pill (Greenblatt, 1980; Drill, 1966).
In 1957 the United States Food and Drug Administration (FDA) gave approval for the
two original progestagens to be used for the treatment of menstrual disorders and
infertility. By late 1959 the first combined oral contraceptive, called Enovid, was
introduced, containing 0.15mg of mestranol and 9.85mg of norethynodrel (Djerassi,
1981; Greenblatt, 1980). Two years later the norethisterone containing pill, Otho-
Novim was marketed. Oestrogen was only included in the first pills by accident, as a
contaminant in the progestagen. It was removed, but the gestagens no longer exerted
such good control over cyclical vaginal bleeding, and it was re-introduced in a
controlled fashion (Djerassi, 1981).
The original pill regime involved giving oestrogen and progestagen from day five until
day 24 of the cycle, i.e. for 20 days, and then allowing one week free of pills in which
bleeding was to occur. The two stated objectives of this regimen were: 1) the inhibition
of ovulation, and 2) the provision of regular cyclical menstruation (Mears, 1966). In
the history of combined OCs only two synthetic oestrogens have been used, but a wide
variety of synthetic progestagens. The original oestrogen, mestranol (MES), is the 3-
methyl-ether of the second, ethinyloestradiol (EE). MES is demethylated in vivo in
order to enable it to bind to the oestrogen receptor. EE, because it does not need to be
i
Norethisterone is known as norethindrone in North America.
Chapter 2 Review of the Literature 11
demethylated, is more potent than MES. It acts more quickly and can be used at lower
doses (Batzer, 1984; Greenblatt, 1980; Mears, 1966). All modern low dose pills
contain EE; MES is rarely used (Guillebaud, 1984).
Approximately nine different progestagens have been developed and used in pills since
the late 1950s. All synthetic gestagens are derived from one of two substrates: 17a-
hydroxyprogesterone or 19-nortestosterone (Runnebaum & Rabe, 1987; Mears, 1966).
The progestagens in the 17a-hydroxyprogesterone class are potently progestagenic,
and not at all oestrogenic. They provide poor cycle control and are not very good at
inhibiting ovulation (Mears, 1966) so are not used in OCs. All synthetic gestagens are
based on slight manipulations of the basic, three 6-membered ring and one 5-membered
ring, structure of the steroid molecule (Djerassi, 1981). The 19-nor-steroids have all
been created by altering the testosterone molecule, namely deleting the carbon from
position 19 (Batzer, 1984). There are three ways of classifying progestagens,
according to chemical structure, biological properties, or affinity for hormone
receptors. However, it is not possible to predict receptor affinity and biological
properties from chemical structure in any consistent way. For example, norethisterone
and norethynodrel differ by only one double bond, yet norethisterone is mildly
androgenic, and norethynodrel not at all (Rozenbaum, 1982) in spite of the fact that
norethynodrel is metabolized to norethisterone in the gastrointestinal tract (Djerassi,
1981). Prediction is further complicated by the fact that progestagen action depends on
synergism with EE (Runnebaum & Rabe, 1987).
The 19-nortestosterone derived compounds may possess progestin-like action which
delays vaginal bleeding, and causes endometrial decidualization. They may be
androgen-like and promote acne and hirsuitism. Or they may behave like oestrogen
(Batzer, 1984). Table 2.01 lists the various substances and their biological activities.
Over the years there has been a consistent effort to reduce the dosage of both synthetic
hormones in the combined pill in order to reduce adverse non-contraceptive effects
(Briggs & Briggs, 1976). In this connection, the progestagens have been continually
refined to improve their potency and specificity. One speaks of first, second and third
"generation" gestagens (see Table 2.01). Most of the low dose pills currently in
widespread use in the U.K. contain second or third generation gestagens2, notably the
2
Although the combined pill was developed in the Americas, none of the newest
gestagens are in use in the United States (Djerassi, 1981). This is probably due to a
variety of factors, not the least of which is the extremely rigid FDA requirements for
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gonanes, which are biologically more effective than their predecessors, the estranes,
and include levonorgestrel (LNG), desogestrel (DSG), and gestodene (GSD)
(Runnebaum & Rabe, 1987).
Table 2.01 The 19-Nortestosterone Progestational Compounds
Contained in Combined Oral Contraceptives
Trade Name Generation Biological Properties









Norethynodrel (NOR) 1st Oestrogenic & not at all androgenic
Lynestrenol (LYN) 1st Oestrogenic
Norgestrel (NRG) 2nd Potently progestagens, most
androgenic & anti-oestrogenic
Levonorgestrel (LNG) 2nd Progestagens, weakly androgenic,
anti-oestrogenic, but not oestrogenic
or anti-androgenic
Desogestrel (DSG) 3rd Progestagens, strongly anti-
oestrogenic, but not anti-androgenic
Gestodene (GSD) 3rd Most progestagenic, but not
oestrogenic
(Information from Runnebaum & Rabe, 1987; Batzer, 1984; Guillebaud, 1984;
Rozenbaum, 1982; Djerassi, 1981; Greenblatt, 1980; Mears, 1966)
Table 2.02 lists the trade names and components of all the low dose combined
oestrogen-progestin pills currently in use in the U.K.. There have been four stages in
the development of the combined pill. First there were the original high dose
oestrogen, high dose progestagens formulations, which were followed by "sequential"
drug safety testing (Smith, Potts & Fortney, 1991), including the obstructive practice
whereby the results of clinical trials carried out outside the United States are not
allowed as evidence, and must be repeated in American samples (David Hollingworth,
1990, personal communication).
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pills which administered oestrogen alone for the first half to two-thirds of the cycle and
then administered about a week of oestrogen plus progestin. In the third stage, pills
began to appear which contained a constant low dose of both steroids, and most
recently various "phased" preparations have been developed, which provide staged
dosages of one or both hormones over the cycle (Batzer, 1984). All modern low dose
pills contain between 20 and 40(ig of EE, and one of six different gestagens. There are
nine different monophasic preparations and four phased ones (see Table 2.02).
Table 2.02 Low Dose Combined OCs Currently Marketed in the U.K.
Monophasic Pill Name Steroid Constituents Regimen
Norimin / Neocon 1/35 EE 35(lg + NET 1000(lg 21 days
Brevinor/ Ovysmen EE 35|ig + NET 500pg 21 days
Conova 30 EE 30|ig + EDA 2000(1g 21 days
Loestrin 30 EE 30(ig + NEA 1500(ig 21 days
Loestrin 20 EE 20pg + NEA 1000(ig 21 days
Eugynon 30 / Ovran 30 EE 30|lg + LNG 250(lg 21 days
Microgynon 30 / Ovranette EE 30|ig + LNG 150|ig 21 days
Marvelon EE 30(ig + DSG 150(ig 21 days
Mercilon EE 20(1g + DSG 150(ig 21 days
Minulet / Femodene EE 30(ig + GSD 75(ig 21 days
Phasic Pill Name Steroid Constituents Regimen
Binovum EE 35(lg + NET 500pg
EE 35(ig + NET lOOOpg
7 days
14 days
Synphase EE 35(ig + NET 500pg
EE 35(ig + NET lOOOpg




Trinovum EE 35(ig + NET 500^ig
EE 35(lg + NET 750(lg




Logynon / Trinordiol EE 30(ig + LNG 50(lg
EE 40(1g + LNG 75(lg




Key: EE-ethinyloestradiol, NET-norethisterone, EDA-ethynodiol diacetate,
NEA-norethisterone acetate, LNG-levonorgestrel, DSG-desogestrel, GSD-gestodene.
It is worth briefly considering the rationale behind the development of the phased
preparations, especially the triphasics. The primary purpose for developing triphasics
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was to reduce the total quantity of steroid ingested over the cycle in order to minimize
metabolic changes and decrease intercycle bleeding (Greenblatt, 1980; Pasquale, 1984;
Hale, 1987; Woutersz, Butler, Cohen, Korba & Canavan, 1987). Table 2.03 shows
the difference in dosage between the triphasic Logynon/Trinordiol and its monophasic
analogue Microgynon/Ovranette. Note that Logynon/Trinordiol is the only triphasic
preparation available in which both steroids vary in dose over the cycle. Greenblatt
(1980) cites that increased understanding of the differential action of the various
gestagens was instrumental in efforts to refine their use and in particular, to generate the
most favourable oestrogen-progestagen ratio. Clinical trials of the three different
triphasic formulations show that the reduction in steroid dose has resulted in fewer
alterations in metabolic pathways, lipid chemistry, coagulation profiles, and blood
pressure (Hale, 1987).
Table 2.03 Comparative Dosage of Steroids in a Monophasic versus
a Triphasic Preparation
Brand of Made Total EE Total LNG Mean EE Mean LNG
OC by per cycle per cycle per day per day
Microgynon Schering 630 pg 3150 |ig 30 pg 150 pg
Ovranette Wyeth 630 |ig 3150 pg 30 pg 150 pg
Logynon Schering 680 pg 1925 pg 32.4 pg 91.7 pg
Trinordiol Wyeth 680 pg 1925 pg 32.4 pg 91.7 pg
Legend- Ethinyloestradiol (EE), Levonorgestrel (LNG).
Hale (1987) notes that "incidental side effects, such as acne, depression, and nausea are
also reduced" while the regime is beneficial because it "emulates the normal menstrual
cycle" (pi058). It is questionable whether or not there is any material benefit to women
in having a pill cycle that mimics the menstrual cycle. But possible improvements in
metabolic parameters and well being may be important in studies of the relationship
between steroid production and cyclical change.
2.1.2.2 Mode of action and ancillary effects of combined OCs
The main target organs of the steroids in the combined pill are the pituitary and the
uterus (Runnebaum & Rabe, 1987; Gilmer, 1987). OCs reduce the release of LH and
FSH from the anterior pituitary and most importantly block the LH surge (Runnebaum
& Rabe, 1987; Loudon, 1985; Batzer, 1984; Greenblatt, 1980; Drill, 1966; Mears,
1966) thereby preventing ovulation. In the early days of pill development they did not
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believe that synthetic steroids had any direct action on the hypothalamic GnRH pulse
generator (eg-Mears, 1966), however, it is now thought that the pill does influence
GnRH release through complex interaction with endogenous opioid peptides
(endorphins), oestrogens, and CNS neurotransmitters (Batzer, 1984; Greenblatt,
1980). Both steroids in the combined pill act on the CNS. EE has a negative feedback
effect on LH and FSH, as does oestradiol, and it also attenuates the CNS suppressive
effects of the progestagen (Loudon, 1985; Batzer, 1984). Early work also suggested
that the pill did not affect the ovary, and that its responsiveness to gonadotrophin was
not altered (Drill, 1966), however it is now understood that 19-nortestosterone derived
gestagens do act directly on the ovary by impairing or suppressing luteal function
(Loudon, 1985). Equally, original animal studies suggested that LII is more easily
suppressed than FSH (Mears, 1966) and recent work seems to confirm this (eg.
Elstein, Morris, Groom, Jenner, Scarisbrick & Cameron, 1976). Thus the pattern of
ovarian follicles recruitment and maturation is disrupted by pill taking, while the
hormone independent changes continue (Batzer, 1984).
OCs have multiple ancillary effects in addition to inhibiting ovulation, many of which
contribute to the method's overall contraceptive efficacy. For example, tubal secretions
and peristalsis are altered (Runnebaum & Rabe, 1987; Batzer, 1984) influencing egg
transport, cervical mucous rapidly becomes progestagenic (Runnebaum & Rabe, 1987;
Greenblatt, 1980; Mears, 1966), basal body temperature is raised, and the vaginal
epithelium is altered, as is hepatic metabolism (Runnebaum & Rabe, 1987). The pill
has profound effects on the uterine endometrium and the breast. OCs inhibit
myometrial contractions but promote glycogen storage in the endometrium (Runnebaum
& Rabe, 1987). The constant administration of both oestrogen and progestin leads to
an inhibition of the proliferative process and premature secretory transformation with
stromal decidualization and glandular atrophy (Pincus, 1965). The normal phase
relationship of steroids in the menstrual cycle is disturbed, notably by the relative
absence of oestrogen (except briefly and at low levels during the pill free interval)
unopposed by progesterone which would normally prime the tissue and promote
progesterone receptors. The consequence is a mixed distribution of secretory and
proliferative glands throughout pill taking, and relative atrophy in the days before
withdrawal bleeding (Baird & Glasier, 1991; Runnebaum & Rabe, 1987; Gilmer,
1987; Batzer, 1984; Mears, 1966). The EE in the pill "stabilizes" the endometrium
(Batzer, 1984), without it, bleeding is erratic and unpredictable, as it may be on
progesterone only pills (POP).
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There is relatively limited information of the influence of OCs on breast tissue.
Progestins stimulate the proliferation of breast lobule epithelium with greater cell
proliferation seen during the would-be late proliferative and secretory phases than is
seen during the normal menstrual cycle (Anderson, 1989, 1988; Gilmer, 1987). This
may help to explain the breast tenderness and/or distension which many women
experience during pill taking, and which has been related to the progestagen content of
the pill (eg- Mears, 1966). Anderson (1989, 1988) has found that the duration of pill
use and the specific gestagen is relatively unimportant in predicting breast hyperplasia
on the pill, but that it is very strongly associated with youth and nulliparity, both of
which are likely to be confounded with pill taking.
A wide variety of serious and so-called "minor" side effects have been reported in
combined pill takers. It is not the purpose of this thesis to make a comprehensive
review of these effects, however, it is important to consider the so-called "nuisance"
effects as many of these are similar to the symptoms and changes which may be
experienced cyclically in relation to the menstrual cycle. They include breast
tenderness, weight gain, withdrawal headaches, changes in libido, acne, depression,
nausea, and breakthrough bleeding. As suggested above, breast changes seem to be
due to the influence of the progestagen component.
Changes in body weight are common on the pill. For example, one study comparing
Marvelon and Mercilon found that between 13 and 19% of participants had gained
weight at the 6th and 12th cycle of use, and 10 to 17% had lost (Tuimala, Saranen &
Alapiessa, 1987). In the U.K. clinical trials of Marvelon the incidence of weight gain
(about 1 lb by cycle 6) was higher, appearing in about one-third of women (Wiseman,
Bowie, Cogswell, Dewsbury, Hamilton, Hutchinson, Kirkman, Loudon, Lincoln,
Lyons, Pullen & Wilson, 1984). It has been suggested that there are two mechanisms
by which weight gain can occur: oedema induced by oestrogenic pills, and genuine
weight gain due to the "mildly anabolic" effects of some gestagens (Mears, 1966).
In some women the sudden withdrawal of steroids at the end of the 21-day pill regime
precipitates a migraine type-headache. These persist with continued pill use (Mears,
1966), and can sometimes be circumvented by taking several packets of pills in a row
without the usual seven day pill free interval. Libido may be increased or decreased by
the pill, and some women become depressed (Mears, 1966). Androgenic, anti-
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oestrogenic pills may promote acne through increased sebum production (Schering,
1989; Mears, 1966), and nausea seems to be related to high oestrogen doses (Mears,
1966). In one study a high incidence of side-effects including decreased libido,
headaches, abdominal pain and bloating, dizziness, and intercycle bleeding were
recorded by women who were given a placebo and told that it was an OC (Aznar-
Ramos, Giner-Velazquez, Lara-Ricalde & Martinez-Manautou, 1969). The authors
suggest that the side effects are psychogenic, but it is possible that these women would
have experienced these changes anyway and were not falsely attributing changes to the
drug. It is difficult to quantify attributions, however, they remain an important and
potentially significant contributor to adverse reactions to oral contraception.
2.1.2.3 Low dose pills: At the margin of efficacy?
There is a growing body of evidence which suggests that the steroid dosage of low
dose combined pills is close to the lower limit for maximum efficacy. Whereas the
original high oestrogen, high progestagen pills probably overdosed women by a factor
of ten- or even one-hundred fold, there may be a real risk of modern pill failure in a
small proportion of women. The conventional pill regimen involves starting a new
formulation on day one or day five of the menstrual cycle, and thereafter following the
21 days of active pills with a seven day pill free interval (pfi), thus creating an artificial
cycle. The "week-off" is intended to permit vaginal bleeding, ostensibly to prevent
endometrial atrophy, to allow metabolic parameters altered by pill steroids to "recover",
and to make the regime acceptable to women who expect to bleed at regular intervals
(Rutter, Knight, Vizzard, Mira & Abraham, 1988; Guillebaud, 1987).
The problem is that, at least theoretically, having seven pill free days may allow
sufficient recovery of the hypothalamo-pituitary-ovarian (H-P-O) axis that
folliculogenesis may have progressed to the mid-follicular phase or beyond by the time
pill steroids are re-introduced. It is therefore important to quantify the extent of
"residual" ovarian function for two reasons: 1) to estimate the degree of risk of escape
ovulation and potential contraceptive failure, and 2) to determine whether or not
continued endogenous hormone production may relate to the experience of cycle-related
changes in well being.
A number of approaches have been used to try and quantify the amount of ovarian and
gonadotrophin activity that occurs in pill cycles including serum and urinary assay of
steroid and gonadotrophin levels, with or without the deliberate omission of pills,
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GnRH challenges, and follicular visualization using abdominal ultrasound scanning.
These strategies are variously concerned to discover: a) whether or not steroid levels
enter the normal range of the menstrual cycle3, b) whether rising oestrogen is
accompanied by ovarian follicular growth at a potentially functional rate4, c) whether a
dominant follicle is recruited and matures sufficiently to be potentially ovulatory, d)
whether LH and FSH are being released in a pulsatile fashion, and e) whether an LH
surge might occur causing ovulation.
In an early study which tracked the hormones of women starting to take Microgynon
only FSH rose during the pfi, but returned to baseline by the end of the first week of
pills (Elstein et al., 1976). The authors conclude that FSH is the most sensitive
indicator of recovery from steroid suppression but that there is no residual ovarian
function on this pill. However, it seems that these conclusions were unwarranted given
that only three women were studied. Another small study of new Microgynon takers
found that steroids and gonadotropins were basal with no peaks during the first month
of use (Olio, el Sokkary, Darwish, Khamis & Souka, 1990).
However, other studies with larger samples, and/or using ultrasound have shown that
significant ovarian function occurs in about 10-20% of women during low dose pill
cycles (Thomas & Vankrieken, 1990; van der Spuy, Sohnius, Pienaar & Schall, 1990;
Hamilton & Hoogland, 1989; Killick, Eyong & Elstein, 1987; Westcombe, Ellis &
Fotherby, 1987; Elstein & Killick, 1985; Molloy, Coulson, Lee & Watters, 1985; van
der Vange, Bennink, Tennekes & Haspels, 1985) particularly if women were required
to miss pills deliberately (Killick, 1989; Smith, Kirkman, Arce, McNeilly, Loudon &
Baird, 1986; Landgren & Diczfalusy, 1984; Wang, Shi, Cekan, Landgren &
Diczfalusy, 1982; Chowdhury, Joshi, Gopalkrishna, Betrabet, Mehta & Saxena, 1980;
Morris, Groom, Cameron, Buckingham, Everitt & Elstein, 1979).
In the majority of women one observes a rise in endogenous oestrogen during the pill
free interval which gradually returns to baseline over the first week of pill taking
(Thomas & Vankrieken, 1990; van der Spuy et al., 1990; Killick et al., 1987;
3
Measures of progesterone are made to detect suspected "escape ovulation".
4
There is generally a fixed relationship between ovarian oestrogen output and the size of
the follicles residing in the ovary at any given time. The amount of serum oestradiol in
pg/ml is roughly equivalent to the sum of squares of the diameter of the follicles in
millimetres divided by two (Killick, Eyong, and Elslein 1987).
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Westcombe et al., 1987; Smith et al., 1986; van der Vange et al., 1985; Landgren &
Diczfalusy, 1984; Wang et al., 1982; Chowdhuury et al., 1980). LH and FSH release
recover to pre-pill levels very quickly over the pfi, with absolute levels, and the
pulsatile pattern of release restored to an early follicular phase pattern by the seventh pill
free day (van der Spuy et al., 1990; Cohen & Katz, 1979). LH and FSH rise after an
intravenous challenge with GnRH, suggesting near normal H-P-0 responsiveness
(Cohen & Katz, 1979; Rubinstein, Moguilevsky & Leiderman, 1978) and that
ovulation can occur, especially if pills are missed around the pfi (eg. Killick, 1989).
Progesterone remains basal unless ovulation occurs. Two studies have reported
ovulation rates of just under 5% in women using the formulation Logynon/Trinordiol
(Westcombe et al., 1987; van der Vange et al., 1985).
The amount of follicular growth seen in ultrasound scans varies from one study to the
next. All women seem to have some follicular growth during the pfi, and in about half
there are multiple follicles of which one is at least 7mm in diameter (Hamilton &
Hoogland, 1989; Molloy et al., 1985). Dominant follicles of between about 15mm and
30mm have been observed in between 5% and 23% of cycles (Hamilton & Hoogland,
1989; Killick et al., 1987; van der Vange et al., 1985). However, it is unlikely that
many of these are capable of fertilization or implantation if they do ovulate since their
growth rate is retarded relative to that of normally cycling controls (Killick et al.,
1987). This may explain the discrepancy between the incidence of large follicles seen
on scans and luteal phase progesterone levels. Several studies have shown a lack of
concordance between steroid levels and follicular size at scanning (Thomas &
Vankrieken, 1990; Elstein & Killick, 1985). This highlights the fact that, if possible,
hormone assay should be accompanied by morphological measurement.
The tendency to experience continued ovarian function seems to be specific to certain
individuals (eg. Westcombe et al., 1987; Landgren & Diczfalusy, 1984), and to persist
over time with continued pill use (Thomas & Vankrieken, 1990; Molloy et al., 1985;
van der Vange et al., 1985; Wang et al., 1982). It has been suggested that some sort of
adaptation through habituation may occur in long established pill users which accounts
for persistent ovarian function (Landgren & Diczfalusy, 1984). There has been
particular concern that the very low doses of steroid contained in triphasic pills might
permit ovulation to occur in some women, and the failure rate of these pills is
marginally higher than monophasics with similar constituents (Fay, 1982; Graham,
1982).
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Though many studies have focused on triphasic pills for this reason, the evidence for a
difference in the degree of residual ovarian function between monophasic and triphasic
pills is equivocal. Molloy et al. (1985) did not find greater follicular size in triphasic
takers, however Smith et al. (1986) did find higher E2 levels in Trinordiol users than
Microgynon users in the first two weeks of pill administration. Overall it appears that
ovarian recovery occurs as a function of the seven day pfi, and that maximal
endogenous oestrogen production is seen at the end of the pfi or in the early days of
subsequent pill taking but that ovulation is unusual. There is evidence of considerable
inter-individual variation in the degree of ovarian recovery, and it is uncertain whether
or not different pill formulations permit variable degrees of II-P-0 responsiveness.
2.2 Patterns of Vaginal Bleeding
One of the most important features which distinguishes woman's reproductive cycle
and that of other Old World primates, from the oestrous cycle of other mammals is
cyclical vaginal bleeding: menstruation. The word menses is the plural of the latin
word mensis for month, which in turn comes from the word for the moon and is
related to latin words for measurement, in this case, of time (Shuttle & Redgrove,
1986). The length of the menstrual cycle has historically been related to the length of
the lunar cycle, or the synodic month, which has a mean of 29.53 solar days (Shuttle &
Redgrove, 1986; Vollman, 1977). Some of the earliest consistent records of menstrual
cycle length, such as that of Clos in the nineteenth century, have sought to relate the
timing of bleeding to particular phases of the lunar cycle (Vollman, 1977). (The
evidence for the manner in which the moon may indeed relate to menstrual cycle
experience will be considered in the section on environmental influences below.)
This section is concerned with describing the mechanism of menstruation and its
characteristics across women, notably the parameters of bleed volume and duration, as
well as the length of the "normal" menstrual cycle. After establishing the background
of the menstrual cycle, the features of bleeding during the OC cycle will be considered.
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2.2.1 Bleeding During the Menstrual Cycle
2.2.1.1 The physiology of menstrual bleeding
In most mammals the thick secretory endometrium which develops under the influence
of oestrogen and progesterone over the cycle is reabsorbed if fertilization does not take
place. Those Old World primates, however, which possess specialized coiled arteries
and arterioles in the endometrium known as spiral arterioles experience spontaneous
uterine bleeding after the fall of steroids at the end of the cycle (Abel, 1985; Shaw &
Roche, 1980). The precise mechanism responsible for the onset of bleeding is not fully
understood. In a series of classic experiments carried out in the 1930s, Markee
transplanted endometrial tissue to the eye in 41 rhesus monkeys, and observed the
cyclical changes in the tissue which accompanied uterine changes over 432 menstrual
cycles (see Shaw & Roche, 1980). The endocrinology and bleeding pattern of the
rhesus monkey is more comparable to that of women than any other primate species.
Observation of the endometrial transplants under the microscope in conscious animals
during the late luteal phase revealed vasodilation and cellular oedema. Then prior to
bleeding, there was a reabsorption of fluid from the stroma and tissue shrinkage of
about 60%. This caused intense constriction of the arteries and spiral arterioles
between 4 and 24 hours before the onset of bleeding resulting in ischaemia and
hypoxia, followed by necrosis, venous dilation, and leukocyte infiltration. The extent
of endometrial shedding was reported to be proportional to the duration of intense
vasoconstriction. Markee proposed that the majority of menstrual blood derived from
short spurts from the arteries while venous bleeding was slighter, but more prolonged
(Shaw & Roche, 1980).
These changes accompany luteal regression. The ubiquitous prostaglandins peptides
(Pg's) have also been implicated in the mechanism of both luteolysis and menstruation
(for reviews see Smith, 1991 and Shaw & Roche, 1980 respectively). PgF20t
stimulates the contraction of the myometrium, and a high ratio of PgF20c to PgE2 is
observed in cases of heavy bleeding. However, the actions of Pg's are thought to be
contributory and not entirely causal (Smith, 1986; Abel, 1985). Hertz (1986) has
suggested that an autoimmune rejection of the endometrium may occur when steroid
levels are at their nadir. Blood flow reduces over the course of menstruation as the
arteries reconstrict. Clotting, or the formation of vascular thrombi also seems to
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contribute to haemostasis. These thrombi are then shed with the endometrium of the
next menstruation (Shaw & Roche, 1980).
2.2.1.2 Menstrual cycle length
Vollman (1977) suggests that the widespread myth that the human menstrual cycle
extends for 28 days from the onset of one bleed to the onset of the next is a cabala
which derived from modern physicians and metaphysicists formalizing women's
reckoning that the cycle is "usually about four weeks" to an actual 28 days. He and
several others in the research literature have shown through careful recording of
consecutive menstrual cycles over many years that rather than une regie absolue of a 28
day cycle, variability is the rule. In particular, Vollman and Treloar have demonstrated
that menstrual cycle length parallels the dynamic, developmental process of
reproductive function over the life course (Vollman, 1977; Treloar, Boynton, Behn &
Brown, 1967).
Treloar et al. (1967) collected data on 2702 American women over 275,947 cycles, or
25,825 woman years of menstrual experience between 1933 and 1961. All of this
information was collected before the introduction of steroidal contraception, and is
therefore purely "menstrual cycle" data. The age range spanned the whole of
reproductive life, and in a few cases the same woman was tracked from menarche to the
menopause. The overall finding was that cycle length changes in a U-shaped fashion
over the reproductive years.
During the first approximately seven years after menarche cycles tend to be longer and
more variable than at mid-life. Equally, cycle length becomes increasingly variable and
the duration longer, as one approaches menopause. The process is like the mirror
image of menarche, but takes about one year longer on average. For example, the
median cycle length in this sample, 18 months after menarche, was 33 days, and 30
days four years post-menarche. With increasing "gynaecological maturity" cycle length
gradually shortens, and becomes less variable. Thus cycle length declines in a linear
fashion between the ages of about 21 and 39 by about 1/10 of a day per year, reaching
its lowest median length at 26 days approximately eight years before the menopause.
After that there is a curvilinear increase in cycle length up to a peak of 44 days 18
months before cycling ends. The variability of cycle length also decreases in a linear
fashion in the middle phase of life; for example, the median SD at 20 years is 2.75 days
versus 1.83 days at 36 years (Treloar et al., 1967). A subsample of young and old age
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cohorts amongst Treloar's population were investigated to clarify the endocrine basis of
age related changes in cycle length. Variable bleeding frequency at the beginning and
the end of reproductive life is due to changes in follicular maturation. Menarcheal girls
have long cycles due to delayed follicular maturation, while in the peri-menopause
cycles get shorter due to more rapid folliculogenesis, and raised gonadotrophin levels
(Sherman & Korenman, 1975).
There is also evidence that young women may not ovulate in all cycles which might
contribute to variable cycle length. Metcalf & Mackenzie (1980) assayed the principle
urinary metabolites of the steroids, oestrone and pregnanediol, weekly for three
consecutive cycles in 254 women aged 15 to 39. All volunteers were at least four years
from menarche. They found that young women aged 20 to 24 (n=108) had ovulatory
pregnanediol levels in only 62% of cycles, compared with 88% of 25 to 29 year olds
(n=58), and 91% of women over 30 (n=44). They also found evidence for potential
environmental influences on the incidence of ovulation as students and women living in
flats or hostels ovulated about 30-40% less often than those living at home with
relatives (see section 2.7.3.2 below).
Vollman's (1977) findings in 691 Swiss women were very similar to Treloar's.
Volunteers ranged in age from 14 to 63 years Fifty-two per cent of women kept
records of their cycles for <lyear, while 48% of the women produced 91% of the data
keeping up monitoring in some cases for as long as 39 years. He found that the actual
and reported age of menarche ranged from 9 to 21 years. During the gynaecologically
mature years of mid-life variability in cycle length tended to be restricted to between 3
and 5 days. "Runs" of more than 2 or 3 successive cycles of the same length were
extremely rare. Amongst 656 women over 31,645 cycle there were only 33 runs of 5
or more cycles which occurred in 32 women, producing a rate of 1.5 runs per 1000
cycles. When runs did occur they were likely to be of 27 or 28 day cycles. These data
completely refute the concept of a regular 28 day menstrual cycle. Twenty-eight day
menstrual cycles were modal in this population, but constituted only 12.4% of cycles,
and 27 day cycles were nearly as common.
Women are often criticised for reporting that they experience very "regular" cycles
when in fact they are quite variable, and are considered "unreliable", or poor at recall or
prediction (eg- Snowden & Christian, 1983). In fact, women seem to use "regular" or
"28 days" as a vernacular to indicate that they consider themselves to be normal in their
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menstrual characteristics (Treloar et al., 1967). Although cycle length does vary across
women, within the individual over time, each woman does tend to have a "central
tendency in menstrual interval" (p.99, Treloar et al., 1967).
2.2.1.3 The parameters of menstrual bleeds: Volume, duration, and
"shape"
Duration and amount of menstrual bleeding also vary, within accepted normal ranges.
Both factors are difficult to measure as they rely on self-report, and therefore depend on
shared understanding of experiences which are elementally individual. Volume is
particularly vulnerable to the problem of making hypothesized comparisons with
others. Because reactions to bleeding experience are very important to the acceptability
of contraception, the World Health Organization (WHO) commissioned a multi-centred,
multi-ethnic survey of the patterns and perceptions of vaginal bleeding (Snowden &
Christian, 1983; WHO, 1981). A general survey was carried out on 5,322 women in
14 settings in ten different countries (Egypt, India [2], Indonesia [2], Jamaica, Korea,
Mexico, Pakistan [2], the Philipines, the United Kingdom, Yugoslavia [2]).
Approximately 500 parous, non-pregnant, non-lactating, non-menopausal women were
interviewed in each setting, and a sub-sample of 10% were required to keep a daily
diary of menstrual bleeding.
The incidence of bleeding, volume, duration, and "shape" were all determined from the
general survey, and related to age, urban/rural residence, social status, literacy,
contraceptive use, and breast-feeding activity. The world-wide modal duration of
bleeding was 4 to 5 days. More Egyptian, Indian, and Mexican women reported lto 3
day bleeds, while British, Indonesian, and Pakistani women reported 6 days or more.
There was a tendency for urban women to report longer bleeds, and illiterate women
short bleeds, however there was a lack of cross-cultural consistency. The majority of
women reporting 1-2 day bleeds were over 30 years old, and also tended to have high
parity. Oral contraceptors were much more likely than non-contraceptors or intrauterine
device (IUCD) and injectable users to have 3 to 4 day bleeds, and less likely to have
longer bleeds (Snowden & Christian, 1983; WHO, 1981).
The concept of volume of blood loss is tied to duration of bleeding. Throughout the
world women reported their bleeding to be "moderate". Urban women were more
likely to report heavier bleeds, but low status women were more likely to report
extremes of blood loss. Contraceptive use was the only other factor which influenced
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volume reporting. Pill users tended to have lighter bleeds than other contraceptors.
The dynamics of bleeding over time, or the "shape", also related to method of
contraception. Forty-five per cent of women reported bleeding heavily at the beginning
of an episode, and more lightly towards the end. Thirty per cent start lightly, become
heavy, and finish the episode with light bleeding. IUD users were more likely to have
the later bleed shape, and OC users to have constant blood volume over the whole
episode (Snowden & Christian, 1983; WHO, 1981). Studies involving the collection
menstrual blood reveal that 78% of bleeding takes place on the first two days of
menstruation, further it is estimated that 95% of women produce less than 60ml of
blood during each period (Shaw & Roche, 1980). Women who bleed more than this
are considered menorrhagic, or to bleed excessively (Abel, 1985; Smith, 1986).
In another large pooled multi-centred data set gathered in Europe, South East Asia,
India, Pakistan, Latin America, Africa, the Caribbean, and China, WHO sought to
relate bleeding patterns to regional, individual, and contraceptive factors (Belsey,
1988a, 1988b; Belsey, d'Arcangues & Carlson, 1988; Belsey, Peregoudon & Task
Force on Long Acting Systemic Agents for Fertility Regulation, 1988). Overall they
found that within a given method of contraception, bleeding patterns were more closely
linked to geographical region than any other demographic or situational factor. The
implication is that distinct cultural styles of reporting experience may account for some
of the observed differences, even with the most carefully and uniformly collected data.
There is evidence that the duration of menstrual bleeding changes over the seasons,
with short bleeds in the summer and longer ones in the winter and spring, which might
also contribute to differences across disparate geographical regions (Datta, 1960).
In summary, there is great variability in the length of the menstrual cycle and the
duration and volume of bleeding episodes across women, and within women over
reproductive life. The 28 day cycle is a myth. However, there are "normal ranges" for
each of these parameters which are dictated by neuroendocrine functioning and by a
variety of situational and constitutionals factors.
2.2.2 Bleeding During the Combined OC Cycle
"Today there are millions of women on steroid contraceptives,
programmed for artificial bleedings at approximately 28-day intervals.
Thus from mythological ages, the cabala of numbers has joined, in
modern times, with engineered manipulations of human reproductive
physiology. In science, as in all human behaviour, fossils survive
development." (p.5, Vollman, 1977)
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The endocrinology, pill taking regime, and state of the endometrium during the OC
cycle were all described above. This section concerns the effects of OCs on vaginal
bleeding experience.
2.2.2.1 The physiology of withdrawal bleeding and pill cycle length
Given the evidence just presented, it is clear that the 28 day pill taking regime is a
highly artificial imitation of the menstrual cycle. It does not seem that any survey was
made during pill development of the bleeding pattern which women would prefer to
experience while using the new steroidal contraceptives (Pincus, 1965). It has been
argued that "incessant" ovarian cycling is a modem anomaly which runs contrary to the
vast majority of human history in which several pregnancies, interspersed with long
periods of lactational amenorrhoea ensured that menstruation was an infrequent event
(Short, 1976). Nevertheless, rather than attempt to emulate pregnancy, for example,
the pill cycle creates an idealized "menstrual cycle".
Instead of menstruation, pill takers experience withdrawal bleeding as a result of the
abrupt removal of pill steroids. Because the endometrium has not been prepared in the
usual way, and in the absence of a CL, bleeding begins as soon as the pill agents are
cleared from the system. The delay to bleeding thus depends on the potency and
clearance rate of, in particular, the gestagen. Generally, combined OCs produce a
highly constrained cycle length with approximately four day withdrawal bleeds during
the pill free interval, separated by 23 to 25 day intervals, thus generating 27 to 29 day
cycles (Belsey, 1988a; Fraser, 1986). Bleed volume and duration are also very often
reduced by the pill (Fraser, 1986; Snowden & Christian, 1983). Because the
progestagen inhibits the proliferative effect of the oestrogen component there is simply
not as much endometrium to be shed. In addition pill steroids may also desensitize the
uterus to prostaglandins which are implicated in heavy bleeding and pain (Schering,
1989; Abel, 1985; Woods, Most & Dery, 1982). Oral contraceptives also reduce
uterine tone, or pressure, and reduce the frequency and severity of contractions during
withdrawal bleeding, all of which leads to a reduction of local ischaemia and therefore
pain with bleeding (Ekstrom, Juchnincka, Laudanski & Akerland, 1989; Schering,
1989).
2.2.2.2 Breakthrough bleeding on OCs
One important difference between bleeding in the pill cycle and bleeding in the
menstrual cycle is that inter-cycle bleeding is far more common on the pill. A
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proportion of women experience slight bleeding at mid-cycle in association with
ovulation, however, in the absence of any uterine pathology it is rare at other times of
the cycle (Vollman, 1977). Bleeding during active pill taking, on the other hand is
relatively common and a small, but notable, percentage of women on the pill develop
amenorrhoea, or "miss" some bleeds. It has already been pointed out that defining and
collecting reliable information about bleeding experience is problematic. This may be
why, although it is often cited as an important reason for pill discontinuation (eg-
Bancroft & Sartorius, 1990; Belsey & Farley, 1988), there is relatively little
information on the control of bleeding (Weijers, 1984). Incidence rates for so-called
breakthrough bleeding (BTB) vary widely. Some factors responsible may be
distinguishing between "spotting"5 and BTB, variable reporting due to differences in
menstrual equipment use, and correcting incidence rates for missed pills or past history
of irregular bleeding (Weijers, 1984).
Most BTB seems to occur in early pill cycles, especially the first three months, whereas
amenorrhoea increases with duration of pill use (Edgren, Nelson, Robert & Keifer,
1989; Fraser, 1986; Weijers, 1984). Increased progestagen dose reduces BTB, while
EE dose seems to determine spotting. In a survey of 16 different trials, Microgynon
generated a BTB rate of 2 to 18% of cycles, while Trinordiol had 24% in the first cycle
and 12% in the 12th (Weijers, 1984). Fraser (1986) quotes a rate of 7.5% overall, but
up to 25% if pills are missed. In a study in which 157 women were randomly allocated
to one of three triphasic pills, the BTB rates were very high: 33% for Trinordiol, 44%
for Tri-Norilyn, and 63% for Ortho-Novum 7/7/7 (Droegemueller, Katta, Bright &
Boes, 1989). The authors suggest that the mid-cycle rise in oestrogen, and or the
greater bioavailability of LNG may account for the lower incidence on Trinordiol. BTB
has been found to vary over the cycle, being lowest on days 5 to 7 and 15 to 18, and
highest on days 10 to 13, and 19 to 21 (Edgren et ah, 1989).
The mechanism behind BTB is not clear. One possibility is that there is insufficient
unopposed oestrogen present during the pill cycle to generate progesterone receptors
uniformly throughout the endometrium. Therefore, some areas of tissue are not
5
Spotting refers to very light bleeding, generally defined as requiring the use of one, or
no, tampons or pads per day. The concept is unhelpful in settings like the Indian
subcontinent, however, as women do not tend to use any menstrual equipment, no
matter how heavy the bleeding (Snowden & Christian, 1983). Therefore, it is probably
best to distinguish spotting from BTB only in industrialized settings where equipment
use is common.
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supported adequately by the gestagen in the pill, resulting in bleeding (Baird & Glasier,
1991). Alternatively, individuals may have different sensitivity to the pill steroids.
There is evidence that "psychogenic" BTB can be induced if women are given a placebo
and told it is an OC, and that they may expect to have BTB (Aznar-Ramos et al., 1969;
Pincus, 1965). Thus while bleeding experience over the pill cycle is more highly
constrained than during the menstrual cycle due to the rigidity of the steroidal inputs,
individual and situational factors may still play a role.
2.3 Cyclical Changes in Emotional and Physical Well Being
over the Menstrual Cycle
For centuries a variety of aspects of well being have been observed to alter alongside
the more or less regular cycle of physiological changes and vaginal bleeding (eg-
Rubinow, Roy-Byrne, Hoban, Grover & Post, 1985). This section is concerned with
what features of well being fluctuate over the cycle, when these changes occur during
the cycle, who experiences them and to what degree, and why women may have such,
cycle-related experience.
The hallmark of the literature on cycle-related phenomena is that there are more
uncertainties than certainties. The first difficulty is to define what is meant by cyclical
change. The main reason for the difficulty is the vast heterogeneity of women's
experience (Gise, 1988) which arises from the fact that every dimension that needs to
be included in a definition varies across individuals and within them over time. These
dimensions include the timing of changes, the degree or severity of change, the aspects
of well being which change, and the level of consistency in timing, severity, and
factors which are required to constitute "cyclical change". It is also important to
distinguish between the different contexts in which variable well being is being
considered, notably, in clinical practice, in research, or in the daily lives of women. In
each of these settings the salience of the various aspects of cyclical change will differ.
While this thesis concerns changes in well being during the pill cycle, it is essential first
to consider those changes which accompany the menstrual cycle, as background, and
because of the potential aetiological significance of similarities and difference in well
being patterns in these two endocrinologically distinct states.
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2.3.1 The Problems of Defining Cyclical Change: The concept of
the premenstrual syndrome
A multitude of factors have been observed to vary regularly in time with the menstrual
cycle. Moos (1969) found that over 150 different symptoms and changes have been
reported in the medical literature including such disparate phenomena as asthma,
seizures, and vertigo (Rubinow & Roy-Byrne, 1984), along with more frequently cited
changes in emotional and physical well being such as tension, irritability, depression,
bloating, breast tenderness, and period-type pain. The concept of "premenstrual
tension" or latterly, the "premenstrual syndrome" (PMS) was introduced in 1931 by a
gynaecologist called Robert Frank (Moos, 1968) who attributed a clustering of negative
moods and physical symptoms in the 7 to 10 days before menstruation to some
dysfunction of the ovarian cycle, which he treated with ovarian irradiation. In the same
year, Karen Horney described the same phenomenon which she attributed to repressed
sexuality and difficulty in accepting the female role, and suggested that it could be dealt
with through psychotherapy (Clare, 1989). The two important features of their concept
of PMT or PMS is that 1) it is characterised by largely negative changes, and 2) these
changes occur in the later half of the cycle, before menstruation.
The most rigid definitions of cycle-related change come from consensus attempts to
create operational definitions which can be used to diagnose women who suffer from a
clinically significant syndrome. For example, PMS has been defined as "the cyclic
occurrence of symptoms that are of sufficient severity to interfere with some aspects of
life and which appear with consistent and predictable relationship to menses" (Gise,
1988). In April, 1983 the National Institute of Mental Health (NIMH) in the U.S.A.
recommended that for research purposes PMS be defined as occurring if a woman
shows an approximately 30% change in one or more mood symptoms from the pre- to
the postmenstruum, and if this is prospectively documented in at least two consecutive
cycles. The premenstrual phase was defined as the 6 day interval before menses, and
the postmenstruum as cycle days 5 to 10 (Hamilton, Parry, Alagna, Blumenthal &
Herz, 1984).
Most recently the American Psychiatric Association (1987) has created the term "late
luteal phase dysphoric disorder" (LLPD) in an effort to standardize the definition and
classification of premenstrual syndrome (Warner, 1992a; Schnurr, 1989; Gise, 1988).
LLPD has been entered in Appendix A of the Diagnostic and Statistical Manual of
Mental Disorders. Third Edition. Revised (DSM-III-R). The idea of LLPD has been
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widely criticised both for the implications of associating a specifically female experience
with psychiatric illness, and as a usable and valid research and clinical tool. For
example, the criteria for LLPD require one to distinguish between women with
predominantly mood versus physical symptoms, to exclude women who are
experiencing another disorder which is exacerbated in the luteal phase, and to confirm
symptoms prospectively over at least two cycles. There is no clear justification for
dividing physical and mood symptoms, nor is the degree of change necessary for
clinical diagnosis specified, nor the means of distinguishing "true" PMS from another
disorder. On the other hand, it is stated that symptoms should remit within a few days
of the onset of bleeding, which ignores a variety of other potential patterns of cyclical
change (Warner, 1992a; Gise, 1988).
2.3.2 The Temporal Organization of Cyclical Phenomena
It is important to strive to standardize diagnostic criteria. Equally to develop a
meaningful and comparable body of research, it is desirable to use similar and
rigourous methodologies across studies. Much research in this area is
methodologically flawed and these problems will be discussed further below. It has
been proposed that PMS is less the presence of specific symptoms, than the temporal
relationship of these variables to menstruation, notably "the premenstrual onset and
postmenstrual offset" of which ever symptoms are troubling (Schnurr, 1989). While
this idea may be helpful as a rough guideline it ignores the temporal complexity of
symptoms across women.
In particular, authors like Katriona Dalton (eg-1983), who played a large role in
popularizing the notion of PMS, emphasize that PMS symptoms must remit with the
onset of menstrual bleeding. However, Dalton later revised her definition, introducing
the concept of the "paramenstruum" which includes the four days before menstruation
and first four days of bleeding (Rubinow & Roy-Byrne, 1984), and has generally used
her own definition inconsistently in different writings (see Bancroft & Backstrom,
1985). And early research (eg- Moos, 1969) illustrated that so-called premenstrual
symptoms could actually persist, or appear during bleeding itself. Asso (1983) rightly
argues that the whole cycle should be studied and not just selected, and pre-defined
phases around menses.
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2.3.3 The Prevalence of Cyclical Changes or Premenstrual
Syndrome
Walker (1987) discusses of the nature of "definition" further with respect to PMS, and
proposes that rather than possessing narrowly definable features PMS is one extreme of
the continuum of women's cycle-related experience. Although it is of theoretical
importance to try and establish the boundaries of what is meant by PMS, this thesis is
not strictly concerned with PMS, but with cyclical change in the broad sense. For
example there may be regular oscillations in well being over the cycle which are not
severe and which may not occur in the premenstrual or menstrual phase in particular,
that may still form a relevant part of the individual woman's experience. The aetiology
of cyclical change in well being, in whatever form, is not yet clear. It is therefore
premature to impose rigid definitions and indeed limits the power of exploratory
research in the area (Warner, 1992a). However, it is possible to gain an impression of
the prevalence and the nature of cycle-related change in women. Almost all symptoms
which have been linked to the menstrual cycle, and are included in the constellation of
factors making up PMS, (with the possible exception of period pain) are common, non-
pathological, subjective states which may be experienced from time to time by any
healthy woman or man.
The prevalence rates for PMS or cycle-related change vary anywhere from 5% to
almost 100% depending on the population studied and the way information about
cyclicity is obtained and cyclicity defined (Metcalf, Livesey, Wells & Braiden 1990;
Yuk, Juddutt, Cumming, Fox & Cumming, 1990; Stewart, 1989; Logue & Moos,
1988; Bancroft & Backstrom, 1985; van den Akker & Steptoe, 1985; Clare, 1983;
Snowden & Christian, 1983; Woods, Most & Dery, 1982; Reid & Yen, 1981; Janiger,
Rifferburgh & Kersh, 1972). However, it is widely agreed that only about 2 to 10% of
women are severely affected by changes that may interfere with their functioning (for
reviews see- Graham, 1989; Walker, 1987, 1992; Bancroft & Backstrom, 1985; Asso,
1983). The sorts of phenomena observed to fluctuate in a regular way over the cycle
have been variously categorized as: psychological, somatic, and behavioural (Hamilton,
Parry, Alagna, Blumenthal & Herz, 1984); pain, concentration, behaviour change,
autonomic reactions, water retention, negative affect, arousal, and control (Moos,
1968, 1969); affect, cognitive, pain, neurovegetative, autonomic, central nervous
system (CNS), fluid/electrolyte, dermatological, and behavioural (Rubinow & Roy-
Byrne, 1984); and systemic changes, bodily changes, nervous system changes, and
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psychological and behavioural changes (Asso, 1983). All of these typologies cover
essentially the same aspects of well being.
The number of specific, "common" cycle-related symptoms indicated ranges from
about 20 to about 50 (Rubinow & Roy-Byrne, 1984: 42 symptoms; Hamilton et al.,
1984: 22 symptoms; Moos, 1969: 46 symptoms). Clearly some of the distinctions
drawn between different symptoms are semantic, and may not actually reflect
meaningful differences in experience. For example, such negative affect symptoms as
tension, anxiety, irritability, anger, restlessness, dysphoria, depression, sadness, etc.
may not describe anything more than negative mood with probable outwardly directed,
and inwardly directed components. Nevertheless, efforts have been made to separately
quantify many of these symptoms.
Walker (1987) has tabulated symptom prevalences across ten different investigations
which used the same terms to describe particular states, including: irritability,
depression, breast changes, abdominal bloating, and period type pain. All symptoms
but period pain had the greatest mean prevalence in the premenstrual phase of about 50
to 60%, followed by the menstrual, about 20 to 30%, and postmenstrual phases, about
0 to 20%. Period pain was most frequent in the menstrual, and then premenstrual
phase. Fifty per cent of women studied reported menstrual, and almost 40%
premenstrual, period pain. With relatively few studies distinguishing severity, and
possible overestimation due to retrospective report (see below), it is clear that these
changes are very common.
Woods, et al. (1982) conducted a general population survey of 179 U.S. women of
different races, ages and socioeconomic status (SES) using the Moos menstrual distress
questionnaire (MDQ- 8 symptom factors described above). More than 30% of the
sample reported weight gain, acne, breast tenderness, irritability, mood swings,
depression, and tension mainly premenstrually, and tension, backache, fatigue, and
period pain mainly menstrually. Headaches and anxiety occurred frequendy, but were
not associated with a particular cycle phase. Only 2 to 8% of symptoms were reported
as severe or disabling, except menstrual period pain (17%), and premenstrual and
menstrual irritability (12%). Other retrospective surveys and reviews have reported
similar patterns (Stewart, 1989; Logue & Moos, 1988; van den Akker & Steptoe, 1985;
Asso, 1983; Clare, 1983; Sheldrake & Cormack, 1976; Janiger, Rifferburgh & Kersh,
1972) with mood changes clustering premenstrually, and physical changes menstrually.
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While some authors report, as do a proportion of women themselves, that there are
changes in cognitive ability and performance associated with the menstrual cycle the
preponderance of findings fail to support this belief. This relationship has been well
reviewed by Sommer (1973, 1992). Nevertheless there is some evidence that central
and autonomic nervous system function do alter over the cycle, which may potentially
mediate changes in well being. The two systems seem to vary independently over the
cycle, with CNS activity higher at mid cycle, and autonomic activity highest
premenstrually (Asso & Braier, 1982; Asso, 1983). Some consequences of these
variations are increased premenstrual susceptibility to adverse conditioning, and
differences in the distribution of REM sleep and possibly in the content of dreams
(Asso, 1983).
2.3.4 Positive Perimenstrual Changes
At least since the introduction of the concept of PMS, there has been a profound
emphasis on the negative aspects of cyclical change. Several authors have challenged
the idea that the perimenstruum is characterized by entirely negative experience. Logue
& Moos (1988) reviewed the literature on the prevalence of positive changes
premenstrually, and found that between 5 and 15 % of women experience increased
excitement, energy, and well being, and there are also reports of increased activity,
heightened sexuality, and improved performance on certain tasks. The arousal scale on
the MDQ (Moos 1968, 1969) includes the positive scales: affectionate, orderly, excited,
well being, and bursts of energy. About 20% of women have mild to moderate arousal
premenstrually, 5% have high arousal, which is linked to low scores on the other
symptom factors (Logue & Moos, 1988).
Parlee (1980, 1982) has proposed that some women may experience a "premenstrual
elation syndrome" in which a premenstrual increase in general neuro-psychological
activation is translated into positive sensations and feelings. Schachter & Singer (1962)
have demonstrated that moods are expressed differently depending on the individual's
background emotional or environmental state. The expression of negativism may also
be somewhat culturally dependent; for example, food craving is considered a positive,
not a negative, symptom by Indian women (Chaturvedi & Chandra, 1989). If women
have higher activation premenstrually they may attend to stimuli less selectively and
may recognize emotional information better (Logue & Moos, 1988). Stewart (1989)
gave 100 consecutive Well Woman clinic attenders a retrospective questionnaire to
complete which contained a list of 25 negative and 14 positive cyclical changes. Sixty-
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six per cent of women reported at least one positive change, including increased sexual
interest and enjoyment, greater tidiness, more efficiency, more attractive breasts, and
increased energy and creativity. It seems likely that failure to observe positive
perimenstrual changes in many studies stems from the failure to ask women the right
questions and the traditional emphasis on negative experience which may limit the
nature of reporting.
2.3.5 Symptom Severity as a Predictor of Prospective
Confirmation: Physical versus Mood Changes
It is now well established in menstrual cycle research that retrospective questionnaire
surveys of the pattern and prevalence of perimenstrual symptoms may overestimate
them to a large degree compared with prospective symptom records (eg- Halbreich &
Endicott, 1985a, 1985b; Rubinow & Roy-Byrne, 1984; Rubinow, Roy-Byrne, Hoban,
Gold & Post, 1984; Endicott & Halbreich, 1988, 1982). The number of women
affected, the severity of symptoms, and the close temporal relationship of symptoms to
menstruation all tend to be over-emphasized retrospectively. Parlee (1974) suggested
that retrospective accounts, from both women and men, elicit stereotypic beliefs about
how women feel over the menstrual cycle rather than producing an accurate description
of experience. The likelihood of "confirmation" by prospective ratings seems to
depend on a number of factors (Endicott & Halbreich, 1982), one of which is the
severity of the perimenstrual change (Cumming, Cumming, Krausher & Fox, 1991;
Coleman, Hart, & Russell, 1988).
Physical symptoms in particular are more likely to be confirmed prospectively, and
seem to affect more women irrespective of whether or not they experience marked
emotional changes (Metcalf, Livesey, Wells & Braiden, 1990; Coleman, et al., 1988;
Slade, 1984; Asso, 1983; Snowden & Christian, 1983; Golub & Harrington, 1981;
Janiger, et al., 1972). For example, Metcalf, et al. (1990) prospectively monitored 44
women who were self-selected for experiencing PMS (+), and 48 women who did not
believe they had PMS (-) over two or three cycles. Using time series analysis on the
data they found that 81% of PMS+ women had significant trends in physical symptoms
over the cycle versus 33% of PMS- women. Further these swings were significantly
more likely to be in the premenstrual phase in the PMS+ women, and to be more
severe. While in a previous survey of these women (Metcalf, Livesey, Wells &
Braiden, 1989) they found that cyclical moods were only evident in the PMS+ group.
The most clearly cyclical changes in both groups were breast tenderness, bloating, and
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food craving. The authors conclude that "premenstrual dysphoria [is] not an intrinsic
part of the menstrual cycle, but [is] typical only of women with PMS" (p.203, Metcalf,
et al., 1990). Physical symptoms are also more likely than moods to occur
independently of one another (Warner & Bancroft, 1990).
Using the MDQ prospectively, and spectral analysis Coleman, et al. (1988) also found
that for most women physical symptoms had a 28-day peak while only about one half
of cycles showed 28 day peaks for depression, behavioural change, tension, and
cognitive symptoms. The authors hypothesize that the reason for the difference in the
incidence of various symptoms may be that as PMS becomes more severe more
symptoms become manifest, thus physical and depressive changes are revealed at lower
severities. Others attempting to factor analyse the experience of women who do and do
not report cyclical change found that on the premenstrual assessment form (PAF;
Halbreich, Endicott & Schacht, 1982) only 20% of non-PMS women did not meet the
criteria for at least one negative syndrome (Yuk, et al., 1990). And that the factors
found for a group of women (n=109) with prospectively confirmed PMS were similar
in quality to non-PMS women (Cumming, et al., 1991). The two groups were
distinguished by severity, and the authors conclude that PMS is simply part of the
continuum of normal experience.
2.3.6 Individual Characteristics Predictive of Cyclical Change
A variety of investigations have focused on possible demographic or other determinants
of cyclical change. These include age (older women- more PMS: Golub, 1988;
Snowden & Christian, 1983; Asso, 1983), parity (higher parity- more PMS: Warner &
Bancroft, 1990; Asso, 1983), cycle length (irregular cycles- more PMS: Rubinow &
Roy-Byrne, 1984; Woods, et al., 1982; Sheldrake & Cormack, 1976; Coppen &
Kessel, 1963), work (women who work outside home- less PMS: Bancroft &
Backstrom, 1985; Asso, 1983; Woods, et al., 1982), marital (married women- more
PMS: Bancroft & Backstrom, 1985; Paige, 1973), or socioeconomic status (negative
relationship of PMS to education and income: Woods, et al., 1982), culture (different
symptoms in different racial groups: Janiger, et al., 1972), religion (orthodoxy in
Judaism and Catholicism- more PMS: Paige, 1973), history of sexual abuse (severe
sexual abuse- more common in PMS patients than controls: Jensvold, Muller, Putnam
& Rubinow, 1989), and personality or psychiatric health (neuroticism, psychosis, and
past history of depression- increased propensity for, or exacerbation of PMS: Warner,
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Bancroft, Dixson & Hampson, 1991; Morse & Dennerstein, 1988; Mira, Vizzard &
Abraham, 1985; Bancroft & Backstrom, 1985; Clare, 1983; Coppen & Kessel, 1963).
The incidence of PMS is classically cited as being highest during the mid thirties, in
women with children, and some authors suggest that there is a shift from the menstrual
onset of symptoms in young women to more prolonged symptoms with a premenstrual
onset (Golub, 1988; Snowden & Christian, 1983; Asso, 1983). However a number of
studies have failed to show a positive relationship of symptoms to age, parity, cycle
regularity, marital status, or socioeconomic status (SES) (Simpson, Shand & Nyhof,
1988; Woods, et al., 1982; Coppen & Kessel, 1963). Warner & Bancroft (1990) have
related cyclical change to the number of years of "natural cycles" a woman has
undergone uninterrupted by pregnancy or oral contraceptive use, etc.. They have
shown that women who have had between three and six years of natural cycles are
more likely than women with fewer than 3 or more than 6 to report significant
perimenstrual changes which are not attributable to stress, which may account for the
equivocal findings of other studies. In particular, they indicate that parous women in
their mid-thirties are most likely to seek help at a PMS clinic, suggesting that their life
circumstances make coping with their cyclical change difficult. Overall, there is little
consensus about which variables are predictive of cyclical change, which probably
arises from the heterogeneity of women's experience, and the variety of different
groups of women studied and methodologies used.
2.3.7 Cycle to Cycle Variability
Another important feature of cyclical change with methodological, diagnostic, and
treatment implications is the variability of symptom patterns from one cycle to the next
in the same woman. It has been suggested that inter-cycle inconsistency may be a
defining characteristic of PMS (Warner, 1992a; Walker, 1991; Schnurr, 1989). The
limited number of studies that have attempted to quantify the degree of inter-cycle
variability have been reviewed by Walker (1991) who assessed the comparability of
self-ratings over consecutive cycles in pill and non-pill takers and found that in a non-
PMS Clinic sample most variables were consistent across cycles and cycle phases.
Schnurr (1989) on the other hand who assessed women seeking treatment for self-
reported PMS found very low consistency. And others (eg- Simpson, et al., 1988)
have found symptom patterns to be very labile in both PMS, and non-PMS reporters,
such that one third of a sample of 117 women showed different patterns in different
cycles indicative of "chronic", "cyclic", or "acyclic" symptoms. This suggests that one
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cycle of either retrospective or prospective data is not sufficient to establish the nature
or severity of a woman's cyclical experience. Indeed, using only one cycle to establish
'cyclicity' is conceptually meaningless.
2.4 Aspects of Well Being which Change in Relation to
the Pill Cycle
It is clear that certain aspects of well being vary in a regular fashion in relation to the
menstrual cycle in a significant proportion of women. Yet an estimated 5% of women
of reproductive age worldwide do not have a menstrual cycle because they use oral
contraceptives (Kols, et al., 1982), and in Britain 23% of women aged 16 to 49 are
using the pill for contraception (Guillebaud, 1991). If OCs have systematic positive or
negative effects on cyclical symptom experience, they will influence a large number of
women. Further, because the endocrine state which exists in pill taking is quite distinct
from ovulatory menstrual cycles, the effects of the pill on subjective state may provide
valuable information about the aetiology of cyclical change.
One difficulty with the study of OCs is that one must distinguish between
pharmacologic 'side effects' of exogenous hormones, and persistent cyclicity in
subjective state. In addition, different gestagens or dose regimens may produce
different subjective responses. Factors such as duration of pill use, sense of
contraceptive security, high discontinuation rates due to side effects or fear of side
effects, and the personality characteristics of women who choose to take the pill, may
influence experience, and ought to be considered in studies of well being and pill use.
While the pill is one of the most researched drugs in history, there is still surprisingly
little research on psychological associations (Pincus, 1965).
Early anecdotal reports and uncontrolled, retrospective, studies indicated that OCs
largely improved, or eliminated cyclical change in well being (Richardson, 1992;
Bancroft & Sartorius, 1990; Graham, 1989; Glick & Bennett, 1982; Reid & Yen,
1981). Many early studies were predominantly concerned with efficacy and the
incidence of side effects, and the means of eliciting and reporting the prevalence of
changes in well being were crude (Graham, 1989). Bancroft & Sartorius (1990) note
that the method of eliciting OC 'side effects' influences rates observed and effects
particular symptoms more than others, for example, depression. The incidence of side
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effects can be up to four times higher when probing versus non-probing approaches are
used.
Ideally, randomized, double-blind, placebo controlled prospective studies would reveal
the incidences of both side effects and cyclical change. However, this methodology
removes the important effects of personality, and expectations and attribution to the pill
as a method of contraception (Bancroft & Sartorius, 1990). Reviews show that the
discontinuation rate for OCs at 6 to 12 months varies from 25% to 75%. The
contribution of side effects to discontinuation has important implications, not least for
the prevalence of changes in well being in those women who persist with pill taking.
The following discussion of the literature will be organized according to research
methodology. The findings of recent retrospective studies of the incidence of cyclical
symptoms in pill and non-pill taking women will be considered, followed by open
prospective studies, and double-blind placebo controlled studies.
2,4.1 Retrospective Surveys of Symptom Prevalence on OCs
A number of studies which have simply compared women who take the pill with those
who do not, regardless of pill type, have found little difference in women's self-
reported cycle related experience. In a large survey of about 3300 university students,
Sheldrake & Cormack (1976) found few differences between the 756 pill users and
non-users. Pill takers reported less backache, period type pain, and irritability, but
more depression and tension. In a recent, smaller survey of students, Richardson
(1992) found a similar pattern with less breast tenderness and cognidve impairment, but
more depression and crying reported by pill users. As women were only asked about
symptoms during the premenstrual phase the results are not directly comparable with
the previous study. Women taking the pill for more than two years had fewer
symptoms especially during bleeding (Sheldrake & Cormack, 1976). This is consistent
with the idea that women with a tendency to cyclical symptoms discontinue pill use,
and relates to a finding that non-pill users over the age of 25 have more premenstrual
mood symptoms, particularly sadness and anxiety, than women still using the pill at
this age (Golub, 1988).
In a random sample survey with 24% pill takers, the only differences found were less
premenstrual and menstrual acne and period type pain in pill users (Woods, et al.,
1982). Women were questioned about any change from their pre-pill experience, and
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34% reported a slight to large decline in physical symptoms on the pill, and 34%
indicated no change, or a slight increase or decrease in psychological symptoms.
Stewart (1989) found that pill taking Well Woman clinic attenders did not differ from
non-users in the number of positive, negative, or total number of changes reported, but
that there was a nonsignificant tendency for pill takers to have fewer positive changes.
In another Well Woman clinic sample in which 101 pill takers were compared with 149
non-pill takers on the PAF, both groups had a similar number and severity of
symptoms overall. Pill takers had somewhat less severe anxiety, fatigue, low mood,
water retention, and impaired social function. Pill type and duration of use were not
related to cyclicity, but past problems with the pill predicted more frequent and severe
symptoms. Pill takers' symptoms were more likely to occur just before bleeding than
non-pill takers' (Graham & Sherwin, 1987). In a further general practice survey no
differences were found between pill and non-pill takers in Modified MDQ status, but
pill takers did tend to have less severe symptoms. Concurrent psychiatric problems
were related to more severe MMDQ scores, but duration of pill use did not influence
scores (Clare, 1983).
A few large retrospective surveys have attempted to relate cyclicity in OC users to the
type of formulation used, age and parity, and genetic factors. Warner & Bancroft
(1988, 1990) surveyed over 5000 Woman magazine readers about their cycle related
symptoms using a Menstrual health Questionnaire (MHQ) which asked respondents to
assess their symptom experience over all phases of their most recent cycle. They
compared the symptom report of a sample of 4112 women using either monophasic or
triphasic pills, or not using the pill (Warner & Bancroft, 1988). Well being and
sexuality covaried in the non-pill users, and was lowest premenstrually and highest
postmenstrually. The OC users had a broadly similar pattern, but less marked peaks
and troughs. Triphasic takers were more similar to non-pill users than monophasic
takers, who tended to have more symptoms during bleeding, suggesting a more marked
withdrawal effect.
There was a high rate of PMS self-report in this sample, 61%, probably because the
questionnaire followed an article about PMS. They found that pill takers were less
likely to report PMS than non-pill takers (Warner & Bancroft, 1990) especially if
nulliparous. Amongst young nulliparous women the highest rate of PMS reporting
was in ex-pill users, and young women were more likely than older women to have
discontinued OCs due to side effects. Forty-one per cent of current pill users timed the
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onset of their PMS to the present episode of pill use. These findings suggest two
important points: 1) pill use and PMS are not mutually exclusive, and 2) PMS sufferers
may be more likely to have an adverse reaction to OCs. Thus studies of women who
are well established on the pill are likely to be composed of individuals with few
cyclical changes, or for whom the pill improves moods and physical changes (Bancroft
& Sartorius, 1990; Reid & Yen, 1981).
Another large survey assessed the genetic versus environmental component of
psychiatric side effects to OCs using a large twin register in Australia (Kendler, Martin,
Heath, Handelsman & Eaves, 1988). Seven hundred and fifteen monozygotic and 416
dizygotic twin pairs with similar OC histories were questioned about specific side
effects experienced on the pill. Two-thirds of the sample were ever-users, and 80% of
these had used the pill for at least one year. Thirty per cent were using the pill when
surveyed. The following rates of side effects were seen in ever-users: 36% weight
gain, 23% irritability, 18% depression, 16% bloating, 14% nausea, 13% bleeding
disturbances, 3% acne. Based on their analyses the authors conclude that genetic
factors play a clear role in pill induced weight gain, bloating, and depression, and
possibly irritability, such that " 'suggestion', 'scapegoating', and confusion about the
maternal role" (p. 158, Kendler, et al., 1988) cannot be the sole factors responsible for
OC related side effects. This study gives important information about the biological
propensity to respond adversely to the pill, but unfortunately does not specify the
severity, duration, or temporal pattern of symptoms, neither does it delineate pill types,
though it is likely that it pre-dates the widespread use of low dose pills.
2.4.2 Prospective Studies of the Effects of OCs on Well Being
As with the menstrual cycle, the certainty of symptom report in retrospective accounts
of pill takers is not always matched in prospective studies. Several recent studies have
found no difference in the prospective negative symptoms of pill versus non-pill takers
(Almagar & Ben-Porath, 1991; Alexander, Sherwin, Bancroft & Davidson, 1990;
Slade, 1984). Yet pill takers reported more positive affect (Almagar & Ben-Porath,
1991), and more satisfying and active sexual relationships (Alexander, et ah, 1990).
Almagar & Ben-Porath (1991) conclude that these differences are due to the fact that
pill takers have secure contraception, no fear of physical symptoms during bleeding,
better relationships, and different personality traits. Two single case studies have
shown that OCs can relieve psychiatric illness, psychotic episodes and clinical
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depression respectively (Feltous, Rubinow & Conroy, 1980; Roy-Byrne, Rubinow,
Gold & Post, 1984). Roy-Byrne, et al. (1984) propose that the antidepressant effect
could be mediated via steroid induced CNS receptor changes.
The variability of response to OCs is illustrated by a comparative study of women
starting the pill (n=152) or a barrier method (n=40) (Herzberg & Coppen, 1970).
Questionnaires about side effect experience were administered pre-pill, at 5 weeks, and
5 and 11 months. By 11 months 20% of women had stopped the pill due to headache,
depression, irritability, weight gain, bloating, loss of libido, fatigue, nausea, or the
wish to become pregnant. Of those continuing, pill takers showed a transient increase
in bloating, headache, and nausea, but less depression, irritability, and period type pain
at all time points. Clearly these findings cannot be taken as evidence that the pill
resolves cyclical change since many women discontinued due to worsened symptoms.
Of those women who became depressed on the pill, 47% had reported prior
premenstrual depression, versus 27% of the whole group. The application of this
study's findings may be limited since six different high dose pills were considered
simultaneously, and assessment of well being was infrequent.
Other research has explored the effects of different gestagens, and more recently
monophasic and triphasic pill regimes. Grant & Pryse-Davies (1968) assessed the
monoamine oxidase (MAO) activity of endometrial biopsies in almost 800 women and
related it and depression and loss of libido, to the oestrogen / progestagen ratio of high
dose monophasic and sequential pills. They found the least breakthrough bleeding, but
highest incidence of depression and loss of libido in high progestin / low EE pills.
They found the lowest rate of mood side effects on the high EE sequentials. Overall,
16% of women experienced depression and / or loss of libido regardless of pill type.
The authors proposed that progestin mediated rises in MAO in the endometrium might
be mirrored by raised MAO in the CNS which has been implicated in the aetiology of
depression. Although there is no objective evidence that MAO in the endometrium will
parallel CNS levels this theory has been much repeated by subsequent authors ( eg-
Kane, 1976; Paige, 1971).
Progestagen dominated pills have been related to increased depression over the pill
cycle (Forrest, 1979; Persky, O'Brien & Kahn, 1976). Forrest (1979) monitored 12
women established on a low dose pill for at least 3 months, over 30 days and found a
steady increase in depression over the cycle, with a peak from pill days 11 to 19, or the
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second half of the cycle. Bancroft, Sanders, Warner & Loudon (1987a) randomly
allocated 114 women to begine taking either monophasic Microgynon, or triphasic
Logynon and monitored well being daily over two or three cycles. A very large
number of women dropped out due to study demands, which may compromise the
generalizability of their findings. However, women on the triphasic (n=19) who had
reported prior premenstrual mood change were more likely than monophasic takers
(n=18) to experience lowered mood and loss of libido. Depression increased in the
second and third weeks of pills, with relief in the pill free interval. While the timing is
consistent with the previous two studies, the relationship to progestagen dose is not,
since triphasics administer less gestagen than monophasics and are relatively EE
dominated.
In a larger prospective comparison of various monophasic (n=35) and triphasic (n=30)
takers versus controls (n=57), Walker and Bancroft (1990) showed that the symptom
experience of pill and non-pill takers, and of pill takers who do and do not undergo an
increase in gestagen dose over the cycle is very similar. The symptom profiles of
triphasic takers were most like controls, yet all three groups were much the same except
for breast tenderness. The monophasic takers had less premenstrual breast tenderness,
and lower well being during bleeding. Bloating, period pain, and breast tenderness
were all more clearly cyclical than moods. The authors conclude that ovulation is not
necessary for cyclical changes in well being, but that a rise in progesterone at the end of
the cycle is for breast tenderness. One difficulty with this study is that cycle phases
were pooled and meaned across more than one cycle. This has the effect of
emphasizing cyclical change around bleeding, while ignoring cycle to cycle variability
in symptom scoring. These findings do not bear out the above conclusions that
triphasic users are more likely to become depressed, or that a greater progestin / EE
ratio generates more negative mood.
It seems that OCs may contribute to worsened mood or improved mood in a proportion
of cases. Another possibility is that pill taking flattens out peaks and troughs in well
being (Warner & Bancroft, 1988). Morris & Udry (1969) monitored the activity of 8
pill takers and 26 controls over one cycle using pedometers. While both groups had a
mid-cycle peak in activity, pill users had a lower level overall. The pill group was
small, and it is possible that the absence of oscillation is a result of taking the mean over
the whole group. However, another study involving the content analysis of speech at
four times over the cycle found that while non-pill takers had a U-shaped pattern of
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negative speech content and ideation around bleeding, pill takers showed no cyclical
mood fluctuation (Paige, 1971). Asso (1983) cites evidence that the pill takes "the
competitive edge" off women's game playing, and that EE dominated pills make
women more assertive and aggressive than progestagen dominated ones. She suggests
that if the pill does cause a general flattening out of well being in women accustomed to
marked fluctuation, this may be perceived as a loss of well being.
2.4.3 Double-Blind Placebo Controlled Studies of the Effect of
OCs on Well Being
There have only been four double-blind, placebo-controlled studies of the pill and well
being. The first involved only 8 women who were given either 2 cycles of Enovid plus
2 months placebo, or the reverse (Silbergeld, Brast & Noble, 1971). Volunteers were
monitored using the mood adjective checklist, the MDQ, and interviews. All variables
were maximal premenstrually or menstrually, but only physical symptoms were really
cyclical, while moods showed a tendency to be worse premenstrually. During Enovid
cycles women reported more nausea, breast tenderness, and bloating than on placebo,
but less muscle stiffness, backache, and irritability. This study suffers from the small
number of volunteers, and the large number of variables studied.
Another study (Morris & Udry, 1972) compared the day-to-day well being of 51
women randomly allocated to one of three high dose MES containing pills, or placebo.
Volunteers were simply asked if they felt better, worse, or the same as usual. Placebo
takers felt worst premenstrually, and on day 2 of bleeding (presumably due to period
pain). Pill takers also felt worst premenstrually, but a proportion felt better or worse
overall due to pill taking. The authors conclude that ovulation is not necessary for the
occurrence of PMS, however, like the previous study, participants were not selected on
the basis of PMS reporting. The study is weakened by the fact that there was no
discrimination made between different symptoms, and all pills studied were high dose.
Cullberg (1972) recognized the difficulty of distinguishing pill side effects from the
psychological effects of contraception, and cycle-related change in well being. He,
therefore allocated approximately 300 women to one of three 50)ig EE pills, or placebo
for two months. Self-ratings and interviews were carried out before starting the tablets,
and retrospectively after two months of pill use, and one month after stopping the pills.
Volunteers were not told that they were taking an OC in order to control for the effects
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of contraceptive expectations. Cullberg found that about twice as many pill takers had
global adverse mental changes as placebo takers (approximately 34% vs. 18%).
Premenstrual irritability and depression as assessed by the MDQ were not relieved by
the pill more than placebo, but there was a trend towards less depression and irritability
in gestagen dominated pills, and more in EE dominated ones. There was a higher
frequency of adverse mood reactions in women reporting prior premenstrual irritability.
This seems to support the idea that some women are inclined to adverse reactions.
However, without prospective monitoring and baseline data, it is difficult to assess the
degree of pill induced change in subjective state.
A fourth study has finally addressed some of the methodological problems inherent in
the previous investigations. Graham & Sherwin (1992) selected women who were
reporting PMS (n= 82 Clinic patients) and assessed them daily over one baseline
month, before allocating them to placebo or the triphasic pill, Synphasic (7x
35jigEE+500|igNET, 9x 35pgEE+1000qgNET, 5x 35qgEE+500qgNET) for three
months. The drop out rate was high, with 5 placebo takers stopping, and 18 OC users,
14 having had side effects. The most frequently reported side effects amongst drop
outs were spotting, breast tenderness, and nausea, or other physical symptoms
(Graham, 1989). Thirteen further women were excluded because they did not show
prospectively confirmed PMS during the baseline month, and one who was anovular.
Thus 20 pill takers and 25 placebo takers confirmed PMS and completed the study.
The authors found that both placebo and active medication reduced irritability and
depression, while the pill was more effective in reducing breast tenderness, and
bloating. Irrespective of mood, sexual interest was reduced in the pill group. There
was no evidence that the timing of symptoms differed in the two groups, except for
bloating which was shifted to the menstrual phase in the pill group. There was also no
evidence that the placebo response diminished over the three months of treatment. The
placebo effect on moods is to be expected as these women were told that they were
being given "weak hormones" as a treatment for their PMS. The reduction in breast
tenderness in the pill group may be exaggerated by the fact that many women with
marked breast tenderness on the active treatment, dropped out. This study nevertheless
shows that there is little significant difference in the cycle-related experience of women
with known PMS when they take the pill (Graham & Sherwin, 1992).
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2.4.4 Consensus on the Effect of OCs on Cyclical Change
It is not possible to make definitive statements about the way in which OCs influence
subjective state. Differences in research methodology, many of which are also
problematic in studies of the menstrual cycle, may account for some of the
inconsistency. Variability in women's reactions to the pill are also responsible. Overall
it would seem that a small proportion of women do have marked adverse reactions to
the pill, reflected most often in depression and loss of libido (Bancroft & Sartorius,
1990), which may have a genetic basis. Women with a prior history of either PMS or
psychiatric disorder may be amongst those most likely to have exacerbated symptoms
on the pill. It is likely that these women discontinue pill use after a relatively short
time. This fact is reflected in the higher rates of PMS reporting in past users of the pill.
It also undoubtedly contributes to the apparently lower rates of severe cyclical change in
current pill users, and may be in part responsible for the observation that pill use
"flattens out" peaks and troughs in well being. Alternatively, flat affect may be pill
induced mild chronic mood change which women do not attribute to the pill until they
stop taking it (Bancroft & Sartorius, 1990). Equally, some women have elevated
mood.
The importance of placebo-blind studies in the assessment of mood reactions is
emphasized by the findings of both Cullberg (1972) and Graham & Sherwin (1992)
who found equal changes in irritability and depression in pill and placebo takers. The
question of how different pill formulations and dose regimens influence users remains
unanswered. The relationship of progestagen dose, or ratio to EE, to subjective state is
uncertain, with some studies suggesting that depression increases with increasing
progestagen dose or a cyclical pattern of administration, i.e. triphasics (Forrest, 1979;
Persky, et al., 1976; Grant & Pryse-Davies, 1968), some that depression decreases
(Bancroft, et al., 1987a; Cullberg, 1972), and others finding no relationship (Walker &
Bancroft, 1990). These studies may not be comparable because of differences in the
actual gestagen studied, and high versus low dose oestrogen. While studies of high
dose pills may be of aetiological interest, they are of questionable relevance to today's
situation in which the vast majority use pills with low dose oestrogen.
In the pill cycle like the menstrual cycle, physical changes show more marked cyclicity
in relation to withdrawal bleeding than do moods. A relatively large proportion of
women seem to have improved physical symptoms, although certainly not everyone.
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Some of the probably physiological mechanisms were discussed earlier in this chapter.
To summarize, while pill use may filter out women with severe cyclical changes, there
is no good evidence that cyclicity is abolished by pill use, or that the timing of specific
symptoms is significantly altered. These facts make OCs a tractable model of the
relationship of steroids to cycle-related change in subjective state.
2.5 Some Methodological Problems in Menstrual Cycle
Research
It is only within the scope of this thesis to cover selected methodological questions.
(See the following for methodological reviews- Warner, 1992a; Halbreich & Endicott,
1985b; Rubinow & Roy-Byrne, 1984). However, it will be clear from the above
discussion that there are many uncertainties, inconsistencies, and sources of variance in
cycle-related experience which present methodological problems for research. There
are unresolved methodological issues about how cyclical change is defined, how data is
gathered, which groups of women are appropriate for research, how data should be
analysed, and how findings are ultimately interpreted. The question of defining
cyclicity has already been considered, and relates directly to the inherent conflict in this
field between the aims of research, and the desire to diagnose and treat women
reporting severe and debilitating variations in subjective state. Attempts at clinical
treatment have preceded real knowledge about the nature and the aetiology of cyclical
change (eg- Warner, 1992a; Hamilton & Alagna, 1988) and have therefore largely
failed. Further, they have led to the medicalization and pathologizing of the menstrual
cycle such that a basic aspect of being female implies illness and has become
susceptible to medical scrutiny and purported cure (Warner, 1992a; Clare, 1989; Laws,
1985).
2.5.1 Retrospective Versus Prospective Assessment
After the problem of definition, comes the question of the most valid way to gather
information about cyclicity. The first problem of assessment is that by its nature it must
be "subjective" and therefore may be confounded by such factors as context, emotional
state, personality, attributions, expectations, study demands, beliefs, etc. (Warner,
1992a). When assessments are made retrospectively, as many as 50 to 80% of women
who report "global PMS" fail to confirm this on prospective ratings (eg- Hamilton &
Alagna, 1988). It is therefore argued that prospective, preferably daily, ratings of
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symptoms over two or more cycles are required to establish the presence of PMS or
other cycle-related cyclicity. However the validity of retrospection seems to depend on
whether or not the information is gathered for the most recent cycle, or for the
"average" cycle (Warner & Bancroft, 1990), and how the data are analysed6 .
Some problems with prospective ratings are that they are demanding and therefore
create selection bias through high attrition rates, there is no consensus about how to
deal with inter-cycle variability, they are "noisy", and they may actually have a
beneficial effect on the symptoms which they seek to measure (Warner, et al., 1991;
Hamilton & Alagna, 1988). Retrospectives questionnaires have the primary advantage
that they can be readily administered to a large number of women, yet they are clearly
vulnerable to the effects of poor, selective, or biased recall in a way that prospective
ratings are not. Prospective ratings do have the advantage that they can be related to
concurrent measures like hormone levels, and cycle phases can be meaningfully, and
consistently designated.
2.5.2 The Absence of Adequate Controls
Another basic problem is that there are no really adequate control groups for menstrual
cycle studies. While captive catarrhine monkeys and apes, especially rhesus monkeys,
chimpanzees, and gorillas, have been observed to undergo variations in behaviour over
the menstrual cycle, such as restlessness and irritability (Janiger, et al., 1972), this
information is not directly comparable to humans. Men are not adequate controls as
they tend to live in close proximity to women and are therefore influenced by them.
Non-menstruating women are poor controls as they will either be prepubertal,
postmenopausal, pregnant, or possess some gynaecological pathology. Women who
take the pill are likely to be highly selected, and may not in fact be a good control for
the absence of a hormonal cycle (Asso, 1983). Thus this leaves women who do not
report cyclical change, and women undergoing hormonal manipulations of some kind.
2.5.3 Sampling Bias and Experimental Demand
Because of the demands of prospective monitoring, samples are inevitably biased in
favour of highly motivated women. Many studies also use captive groups like nursing
and psychology students. The "college sophomore phenomenon" of conducting
6
For example, Livesey, Wells, Metcalf, Hudson & Bates (1989) have found that in
women reporting PMS the rate of confirmation is around 70% when time series
analysis is used to detect cyclicity.
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research on women aged 20 to 25 (Dan, Graham, Beecher, Bart, Komnenich, Krueger,
Pital & Ruble, 1980) has the effect of biasing samples in favour of young, nulliparous
women who are less likely to be experiencing notable variation in subjective state,
particularly mood (Golub, 1988, Woods, et al., 1982). Knowing that a study concerns
the menstrual cycle is also likely to affect the amount of cycle-related change observed.
A number of studies concerning "experimental demand characteristics" have shown that
attribution of negative mood and physical states to the premenstrual phase of the cycle
is more frequent when women know the study concerns the cycle (Jarvis & McCabe,
1991; Englander-Golden, Sonleinter, Whitmore & Corbley, 1986; AuBuchon &
Calhoun, 1985; Ruble & Brooks-Gunn, 1979; Ruble, 1977).
Parlee (1974) found that both men and women responded similarly to the Moos MDQ
when men were asked to complete it describing the experience of women "in general",
and women, their own experience. She concluded that both women and men respond
in terms of stereotypic beliefs about menstruation and the cycle. Stereotypes are
defined as:
"
[Generalizations about specific groups on which there is considerable
social consensus and little or no supporting data....[B]eliefs seem to be
more strongly held by those with little opportunity to acquire falsifying
information (i.e. men7, my emphasis ) and to be formulated in such a
way as to justify the social distance arrangements prevailing in the
society." (p.240, Parlee, 1974)
In a now classic experiment, Ruble (1977) told women they were immediately
premenstrual, or not to expect a period for 7-10 days using a sham EEG. Others were
given no information about cycle phase. MDQ scores in the "premenstrual" group were
significantly higher for water retention, pain, change in eating habit, and sexual arousal
than the other two groups. Negative affect was not significantly different by group,
which may reflect the fact that this was a University student sample. The author
attributes the findings to stereotypic beliefs. Yet the "control" women were more
similar to the "premenstrual" than the "intermenstrual" group. All women were actually
within 6 or 7 days of a bleed, and it is possible that rather than reflecting false
attributions amongst the "premenstrual" group, the findings show the tendency for the
women who thought a period was over a week away to discount that their physical
sensations were related to an impending bleed.
7
Parlee (1974) found that men often reported 'symptoms' to be more severe than women
did.
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However, the notion of false attribution is supported by prospective studies in which
the menstrual focus of the research was concealed (Aincough, 1990; Slade, 1988;
Slade, 1984). In a study of 118 student nurses completing the MDQ daily for eight
weeks as part of a "general health study", Slade (1984) found that only peaks of pain
and water retention were located before or during bleeding, while emotional changes
occurred randomly over the cycle. It was concluded that negative experiences were
attributed to the biological influences of the perimenstrual phase, while positive
experiences are more often attributed to other variables. Morse & Dennerstein (1988)
conducted a prospective study of women seeking treatment for PMS, and also found
that quite a lot of psychological symptoms occurred during the follicular phase. In
contrast to Ruble (1977), they concluded that sensitivity to pre-existing symptoms
changes during the luteal phase to generate PMS. The picture is further complicated by
findings that women in another study who showed no prospective evidence of cyclical
mood change, nevertheless reported PMS-type experience when asked retrospectively
about the past two months during which they collected diaries (Aincough, 1990).
2.5.4 The Complexities of Analysis
In addition to the uncertainty of how best to gather valid data is the question of how to
analyse it. Given a high degree of inter-individual variation it is of doubtful validity to
summarize data using arithmetic means within women in arbitrarily defined cycle
phases, and across women and cycles (Warner et al., 1991; Warner, 1992a). The
uniqueness of women's experience may be of potential aetiological significance.
Walker (1987) has summarized the purposes of analysis as follows: 1) to diagnose
PMS, 2) to relate well being to change over time, 3) to relate well being to changing
physiological state, eg- steroid hormones, and 4) to assess the efficacy of a particular
treatment. The research reported in this thesis is primarily concerned with the second
and third objectives.
Because of the implicit or explicit assumption that well being varies in relation to
menstruation, analysis using conventional parametric statistics (eg- t-tests and Analysis
of Variance, ANOVA) has tended to focus on establishing a statistically significant
difference between the "premenstrual" and "postmenstrual" phases of the cycle (eg-
30% change described above) More recently analyses have centred on a variety of
mathematically complex time series analyses (Livesey, Wells, Metcalf, Hudson &
Bates, 1989; Schnurr, 1989; Magos & Studd, 1986) which take account of all data
points over the whole cycle. A critique of these methods for use with daily self ratings
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can be found in Walker (1987) or in section 6.4.6.1. It has been concluded that the
method which one uses will continue to depend on the reason for which the data have
been collected, eg.- for research or clinical use (Schnurr, 1989).
2.5.5 Symptom Subclasses
Yet another consideration is whether or not different women have different patterns of
symptoms which suggest the existence of several menstrual cycle-related syndromes,
and if there is a consistent factor structure of symptoms (Warner, et al., 1991;
Cumming, et al., 1991; Yuk et al., 1990; Morse & Dennerstein, 1988; Halbreich &
Endicott, 1985b). The PAF of Halbreich, et al. (1982) was developed specifically to
sub-type perimenstrual change, but recent studies have found it ineffective at
differentiating homogeneous research samples (Cumming, et al., 1991; Yuk et al.,
1990). Further, factor analyses of different daily rating scales seem to produce
different components in different samples, and to explain relatively little variance
(Morse & Dennerstein, 1988; Sanders, 1981). Cyclical change characterized by
depression may have a distinct aetiology (eg- Warner, et al., 1991; Halbreich &
Endicott, 1985a; Rubinow, et al., 1985; Endicott & Halbreich, 1982). It has been
emphasized because depression is a particularly troubling symptom which effects many
women, and because relating cyclical change to affective disorder may shed some light
on the aetiology of both conditions. However, efforts to separate different symptom
experiences into sub-syndromes may be a spurious means of fitting data to
unsubstantiated unitary, biological theories of aetiology (Walker, 1992).
2.6 Existing Theories of the Aetiology of Cyclical Change
A great many theories have been put forward to explain change in subjective state in
relation to the menstrual cycle. In particular, much research has been directed at
uncovering some physiological abnormality of the H-P-0 axis or other concomitant
biochemical change which would explain symptom experience. There is also a parallel,
and often opposing, line of research which seeks social / psychological causes.
Ultimately, it seems unlikely that either biology or psychology on its own is able fully
to explain the variability of women's experience. There is a need for a genuinely
integrated, and multifactorial approach to both the study and management of cycle-
related change. Each of these positions will be considered in turn, before finally
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discussing the possibility of a novel aetiological theory, which is the basis of the
research undertaken in this thesis.
Given the close temporal relationship of changes in well being to particular phases of
the menstrual cycle it is not surprising that an aetiological link has been sought. Yet
this area has been widely researched and repeatedly reviewed and the consensus is that
no change or abnormality in any one hormone, electrolyte, neuropeptide,
neurotransmitter, vitamin, etc. has been consistently associated with cyclical well
being. Biological theories to explain mood and / or physical changes have included the
following: oestrogen (excess), progesterone (excess, deficiency, or autoimmunity),
altered timing of steroid dynamics, prolactin, aldosterone, renin / angiotensin,
vasopressin, endogenous opioid peptides (endorphins and enkephalins), oc-melanocyte
stimulating hormone, glucocorticoids, androgen, insulin (hypoglycemia / increased
glucose tolerance), melatonin, biogenic amines (serotonin, dopamine,
norepinepherine), acetylcholine, vitamin B^, magnesium, zinc, and prostaglandins
(Walker, 1992; Graham, 1989; Walker, 1987; Bancroft & Backstrom, 1985; Hamilton,
et al., 1984; Rubinow & Roy-Byrne, 1984; Backstrom, et al„ 1983a; Clare, 1983;
Reid & Yen, 1981).
The lack of substantiation for such theories is probably due to three causes: 1)
methodological problems and inconsistencies, 2) basing theories on inferences about
the potential actions or mediating power of substances in the menstrual cycle, and 3)
failure to accomodate the complexity and variability of the phenomenon. In spite of
equivocal evidence for all of these theories [or evidence that they only influence one
particular symptom- eg. prolactin and breast tenderness (Andersen, Larsen, Steenstrup,
Svendstrup & Nielsen, 1977)] many authors persistently argue that cyclical change
must have a biological cause rooted in the menstrual cycle, and propose a variety of
radical and potentially dangerous treatments which are probably no better than placebo,
i.e. high does progesterone (eg- DeVane, 1991; Watson & Studd, 1990; Magos, 1989;
Watson, Studd, Savvas, Garnett & Baber, 1989; Backstrom, et al., 1983a; Dalton,
1983; Osborn, 1981; Reid & Yen, 1981).
Bancroft & Backstrom (1985) describe a variety of ways of studying the biological
basis of cyclical change. Three of these are of particular interest to the theoretical
2.6.1 Biological Theories: "Raging Hormones"
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consideration in this thesis; namely, looking at cyclicity in naturally anovular cycles,
manipulating the hormonal cycle and looking for an effect on symptoms, and using
hormones to produce symptoms. There is a good deal of evidence that cyclical
symptoms can persist in anovular cycles, whether these are spontaneously anovular, or
hormonally manipulated, like the pill cycle (eg- Walker & Bancroft, 1990; Walker,
1987; Bancroft, Boyle, Warner & Fraser, 1987b; Bancroft & Backstrom, 1985; Reid &
Yen, 1981; Andersen, et ah, 1977; Adamopoulos, Loraine, Lunn, Coppen & Daly,
1972).
However, as in pill taking, the nature of symptoms may be different in spontaneously
anovular cycles. Backstrom, Sanders, Leask, Davidson, Warner & Bancroft (1983b) in
a study relating steroids to well being, found that there were no mood changes in five
anovular cycles, but there was cyclical breast tenderness and bloating. Since volunteers
were not selected on the basis of severe mood change, it is not clear whether
anovulation was responsible for the absence of mood changes, or whether this would
have happened anyway. Walker (1987) has reviewed the evidence for cyclical change
at the points of reproductive transition, around menarche, during and after pregnancy,
and at the perimenopause, and concluded that too little information exists to assess
whether cyclical changes occur at these times.
It has already been shown that cyclical symptoms can persist, and may even be
worsened by the combined pill. Other information about the efficacy of induced
anovulation comes from hormonal treatment studies, and from studies of women
having hysterectomies with or without the ovaries conserved. Danazol is a synthetic
steroid with anabolic properties that acts as a powerful anti-gonadotrophic agent and
thus abolishes ovulation (Walker, 1992; Magos, 1989). In a double-blind cross-over
trial of Danazol in 39 women with severe PMS, Danazol caused a significant
improvement in depression, mood swings, irritability, tension, breast tenderness, pain,
fluid retention, concentration, and behavioural change over placebo. However, 19 of
the 39 participants dropped out of the trial. While only three are reported to have
dropped out due to 'side effects', it is difficult to assess their findings with such high
noncompliance (McKay-Hart, Hawthorn & Gilmore, 1985).
In a further double-blind study of 40 women with PMS, three different doses of
Danazol or placebo were given daily for 3 months (Watts, Butt & Logan-Edwards,
1987). Only women who had prospectively confirmed PMS in 2 baseline cycles were
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included. In the first treatment cycle most symptoms were improved by placebo, but
by the third cycle 8 symptoms were improved on one dose of the active versus 3 on
placebo. By the end of the trial more than 75% of women on Danazol were virtually
free of breast tenderness, lethargy, anxiety, and increased appetite, but other, mainly
mood and vasomotor symptoms were unchanged. Results were very variable for
different women and different symptoms, and 13 women dropped out of the trial
because they had experienced no improvement. It is possible that individual responses
were due to variable degrees of gonadotrophin and steroid supression, but
unfortunately endogenous hormones were not monitored in either this or the previous
study.
Another synthetic agent able to generate "medical ovariectomy" is the GnRH (LHRH-a
or GnRH-a) agonist. It is a new innovation introduced in the 1980's which works by
desensitzing the pituitary to LHRH, and thus switching off the ovarian cycle. It has
been shown to effectively abolish PMS symptoms when given by injection or
subcutaneous implant. When given in nasal spray (Buserelin), there is a more variable
respone (Walker, 1992; Magos, 1989). This may be due to poorer adsorption through
this route, however most women have suppression of ovulation within the first one or
two months of use (Bancroft, Boyle, Davidson, Gray & Fraser, 1985).
Bancroft, Boyle, Warner & Fraser (1987b) carried out an exploratory treatment trial of
Buserelin with 20 PMS clinic patients and found that 10 women each had positive and
negative reactions to it. Ovulation occurred in less than 10% of the 95 months
monitored, and six out of eight of these were the first cycles of use. The drug tended to
stimulate the H-P-0 axis initially producing a worsening of PMS-type symptoms
whether or not it was begun in the follicular or luteal phase. Four of the ten women
with a positive reaction to Buserelin continued to bleed at regular intervals although
they did not ovulate, while the other six were amenorrhoeic. These two groups did not
differ on mood scores, yet those women who bled continued to have "premenstrual"
physical symptoms, notably breast tenderness and bloating. The opposing reactions of
different women who have confirmed cyclical changes is curious, and it is not clear
whether the mechanism of action relates to steroid supression, gonadotrophin
disruption, or some other drug mediated effect. GnRH analogues offer a valuable
aetiological research model with which to abolish ovarian cycling without the re-
introduction of steroids. Their usefulness for research however may not be matched by
long term therapeutic use because they induce a state of hypo-oestrogenism and
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therefore precipitate menopause type changes such as loss of bone density (Magos,
1989; Bancroft, et al., 1987b).
Another recent study has attempted to circumvent this problem by giving GnRH-
agonist with replacement oestrogen and progestagen (Mortola, Girton & Fisher, 1991).
Eight women with severe PMS were monitored over 9 months including 2 control
months, 2 months with GnRH-agonist alone, four months of double-blind cross over
with four different one month treatments, and one final control month. The steroid
supplements included a month with GnRH-a and conjugated equine oestogen (CEE- as
used in hormone replacement therapy) on days 1 to 25; a month with GnRH-agonist
and medroxyprogesterone acetate (MPA) on days 16 to 25; a month with both of these;
and a month with placebo alone.
The authors note a significant improvement in daily mood and physical scores in the
luteal phase from the control months to the second half of the two unblinded months
with GnRH-agonist. During the subsequent placebo month luteal phase physical
symptoms remained significantly lower than control, but mood symptoms returned.
And in the cycles where oestrogen and progestin were reintroduced alone both physical
and mood symptoms returned to control levels. During the CEE+MPA cycle, moods
were 60% better than control cycles, yet physical symptoms were not significantly
improved. Nevertheless, the authors conclude that GnRH-agonist with or without
replacement steroids is able to improve physical well being, yet only alone or with
combined oestrogen-progestin does it improve moods.
The authors describe the reintroduction of "behavioural symptoms" in the placebo
month as a "reverse placebo effect". What volunteers were told to expect during the
steroid reintroduction phase is not stated, but the authors attribute the effect to
"subjects' anticipation of worsening of symptoms during the estrogen and progestin
administration" (p.252D, Martola, et al., 1991). The authors were also surprised to
find that while placebo, CEE, or MPA alone reproduced symptoms to some degree but
combined therapy did not. While the authors conclude that their findings are due to a
lower dose of replacement hormone than a previous study which found PMS re¬
instated by hormone replacement therapy, the results are confusing and suggestive at
best. The variety of difficulties with this study include the small number of women, the
potential placebo effect of the unblind GnRH-agonist injections, the strong potential
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carry over and order effects of the four steroid replacement months, and the potential
confounding factor of different degrees of ovarian supression by the GnRH-agonist.
Other authors have claimed the success of oestradiol and progestin treatment for PMS
without GnRH down regulation (Watson & Studd, 1990; Magos,1989; Watson, et al.,
1989). Watson, et al. (1989) administered E9 patches or placebo patches and
norethisterone (days 19-26) in a double-blind cross-over fashion to 40 women with
severe PMS. Both treated and placebo groups improved over the first three months of
the trial, and women who started with placebo and changed to active treatment showed
sustained improvement over three further months. However, women who started with
active and changed to placebo treatment generally showed a decline in well being.
Combined therapy of this kind abolishes ovulation, and the authors rather dogmatically
insist that PMS can be completely eliminated by abolishing ovulation in this way. They
attribute persistent symptomology to the high dose of cyclical progestin which is used
to prevent endometrial hyperplasia. They note that "patients on active treatment had
symptoms of premenstrual syndrome during the first few weeks of therapy, when
normally they would be expected to be improving after menstruation" (p.731, Watson,
et al., 1989). This appearance of follicular phase symptoms parallels the experience of
women starting on GnRH analogues, and suggests an uncertain physiological effect of
H-P-0 suppression on symptom experience which may be of aetiological significance.
In spite of equivocal evidence, some authors believe so strongly in the role of ovulation
in cyclical change that they espouse surgical castration if "medical ovariectomy" does
not work (eg- DeVane, 1991; Watson & Studd, 1990; Magos, 1989). While such
extreme interventionism is ethically and politically questionable, the effect of
hysterectomy and ovariectomy on cyclical change do inform the aetiological discourse.
There is now a good deal of evidence that cyclicity does persist after hysterectomy,
although the timing and severity of symptoms seems to be changed by the absence of
menstrual bleeding and the uterus itself (Walker, 1992; Metcalf, Livesey, Wells,
Braiden, Hudson & Bauer, 1991; Walker, 1987; Osborn, 1981). This suggests the
influence of some menstrual / uterine factor in cyclical change (Bancroft, Williamson,
Warner, Rennie & Smith, 1992) and argues against the idea that cyclicity is entirely
attributable to expectation and attribution to menstrual bleeding (eg-Osborn & Gath,
1990; Osborn, 1981).
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While recent evidence suggests that bilateral ovariectomy does abolish symptoms, the
results have been questionned due to the problems of phase definition without
menstruation (Walker, 1992). Other problems for the design and interpretation of
hysterectomy studies include timing in relation to surgery, dealing with individuals in
possible ill health, controlling for operation-induced stress and disruption, and
assessing placebo response. It is widely acknowledged that there is a substantial
placebo response to treatments for cyclical change, but this does not seem to be
considered in hysterectomy studies. The degree of placebo response is dependent on
the perceived potency of the treatment, with 50% overall, 89% for tablets, and 94% for
implants (Magos, 1989). Having allowed herself to be castrated to treat her PMS a
woman has a tremendous incentive to be "cured". Further, since the placebo response
tends to be more marked for mood than physical symptoms, and hysterectomy removes
the major source of cyclical physical discomfort, the effect will appear that much more
marked.
In summary, while there is evidence to suggest a biological component in cyclical
change, no single biological cause has been identified. Certain consistent findings
emerge from the variety of investigations in which the cycle is medically or surgically
disrupted. They show that: 1) a proportion of women experience a significant
improvement (eg- on OCs), 2) others find no change or show significant worsening, 3)
PMS-type symptoms can occur in the absence of ovulation, and even in the hormonal
conditions of the follicular phase, and 4) different symptom types, particularly moods
and physical changes, respond differently to the ovarian cycle and its disruption.
2.6.2 Psychological and Social Theories for Cyclicity: "It's All in
the Mind"
2.6.2.1 The female role, personality, and psychiatric illness
In parallel, and sometimes opposition to, biological theories are a number of theories
for psychogenic causes of cyclical change. Historically, a psychoanalytic approach has
been taken (Stout, 1989), and as the following quote shows this point of view is still
active in some quarters:
Blood and menstruation symbolize warmth, security, intercourse and
satisfaction (Simpson, 1976) and have psychological links with
childbirth, sexual relations and marriage. Frustrations or
disappointments in these areas may be expressed through the menstrual
cycle in the form of anxieties and morbid preoccupation, thus giving rise
to symptoms, (p. 107, Carney, 1980)
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In this school of thought it is argued, for example, that women generate very irregular
bleeding patterns in order "to communicate in a non-verbal pre-cognitive way" while
women with slight "cycle disturbances" are using a "broader repertory of
psychosomatic signals...to communicate their unhappiness" (Eder, Kemeter &
Springer-Kremser, 1982). Early studies focused on relating PMS-type experience to
neuroticism and to a failure to accept the traditional female social role. While
psychoanalytic studies have found a relationship between role rejection and symptoms,
studies using standard psychometric tests like gender inventories have tended to find
the opposite, that symptoms are related to traditionalism, passivity, and inability to
express emotions, particularly anger (Stout, 1989).
In a study which compared women seeking treatment for PMS, women with sexual
dysfunction, and non-treatment seeking controls, women who scored highly for
masculinity on the BEM gender inventory had high self esteem, internal locus of
control, and more positive attitudes to menstruation, their bodies, genitals, and sex.
While these women tended to be controls, there was no evidence that women reporting
PMS differed from others in their attitude towards the traditional female role. Women
with sexual dysfunction had the lowest self esteem, and the most negative attitudes,
followed by PMS patients (Spencer-Gardner, Dennerstein & Burrows, 1983). In
another, population based, survey of 179 women, sex role orientation and sex typing
were not related to PMS reporting, while women engaged in more traditionally female
occupations did report more severe perimenstrual negative affect (Brown & Woods,
1986). Slade & Jenner (1980) found in a group of young students that femininity was
unrelated to symptoms but that women at the extremes of sex role attitudes, very
traditional or egalitarian, were both more likely to report higher levels of symptoms
during bleeding, but not premenstrually. They propose that both groups may dislike
the reminder of their sex provided by bleeding.
Another theory is that negative attitudes towards menstruation may translate into
negative labels for physical experiences and moods before and during bleeding, and/or
emotions and behaviours which are considered out-of-role for women may be attributed
to menstruation generating symptom experience in particular cycle phases (Jarvis &
McCabe, 1991). The "cognitive labelling approach" to the study of emotions argues
that the same bodily state can be described in different emotional terms depending on
the external referents in the environment (Schachter & Singer, 1962). Parlee (1976)
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argues that PMS may be conceived of as it is because hormone levels, rather than
producing specific moods, alter "arousal levels" which are labelled negatively because
of the social expectancies and negativism surrounding menstruation and femaleness.
She notes that moods like irritability and depression have been culturally
"highlighted...as the appropriate ones to feel in the premenstrual and menstrual
phases".
Koeske & Koeske (1975) compared women's and men's negative attributions to the
menstrual cycle using stories about a hypothetical fellow student in which her overall
mood and the events in her day were construed as positive or negative. They found
that female students were more likely to attribute emotionally expressive behaviour to
the woman's personality and biology, than to extenuating circumstances in her
environment. Inconsistencies between the tenor of mood and events produced more
internal attributions, while if moods and events were consistent, moods were attributed
to the events. Women are probably encouraged to make more negative self attributions
than men because of different socialization (Asso, 1983; Dan, et al., 1980). In a study
using the same sample as Brown & Woods (1986) above, the effects of menstrual
socialization and stress on symptoms were examined (Woods, 1986). A stressful
environment went part way to explaining cyclic symptoms, particularly negative affect.
Socialization was related to attitudes towards the cycle, but not symptom experience.
The degree of disability reported related directly to the severity of symptoms, again
especially to negative affect.
It has been argued that awareness of cycle phase in relation to menstruation produces
phase attributions (eg- Ruble, 1977). In a prospective study of cycle and non-cycle
attributions, women taking the pill, who knew their cycle phase, made more cycle
attributions during the premenstrual phase than non-pill takers. The non-pill takers
made more attributions during bleeding, suggesting that fore-knowledge of cycle phase
enables one to make premenstrual attributions of negative mood, etc. (Campos &
Thurow, 1978). How such an attribution process works for individuals is not clear,
for groups which might be expected to view menstruation more negatively, such as
infertile women, show no evidence of worse cycle phase attributions (Slade, 1981). It
is argued that attribution cannot be fully responsible for cyclical changes since women
with PMS do not make more negative attributions to biological events than other
women, and that PMS seems "to occur on a background free of psychiatric or
physiologic illness" (p. 1209, Reid, 1991).
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The tendency to experience cyclic symptoms has been linked to certain personality traits
and a history of psychiatric illness, namely neuroticism and affective disorders.
Coppen & Kessell (1963) are often cited for making an early association between
neuroticism and PMS. They found that even after controlling for the elements in the
MMPI measure of neuroticism which might be confounded with PMS that a
relationship persisted in women who reported irritability, depression, and tension.
Neuroticism was not significantly correlated with irregular cycles or dysmenorrhea.
The authors note that the relationship between neuroticism and PMS is not "simple"
since not all neurotic women have PMS, nor do neurotic women whose neuroses
improve with treatment necessarily loose their PMS.
Others have subsequently endorsed the relationship (eg- Bancroft, et al., 1992; Mira,
Vizzard & Abraham, 1985; Slade & Jenner, 1980; Watts, Dennerstein & Home, 1980),
but have not addressed the important question of confounding. It seems that
neuroticism is not just higher in the luteal phase in women with PMS, but over the
whole cycle (Mira, et al., 1985), is related to prolonged perimenstrual depression
(Bancroft, et al., 1992), and shows a stronger relationship with severe symptoms
(Stout, 1989). State and trait anxiety have also been linked to cyclical change, and
curiously "trait" anxiety which is held to be a constant personality factor was higher in
the luteal than follicular phase in women with PMS (Mira, et al., 1985; Watts, et al.,
1980). There is evidence that women with PMS are more likely to have type-A
personalities, which make them more reactive and vulnerable to stressors involving a
loss of control, eg. menstrual bleeding (Ussher, 1992).
There are three ways in which psychiatric illnes may relate to cyclical change. Existing
illness may be exacerbated premenstrually or menstrually, PMS may mark a stage in the
development of an illness such as depression, or cyclical mood change may be a
distinct type of affective disorder which is entrained to the menstrual cycle (Stout,
1989). There are reports of menstrual exacerbation of psychosis, but PMS is not more
common in psychotic women not having a current episode (Clare, 1983). Panic-
anxiety syndrome, and bulemic episodes are observed to cluster at the paramenstruum
(Rubinow, Roy-Byrne, Hoban, Grover & Post, 1984). In a general practice survey of
about 450 women, Clare (1983) found that women with severe perimenstrual changes
were more likely to have a current psychiatric problem, and that psychiatrically ill
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women with PMS had more, and more severe mood changes, but not necessarily
physical ones.
The depression seen with the menstrual cycle is most characteristic of "atypical"
depression (Rubinow, et al., 1985), but has been described as quantitatively and
qualitatively similar to major depressive disorder (Warner, et al., 1991). Warner, et al.
(1991) have related the severity of premenstrual depression to a previous history of
postnatal depression, and its duration (premenstrual and menstrual) to a history of
treatment with antidepressants. The authors suggest two aetiological components of
perimenstrual depression: 1) a menstrual cycle-related factor which precipitates severe
premenstrual depression in "vulnerable" women, and 2) a general propensity to
depressive illnes which generates prolonged cycle-related depressive changes.
2,6.2.2 Taboo, secrecy, and restriction: Attitude, belief, and
behaviour
Menstruation and hormone withdrawal bleeding are not simply biological events;
vaginal bleeding is political and polemical. Throughout written history the menstrual
cycle and bleeding itself have been embued with social meanings, and have been the
focus of many complex systems of belief and behavioural proscription. Its symbolism
extends far beyond its physiological role. Menstruation has inspired a good deal of
research based on the apperception that "[t]he belief system surrounding
menstruation...is handed down from one generation to the next during the process of
socialization" (p.53, Snowden & Christian, 1983), and the inherent knowledge that
"[mjenstruation may not be important in itself, but it is highly symbolic of femaleness,
and the ways in which people deal with it show us a lot about how women are viewed"
(p.207, Laws, 1990). The idea that vaginal bleeding and its sequelae are culturally
symbolic is fundamental to our understanding of the way in which women process and
report their experience.
For the sake of argument, menstrual values can be viewed separately at the level of the
individual and at the level of the society, although in practice they are elements of one
another. Individuals are taught their menstrual values through gender socialization.
This process has been described as "largely non-verbal, subtle, and indirect"
(McKeever, 1984). For girls sexual socialization is difficult, contradictory, and largely
negative emerging as it does from a social order in which female genitalia are either
"eclipsed" or "exposed" (Ussher, 1989). Within this context communication between
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mothers and daughters about sexual matters is generally "strained" and usually limited
to a minimum of technical information about menstruation, and practical advice about
hygiene (Matlin, 1987; McKeever, 1984). Martin (1989) notes that vaginal bleeding is
portrayed in society, largely through the advertisement of menstrual equipment, as a
"hygienic crisis". McKeever (1984) summarizes her assessment of the social position
ofmenstruating women:
"In conclusion, current social norms concerning menarche and
menstruation emphasize cognitive understanding and proper use of
sanitary devices to reduce fear of excretory soiling and successfully
conceal all evidence from others. Thus the age old menstrual myths
continue to influence attitudes and behaviours ensuring that a major
characteristic of being a mature female remains a source of shame,
embarrassment, and secrecy, (p.45)"
Individual families will approach the subject of menstruation differently, which is
perhaps why simple sociological theories do not fully explain women's cycle-related
experience. "Even within one society it is not possible to make simple statements about
the meaning of menstruation. It is not a unitary phenomenon, not a single thing,
socially; menstruation means all manner of things to all manner of people." (p.211,
Laws, 1990) Information about the multifactorial nature of beliefs emerges from
surveys of attitudes. For example, Brooks-Gunn & Ruble (1980) using the Menstrual
Attitudes Questionnaire which included 33 statements with which women could agree
or disagree, found five factors relating bleeding to: psychological and physical
disability, a natural event, a bothersome event, a predictable event, and a non-event that
does not or should not influence behaviour. They compared the beliefs of various
groups including students, pre- and post-menarcheal girls, men, and older women.
Overall, college women saw menstruation as natural, somewhat bothersome, but not
very debilitating or predictable. Menarcheal girls and men perceived it as more
debilitating than older women who were more likely to see it as a nuisance and a non-
event.
The consensus of similar surveys and reviews is that bleeding is natural and womanly,
and it is probably wrong or dangerous to interfere with it. On the other hand, it is
embarrassing, a source of shame, should be concealed, is messy, and is troublesome
when it causes symptoms (eg- Laws, 1990; Martin, 1989; Paige-Ericksen, 1987; Birke
& Best, 1982; Brooks-Gunn, 1985; McKeever, 1984; Snowden & Christian, 1983;
Brooks-Gunn & Ruble, 1980; Ruble & Brooks-Gunn, 1979; Paige, 1973; Berry &
McGuire, 1972). Negative themes dominate. McKeever (1984) discusses a 1983
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survey in which two-thirds of U.S. adults indicated that menstruation should not be
discussed in the office or socially, and one quarter that it should not even be discussed
in the home. She describes the system of restrictions surrounding menstruation active
in Western cultures which includes restricted communication, altered activities, and
concealment.
Paige-Eriksen (1987) describes the results of a survey of attitudes carried out for the
Tampax Corporation in the United States in 1981, noting that men's and women's
responses "appear to reflect an underlying belief about women's inferiority as persons"
(p. 176). For example, nearly all men and women replied that menstruation makes
women more emotional, 89% of men and 66% of women that menstruating women do
not function well at work, 66% of both sexes that women should conceal menstruation
in social situations and 50% that women smell different while bleeding. And about a
quarter to a third of people felt that menstruation affects women's ability to think, that
physical activities should be restricted, that women look different, that period pain is
psychological, and that women should not bathe or swim while bleeding. Twelve per
cent of men and 5% of women even believe that menstruating women should stay away
from other people.
2.6.2.3 The acceptability of induced changes in bleeding patterns
A small number of studies have explored women's willingness to eliminate bleeding for
a time (Warner, 1992b; Jarvis & McCabe, 1991; Rutter, Knight, Vizzard, Mira &
Abraham, 1988; Fraser, 1986; Snowden & Christian, 1983; Miller & Smith, 1975),
and an equally small number have investigated the effects and acceptability of actually
implementing such manipulations (Kornaat, Geerdink & Kiltsie, 1992; de Voogd,
1991; Hamerlynck, Vollebergt, Doornebos, & Muttendam, 1987; Loudon, Foxwell,
Potts, Guild, & Short, 1977). The fears and support that women express for the
prospect of induced amenorrhoea reveal a great deal about their fundamental beliefs
about bleeding.
What all surveys of women's willingness to try eliminating bleeds have shown is that
there is an inherent contradiction between their desire to eliminate the "hassle" and
inconvenience of bleeding, balanced against a fear of the loss of an essentially female
experience and a fear of health risks. Miller & Smith (1975) summarize that there is a
"central conflict...between the potent loss of self image and the potential utilitarian
gain", and go on to add that women possess a "prevalent normative structure" in
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relation to bleeding experience. That is, women seem to have internalized boundaries
for what they consider to be their normal experience which must function within the
limits of what they imagine to be normal relative to other menstruating women.
Experiences which deviate from these norms tend to cause alarm, and be unacceptable.
This concept is consistent with the widely held view that one's menstrual experience is
a barometer of reproductive and general health. A similar theme emerged from a
comparative study of women seeking medical help for PMS, menorrhagia, or
dysmenorrhoea. Rather than wishing to adopt a hypothetical treatment which
eliminated their periods, these women wished for some treatment which would make
their periods "normal" (Warner, 1992b).
In their early study. Miller & Smith (1975) found that 79% of women in their white,
unmarried, nulliparous, lower to middle class sample would very likely or possibly
eliminate bleeding if it could be done safely for a time. Jarvis & McCabe (1991) also
found that 79% of their sample "would like to have their menstruation reduced". In an
Australian study of women's attitudes and beliefs about withdrawal bleeding and their
knowledge and beliefs about the pill, Rutter et. al (1988) found that about 45% of
female doctors and patients had used the pill to alter the length of their cycle in the past.
When women were asked how they would choose to take the pill if they could design
their own pill regime about 50% said they would continue to bleed monthly, 24% 3-
monthly, 4% 6- to 12-monthly, and 23% never. Yet apparently in direct contradiction,
83% of the same women said that it is necessary to bleed monthly while on the pill, and
69% that continuous pill use is undesirable.
In the WHO survey (Snowden & Christian, 1983) the fears that women expressed
about induced amenorrhoea included fear of a loss of femininity, loss of fertility, loss
of sexuality, loss of the reassurance of non-pregnancy, and loss of good health in that it
would be unnatural, interfere with metabolism, and cause side-effects through the build
up of "bad blood". Those women who would accept amenorrhoea tended to be young,
educated, and urban, but would want to be certain that it would have no long term
effect on health or fertility. The reasons that women in the Australian sample believed
withdrawal bleeding to be important were similar: they allow the body to function
normally, they copy what happens normally, they rid the body of waste, they prevent
the womb lining building up, they let one's hormones settle down, they prove one's
fertility, they prevent breakthrough bleeding, they allow one to avoid other symptoms,
and they help to avoid cancer.
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Thus a stated willingness to eliminate bleeding does not necessarily mean that a
majority of women will actually do so, but equally a reluctance to try manipulating the
cycle also does not mean that women will not tolerate such manipulations if they
actually experience them. After all two of the most widely used methods of birth
control world wide, hormonal contraception and interuterine devices, do alter women's
actual bleeding experience. It would seem that within their personal "normative
structure" women accommodate changes in their vaginal bleeding experience. The
important implication of this process is that while novel contraceptive methods, or
treatment strategies for cycle-related change, must take account of women's beliefs,
with knowledge, support, and education novel approaches can be successfully
introduced.
2.6.2.4 Silent bias in the social construction of the cycle and its
research
Some authors have challenged the whole concept of PMS, and the illness model of the
menstrual cycle as a misogynist product of the dominant, patriarchal ideology of
Western society (eg- Ussher, 1992; Laws, 1990; Martin, 1989; Clare, 1989; Taylor,
1988, Rome, 1986: Sayers, 1986; Laws, Hey & Eagan, 1985; Koeske, 1983; Birke &
Best, 1982). This, predominantly feminist, view does not seek to trivialize "biomedical
fact", but seeks a more "complex, interactive" approach to menstrual cycle research and
health care; it "challenges the view that science is disinterested and looks for linkages
between beliefs about women and the social and political forces affecting women's
lives" (p.2, Koeske, 1983). It is argued that "[s]cience...is used in our society to
reduce discontent to biological malfunction." (p. 125, Martin, 1989).
PMS is taken to be a social construction (Laws, 1985) which "...understood in the
context of a patriarchal social order, ...is yet another ideological weapon used to define
and control women" (p. 15). Women are perceived as the "products and prisoners" of
their menstrual cycle (Clare, 1989) such that their unhappiness canTegitimately be
viewed as consequence of their biology (Jarvis & McCabe, 1991; Laws, 1990, 1985;
Koeske, 1983). A more practical argument for the modern emergence of the concept of
PMS around the time of the World Wars, is that it provided a strategy for excluding
women from the paid work force when the men returned:
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Women are perceived as malfunctioning and their hormones out of
balance rather than the organization of society and work perceived as in
need of a transformation to demand less constant discipline and
productivity, (p. 123, Martin, 1989)
The symptoms of PMT which the doctors show most concern over-
depression, anxiety and so on- are mental states which do not 'fit' with
women's cultural created notions of ourselves as nice, kind, gentle,
etc....[C]hange as such is not culturally acceptable, (p.35, Laws, 1985)
These concepts fit comfortably with the tabooed nature of the menstrual cycle in our
society. As Douglas (1966) argues the degree of menstrual proscription in a society
depends on the degree of men's security in their domination of women.
...[Wjhen the principle of male dominance is applied to the ordering of
social life, but is contradicted by other principles such as that of female
independence, or the inherent right of women as the weaker sex to be
more protected from violence than men, then sex pollution is likely to
flourish, (p. 142)
Douglas identifies that "[pjurity is the enemy of change, of ambiguity, and
compromise" (p. 162) which means theoretically that because women's bodies change,
women cannot be pure. Indeed, historically women are an aberration of the real human
model, the male (Jackson, 1985).
Most menstrual cycle research is carried out using a reductionist, ahistorical, and
atomistic approach which claims to be value free using so-called "objective measures"
which are "neutral" and relatively "error free". Thus biochemical variables are
considered more "reliable and valid" and also causal than psychological and social
variables (Walker, 1992). Yet an analysis of the language used in the medical and
psychiatric literature reveals the "normative and correctional foundations of the
scientific perspective" (p.3, Koeske, 1983). For example, the medical literature
"...tends to underwrite the notion that women are less capable of meeting intellectual
demands" with the use of terms like "confusion", "inability to concentrate", "lowered
judgements","forgetfulness" (pp. 172-173, Birke & Best, 1982). [See Laws (1990) or
Birke & Best (1982) for an analysis of the manner in which modern medical texts deal
pejoratively with menstruation and women as menstruators.] Ussher (1992) lays the
problem at the feet of researchers:
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[R]esearchers are rarely exposed; they remain shadowy figures
identified only by name and institution, their assumptions and
motivations clear only to themselves. This is an accepted part of the
scientific discourse because researchers are conceptualized as objective,
value-free rational observers. The very language that scientists adopt
underlines their objective impersonal front, their presentaion of
themselves as removed from any personal involvement in research
activity. Their subjectivity, their own position within the scheme of
things, is seen as irrelevant: Thus the researcher can remain on the
outskirts, their pseudoanonimity protected by their very membership in
the scientific elite, (p.144, Ussher, 1992)
Science is not above the stereotypic, and the means of extracting information as well as
reporting it will reflect to a greater or lesser degree the stereotypic belief system (eg-
Olesen & Woods, 1986; Laws, 1985).8
Biological explanations are not sufficient on their own to account for cycle-related
experience, but current social and psychological theories also do not seem adequate to
account for the irrefutable presence of some cyclical changes in some women. Can a
negative societal view of women, bleeding, and the menstrual cycle really precipitate
regular negative subjective states at a particular phase of the cycle? It seems likely that
very severe symptoms or heavy bleeding may be associated with negative attitudes
towards the cycle, and possibly more negative expectation and attribution to the
perimenstrual phase. Perhaps some women do have a propensity to mental illness with
facilitates negative cyclic changes. However, the evidence that cyclical change is linked
to particular personality traits or social adjustment is suggestive but equivocal, and a
causal relationship is not clear.
2.6.3 The Need for an Integrated Research Perspective
Evidently neither biological nor social theories of aetiology are adequate alone.
Feminist authors, in particular, increasingly argue in favour of an integrated and
multifactorial approach to researching the menstrual cycle (eg- Asso, 1992; Ussher,
1992; Gise, 1988; Hamilton, et al., 1984; Dan, et al., 1980; Koeske, 1980; Parlee,
1980, 1982; Sommer, 1973). Hamilton, et al. (1984) purport that the most appropriate
8
In the section entitled "The seduction of science" in her recent book, Gloria Steinem
(1992) quotes Einstein who said that, "[i]t is the theory which decides what can be
observed." Steinem goes on to observe that "even the most objective areas of education
need always to be questioned; the more they present themselves as value-free, the more
the need for questions" (pp. 131-132).
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concept of PMS, etc. which fits in with current research findings is that it represents a
physiologically mediated "alteration in responsivity", and that researchers will need to
explore neuropharmacologic models that "acknowledge multi-regulatory mechanisms".
Gise (1988) has described cyclical change in terms of predisposing, precipitating, and
sustaining factors. These might include: predisposing- past history of PMS, postnatal
depression, or sexual abuse, family history of mental illness or of alcoholism;
precipitating- pregnancy and childbirth, stopping the pill, tubal ligation, hysterectomy;
and sustaining- life style factors such as diet, smoking, alcohol, exercise, and stress
(Gise, 1988). Ussher's (1992) model which includes such contributory factors as
personality traits, perceptions and attributions of physiological arousal, social support,
utilization of coping mechanisms, and politics and culture is reproduced in Figure 2.02.
Sommer (1973) suggests that individual expectations about the menstrual cycle ought to
be fitted into the larger social pattern of its role in relationships, in the interrelations of
persons and institutions.
Most such models are little more than theoretical conceptions, and no author has
proposed how one would actually test hypotheses using an integrated approach. The
most complete theories centre around the notion of increased activation or arousability
at particular phases of the cycle (Asso, 1992; Koeske, 1980; Parlee, 1980, 1982).
Asso (1992) has recently delineated a model based on the idea that cyclical fluctuations
in hormones mediate changes in both central nervous system, and autonomic nervous
system arousal, called respectively energetic and tense arousal, after Thayer (1989).
Within this model these two sorts of arousal interact to produce changes in behaviour,
mood, pleasurable bodily sensations, perceptions of self and of problems, memories of
past events, and assessment of the likelihood of future outcomes. Tense arousal may
be raised premenstrually, while energetic arousal is low leading to an enhanced
responsiveness to strong stimuli. Koeske (1980) found large individual differences in
the mode of expressing this sensitivity in her survey of university students, and also
that at mid-cycle there was discordance between moods and external stimuli, while
premenstrually external events were strongly related to moods. The implication of this
is that women may be able to distance themselves from the realities of their lives
through most of the cycle, but not premenstrually.
It seems inevitable that previous one-factor-one-cause theories must give way to a more
complex aetiology of cycle-related phenomena (Parlee, 1980). One potential theoretical
framework which has not been explored is the relationship of biological rhythms and
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Seeking intervention for PMS
Self-diagnosis of PMS
Figure 2.02 A multivariate model of the premenstrual syndrome from Ussher
(1992), p.161.
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well being to the menstrual cycle. This is a model which may account for biological
and social contributions, for two way interactions between the internal and the external
environment, and for individual variability.
2.7 A Novel Aetiological Theory for Cyclical Change:
An Endogenous Biological Rhythm of Well Being
It has been noted that it is a fundamental error of experimental science to approach the
organism and its responsiveness as constant phenomena because at different temporal
stages the organism is a different biochemical entity (Halberg, 1980). The external
environment is composed of a sequence of regularly changing conditions which exert
selective pressure on organisms to which they must adapt in order to survive (Aschoff,
1980). The outcome of these selective pressures has been the evolution of biological
rhythms. Although biological rhythms were first systematically studied in the 1700s,
their genetic basis was only established in the mid 1930s, and a unified theory and
disciplinary structure have only existed for about the last 50 years (Garfield, 1988).
Several authors have now proposed that there may be a mood cycle based in the brain
which oscillates at about the same frequency as the menstrual cycle, and which
constitutes a biological rhythm entrained to the steroid cycle (eg. DeVane, 1991; Reid,
1991; Walker & Bancroft, 1990; Rubinow, Hoban, Grover, Galloway, Roy-Byrne,
Andersen & Merriam, 1988; Blumenthal & Nadelson, 1988; Hamilton, Parry &
Blumenthal, 1988; Hamilton, et al., 1984). A variety of theoretical and indirect
evidence exists in support of this idea, as does a small amount of recent experimental
evidence. After a brief description of the background, definitions and basic properties
of biological rhythms each kind of evidence will be considered in turn.
2.7.1 The Basic Properties of Endogenous Rhythms
The four major temporal cycles in the geophysical environment are the tides, the solar
day, the lunar cycle, and the seasons (Aschoff, 1980, Rensing, 1972). However,
biological rhythms have been documented which last for a fraction of a second or many
years. The convention is to divide rhythms up into three classes by their duration:
"ultradian" rhythms last for less than 24 hours, often a fraction of a day; "circadian"
rhythms last for approximately one light/dark cycle or day and may be between 20 and
28 hours long; "infradian" rhythms last for more than 24 hours, usually many days
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(Edlund, 1987; Moore-Ede, Sulzman & Fuller, 1982; Aschoff, 1981; Pittendrigh,
1981; Reinberg, 1974; Sollberger, 1965). Halberg introduced the term "circa" in 1959
to indicate the approximate nature of the rhythm with respect to a particular geophysical
period. Thus there are also terms for weekly, fortnightly, monthly, and annual
rhythms: respectively, "circaseptan", "circatidal", "circamensual" (also "circatrigintan"-
about 30 days, "circasidereal" -about one tidal month of 27.3 days, and "circasynodic"-
about one lunar month of 29.5 days), and "circannual" (Aschoff, 1981; Halberg,
Halberg, Halberg & Halberg, 1980; Reinberg, 1974; Sollberger, 1965).
There are biological rhythms which correlate with all of these time periods. A
biological rhythm is thus defined as the regular recurrence of an event at approximately
regular intervals (Aschoff, 1981). Many biological rhythms have become built into the
organism within a genetically determined physiological system of time measurement,
and are therefore known as "endogenous". Such rhythms are responsive to signals
from the external environment which give information about the cycles on which they
were originally based, but are not dependent on these signals for their continued
expression. In other words endogenous rhythms have the capacity to "freerun", or
"persist for many periods without attenuation" when isolated from the synchronizing
cycle (Aschoff, 1981; Pittendrigh, 1981). There are also "exogenous" rhythms which
are driven by external fluctuations and will not persist in isolation from these cues.
Some rhythms are only partially endogenous. Under freerunning conditions the partial
rhythm is likely to continue for a short number of oscillations, with damped amplitude
and perhaps lesser frequency, until eventual arhythmia (Sollberger, 1965).
Cues from the external environment (or in some cases from the internal environment of
the organism) have been variously described as "zeitgebers"- or time-givers by
Aschoff, "entraining agents" by Pittendrigh, and "synchronizers" by Halberg (Garfield,
1988). While each scientist originally proposed a slightly different definition, in
practice all terms are now used interchangeably. The predominant zeitgeber for most
organisms is solar illumination. Secondary signals are moonlight, temperature,
barometric pressure, and electromagnetism (Sollberger, 1965). For humans an
additional and important entraining influence is exerted by so-called "information
zeitgebers", or social cues (Eastman, 1991; Edlund, 1987; Moore-Ede, et al., 1982).
In the early 1960s individuals were kept in isolation in underground bunkers or caves
for periods of a few weeks to many months. Several different experiments have
revealed that the mean freerunning sleep-wake cycle in humans is approximately 25
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hours. When these individuals were exposed to minimal "social information" like bells
to indicate times to eat or wake up, they re-entrained to a 24 hour schedule (Moore-Ede,
et al., 1982; Aschoff, 1980). The existence of circadian or diurnal rhythms is now well
known in humans (eg.- Krieger & Hughes, 1980). Each species has a mean
freerunning period length for each endogenous rhythm and individuals of the species
have free-running period lengths that are normally distributed around the species mean
(Aschoff, 1981).
Another alternative to a clearly endogenous rhythm, like circadian sleep-wake cycles, is
the weak endogenous oscillator. Certain rhythms, at least in the circadian system, are
known as dominant oscillators, while others are termed weak oscillators. This reflects
how robustly they maintain their properties when freerunning, and thus their biological
basis. One might imagine that it would be of greater selective utility for the organism to
be able to anticipate some regular changes in the geophysical environment above others.
Or in the case of rhythms which control the internal environment of the organism, it
might be more important for that individual's survival to maintain some systems at the
expense of others (Zucker, 1980). The parallel to this phenomenon in the external
environment, is that there are both primary and secondary zeitgebers (Sollberger,
1965). The seasonal progression of solar day length is relatively invariate from year to
year, yet the temperature pattern over the year is less predictable. Thus seasonal
migration and reproductive behaviours are foremost determined by day-length and only
secondarily by ambient temperature (Edlund, 1987). This way the animal cannot be
readily tricked, or misread cues and behave in an unseasonable way, while it also
provides the safeguard of secondary messages from the environment.
In humans there are two classes of circadian oscillator: 1) the dominant oscillator of
body temperature, urine potassium excretion, cell division, plasma Cortisol, REM
sleep, etc. is robust and not easily disturbed, while 2) the weak oscillator of slow wave
sleep, skin temperature, plasma growth hormone, and urine calcium excretion can
readily deviate from a 24 hour cycle (Edlund, 1987; Groos, 1983; Moore-Ede, et al.,
1982; Aschoff, 1980, 1981; Pittendrigh, 1981). Normally these two oscillators are
"coupled" to one another, or operate in parallel, but under freerunning conditions the
two systems tend to uncouple and freerun at their own characteristic frequencies after
about one month (Moore-Ede et al., 1982). One consequence of the "weakness" of the
sleep-wake cycle is that it is easier to phase-shift for therapeutic purposes than the
circadian temperature rhythm.
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The implication of this theory is that some rhythms will have greater functional
significance than others, and therefore are more potent in the face of perceived
disruptions. In this context, infradian rhythms may be seen as subordinate to circadian
ones, and perhaps circadian to ultradian. There is, therefore, a hierarchy of rhythms
within the individual with some that are essential for the proper function of others.
Indeed, it would appear that some rhythms take their time cues from others, and that the
manifestation of the "severity" of certain rhythms may depend on their phase
relationship to more dominant rhythms (Aschoff 1981). These are sometimes known
as "slave oscillations" (Pittendrigh, 1981).
The presence of two independent rhythm systems is supported by the physiological
evidence for a brain based "biological clock". In 1972 two groups working
independently isolated the pair of small bi-lateral nuclei now known as the
suprachiasmatic nuclei (SCN) (see Moore-Ede et al„ 1982). The SCN, in the anterior
hypothalamus, are thought to be the seat of the "biological clock" in humans. If the
SCN is damaged or removed, however, the circadian basal body temperature rhythm
persists through some other mechanism (Aschoff, 1981). Moore-Ede et al. (1982)
suggest that the pacemaker for the sleep-wake cycle is located in the SCN, while the
temperature pacemaker is found elsewhere, possibly in the ventromedial hypothalamus.
The SCN receive light cues directly from the environment via neuronal connections
from the retina. The SCN also responds to melatonin manufactured by the pineal
gland. The pineal in mammals is known as a "neuroendocrine transducer". Melatonin
is synthesized in response to neuronal signals from the neurotransmitter,
norepinephrine, and is closely linked with the sleep-wake cycle being high at night. The
synthetic pathway is as follows: tryptophan to 5-hydroxytryptophan to serotonin to n-
acetylserotonin to melatonin (Brzezinski & Wurtman, 1988). In humans, melatonin is
thought to act exclusively on the SCN, and functions as an "internal zeitgeber" which
signals the "biological clock" about day length (Cassone, 1990).
The timekeeping mechanism for longer term rhythms is not yet know. It used to be
assumed that infradian rhythms were the sum of their component circadian rhythms,
however some chronobiologists now believe that they must have an independent
timekeeping mechanism (eg.-Menaker, 1974). Some examples of infradian rhythms
are oestrous and menstrual cycles, and seasonal hibernation and aestivation, the 7 day
rhythm of urinary 17-ketosteroid excretion, the 14 day rhythm of memory, the 21 day
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rhythm of testosterone excretion in men, the monthly basal body temperature and
steroid rhythms in women, and the 4 weekly rhythm of weight gain in men (LeConte,
1989; Edlund, 1987; Moore-Ede, et al., 1982; Aschoff, 1981; Luce, 1973). Such
infradian rhythms might be expected to possess the same features of other circa-
rhythms, namely, the ability to persist or freerun when the primary zeitgebers are held
constant, and possess a regular mean phase length around which the freerunning phase
of individuals will be distributed.
Certain terms and concepts are commonly used in biological rhythm research. The
"cycle" or "rhythm" is any event which recurs at a predictable interval. The "period" is
the amount of time it takes to complete one cycle. The "frequency" is the reciprocal of
the period: eg. the frequency of sleep is once in 24 hours or 1/24. The "amplitude" of a
rhythm is the amount that the cyclic parameter changes over the period. The period and
the amplitude of rhythms may be variable, across and within individuals. The "phase"
of a rhythm is the relationship of its peak or through to some other cycle in the body or
an external marker. (Luce, 1973; Sollberger, 1965)
The concept of "phase" is very important in research because responsiveness to stimuli
are often dependent on phase, and changes in phase or "shifts" may provide
information about the mechanisms controlling a rhythm, and its degree of endogenicity.
For example, Eastman (1991) found that there is a "phase response curve" (PRC) in
individuals susceptibility to entrainment by bright light when attempting to compare the
efficacy of gradual versus sudden phase changes in shift-work. Equally, Eastman &
Miescke (1990) found that three quarters of volunteers could re-entrain to a 26 hour
sleep-wake schedule while experiencing the conflicting zeitgebers of the 24 hour day, if
they were exposed to bright light in the evenings. Yet they did not respond to morning
light, or no light. There is also evidence that behaviourally arousing events have
different potential to influence rhythm entrainment depending on where in the circadian
cycle they occur. The degree of re-entrainment depends on both the timing and the
duration of behavioural stimuli. For example, a 10km run in the early morning phase
shifts the body temperature peak two hours earlier, while an early evening run does not
alter body temperature (Mrosovsky, Reebs, Honrado & Salmon, 1989).
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2.7.2 Evidence for Sex Related Differences in Biological Rhythms
Particularly in Relation to Well Being
While the menstrual cycle is often cited as a long term biological rhythm, and authors
proposing multifactorial causes for cycle-related change suggest that the relationship
with circadian rhythms ought to be explored (eg- Reid, 1991; Hamilton, et al., 1984)
little direct evidence for a biological rhythm of well being yet exists. However, there is
evidence that certain affective disorders may have an endogenous rhythm component,
namely depression, and seasonal affective disorder (SAD). Given that both of these are
more common in women, it is possible that they may interact in some way with the
hormonal changes that are unique to women.
SAD is an affective disorder with a clear temporal aspect. It takes the form of marked
depression during the winter with increased appetite, increased sleep, carbohydrate
craving and lethargy which resolves, or may turn to hypomania, during the light days
of summer. SAD occurs mainly in women, and is effectively treated by bright full
spectrum light administered for two hours in the morning and two hours in the evening,
alternated with washout periods without light (Edlund, 1987). The hypothesized effect
is to stimulate pineal melatonin secretion. SAD is not generally linked with a
"neuroanatomical abnormality", however, recently a 45 year old woman developed
recurrent winter depression and summer hypomania after an arterio-venous accident
which caused damage to the right fronto-temporal region of her brain. The site of her
lesion is consistent with that of patients with accident induced mania, and also with the
idea that bipolar affective disorder may be associated with abnormality in the deep
fronto-temporal region of the right side of the brain (Hunt & Silverstone, 1990).
Mania and depression have been known to be seasonal since ancient time. Depression
shows a bimodal peak in spring and late autumn which may be related to circadian
phase shifts induced by changes in daily photoperiod (Wehr, Wirz-Justice & Goodwin,
1979). It has also been know for about a century that sleep deprivation elevates mood
in depressives. Much of the research relating biological rhythms to depression has
been carried out at the National Institute of Mental Health in the United States by Wehr
and colleagues. They have observed that a proportion of depressives have circadian
rhythms of less than 24 hours, and thus possess sleep patterns in which the circadian
rhythm of temperature and REM sleep, etc. are shifted 1 to 3 hours earlier (i.e.- "phase
advanced") relative to normals (Edlund, 1987). This phenomena is marked in manic-
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depressives, and there are many changes in circadian organization when they switch
from mania to depression or vice-versa (Groos, 1983). So in order to compensate for
the distorted phase relationship of internal rhythms, sleep can be phase advanced, or
deprived altogether. Depression remits after sleep disruption, but only for about two
weeks, a duration which is similar to the time it takes to restore circadian phase
relationships after transatlantic air travel (Wehr, et al., 1979).
Evidence that circadian dysregulation does exist comes from sleep polygraph
differences between depressed people and controls. Normally REM sleep dominates
the latter half of the sleep period, but depressed individuals showed REM sleep within
40 to 50 versus 65 to 80 minutes of falling asleep. They also had less delta sleep and
more REMs per minute than normals (Gillin & Borbely, 1985). These changes in sleep
architecture are similar to those which naturally occur with increasing age.
Interestingly, the incidence of depression increases with age, as may PMS. The
tendency to experience internal desynchronization has also been linked to certain
personality factors (Lunel, 1974). What is responsible for internal desynchronization is
not entirely clear since some research finds no major alteration in melatonin function in
depressives (Jimerson, Lynch, Post, Wurtman & Bunney, 1977).
It has been proposed that loss of social zeitgebers in the form of people, demands, or
tasks that set the biological clock may contribute to the onset of a major depressive
episode in vulnerable individuals. Life events occur which disturb social rhythms
which in turn upset the stability of biological rhythms causing somatic and
psychological symptoms. Some potential intervening variables are coping, social
support, gender, and personality (Ehlers, Frank & Kupfer, 1988). It is also suggested
that vulnerability to depression may be related to the quality of parental care received in
infancy (Finklestein, 1989), which is responsible for establishing the pattern of and
susceptibility to social entrainment of biological rhythms (Luce, 1973).
Further support for the notion of rhythm desynchronization in affective disorder comes
from evidence that psychotropic antidepressant drugs may work by altering circadian
phase positions and frequencies (Wirz-Justice & Wehr, 1983). The neurotransmitters
serotonin, epinephrine, dopamine, the endorphins, and many of their metabolites which
are involved in circadian time keeping, have circadian patterns of release themselves.
All of the neurotransmitters and brain amines so far studied are phase-delayed by the
tricyclic antidepressants. Lithium, which is used to treat a variety of "cyclic disorders"
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including manic-depression, cyclic migraine, periodic hypersomnia, and periodic
catatonia, also phase delays important rhythms such as calcium and magnesium release.
Thus these drugs appear to exert their effect by correcting the phase advance of the
dominant human oscillator in relation to the sleep-wake cycle (Edlund, 1987; Wirz-
Justice & Wehr, 1983). It is not clear whether circadian phase disruption is aetiologic
in mood disorder or an epiphenomenon (Edlund, 1987; Gillin & Borbely, 1985).
It is not evident that there are sex differences in the efficacy of psychotropic drugs or
variable efficacy in relation to the menstrual cycle, however there is twice as much
depression in women of reproductive age as men (Parry, 1989). Edlund (1987)
includes PMS amongst "diseases that clearly possess desynchronization of
physiological rhythms". Curiously, oestradiol and testosterone are two of a very few
substances which have the power to alter circadian phase or rhythm frequency (Wirz-
Justice & Wehr, 1983). It is probably not a coincidence that the site of the "biological
clock", the hypothalamus, is also the endocrine "command centre" of reproductive
function in women.
So efficient is biological timekeeping that humans can estimate short intervals of clock
time (objective time) with great accuracy. Distortions of subjective time, that is the
sensation of how quickly or slowly time "seems" to be passing are much more common
than of objective time. Gross distortions in the ability to estimate objective time do
occur in acute mental illness and during fever, while a common feature of depressive
illness is that the future is (subjectively) "blocked off". Objective time estimation is
linked to body temperature, and metabolic rate which may help to account for
differences in subjective time experience in children versus adults. Given that women
experience a regular shift in body temperature over the menstrual cycle it is not
surprising that objective time estimation is more variable in women than in men
(Edlund, 1987).
Another sex difference in biological rhythms is in the rate of chromosomal damage.
Women show a cycle-related change in the amount of cellular genetic damage: sister
chromatid exchanges and chromosome aberrations. There is more damage during the
periovulatory/oestrogenic phases than the progestagenic phases. The authors of this
research suggest that the sex difference may be due to more misrepair or errors of
chromosome exchange in rejoining under hormonal influences at the cellular/receptor
level (D'Souza, Thomas & Das, 1988). The above discussion suggests that the
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reproductive hormone cycle may dispose women to biological rhythm disruption and to
associated mood change.
2.7.3 The Interrelation of The Menstrual Cycle and Environment:
Evidence for an Endogenous Infradian Rhythm of Well
Being
The term "circamensual" testifies to the fact that the menstrual cycle is implicitly
considered a biological rhythm. It certainly has the power to freerun without
reinforcement from the external environment. And like other endogenous rhythms
there is evidence that its length and other properties, such as the incidence of ovulation
can be influenced by zeitgebers in the external environment.
2.7.3.1 Seasonal variation in reproductive rhythms in humans
Both male and female reproduction may be influenced by photoperiodic zeitgebers.
Spermatogenesis in men has a seasonal pattern, with highest sperm counts in winter
and spring, and lowest ones in summer (Politoff, Birkhauser, Almendral & Zorn,
1989). The evidence for an annual, light mediated cycle in the timing of human
menarche has been reviewed by Reinberg (1974). Several studies show that there is a
late autumn/early winter peak in menarche of about 30% (December to February) with a
secondary peak of about 18% in summer (June to August). Further the occurrence of
temporary amenorrhea (cycle of greater than 57 days) is twice as likely to occur during
July and August than in any other two months of the year. It has been observed that
menarche occurs earlier in prematurely born girls with impaired vision compared to
controls, particularly if light perception is also lacking. Women kept in isolation
without light cues show a free running circadian period of more than 24 hours, but "a
circamensual spectral component" of body temperature shortens by about 3 days to
25.9 days on average, as does menstrual cycle length (Reinberg, 1974). Reinberg
(1974) suggests that light may inhibit, or darkness stimulate, the human ovary, and that
changes in day length over the year may act as a synchronizer. A circatrigintan
temperature rhythm has also been observed in a male not exposed to any woman's
menstrual cycle, and in premenarcheal girls (Halberg, et al., 1980).
In a study of 38,000 woman years of data reported by Hamilton & Alagna (1988) a
tendency was found for cycles to be longer in the winter and shorter in the summer.
Hamilton & Alagna (1988) report a similar pattern in their PMS clinic attenders which
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they believe may account for cycle to cycle variability in PMS. They link long cycles to
greater symptom severity, and note that more than 75% of women with SAD also
report PMS. There is a marked temporal structure within the menstrual cycle itself.
The LH surge seems to occur at a regular time of day from cycle to cycle (Dye, 1992;
van Vugt , 1990). Women being monitored for spontaneous LH surges for oocyte
recovery in IVF showed 42.5% of LH surges between 1:30am and 4:30am. The
highest percentage of LH surges occurs in the early morning during the summer,
autumn, and winter, but are 12 hours later in the spring (van Vugt, 1990).
The timing of labour and natural birth is no less precisely timed. The circadian peak in
birth time estimated from over two million births is about 4am. The timing of still birth
on the other hand differs from natural birth by about 12 hours, peaking at 5pm
(Reinberg, 1974). Seasonal cycles in birth rate have been calculated from over 100
years of data from North American Eskimos. Births peak in March and are fewest in
June, implying that conception actually peaks in June (van Vugt, 1990). Van Vugt
(1990) argues that the lack of direct evidence for seasonal, photoperiod mediated
reproduction in humans may be due to a loss of ability to respond to environmental
cues due to our "artificial" environment. For example, monkeys reared indoors are
unable to respond to photoperiodic cues once exposed to them.
Social cues may be of greater importance to people. Rossi (1980) has prospectively
monitored mood cycles over the social week, and found that while men show greater
weekly variation in mood than women, there is a reinforcing effect between mood
response to the social week and menstrual cycle when they are synchronized. Regular
weekly phase shifts in the sleep wake cycle also exist which are reentrained by alarm
clock use (Binkley, Tome & Mosher, 1989). However, the sensitivity of some
individuals to light cues may be underestimated. Melatonin levels do vary over the
menstrual cycle, but the evidence for the timing of peak level is contradictory.
Nevertheless, responsiveness to light cues may vary over the cycle. OC users have
higher 24 hour melatonin profiles than non-users, thus there seems to be a positive
relationship between melatonin and progesterone (Brzezinski & Wurtman, 1988).
Inter-individual differences in cycle length may reflect variable sensitivity to light via
melatonin (Asso, 1983). It is suggested that melatonin may influence ovarian function
directly. Two possible modes of action are that melatonin modulates steroid synthesis
by affecting enzyme systems in the follicular granulosa cells, or that it inhibits follicular
proliferation (Brzezinski & Wurtman, 1988). The possibility of a direct effect of
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internal synchronizers on the ovary might help to explain the effects of light, social
interaction, and stress on the cycle which are reported in the next section.
2.7.3.2 The internal and external environments as modulators of
cycle events
It was suggested in section 2.2.1.2 above that living circumstances can influence the
incidence of ovulation (Metcalf & Mackenzie, 1980). There is an increasing body of
evidence that social contact between women, social contact between women and men,
and psychological and nutritional stress may all influence cycle events.
The oestrous cycle of rats and mice has been observed to alter in a number of ways in
response to "social contact" with conspecifics. Female mice living in overcrowded
cages are anoestrous, but if a male is introduced all the females come into oestrous
synchronously. This is known as the Whitten Effect, and the proposed mechanism is
that pheromones in the male's urine causes a drop in progesterone and an increase in
gonadotrophin pulsatility. The Lee-Boot Effect refers to the higher than normal rate of
pseudopregnancy in groups of 4 to 8 female mice housed together. Again the proposed
mechanism is pheromones which increase FSH and prolactin stimulating the corpus
luteum to secrete high levels of progesterone. The exposure of a recently mated mouse
to a strange male results in frequent pregnancy failure via the introduction of cycling
and an LH surge in the Bruce Effect. The Vandenberg Effect refers to the ability of
some substance in male urine to advance sexual development in prepubertal female
mice, (van Vugt, 1990; Campbell & Turek, 1981; McClintock, 1971).
Some of these effects have corollaries in humans. The effect of social contact on the
menstrual cycle can be divided into the effect that women have on other women, which
seems to be to promote menstrual synchrony, and the effect that men have on women,
which is to ensure ovulation. McClintock (1983) has reviewed the evidence for
pheromonal regulation of the ovarian cycle, and proposed a "coupled oscillator" model
to explain how social contact mediated through pheromones influences the cycle. In
short, follicular odours shorten the cycle while ovulation phase odours lengthen it. The
coupled oscillator implies the presence of both phase advance and phase delay
mechanisms which have differential effects depending on the cycle phase of the
signaller in relation to the recipient. Menstrual cycle synchrony for example arises
when the oscillators of different individuals are coupled or mutually entrained. Graham
(1991) suggests that it is the hormonal events of the follicular phase which determine
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synchrony in rodents and in humans. Thus similar cycle lengths reflect sychronization
of the events leading up to ovulation. If this is so, then studies of menstrual synchrony
should only include women who are ovulating, and should assess the timing of
ovulation rather than the timing of menstruation. Graham proposes that discrepancies
in the synchrony literature may be due to the fact that the research to date has focused
on the timing ofmenstruation rather than of ovulation.
Rhythm coupling depends on the quality of social communication between individuals.
Grooming in mice increases the effectiveness of chemosignals, and in humans it is
evident that sharing the same physical environment is not enough to cause menstrual
synchrony or induce ovulation. There is now a good deal of evidence that the
menstrual cycle lengths and timing of menstrual onsets of women in close social contact
like close friends and coworkers tend to converge (Graham, 1991). While there have
been some negative findings and criticisms that synchrony may be no more than a
tendency for the menstrual onsets of cycles of different lengths to randomly overlap one
another (eg- Wilson, Kiefhaber & Gravel, 1991; Wilson, 1987) the bulk of evidence
favours synchrony in a proportion of women (eg- Graham, 1991; Preti, Cutler, Garcia,
Huggins & Lawley, 1986; Jarett, 1984; Quadango, Shubeita, Deck & Francoeur, 1981;
Graham & McGrew, 1980; McClintock, 1971, 1983).
Menstrual synchrony has been documented in women at all-female colleges, women in
co-educational colleges, co-workers and resident nurses (Graham, 1991) and may
occur in small groups of women as well as pairs (Quadango, et al., 1981). Synchrony
is rarely perfect, but an increase of a factor of two over the random level of synchrony
is common. Between 17 and 31% of women fail to synchronize (McClintock, 1983).
Most studies have shown that synchrony takes 3 to 4 cycles to develop (Graham, 1991;
McClintock, 1983). Volatile fatty acid levels in vaginal secretions vary over the
menstrual cycle with higher lactic acid concentrations at ovulation (Preti & Huggins,
1975). Olfactory sensitivity fluctuates over the menstrual cycle, with heightened sense
of smell around ovulation (Asso, 1983). This indirectly supports the notion of a
pheromonal mechanism.
A number of factors influence the likelihood of synchrony. The relationship between
women needs to be emotionally close or interdependent, and they may have to spend
more than a threshold amount of time together. Longer bleeds and the use of towels
instead of tampons seems to be associated with greater synchrony. Women with
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regular cycles may be more likely to "drive" women with irregular cycles. Personality
variables may influence synchrony. Close friends with similar neuroticism scores on
the EPI tend to show greater synchrony. In somewhat contradictory findings it has
been shown that women who do not tend to "affiliate" with others, as well as women
who have a high need for "social recognition" by others are more likely to synchronize
with their college roommates. There is also some evidence that women who are highly
stressed are not as likely to show menstrual synchrony, perhaps because they are
refractory to signals from others. (Graham, 1991; Jarett, 1984).
Male-female contact seems to have a different effect on the cycle than female-female
contact. Phylogenetic evidence supports the notion that humans may have the potential
for reflex ovulation. Penile spines are always present in genera which ovulate reflexly,
with the exception of certain primates species. Several species of primate including
gibbons, orangutans, and chimps have penile spines, yet they are not reflex ovulators.
However, primates are descendent from insectivores which have penile spines, and
reflex ovulate. Laproscopic investigations have shown that conceptions can occur at
any phase of the menstrual cycle and that the ovary may have the potential for ovulation
at times other than midcycle. Clark & Zarrow (1978) cite reports that conception can
result from rape at any phase of the cycle, possibly due to "the intensity of coitus".
There is evidence from both non-human primates and humans that the incidence of
ovulation in females who are isolated from males is low. For example, isolated female
rhesus monkeys only ovulate 50% of the time (Clark & Zarrow, 1978), and the
incidence of secondary amenorrhea in girls at boarding schools, convents, military
academies, and drug rehabilitation centres ranges from 22 to 83%, far higher than in the
normal population (Yamamora & Reid, 1990).
Winnifred Cutler and colleagues have published a large number of studies which
suggest that regular sexual contact with a man "normalizes" a woman's cycle length and
promotes presumptivley fertile basal body temperature rhythms. In one study of 94
gynaecologically mature undergraduates weekly coitus was associated with 29.5±3 day
cycle lengths, while celibate women or those having sporadic sexual contact had more
long or short cycles which are less likely to be ovulatory (Cutler, Preti, Huggins,
Erickson & Garcia, 1985). Masturbation to orgasm was not associated with regular
cycle lengths, while either coitus or genital stimulation by a male was. Ninety per cent
of women having weekly coitus had apparently fertile basal body temperature rhythms,
while only 55% of women having sporadic coitus, and 44% of celibate women did so.
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In a later study regular coitus was shown to be related to significantly higher oestradiol
levels during the luteal phase (Cutler, Garcia, Huggins & Preti, 1986a). Other studies
have shown that sexual intercourse may not be necessary for fertility, as exposure to
the axillary secretions ofmen9 or spending two or more nights a month with a man will
also promote fertile cycles (Veith, Buck, Getzlaf, Dalfsen & Slade, 1983; Cutler, Preti,
Krieger, Huggins, Garcia & Lawley, 1986b).
Infertile women have been shown to have a significantly later age at first coitus, and
more short luteal phases. The authors propose that luteal phase intercourse may play an
important role in maintaining luteal function (Cutler, Garcia & Krieger, 1979a; Cutler,
Garcia & Krieger, 1979b; Cutler, Garcia & Krieger, 1980). It seems that coitus may
also influence male fertility. In an anonymous single case study, a male scientist
recorded his beard growth while working in isolation on a remote island and related it
to subsequent coital activity with his partner. While alone beard growth was slight, but
one day before reunion with his partner it accelerated greatly, and remained high until
two days after coitus. The importance of these findings are 1) that coitus can influence
beard growth and therefore testosterone secretion, and 2) that accelerated growth
precedes actual contact with the opposite sex (Anonymous, 1970). Thus, social cues
appear to be powerful internal mediators of reproductive function.
Clearly social zeitgebers modulate the menstrual cycle. So too may lunar gravitation,
nocturnal illumination, and psychophysiological stressors. There is a correlational
relationship between phase of the lunar cycle and phase of the menstrual cycle. In
several prospective studies, one of which was double-blind, a significant majority of
women with approximately 29.5 day menstrual cycles (one synodic month) were
observed to ovulate during the dark phase of the moon, and to begin to bleed during the
light phase (Cutler, Schleidt, Friedmann, Preti & Stine, 1987; Friedmann, 1981;
Cutler, 1980). Gravitational effects on the earth and its organisms are greatest during
the new moon. Given that humans are composed mainly of water it is not unreasonable
to imagine that they will be influenced by gravitational pull. Nocturnal low intensity
bedside light shortened the cycle length of nine women from 45.7 days on average to
33.1 days (Lin, Krife, Parry & Berga, 1990), confirming Dewan's early finding that
exposure to night-time illumination of a similar intensity to moonlight can shorten cycle
length (Shuttle & Redgrove, 1986; Luce, 1973). This practice has probably been used
9
This research has been criticised on methodological grounds (Wilson, 1988) and the
criticisms answered (Cutler, 1988).
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for hundreds of years to "regularize" cycle length (Graham, 1991; Shuttle & Redgrove,
1986; McClintock, 1983; Cutler & Garcia, 1980).
Stress has long been known to disrupt the menstrual cycle. "War amenorrhea" refers to
the frequent loss of menstrual cycling during wartime. In internment camps in Manila
23% of nurses and 15% of civilians developed amenorrhea before any nutritional effect
could have occurred. Twenty-five percent of women in concentration camps who were
not threatened with extermination were amenorrheoic versus 54% who were threatened.
The extreme emotional shock of aerial bombardment can arrest endometrial
development. (Yanamora & Reid, 1990; Sanders, 1984). There are case histories that
acute psychological stress can even override the effects of exogenous hormone
stimulation. In keeping with the coupled oscillator model of exogenous synchronizers
and the menstrual cycle, environmental traumas cause different sorts of menstrual
disruptions depending on whether they occur during the follicular or luteal phases
(Sanders, 1984). Stress does not influence all individuals in the same way. If it did
then all women in concentration camps would have been amenorrheoic. Some potential
mediating factors are cognitive appraisal, behavioural adaptations, and the social and
personal characteristics of the individual (Yanamora & Reid, 1990).
The circadian phase disruptions which long-haul flight attendants experience very often
produce cycle irregularity, as does hospitalization for non-gynaecological surgery
(McKeever & Galloway, 1984; Iglesias, Terres & Chavarria, 1980). Stress may also
be nutritional or hypoxic. Both obesity and anorexia can result in cycle irregularities,
and it is arguable that one objective of anorexia is to produce amenorrhea. Intense
exercise may also alter the cycle. (For review of psychosomatic aspects of amenorrhea
see Sanders, 1984).
There is thus considerable evidence that the menstrual cycle constitutes a long term
infradian rhythm that is susceptible to the influence of the primary entraining agents in
humans: photoperiodic and social cues. It also seems that the stability of the rhythm in
the face of potential disruptions is mediated by the characteristics of the individual and
her immediate environment.
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2.7.3.3 Experimental evidence for an endogenous infradian rhythm
of well being
What evidence is there for an infradian rhythm of well being which parallels the
menstrual rhythm? Hamilton, et al. (1988) propose that the mood cycle is "periodically
entrained" to the menstrual cycle, such that menstrual and affective symptoms may
overlap for months or years and then dissociate, or symptoms occurring monthly may
continue even after the cessation of ovarian functioning. It seems likely that the steroid
cycle "entrains" the mood cycle to it, and that at times when the steroid cycle is
disrupted or suspended the mood cycle will also loose entrainment. Metcalf, et al.
(1991) note that after hysterectomy there seems to be a "loss of entrainment" of PMS
symptoms with shifts in timing to phases other than the luteal phase. Such a
mechanism might also explain the transient worsening of symptoms that occurs with
the use of oestradiol patches or GnRH analogues (Mortola, et al., 1991; Watson, et
al., 1989; Bancroft, et al., 1987b). DeVane (1991) posits that there may be a dose
dependent relationship between cycling steroids and entrainment of the mood rhythm.
This might help to explain why OC use often alters the nature of mood and other cycle-
related symptoms but does not abolish them.
Rhythms of different frequencies may influence one another. It has been suggested that
circadian rhythms gradually shift their phasing over the menstrual cycle, and that PMS-
type symptoms arise from progressive phase desynchronization, or a sort of cumulative
"jet-lag" effect (Dye, 1992; Parry, 1990; Parry, Rosenthal, Tamarkin &Wehr, 1987).
In a case which seemed to encompass the interaction of menstrual, mood, and seasonal
rhythms a woman experienced PMS only during the autumn and winter, but was
symptom free in the spring and summer. She was effectively treated with bright light
therapy as in SAD, and this effect was reversed by the administration of melatonin.
The effect of the melatonin was then overcome by the administration of melatonin
inhibitors: Propanadol, Atenolol, and B-antagonists (Parry, et al., 1987). Maurizi
(1988) suggests that normal melatonin rhythms may be antidepressant, while if the
phase relationship of the melatonin rhythm and other circa-rhythms is disrupted it may
promote depression. Women with PMS characterized by depression do not have the
same abnormalities of sleep architecture as depressed patients, however they respond as
well as, or better than, depressives to sleep deprivation. Eighty per cent of depressed
PMS sufferers had no more depression for the remainder of the cycle after a night of
sleep deprivation during the luteal phase (Parry, 1990). Parry concludes that
"...[Cjircadian dysregulation, whether induced by lifestyle, environment, or the
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reproductive system, may be a common pathogenetic factor in PMS and possibly in
other cyclic mood disorders." (p.86, Parry, 1990)
The alternative to circadian dysregulation is that there is a genuinely infradian rhythm
which manifests itself as a mood and physical cycle in harmony with menstruation.
Only one study to date has explored this possibility. In an ingenious experiment
Schmidt, Nieman, Grover, Muller, Merriam & Rubinow (1991) used the anti-progestin
RU486 to curtail luteal function and advance menstruation in women with prospectively
confirmed PMS. Three groups of seven women each were randomly allocated to one
of three experimental treatments in a double-blind placebo design. The 21 women had
prospectively confirmed cyclical symptoms in the luteal phase in at least two out of
three baseline cycles. Group 1 had their cycles truncated with the administration of
RU486 seven days after the LH surge, and placebo saline injections on days 6, 7, and
8 after the LH surge. The physiological outcome was luteolysis followed by vaginal
bleeding within 72 hours, and normal ovulatory steroid profiles in the next cycle.
Group 2 was also given RU486, but in a lower dose along with injections of hCG in
order to produce bleeding, but preserve luteal function. The regime had the desired
outcome, and these women continued to have luteal phase steroid profiles, and to have
a second bleed at the end of the luteal phase 8 to 10 days after hCG was given. Group
3 was given a placebo tablet on day 7 and saline injections on days 6 to 8 after the LH
surge. Their luteal function was not affected, and they did not bleed undl the end of the
normal luteal phase.
For the treatment period women completed daily 16-item self rated visual analogue
scales, and a 21-item 6-point scale rating form. Daily ratings were analysed using
analysis of variance for repeated measures. The seven days prior to the LH surge were
compared with seven days beginning five days after the administration of RU486 or
placebo. This was meant to compare the follicular and real or "would be" luteal phase.
The authors found that neither mood nor somatic symptoms differed in timing or
severity over the three groups. They conclude that: "[njeither blockade of the action of
progesterone alone nor the truncation of the luteal phase of the cycle altered the course
or severity of the symptoms of PMS, and these symptoms developed and progressed
during the hormonal conditions of the follicular phase." (p. 1177, Schmidt, et al., 1991)
They offer two potential explanations for why PMS symptoms occur with consistent
period: 1) PMS is caused by hormonal changes, or by abnormal sensitivity to hormone
changes. Thus, symptoms could be triggered by some hormonal event which occurs
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earlier in the cycle than the luteal phase which would explain "follicular phase"
symptoms with RU486; 2) PMS symptoms are caused by a cyclic mood disorder
which is synchronized with the menstrual cycle wherein the steroid cycle acts as the
main zeitgeber, but are not directly caused by it. These findings are consistent with the
existence of an infradian oscillator, as opposed to progressive, hormone mediated
circadian dysregulation.
RU486 provides a useful experimental tool for exploring the aetiology of cyclical
change, however, it does not lend itself to easy and repeated cycle phase manipulation.
A readily available, and safe alternative method is to use oral contraceptives to alter
cycle length, or cycle phase. Although the pill cycle is hormonally distinct from the
menstrual cycle, there is ample evidence that changes in well being are similar under the
two conditions. The pill cycle offers great scope to explore the consequences of
altering the timing of steroid withdrawal and bleeding on the purported infradian well
being oscillator.
A few studies have examined the effects of extending pill taking in order to postpone
withdrawal bleeding. These studies have been particularly interested in assessing the
acceptability of contraceptive regimes which induce amenorrhea, or reduce the
frequency of bleeding, but none has systematically investigated the relationship
between steroid cycle length and well being. The four studies conducted to date are
summarized in Table 2.04. In the region of 80 to 90% of women found extended pill
taking acceptable, although breakthrough bleeding was common. Bleeding occurred
least on the high dose pill Minilyn, and the gestodene containing 30p.g pill Minulet.
Side effects of the sort often reported during the conventional pill cycle were indicated,
and in only one study was PMS mentioned. Loudon, Foxwell, Potts, Guild & Short
(1977) indicated that many women noted that they had a reduction in "menstrual and
premenstrual symptoms", but they do not elaborate on the nature of the changes. In
spite of no adverse medical consequences, the medical staff were more reluctant about
extended pill taking than the volunteers.
The discrepant findings of these studies probably relates to a number of methodological
problems including: 1) no control cycle to assess the baseline rate of breakthrough
bleeding, 2) no separation of women starting the pill and women established on it, 3)
no hormonal tracking, 4) no distinction between spotting and breakthrough bleeding,
and no consistent definition of either, 5) different information to volunteers about what
Table2.04StudiesofthEffectandAcceptabilityM ni ulatingOr lContra ptivey eLeng h StudyPillType/sRegimeEffectonBle ding
Other'SideEffects'
Acceptability
Loudon,F xwell Potts,Guild& Short(1977) n=196 Hamerlynck, Vollebregt, Doomb s& Mutendam(1987) n=101;37,29& 34respectively deVoogd.(1991) n=105 Kornaat,Geerdink &Klitsie(1992) n=55
Minilyn 50pgEE +2500|igLYN 1)Microgynon 30pgEE +150pgLNG 2)Marvelon 30|igEE+ 150pgDSG 3)Logynon 30-40pgEE+ 50-125|igLNG Marvelon 30pgEE+ 150pgDSG Minulet 30(igEE+ 75pgGSD
84daysactive* 6pillfreedays, repeated4tim s over1yea monophasics- 42daysctive* 7pillfreedays triphasic- 21days+2x3rd phase=41day active+7pill freedays 42daysctive* 7pillfreedays 42daysactive+ 7pillfreedays
24%spottingin'cycle'1 &3%btb;ofthose remaining4%spotti &0%btbin4 h'cycle' significantriseibtb andspottingfterday21 withmorebtbin triphasicakers,55%of womenhads e bleedinginw eks4-6of continuouspilltaking btbandspottingn distinguished,75%of womenfreofbleedi g inweeks4-6 96%hadnobtb,81 hadnobtborspotting
dysmenorrhea9%, weightgain(2k +) 46%,headaches11 reducedmens sr lat 'symptoms'20% breasttenderness, abdominalpa , headache,weig tg in anddepressionnoted, butcouldnote attributedtopillypor regime,noincidences given noinformationgive breasttenderness7%, nausea4%,bloating 4%,headache2 periodtypeain2%
82%ofwomenere happywiththereduction
inbleedingandother 'symptoms',Clinicstaff werelessaccepting acceptabilityrelatedto bleedingexperience, 49%ofwomenuld favourbleedingevery3- 6months,32%w uld liketouilamenorrhea, 29%ofwomenith bleedingfoundthe regimeacceptable womenithbtbere significantlylessikely toaccepthregime, though87%overallsaid theywouldds 90%ofrespondents weresatisfi dithble d postponement,and4% weredissatisfied
Key:EE-ethinyloestradiol,LYN-ly estrenol,NG-levon rgestrel,DS -desogestrG D g t dbtb-reakthr ughl din .
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to expect from manipulations, 6) no measure of the influence of women's attitudes on
drop out rates or reported acceptability, and 7) biases in results due to the attrition of
women who had bleeding or other difficulties.
2.8 Overall Conclusions and Strategies for This Research
A wide body of literature has been drawn upon in the above discussion, and a number
of general, interrelated themes emerge. They may be summarized briefly as follows: A
significant proportion of women experience emotional and physical fluctuations in their
well being in close temporal relation to the menstrual cycle. The bulk of evidence
suggests that both hormonal and social/psychological factors play a role in the aetiology
of cyclical change. However, the relative contribution and the mechanism of each of
these is not adequately understood, and multifactorial research and explanations are
essential. The variability of the menstrual cycle itself, and of individual women's
experience of it, presents a number of methodological problems for research. The
experience of most pill takers is not markedly different from that of women having
spontaneous menstrual cycles. However, the mode of action of OCs and the degree of
ovarian suppression generated by low dose pills is not fully understood. There is
increasing evidence to support the notion that the menstrual cycle and its sequelae form
endogenous biological rhythms which are susceptible to the entraining influence of a
variety of factors in the external and the internal environments.
The combined oral contraceptive pill presents a useful experimental model of the steroid
hormone cycle in women which is potentially more tractable and less variant than the
menstrual cycle. The possibility that persistent cycles of well being on the pill arise
from residual ovarian function has not been explored. The possibility that endogenous
hormonal change, even of a modest level, without ovulation can drive such changes
needs to be explored. In addition to assessing the hormonal factors it is also essential
to develop a broader understanding of women's beliefs about menstrual bleeding, the
pill, and cyclical changes. Such examinations might help to clarify the mechanisms by
which beliefs held by society and individuals can influence subjective experience.
Finally the inadequacy of previous unitary theories for the aetiology of cyclical change
demand a novel approach. The existence of an infradian rhythm of well being which is
linked to the steroid cycle can be readily tested by manipulating the purported steroid
zeitgeber, and exposing the rhythm to freerunning conditions. Should such a rhythm
exist it might account for much of the inconsistency of previous findings.
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Four investigations are reported in the subsequent four chapters which address these
research questions in turn. This research is not concerned with the question of PMS as
such, but with the fundamental exploration of the nature of cyclical changes in samples
of women from the normal population. Methodological issues differ widely in the
various investigations due to diverse disciplinary underpinnings. Therefore, questions
of methodology are addressed as appropriate in each chapter, and not concentrated in
one chapter on methods and materials. There was obviously overlap in the techniques
used to assess endogenous steroids and subjective state, therefore, the methodology is
described the first time the technique appears and not described subsequently unless
some modification has been made in a different investigation.
Chapter 3 Ovarian function during low dose pill
cycles and its association with variations
in subjective state
3.1 Introduction
Two of the important facts which were established in the previous chapter were: 1) that
the ovary continues to function at a reduced level during modern low dose OC use, and
2) that women who use OCs experience cycle-related changes in subjective state in a
similar manner to women having spontaneous menstrual cycles. One possible
aetiological explanation for the persistence of cyclical oscillations in well being for a
proportion of women during the hormonally distinct conditions of the pill cycle may be
residual ovarian function. An investigation of the previously unexplored relationship
between these two phenomena is described in this chapter.
3.2 Aims of Study
This study aimed to assess : 1) the degree of folliculogenesis which occurs in long term
pill takers; 2) the degree of cyclical variation in subjective state which occurs; 3)
whether monophasic and triphasic takers differ with respect to either of these factors
and ; 4) whether there is any association between the timing and severity of fluctuations
in well being, and the degree and timing of ovarian hormone output. In addition to
these primary aims, the relationship between retrospective PMS reporting and
personality was explored.
3.3 Study Design
The design of the study is represented schematically in Figure 3.01. Volunteers well
established on either a monophasic or a triphasic preparation were monitored over a
period of ten weeks, or two and a half pill cycles. During this time each woman kept a
daily record of her physical and emotional well being, and collected first morning urine
samples for hormone determination. Daily monitoring began on day fifteen of the pill
cycle, the beginning of the third week of pills. This timing was chosen in order to
include three pill free intervals (pfi) as the weeks surrounding the pfi are hypothetically
the time when hormonal events, as well as changes in subjective state, are likely to be
concentrated. Volunteers were enrolled in the study at a structured questionnaire based
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interview. After the ten weeks ofmonitoring, a semi-structured interview was carried
out concerning volunteers' attitudes towards and beliefs about menstruation,
contraception, and other aspects of reproduction and gender. The findings of this
interview are reported in Chapter Four. A subgroup of women were monitored over
one pill cycle using abdominal ultrasound. The methodology and findings of this
subsidiary investigation are reported in Appendix 3.01.
The two formulations of OC targeted for examination in this study were
Microgynon®/Ovranette® and Logynon®/Trinordiol®. The comparative dosage of
synthetic steroids in these formulations are given in Table 2.03, and their other
properties are discussed in section 2.1.2.1. These two formulations were chosen
because they are 'low dose' (<35|lg per day), are widely prescribed, and contain
analogous steroids, so they may be sensibly compared. This triphasic formulation is
also the only one in which both oestrogen and progestagen doses vary over the cycle.
And finally, these pill types have been quite widely used in investigations both of
folliculogenesis (e.g.- Molloy et al., 1985; Smith et al., 1986; van der Spuy et al,
1990), and of subjective state changes over the pill cycle (e.g.- Bancroft et al., 1987a;
Walker and Bancroft, 1990; Walker, 1987). Figure 3.02 schematically compares the
synthetic hormone regimes with the urinary steroid profiles of the 'normal' menstrual
cycle. Note that the 'shapes' of the triphasic profiles roughly approximate the profiles
of endogenous steroid. The profiles of oestrone-3-glucuronide and pregnanediol-3-
glucuronide shown here are derived from normative data for the In-house urinary
steroid ELISA's for these hormones.
Ethical approval for this study was obtained in writing from the Paediatric/Reproducdve
Medicine Ethics Sub-Committee based in the Simpson Memorial Maternity Pavilion of
the Royal Infirmary of Edinburgh. The Committee did not request any changes to the
protocol as submitted, and approval was granted in September, 1988.
3.4 Selection Criteria and Recruitment Procedure
Individuals were recruited from the Lothian Health Board, Family Planning and Well
Woman Services Dean Terrace Centre (FPC) in Edinburgh. This was thought to be an
appropriate location from which to draw a 'normative' sample of hormonally
contracepting women as more than 60% of Clinic attenders use the pill. Permission to
recruit from the FPC was obtained in advance from the then Director, Dr. Nancy
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Figure 3.02 Schematic graph of the levels of synthetic steroids in the
monophasic and triphasic combined pills used in the
folliculogenesis study in comparison to the levels of endogenous
urinary steroids during the normal menstrual cycle.
Chapter 3 Ovarian Function and Subjective State 94
Loudon. Further discussion of the characteristics of the FPC population is contained in
Chapter Four.
A large poster was placed in the Clinic waiting room that summarized the selection
criteria: PARTICIPANTS NEEDED: DO YOU TAKE THE PILL? DO YOU TAKE
ONE OF THESE FOUR BRANDS? (Microgynon, Ovranette, Logynon, or Trinordiol)
HAVE YOU TAKEN THIS SAME BRAND OF PILL FOR SIX MONTHS OR
LONGER? ARE YOU AGED BETWEEN 20 and 35? IF YOU HAVE ANSWERED
"YES" TO ALL THESE QUESTIONS, YOU MAY BE ABLE TO HELP US BY
PARTICIPATING IN A STUDY ON THIS SUBJECT. PLEASE TAKE A LEAFLET
FROM THE POCKET BELOW TO LEARN MORE ABOUT OUR
INVESTIGATION, AND THE ROLE YOU MIGHT BE ABLE TO PLAY IN IT.
The age criterion was based on the fact that women younger than twenty and older than
thirty-live may not ovulate as frequently as women in the 20 to 35 year age range who
are likely to ovulate about 90% of the time if they are not using hormonal contraception
(Metcalf & MacKenzie, 1980). This study was concerned with monitoring ovarian
function, hence women with maximum ovulatory 'potential' were selected. Each
woman had to have taken one of the four brands of contraceptive mentioned above for
at least six months, be healthy, not taking psychotrophic drugs, and able to meet all the
study demands, eg.- possess a freezer to store urine samples. Women were not
selected according to whether or not they reported cycle-related fluctuation in well
being. Recruiting leaflets which explained the purpose of the study more fully were
held in a pocket beneath the poster (see Appendix 3.02).
In addition to the poster, I attended a number of daytime and evening family planning
sessions at the FPC over the course of several weeks during September and October,
1988 to approach women myself. If I was not in the Clinic, women who had an
interest in the study were requested to hand their name and address in to the staff at
reception. I attended clinics until I had secured a commitment from ten women using
each formulation. It was not possible to keep track of the exact number of women
who were approached to take part. At least ten women were asked for every one that
was suitable and wished to volunteer. Women who dropped out of the study, or
changed their minds after initial agreement were replaced so that the total would remain
twenty. Each woman was approached before or immediately after she had seen the
doctor. I briefly explained what the study would involve and ascertained whether or
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not she met the selection criteria. If she was interested in taking part I offered her the
information sheet to read (see Appendix 3.03), took her name and address, and if
possible fixed a time for our initial appointment.
3.5 Methods of Assessment
Folliculogenesis and subjective state were measured in five ways. The status of the
ovary was assessed by steroid hormone assay of first morning urine samples and by
ultrasonography in a subset of women. Biographical data and measures of subjective
state were collected using questionnaires, and daily self-reported diaries. Interviews
employing discourse analysis techniques were used to gather qualitative information
about women's reproductive attitudes. The sections below describe the measuring
techniques in detail.
3.5.1 Initial Interview
The initial study interview took place approximately one week before each woman
began daily recordings. Interviews were conducted by the author, in the woman's
home, or at the Centre for Reproductive Biology, Edinburgh according to the
volunteer's convenience. Each session took about one hour. The following schedule
was adhered to in all cases.
I ensured that the woman had read and understood the Information Sheet (Appendix
3.03) describing the study requirements. I obtained her General Practitioner's address
in order to let her/him know that her/his patient was taking part in the study. I then
gave her the Menstrual Health and Reproductive Attitudes Questionnaire (MHRAQ-1)
to complete. Although she filled in her responses herself, the questionnaire was
completed interactively. She was free to ask for help, and I for elaboration at any time
(which I noted). MHRAQ-1 generally took about 45 minutes to complete, and thus
accounted for most of the hour. After she had completed the MHRAQ-1,1 asked her to
read the instructions for, and complete, the Eysenck Personality Inventory (EPI), Form
A. She did this on her own, and it generally took about five minutes. Once both
questionnaires had been filled out, I explained the method of urine collection, and how
to complete the daily diaries.
Chapter 3 Ovarian Function and Subjective State 96
3.5.1.1 Menstrual Health and Reproductive Attitudes Questionnaire
- Version one (MHRAQ-1)
As it name suggests the Menstrual Health and Reproductive Attitude questionnaire used
in this thesis was designed to elicit information about women's menstrual bleeding
patterns, past bleeding experience, and cycle-related change, along with demographic
information, history of pill use, and certain related attitudes. A copy of MHRAQ-1 is
contained in Appendix 3.04.
All of the versions of the questionnaire used in this thesis were based on an instrument
that was originally developed in Edinburgh in 1984 by Dr. John Bancroft's research
team, called the Menstrual Health Questionnaire (MHQ). An early version of the MHQ
was used to survey 7000 Woman magazine readers in 1985. The design and piloting
of the questionnaire and the results of this survey are described in Bancroft & Warner
(1987) and Warner & Bancroft (1990). The MHQ has been used in several other
Edinburgh studies since 1984 (eg. Bancroft, et al., 1992; Warner et al., 1991; Walker,
1987), and has received a number of modifications over time.
Modifications have been a function of the research use to which it is being put. For
example, the questionnaire was originally devised to measure the incidence and features
of cycle-related change in physical and emotional well being, but was expanded to
include questions about amount of menstrual bleeding and pain (Bancroft, et ah, 1992).
The MHQ is also routinely used at "booking" in the Premenstrual Syndrome Clinic at
the Royal Infirmary of Edinburgh to provide information about change in cyclical well
being and previous treatments used for PMS.
The first version of the Menstrual Health and Reproductive Attitudes Questionnaire,
(MHRAQ-1) differs from the MHQ in three principle ways. Firstly, the language and
questions have been modified to be appropriate to pill takers. Menstrual periods are
referred to as "bleeds" to denote hormone withdrawal bleeds, and to avoid reinforcing
the concept that a withdrawal bleed is equivalent to, or the same thing as a menstrual
bleed. Further, questions have been added about pill taking history, beliefs about the
benefits and risks of the pill, and about the pill's influence on bleed volume and the
physical and emotional concomitants of the cycle.
The second major change is that questions have been added about women's menarcheal
experience, and current beliefs and attitudes relating to vaginal bleeding. The content
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and phrasing of these questions was developed through an assessment of prominent
themes in the literature on attitudes, as reviewed in Chapter Two. The questions in the
MHQ concerning treatments tried for heavy or painful bleeding and PMS were omitted
from the MHRAQ-1, while questions relating to pregnancy experience and psychiatric
history were retained. The MHRAQ-1 also differs from the MHQ in the manner in
which women were questioned about their retrospective experience of cyclical changes.
In the MHQ women were requested to describe the "symptoms and changes" that they
experienced "before, during, and after" their last period. Volunteers, on the other
hand, were asked to describe a summary view of their "usual" cyclical experience.
MHRAQ-1 was piloted in interactive interview sessions with three volunteers. The
objective of this exercise was to establish whether or not questions were clear,
meaningful and salient (face validity), to eliminate repetition, and to determine how
long it would take to complete. The instrument was modified based on these sessions,
and consultations with John Bancroft, Anne Walker, Pam Warner, and Lynn
Williamson all of whom have used earlier versions of the MHQ in previous research
projects.
3.5.1.2 Eysenck Personality Inventory (EPI)
Anastasi (1982) describes psychometric personality tests as "instruments for the
measurement of emotional, motivational, interpersonal, and attitudinal characteristics,
as distinguished from abilities" (p.497). The Eysenck Personality Inventory (EPI) is a
widely used psychometric test designed to assess two different aspects of personality:
extroversion and neuroticism. As indicated in Chapter Two, high neuroticism (N)
scores on the EPI have been shown to correlate with the severity of reported PMS
symptoms. The EPI has some shortcomings. The language is somewhat dated, and
there is a slight gender bias: women tend to score higher on neuroticism and lower on
extroversion than men. It arguably produces a fairly unrefined description of
personality. However, it remains useful in a research setting since it is valid and takes
far less time and expertise to administer than the other commonly used personality
inventories (eg.- Minnesota Multiphasic and Cattell Personality Inventories). The
completed forms were coded using the published scoring template, and scores were
related to the normal population means (Eysenck & Eysenck, 1964).
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3.5.2 The Daily Visual Analogue "Diary"
3.5.2.1 Content, instructions and coding
In a study relating well being to physiological change it is extremely important to have
an appropriate means of measuring subjective state. As noted already, there is an on¬
going discourse in menstrual cycle research about the utility of retrospective versus
prospective techniques for monitoring cycle-related change. It is now widely accepted
that prospective monitoring is essential for methodologically rigourous research of
phenomena associated with hormonal cycles. A variety of different formats have been
used by the Edinburgh research group for self-rating scales. All of these take the form
of a one page 'diary' on which volunteers or patients are required to rate themselves on
a number of pre-formatted scales of commonly reported symptoms and changes
associated with the menstrual cycle. For further description of diary development and
validation see Sanders (1981) and Walker (1987).
Three forms of the daily diary were used in this thesis. The later two are described in
Chapters Five and Six. The first diary, shown in Figure 3.03, was comprised of
twenty-one (21) predefined unipolar 100mm visual analogue scales (VAS), and two (2)
blank scales on which a woman could record other cyclical changes besides those mood
and physical scales already designated. Seven one-page A-4 forms were stapled into
weekly booklets.
The final composition of scales included in the diary was based on careful consideration
of the frequently reported cycle-related changes in the research literature, discussions
with the members of the Edinburgh group who have prior experience of daily diaries,
and theoretical consideration of the nature of PMS and cyclical change. An effort was
made to include positive as well as negative feelings. Thus there were six positive and
seven negative mood variables, five physical variables which may be construed as
being largely negative, and three scales relating to sexuality. All scales were
demarcated with a '0' for 'the least you have ever felt this' and '10' for 'the most you
have ever felt this'. Five scales were described by more than one adjective in order to
help the woman "conceptualize" the mood. It was hoped that this approach would help
to generate ideas whose meaning was consistent across women.
"Feeling sexually attractive" was intended as a barometer of sexual self image, but not
necessarily of active sexuality. "Sexual interest" on the other hand was supposed to
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CODE NO: □ □ □ □ DATE: □□/□□/□□
Time ofWaking Time of Retiring □ □ i □ □
Caffeine Intake (No. cups coffee, tea, or Coia)
Smoking (No. cigarettes)
1) CHEERFUL AND HAPPY 0 10
2) DEPRESSED AND UNHAPPY 0 10
3) ENERGETIC AND ACTIVE 0 10
4) FATIGUED ANT) TIRED 0 10
5) CREATTV E 0 10
6) IRRITABLE 0 10
7) RELAXED 0 10
8) AGGRESSIVE 0 10
9) MOOD UP AND DOWN 0 : 10
10) TENSE ANT) ANXIOUS 0 10
11) FEELING GOOD ABOUT SELF 0 10
12) LACKING SELF CONTROL 0 10
13) GETTING ON WELL WITH OTHERS
0 10
14) BLEEDING 0 10
15) BREASTS TENDER 0 10
16) FEELING BLOATED/SWOLLEN 0 10
17) PERIOD TYPE PAIN 0 10
IS) CRAVING PARTICULAR FOODS (e.a. sweet or salty)
0 10
19) FLG SXL ATR 0 10
20) SXL INTR 0 10
21) SXL ACTV YO NO 0 10
SD P □ ID22) 0 1023) 0 10
DRUGS/MEDICATION- Your Oral Contraceptive Pill: YES □ NO □
Time Taken □ □ " □ □
- Other
PHYSICAL CHANGES (Other than those mentioned above)
Did anything important happen today to affect the way you feel?
If the way that you felt changed over the day can you describe these changes and their timing? (e.g. Were
you energetic in the morning and evening but not in the afternoon? Were your period pains worst at night?
Did you feel about the same all day? Etc.).
Figure 3.03 The daily visual analogue scale diary. Not actual size, lines are
100mm long.
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measure desire for sexual contact, while "sexual activity" was designed to monitor
satisfaction with actual sexual encounters. The three boxes marked S, P, and I were to
denote masturbation, sexual activity with a partner, and intercourse, respectively. The
reason for making such fine distinctions, apart from a general theoretical interest in the
constitution of female sexuality, was to assess whether there might be a relationship
between frequency and kind of sexual activity and degree of residual folliculogenesis.
A few other unusual features of this diary were questions relating to day-length,
circadian variations in well being, and amount of nicotine and caffeine intake. These
were included as exploratory variables, as all were thought to have potential effect on
subjective state over time. An analysis of these factors is not included in this thesis.
Instructions about how to complete the daily diary were given verbally at the time of
each woman's enrollment interview, and were also given in writing (see Appendix
3.05). It was emphasized that one should not look back at scales from the previous
days, as these might influence subsequent ratings. Although it is advised that the order
and orientation of VAS which are used repeatedly be varied (Gift, 1989) they were not
in this study. The main reasons were practical, because it would have been more costly
to produce more than one version of the form. It was also decided that it would be
better to risk some response bias than to risk confusing the volunteer and generating
invalid data. Volunteers were encouraged, as is advised (Monk, 1989) to practice the
diary for one week before the start of the study proper to accustom themselves to the
scales. Diaries were collected from volunteers at approximately four week intervals,
and were coded using a specially designed template. Values in mm were entered into
Microsoft Exel® spreadsheets before being analysed.
3.5.2.2 Methodological considerations of visual analogue scales
Visual analogue scales are considered to be a valid, reliable, and sensitive means of
repeatedly measuring moods and physical sensations (Monk, 1989; Gift, 1989;
O'Brien, 1987; Casper & Powell, 1986; Luria, 1975; Aitken, 1969; Zealley & Aitken,
1969). VAS are normally presented in the form of a 100mm line, which can be
oriented vertically or horizontally (Gift, 1989), upon which the individual is required to
make a mark reflecting the degree to which s/he is experiencing a sensation. The two
ends of the line represent the extremes of a sensation, but rather than being 'anchored'
to some arbitrary linguistic or enumerative point, the poles are intended to represent the
extremes within the individual (Monk, 1989). Thus the scale is less vulnerable to
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differences in symbolic representations across individuals than nominal or ordinal
scales.
The scales may be either bipolar or unipolar. Apparent linguistic opposites are
normally placed at the ends of a bipolar scale. The difficulty with bipolar scales is that
these sensations are not necessarily opposites, or mutually exclusive. Monk (1989)
found that while there was a 100% negative correlation between ratings of alert and
sleepy in social isolation experiments, there was only a 76% negative correlation
between calm and tense, and 68% between happy and sad. While it is immediately
obvious on a unipolar scale whether or not the individual is responding sensibly, a
mark in the middle of a bipolar scale may be difficult to interpret (Monk, 1989).
Other advantages of VAS are that they are continuous and generate "approximately
Gaussian" distributions, for which parametric statistics are appropriate. They are also
sensitive to subtle change over time (Monk, 1989; Aitken, 1969). A prime advantage
of the technique is that it is very quick and easy for the volunteer (Monk, 1989; Gift,
1989; O'Brien, 1987; Casper & Powell, 1986; Luria, 1975; Aitken, 1969; Zealley &
Aitken, 1969). And apart from the more obvious risk of response sets arising from the
use of ordinal scales, VAS may be less prone to these by virtue of their ease. Monk
(1989) notes that when using a within subject repeated measures design it is very
important that the instrument not be "unduly burdensome", as this might itself influence
feelings and generate "stereotyped responses". VAS have also previously been used
successfully in the assessment of PMS, and have been validated against descriptive
scales for this use (O'Brien, 1987; Casper & Powell, 1986, Rubinow, Roy-Byrne,
Hoban, Gold & Post, 1984; Sanders, Warner, Backstrom & Bancroft, 1983).
VAS are not without drawbacks. Gift (1989) describes some of these. She notes that
"some people find it difficult to convert a subjective sensation to a straight line". And
the fact that VAS scales are conceptually difficult for some people is reflected in the fact
that a higher percentage of people fail to use them correctly after one explanation than a
graphic rating scale. When multiple horizontal scales are used individuals may tend to
mark all of them towards the middle, particularly if they are monitoring different
dimensions of one sensation. VAS scores may be skewed, however, Gift indicates that
significant differences in sensitivity are not detected between scales which are and are
not transformed to account for skewness1. Although VAS are sensitive, they are
t
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relativistic. If an individual marks the maximum for a sensation, but subsequently feels
it more intensely, s/he has already exhausted the range of the scale and all future ratings
will be inaccurate. The relativism also means that scales are difficult to compare across
individuals. VAS are also time consuming for the researcher to rate, as scoring
requires that each scale be measured in mm's from the low point of the scale to the
mark made on the line.
3.5.3 Enzyme Linked Immunosorbent Assays (ELISA's) for Urinary
Steroids
Daily early morning urine (EMU) samples were collected for steroid hormone
determination. Antibody-antigen reactions have been exploited to measure the quantity
of steroids in bodily fluids such as serum and urine for over thirty years now (Chard,
1987). Conventionally radioactively labelled antigens have been used in competitive
binding assays: radioimmunoassay (RIA). Oestradiol and progesterone secreted from
the ovary can be reliably measured in human plasma using RIA. More recently assay
techniques have become available that allow the the primary urinary metabolites of the
ovarian steroids, oestrone-3-glucuronide (E-3-G) and pregnanediol-3-glucuronide (P-
3-G), to be measured in EMU samples without the use of radioactivity. Enzyme
Linked Immunosorbent Assays (ELISA) use an enzyme labelled hapten and
immobilised captive antibody. The bound hapten can be quantified by the optical
density reading of the coloured product of the enzyme-substrate reaction.
3.5.3.1 Oestrone-3-Glucuronide ELISA
It has been demonstrated that 95% of serum oestradiol during the menstrual cycle
comes from the ovaries, with about 80% from the ovary with the preovulatory follicle,
and the rest from the contralateral ovary (Baird, 1970)2. E-3-G is one of several
urinary metabolites of oestradiol. In studies of ovarian function E-3-G has been shown
to be the best metabolite to track because it closely parallels the secretion pattern of
oestradiol, and is present in significant quantities in urine (WHO, 1982 [RIA];
Khatkhatay, Sankolli, Meherji, Chowdhury & Joshi, 1988 [ELISA]). Oestrone also
correlates well with follicular size, as visualized on ultrasound scan, in ovulatory
menstrual cycles (Khatkhatay, et al., 1988).
This may have implications for statistical tests that require data to be normally
distributed (eg. ANOVA).
2
The remaining oestrogen comes from the adrenal gland.
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At the time when this study was being designed an In-house RIA for E-3-G was used
routinely, and an In-house ELISA was being developed by Ian Swanston of the MRC
Reproductive Biology Unit, Edinburgh. The performance of the ELISA was compared
with the RIA by George Johnston of the NHS Reproductive Endocrinology
Laboratories (REL), Edinburgh in March, 1989 and had a high correlation (r=0.99).
The ELISA for E-3-G was performed according to the following protocol. Nunc F-
Immuno Plate (GIBCO) microtitre plates were coated with the second antibody,
Caprylic acid-purified Donkey Anti-Rabbit Serum (DARS) at a dilution of 1:100 in
0.1M Sodium Carbonate buffer (pH 9.6), and left to incubate for a minimum of 24
hours at 4" C. The DARS was provided by the Scottish Antibody Production Unit
(SAPU), and was purified by IS or by the staff of REL. Plates were then blocked with
three washes of 0.1% TWEEN 20, after which the blocked plates were washed five
times in distiled water and blotted dry.
The primary antibody was Rabbit Anti-Oestrone-3-Glucuronide-B.S.A. Bleed I
9/12/88 which was provided by the MRC/AFRC Comparative Physiology Research
Group, Institute of Zoology, London. Label was E-3-G-horseradish peroxidase
prepared by IS (lot IS/86). The antibody and label were both stored neat in frozen
aliquots at -20° C. Stock solutions of label were made up to a dilution of 1:100 in
assay buffer and stored at 4° C for a maximum of four weeks. The working antibody
solution was prepared from frozen aliquots of 1:100 in assay buffer. Frozen urine
samples were collected from volunteers, thawed and aliquoted into 5ml. Sterilin® vials.
These were stored at -20° C until assay.
Reagents and samples were diluted in 0.1M Phosphate Buffered Saline plus Gelatine
(pH 7.4). Fifty fil each of label (1:5,000), and antibody (1:45,000) were combined
with lOOpl of sample (1:100) on the washed plates. This assay was designed for
samples to be diluted at 1:200, however, because these women were taking the pill and
their basal levels were extremely low all samples were diluted to 1:100 in order that
values could be read from a more sensitive portion of the standard curve. Samples were
assayed in duplicate, and standards in triplicate. There were 9 standards which ranged
from the dose equivalent of 3.9 to 1000 ng/ml.
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Once the reagents and sample had been added the plates were sealed and incubated at
room temperature for one hour, before the assay incubate was 'flicked out' and washed
five times in distiled water as before. A 5mM a-Phenylenediamine/ 0.03% Hydrogen
Peroxide solution was made up freshly for each use in 0.1M Citrate/phosphate
substrate buffer (pH5.0). In this temperature and light sensitive step, 200(il of the
substrate was added to each well, and the plates were incubated in the dark, at room
temperature for 30 minutes. The colour reaction was stopped by adding 50)il of 2N
Sulphuric Acid to each well, and the optical density was read using a Titertek
Platereader at 492nm. The results were read directly from the Platereader into the
Apple Macintosh package Assayzap© and analysed.
The intra-assay coefficient of variation ranged from 5.3 to 6.8%, and the inter-assay
C.V. were as follows: low quality control- 25.3%, medium QC-13.5%, high QC-
10.8%. It was usually not possible to fit all samples for an individual woman into the
same assay. So efforts were made to assay all of a woman's samples on the same day
in consecutive assays, using the same batch of standards and reagents. Creatinine is a
waste product that is excreted in the urine at a constant rate over 24 hours. E-3-G
levels were related as a ratio to creatinine in order to control for the concentration of the
urine sample collected. Creatinine (Crt.) levels were assayed in all samples using the
alkaline picrate method (Khatkhatay, et al., 1988). Final values were expressed in
ng/mg Crt..
3.5.3.2 Pregnanediol-3-GIucuronide ELISA
The rational and procedure for the measurement of pregnanediol-3-glucuronide (P-3-G)
is the same as for E-3-G, except that the reagents are specific to P-3-G and the
incubation is 2 hours (also see Walker, 1987). Performance was also tested by GJ of
REL. No cross reactivity studies were preformed. Comparison with the previous In-
house Gas Chromatography, and RIA methods showed a high correlation (0.94 and
0.97 respectively).
The primary antibody for this assay was Rabbit Anti-P-3-G-B.S.A. Bleed F 27/7/87,
also from the MRC/AFRC Comparative Physiology Research Group, which was used
at a dilution of 1:30,000. The label was P-3-G-Horseradish Peroxidase lot IS/86, used
at 1:5,000 in assay buffer. The sample dilution was 1:800, which is the usual dilution
for this assay, and was not changed to take account of pill use. The 8 standards ranged
from the dose equivalent of 15.6 to 2000 pg/100p.l. All other procedures are as above.
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The intra-assay coefficient of variation ranged from 3.8 to 4.6%, and the inter-assay
C.V. was as follows: low quality control- 26.1%, medium QC-8.9%, high QC-
12.6%. Final values were expressed in pg/mg Crt..
3.5.4 Analysis of the Visual Analogue Scores and Hormonal Data
The difficulties of analysing data derived from daily self-ratings of well being were
considered in Chapter Two. Because there is no uniformly accepted statistical
procedure to deal with such data, the techniques used to analyse the data reported in this
chapter are based on the research questions outlined in section 3.2. Thus the analysis is
directed at 1) detecting cyclical change over time in volunteer's well being, 2)
comparing the degree of variation between the two pill groups, and 3) relating well
being to endogenous steroids. A variety of different, complimentary methods were
used. Statistical advice was sought from two local statisticians: Jim Slattery (JS,
Clinical Trials Unit, Western General Hospital, Edinburgh) and Pamela Warner (PW,
Behaviour Research Group, MRC Reproductive Biology Unit, Edinburgh). Some of
the analyses were carried out by Jim Slattery, which are indicated below.
3.5.4.1 Principle components analysis of visual analogue scores
A large number of variables were measured by the VAS diary. So in an effort to
examine the manner in which the scales related to each other and to reduce the large
number of data points generated over the study, a factor analysis was carried out.
Principle components analysis (PCA) is a mathematical method which essentially
performs concurrent correlation and regression analyses on a body of data to determine
the relationship of the variance of the factors to one another. It has two potential uses:
data reduction and data description. With regard to data reduction, if the first few
components account for a large part of the variance then "the observed variates may be
replaced by a smaller set of derived variates....without serious loss of information"
(Maxwell, 1977). In a "successful" PCA a large proportion of the variance in the data
is explained by the top six, or fewer, components. The proportion of variance
explained may be as much as ninety per cent (90%) or more. In addition, the first
unrotated component may explain the majority of the sample variance and contain
weightings for all the variables in the analysis. The first component thus may represent
an overall summary variable of the data set.
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The main purpose of the PCA in this investigation was to reduce the dataset, and a
secondary aim was to compare the two pill groups. The analysis was carried out by JS
using the Bio-Medical Data Processing package (BMDP) in the manner outlined in
section 18.1 of the BMDP manual (pp. 480-485, Dixson, Brown, Engelman, Frane,
Hill, Jennrich & Toporek, 1981). Separate analyses were carried out to compare the
diary results of the two different pill types and then a second analysis was undertaken
including all women. Both unrotated and orthogonally rotated components were
derived. As will be discussed in the results section below, the PCA did not succeed in
explaining the majority of the variance, therefore only the top two component scores
relating to affect were used to condense the data for subsequent analyses.
3.5.4.2 Standardization of pill cycle length and division into phases
In addition to reducing the number of diary scales into several components, it was also
necessary to standardize the length of women's cycles so that cycles of different lengths
might be sensibly compared. Further, because it is conceptually easier to deal with a
number of defined phases of the cycle across individuals than to describe daily data
points, the diary and hormone data were broken up into a number of meaned phases.
Cycle length was standardized according to the procedure described by McCance, Luff,
and Widowson (1937). This involves adjusting cycle length by weighting each day so
that all cycles become 28 days long by dividing the actual cycle day by the total cycle
length and then multiplying by 28 to create a fraction which is rounded to the nearest
whole number. This way if a cycle is shorter than 28 days the appropriate number of
days are omitted from the string, while if it is longer the appropriate number of days are
duplicated. While this is a purely mathematical procedure, it has the advantages that it
is not arbitrary, and when used in conjunction with the generation of phase means, no
data points are lost.
In this study a "cycle" was taken to be the interval from the onset of one withdrawal
bleed to the next. Unlike the menstrual cycle, the pill cycle is highly circumscribed in
length because it is 'driven' by the regime of 21 days exogenous steroids plus seven
days off. Therefore a technique which standardizes cycles to 28 days is meaningful in
this case. If one discounts breakthrough bleeding, withdrawal bleeding as a
consequence of the pill free interval, almost always occurs within a specified number of
days from the cessation of active tablet taking. Although there may be some variability
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in cycle length from one bleed to the next within the individual it is not likely to be more
than a few days.
There is considerable debate and inconsistency about the appropriate way to divide the
menstrual cycle into phases. Generally, phases are determined arbitrarily with regard to
the timing of menstrual bleeding based on the clinical impression of the timing of
cyclical symptoms, in order to "capture" symptoms in one phase, and exclude them
from others. Once again the transformation used here was purely mathematical.
Cycles of diary ratings and hormone values were divided into seven mean phases of
four days each, beginning at day one of withdrawal bleeding. In cycles greater or less
than 28 days the phases were weighted according to the standardization procedure
described above. In short cycles some phase means are made up of only three data
points, while in long cycles some are made up of five data points.
While these phases may not be as physiologically meaningful as those of the menstrual
cycle, certain endocrine events clustered in particular phases: Phase 1) bleeding; Phases
2 or 3) rising endogenous oestrogen; Phases 3 or 4) suppression of endogenous
oestrogen to baseline by the exogenous steroids; Phases 4 to 6) basal endogenous
steroid levels; Phase 7) pill withdrawal and the endocrine events which precipitate
withdrawal bleeding.
3.5.4.3 Calculation of the standard score z for the PC's
Because VAS are relative to the individual who is using them it is likely that the raw
scores across all volunteers will not be normally distributed. In order to use parametric
statistical tests raw scores for the principle components were converted into z scores.
The standard score z expresses data points as a number of standard deviations from the
group mean, (z = {raw score - group mean for variable}/ SD of the group mean for
variable). The final unit is the number of standard deviations, and may therefore be
positive or negative. Certain assumptions are made with the use of z scores: 1) the
population from which the distribution of scores arises is assumed to have equal means
and dispersions in all variables measured, and 2) the form of the distribution in terms of
skewness and kurtosis (height) must be very similar from one variable to another
(Guilford, 1965). In practice, it is virtually impossible to determine if these
assumptions are met by the data, therefore, one must proceed as if they were. Even
within these limitations it is likely that the standard scores provide more "nearly
comparable" values than raw scores , although the procedure does not normalize the
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distribution (Guilford, 1965). The z scores for the top two principle components (PCs)
were used in all the subsequent analyses.
3.5.4.4 Analysis of transformed diary data and hormone parameters
A number of different analyses were undertaken using the principle components, and
transformed diary ratings and hormone results. Descriptive statistics (eg. mean,
standard deviation) were used along with analysis of variance (ANOVA) techniques,
and tests of significance, such as t-tests. The discussion that follows focuses on uni-
and multivariate analysis of variance. Other methods used in the chapter are described
in the relevant results sections.
ANOVA is a statistically powerful means of investigating significant differences across
groups, time, or experimental situations. Parametric tests assume the independence of
observations, equal dispersion of variance across groups, and normal distribution of
data within groups. Daily diary ratings may not be independent from one day to the
next and hormone levels certainly are not. Equally there is likely to be a trend in
consecutive ratings that may produce type one error. This problem can be overcome by
combining time points. This technique is used in this thesis by the creation of mean
phases.
ANOVA was used in three different ways with this data set. In the first case univariate
tests were earned out on the standardized phased data for all women for all diary scales
and principal components 1 and 2 in order to assess the relationship of subjective state
to bleeding and to endogenous oestrogen within the individual. In one set of tests, the
phases entered into the analysis began with the first bleeding episode in the first pfi of
the study. This analysis was directed at assessing a phase effect over the cycle relative
to bleeding, within the individual. The repeated measure in this analysis was the two
cycles, with seven phases each. In the second set of tests the mean phases were
aligned by the phase in which endogenous oestrone reached its peak. This may be seen
as analogous to centring menstrual cycle data around the time of ovulation. The object
of this analysis was to determine whether or not subjective state variables varied
predictably relative to E-3-G levels. In those women for whom oestrogen peaked in the
same phase in both cycles, the data remained temporally continuous. However, for
some women one phase had to be repeated or omitted in order to position the peak at
the same time point in both cycles. This arguably distorts the data, however, it is a
means of determining whether or not there is regular change in well being in relation to
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steroids as opposed to bleeding. These analyses were carried out on the University of
Edinburgh main frame computer using the Statistical Package for the Social Sciences,
second edition (SPSS-x).
The second ANOVA was ANOVA for repeated measures which was carried out for
each principle component at the group level (monophasic versus triphasic) by JS using
BMDP on the main frame to examine whether or not there was significant fluctuation in
any component over the cycle. E-3-G was entered as a covariate, and pill day as a
twenty-eight (28) level categorical variable in order to test the relationship of change in
subjective state over time to E-3-G. He compared bleeding and non-bleeding days, pill
types, self-reported PMS status, and gynaecological age within the sample.
Finally, multivariate ANOVA (MANOVA) was undertaken using SPSS-x for selected
variables and principle components. MANOVA has the advantage over multiple
univariate tests that it takes into account possible correlations and differences in
variance between all the variates at once (Maxwell, 1977). Four different groupings of
volunteers were generated on the basis of distinct aspects of oestrogen dynamics.
These were organized around potentially biologically meaningful aspects of oestrogen
change, and are described in the results section below. The analysis had a 2 or 3
(group), by 2 (cycle) by 7 (phase) design. The between subject effect was the 'group',
and 'phase' and 'cycle' were the two within subject effects. The phases were
oestrogen-peak-centred in the manner described above. SPSS was used to carry out
tests to detect the homogeneity and sphericity of the data. These are the "symmetry
conditions" which must be met if MANOVA is to be used and are the same as those for
ANOVA (Hand & Taylor, 1987; Guilford, 1965). The SPSS analysis allows a number
of post hoc univariate test statistics to be calculated following the multivariate tests,
which have more degrees of freedom, and therefore greater statistical power. The post
hoc tests used in this analysis are described in the results section below.
3.5.5 Final Semi-Structured Interview
A semi-structured interview was conducted with each woman in her home after the ten
weeks of monitoring had ended. The purpose of this interview was to allow women to
describe the attitudes and beliefs which they hold about vaginal bleeding, contraceptive
use and other reproductive and gender issues. It is widely acknowledged that psycho¬
social factors may influence women's responses to and reporting of their reproductive
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experience. However, the nature of attitudes and beliefs, the range of ideas women
hold, and the mechanisms by which these modulate experience and reporting have not
been adequately researched in the past. Although not the primary research aim of this
thesis, the information gathered from these interviews provided insight into the social
and personal psychological context in which the more experimental studies were carried
out. At a practical level interview material was used to generate the second version of
the MHRAQ, that in addition to providing valuable information in its own right, links
this investigation with a subsequent study. Interviews took about one hour, were
audiotaped, and later transcribed. The development of the interview schedule, details
of the qualitative interview technique, and the results are discussed in detail in Chapter
Four.
3.6 Results
3.6.1 Sample Size and Coding
Twenty women enroled in the study and four women dropped out during the ten weeks
ofmonitoring. These four were replaced using the same recruitment procedure in order
to maintain groups of ten women on each formulation. All four dropped out because
they did not wish to, or were not able to meet all the study demands. Notably they
found daily urine collection and storage onerous. Volunteers were given consecutive
code numbers as they entered the study to denote which type of formulation they were
using. Thus, volunteers are referred to throughout the text by their code numbers: Ml
to M10 for the ten monophasic takers, and T1 to Til, excluding T5 for the triphasic
takers.
3.6.2 Volunteer Characteristics: Results of MHRAQ-1
The biographical details which are directly relevant to this study including pill taking
history and reported experience of cycle-related change are reported here. Other
characteristics of volunteers, aspects of experience, and attitudes are reported in
Chapter Four. General demographic information is contained in Table 3.01, which
also compares the monophasic and triphasic groups. The majority of volunteers were
in their mid- to late twenties, married or living with a partner, well educated, in full-
time white collar employment, nulliparous, and protestant but not active in their
religion. There were no significant differences between the two pill groups except in
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the duration of pill use. The monophasic takers had used OCs for significantly longer
than the triphasic takers which probably reflects the fact that the monophasic takers
were slightly younger when they started using the pill and they were slightly older on
average. All twenty women who completed the study were taking the pill for
contraception, although two initially started it due to irregular and/or painful periods,
and one also used it to control her PMS.
The mean age at menarche for the monophasic takers was 12.5 years (SD1.3) and 13.1
years (SD1.7) for the triphasic takers. The overall range of ages at which first periods
occurred was between 10 and 16 years (10-15 mono., 11-16 tri.) with a mean of 12.8
years (SD1.5). Gynaecological age is the number of years between menarche and the
present, or number of years of menstrual cycles. After seven years of cycling
"gynaecological maturity" is assumed to have been reached (Metcalf & MacKenzie,
1980). Thus, with gynaecological maturity the likelihood that ovulation will take place
in any given cycle, and that the cycle will be of an appropriate length to be potentially
fertile is 90% or greater. Because the monophasic takers were slightly older, and had
slightly earlier menarche, they were gynaecologically older. While most volunteers
were gynaecologically mature when they entered the study, they were not generally
mature when they started taking the pill. This fact has potential implications for the
amount of residual ovarian function that one might observe during a pill cycle, which in
turn has relevance for the study of its relationship to subjective state3.
3
It is not known whether gynaecological maturity is a straightforward function of
chronological age, or a process which is affected by interruptions to ovarian cyclicity
such as pill taking, or pregnancy and childbirth. (Baird, 1989 personal communication)
It is not clear, for example, that a woman who has had five years of natural cycles and
five years of pill use since menarche is the same as a woman who has had ten years of
uninterrupted natural cycles. The fact that women who have and have not taken the pill
do not differ significantly in the time at which they reach the menopause (Batzer, 1984)
however, suggests that ovarian maturation is dependent on time rather than duration of
natural cycles. If this is the case then most of the women in this study, based on their
ages and the number of years since their menarche, might be expected to experience a
normal ovulatory cycle if they were not currently using the pill.
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Table 3.01 Biographical Details of the Sample:
Comparison of the two pill types
Variable Classification Monophasic Triphasic Signif.
Age mean years (range) 27.3 (19-34) 26.6 (21-35) NS
Relationship Married/Cohabiting n=7 8 NS
status Single 3 2
Education School leaver/Highers 3 2 NS
University/Poly etc 7 7
Postgraduate 0 1
Occupation Scientist/Engineer 1 n NS
Nurse/Social Work etc 3 3
Management/Admin. 2 3
Secretary/Support etc 3 1
Student 1 0
Actress 0 1
Religion Protestant 5 7 NS
Catholic 2 1
None 3 2
Parity Nulliparous 10 10 NS
Time on pill mean years (range) 9.8 (3-17) 5.7 (3.5-9) p=0.018
Gynae. age mean years (range) 14.8 (4-21) 13.5 (6-22) NS
Gyn.age on pill mean years (range) 5.2 (1-10) 6.6 (3-15) NS
Bleed volume Light 4 4 NS
Moderate 6 5
Heavy 0 1
Bleed duration mean days (range) 4.2 (2-6) 4.5 (3-6) NS
Pill effect on Lighter 7 8 NS
bleeds No effect 0 1
Heavier 1 0
Don't know 2 1
Note- Significance levels indicate whether or not there is a significant difference
between the two groups for each variable, and relate to t-tests or Chi square tests as
appropriate. Gynae. age= Age - Age at menarche; Gyn.age on pill= gynaecological age
at first pill use.
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The most frequent average duration of vaginal bleeding reported by the sample was
four or five days (80% of women), and most women reported moderate or light blood
loss.The majority also reported that OC use had made their bleeds lighter and less
painful. The two pill groups were not different with regard to the length or volume of
bleeding. One woman in this sample (M3) routinely takes three to four packets of pills
in a row (the "tricycle regime"), and so has been excluded from subsequent analyses
relating to the timing of bleeding.
3.6.3 Self Reported PMS Status in Relation to Neuroticism
On the MHRAQ-1 volunteers were asked whether or not they considered themselves to
have PMS (see Appendix 3.04). The possible replies were 'yes', 'no', 'maybe', and
'don't know'. The distribution of replies is shown in Table 3.02 below.
Table 3.02 Self Designated Retrospective PMS Status
Pill Group Yes Maybe No Don't know
Monophasics 1 3 5 1
Triphasics 5 4 1 0
Total 6 7 6 1
There was no significant difference between the two pill groups for Neuroticism (N) or
Extroversion (E)4. The mean monophasic N score was 10.8 (SD5.6) and the mean
triphasic N score 10.5 (SD5.6), t=0.12, p=0.91. Similarly, the mean monophasic E
score was 14.4 (SD2.2) and the mean triphasic E score 13.0 (SD5.0), t=0.81, p=0.43.
Thus the overall means for the sample were N 10.7 (SD5.5) and E 13.7 (SD3.8) which
are both slightly higher than the normal population means given by Eysenck & Eysenck
(1964) at N 9.1 (SD4.8) and E 12.1 (SD4.4). Eysenck & Eysenck (1964) indicate that
women tend to score slightly higher on N than men, and lower on E, but they do not
quantify the amount of difference. The N scores in this sample are consistent with the
4
One quarter of women had lie scale scores of 4 or 5 (lmono., 4 tri.), which is the
suggested cut-off point for accepting the inventory responses (Eysenck & Eysenck,
1964). No L scores exceeded 5, and therefore no woman's scores were excluded from
the analysis.
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expected sex difference, and the higher E score in this group probably reflects the fact
that extroversion is likely to be a prerequisite for participation in a study of this kind.
Because neuroticism has previously been related to cyclical symptoms, N scores on the
EPI were compared with retrospectively reported PMS status. A Student's t-test
showed that women who said 'yes' or 'maybe' to PMS had significantly higher N
scores than women who said 'no' or 'don't know': Yes/Maybe mean N 12.8 (SD4.9),
No/Don't know mean N 6.7 (SD4.2), t=-2.75, p=0.01.
3.6.4 Description of Hormone Results
Most volunteers complied very well with daily urine collection. Six individuals
produced all 70 samples. The largest number of missed samples was 17 or 24%. The
mean number of samples missed by the monophasic group was 3.5, and 4.9 by the
triphasic takers. As a rule missed samples were dispersed over the whole study and
therefore no woman was excluded due to inadequate sample numbers. Hormone
values in this section are dealt with as daily measures, and the 'analysis' is largely
descriptive. Two women extended the length of their pill cycle. M3 (see above) and
T3 who took a course of antibiotics during the 6th week of the study, and was advised
by her doctor not to have a pill free interval. The effect of these changes on steroid
levels are discussed here, but these individuals have been excluded from the subsequent
analysis of daily diary scores in relation to hormones.
Figure 3.04 shows the mean E-3-G and P-3-G levels for the monophasic and triphasic
takers over two complete cycles. A Students t-test shows that there is no significant
difference between the groups for oestrone: t=0.97, p=0.33. As expected, the bulk of
endogenous oestrogen was secreted during the pfis and the first weeks of pill taking.
All women showed some degree of response, although its magnitude and timing varied
considerably across women. If ovulation has occurred P-3-G levels will show a
sustained rise over 1.5-2.0 pg/mg Crt.. In these women levels were extremely low at
all phase of the cycle. Within the individuals P-3-G oscillated slightly around a unique
baseline level, but there were no sustained rises observed, and it was concluded that no
one had ovulated. So, although the two pill groups differed significantly in P-3-G level
(t= 14.82, p=0.00) it is unlikely that the difference is clinically significant. The overall
daily mean levels of steroid are presented in Figure 3.05.
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Figure 3.04 Comparison of daily oestrone and pregnanediol levels by pill
type over two consecutive pill cycles.
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Mean Urinary Steroid Levels (n=18)
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Figure 3.05 Mean daily urinary steroid levels for all folliculogenesis study
volunteers over two consecutive pill cycles.
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Eight of the 18 women who had two normal pill cycles showed a clear pattern of
cyclical oestrogen rising in the pill free interval of both cycles. Figure 3.06 shows the
individual profiles for two women on each pill type. The plot for T9 illustrates that the
magnitude of peak oestrogen may vary from one cycle to the next, however, most
women show uniformity over time. Figure 3.07 gives examples of the other ten
profiles in which E-3-G oscillated erratically over the cycle, and in which the pfi
seemed to have a limited effect on release from suppression. The very low overall
levels for these women contrast with high baseline and peak levels achieved by the
women shown in Figure 3.08. Volunteer Ml experienced a sustained rise in oestrogen
which peaked in the second week of pill taking, and did not return to baseline until the
beginning of pill week three. The only other woman who showed considerable
oestrogen change was T3, mentioned above. She had raised E-3-G well into the third
week of pill taking after the first pill free interval. Curiously, this rise occurred before
she took a course of Erythromycin® which might have interfered with pill absorption.
Neither of these women had progesterone changes indicative of ovulation.
The peak was defined as the highest single value occurring between day one of the pfi
and day eight of pill taking. Figure 3.09 shows the distribution of the timing of peaks.
The distribution is skewed towards the pfi but the commonest day for E-3-G to reach
its maximum is day 2 of pill taking. There were no significant differences in the peak
E-3G values achieved by the two pill groups: monophasic mean peak 34.1p.g/gr
(SD18.9) and triphasic mean 34.4p.g/gr (SD17.8), t=0.06, p=0.95.
3.6.5 Analyses of Prospective Daily Diary Ratings and their
Relationship to E-3-G Profiles
3.6.5.1 Amount of usable data and the distribution of cycle lengths
In this sample the interval between stopping pills to beginning to bleed was 2.35 days
for the monophasic takers, and 2.08 days for the triphasic takers. Consequently, 56%
of cycles were 28 days long, and the other 44% of cycles were 28±l-2 days. In the
few cases where breakthrough bleeding occurred towards the end of the pill packet
(mono. n=l, tri. n=4), and ran on into the pill free interval, the first day of the pill free
interval was taken as cycle day one. In addition to the 2 women with extended cycles
two cycles were incomplete because diary keeping did not continue until the onset of
the final bleed (M2 and T4). The data for these two women were used where there
were sufficient phases for the analyses, eg- the first cycle was used in group analysis.




































Figure 3.06 Individual urinary steroid profiles for two women in each pill
group who show clear patterns of oestrone secretion in response
to the withdrawal of pill steroids during the pill free interval.
Dotted lines indicate the day active pills were resumed.
















Figure 3.07 Individual urinary steroid profiles for one woman in each pill
group who showed erratic patterns of oestrone secretion, with no
apparent relationship to the withdrawal of pill steroids during the
pill free interval. Dotted lines indicate the day active pills were
resumed.












































Individual urinary steroid profiles for those women who showed
high baseline and peak levels of oestrone secretion. Dotted lines
indicate the day active pills were resumed.
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22 23 24 25 26 27 28 1 2 3 4 5 6 7 8
Day of the pill cycle
Figure 3.09 The distribution of peak oestrogen values by day of the pill cycle
for 36 cycles.
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3.6.5.2 Principle components analysis for data reduction
Separate principle components analyses were carried out for the two different pill types
(n=9 in each) by JS, but there was no difference between them in terms of the amount
of variance explained by the factors, or the grouping of variables. Thus a second
analysis was undertaken including all women (n=18). The results that follow are
derived from this whole sample analysis.
Both unrotated, and orthogonally rotated components were derived. The rotated and
unrotated components did not differ very much in the proportion of the variance which
they explained or the weighting of individual variables. This implied that the 'rotation'
had not changed the components substantially. So, for this reason and the apparently
conceptually meaningful nature of the rotated components, these were used in
subsequent analyses. This analysis was moderately successful as a data reduction
exercise, explaining about 67% of the variance in the data in the top six components.
The results of the analysis were as follows:
Top 6 factors for 18 cases, explaining 67% of the variance.
Factor Eigen value Per cent variance explained
1) Feeling good about yourself 0.857
1) Cheerful & happy 0.836
1) Getting on well with others 0.836




2) Mood up & down 0.793
2) Aggressive 0.769
2) Tense & anxious 0.722
2) Depressed & unhappy 0.706
2) Lacking self control 0.651
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Factor (continued) Eigen value Per cent variance explained
3) Sexual interest
3) Sexual activity





4) Period type pain
0.868
0.830 7.7%









Eigen values listed here if they exceeded 0.5.
These factors are conceptually meaningful. The first and second factor seem to
represent a positive affect component (PCI) and a negative affect component (PC2),
respectively. Factor three clearly shows that the three indices of sexuality covary.
Factors four to six indicate relationships between various parameters of physical well
being. All twenty-one scales are accounted by these six factors. PCs 1 and 2 will
subsequently be referred to as positive and negative affect.
3.6.5.3 Detection of cyclical change in individuals
A) Change from the premenstrual to the postmenstrual phase. Pre- to
postmenstrual change scores were calculated using the '30% rule' (Hamilton, et al.,
1984) as a means of assessing how many women in this sample experienced notable
changes in particular mood or physical parameters around the time of bleeding. The
mean of the two phases preceding the bleed were compared with the mean of the two
phases following the bleed in both cycles for negative and positive affect5, and for the
four physical symptoms: breast tenderness, bloating, period pain, and food craving.
These were considered separately because they explained such a small proportion
5
Standard z-scores used.
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(<10% each) of the sample variance within principle components 4 and 5, and because
they may have different aetiologies.
The data which are summarised in Table 3.03 below represent the percentage change in
physical variables based on the range of the scale used by that individual. Thus change
values are only indicated 1) if there was at least a thirty per cent change from the pre to
postmenstrual phase for that variable, and 2) if the individual used at least one third of
the possible range of the visual analogue scale in question.
Table 3.03 Pre to Post Menstrual Change in Physical State (n=18)
% Reduction for those women who showed >30% change
M2 M6 M10 T7 T8 T10 Til
symptom Cyl Cy2 Cyl Cy2 Cyl Cy2 Cyl Cy2 Cyl Cy2 Cyl Cy2 Cyl Cy2
Brsts tender nc 58 86 35 nc 39 74 45 nc 38 nc nc nc nc
Bloating nc nc nc nc nc nc 63 34 43 30 100 30 nc nc
Period pain nc nc nc 37 nc nc 34 nc nc nc nc nc nc nc
Cravings nc nc 100 nc 37 nc nc nc nc nc nc nc nc 36
Key: Cyl- cycle 1, Cy2- cycle 2, Brsts tender- Breasts tender, nc- no change of
>30%, figures in bold indicate those women who showed >30% change in both cycles
Of the seven women indicated above only four showed notable pre to post change in
both cycles for a given symptom, either breast tenderness or bloating. All symptom
scores were worse premenstrually and improved or returned to zero after bleeding.
Cyclical change in breast tenderness and bloating were more common than period pain
or food craving (7/14 cycles and 6/14 cycles versus 2/14 cycles and 3/14 cycles).
Eight additional women's scores changed by at least thirty per cent from the pre to
postmenstruum. However, their actual scores never exceeded 33mm on the visual
analogue scale, so their level of symptom experience was very low, and these data are
not included in the table. Amongst these women breast tenderness and bloating
changed by >30% of their range in eight cycles each, and period pain and cravings in
two and seven cycles respectively.
The Table 3.04 summarizes the pre to post menstrual change scores for positive and
negative affect. The principle component scores for pre and postmenstrual phases were
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calculated for each woman on the main frame computer using a fortran programme
written by Dilys Rennie (DR). Scores were generated for the cycle phases using the
daily data weighted according to the eigen values from the whole-group factor analysis.
Only eigen values of > 0.250 were included. Individual factor scores were then
transformed to z scores. Only those women with at least a thirty per cent change in at
least one of the components are included in the table. The sign of the number indicates
whether the component improved (+), or worsened (-) from the pre to postmenstruum.
In classical PMS, one would expect positive affect to have increased and negative affect
to have decreased.
Table 3.04 Pre to Post Menstrual Change in Mood State (n=18)
% Reduction for those women with >30% change in mood
M4 M5 M7 M8 M9 M10 T1 T2
Factor Cyl Cy2 Cyl Cy2 Cyl Cy2 Cyl Cy2 Cyl Cy2 Cyl Cy2 Cyl Cy2 Cyl Cy2
Pos.affect +36 nc nc +39 +70 nc nc -51 nc -47 -41 -42 -32 nc -41 nc
Neg.affect +40-71 nc -62 -46-54 -31 nc nc nc + 34-35 nc nc +60 nc
T 4 T6 T7 T8 T9 T10 Til
Pos.affect 0 i 01 nc -46 nc +64 nc nc nc +60 nc nc +77+32
Neg.affect nc nc nc -31 nc nc nc -31 -65 nc 3O i O nc -33
Key: Cyl- cycle 1, Cy2- cycle 2, Pos.affect- Positive affect component, Neg.affect-
Negative affect component, nc- no change of >30%, signs indicate the direction of
change from pre to post menses, figures in bold indicate those women who showed
>30% change in both cycles
Very few women showed at least a thirty per cent change in both cycles. Only two
women were cyclical by this criterion for positive affect: M10 and Til. Til was
happier after bleeding in both cycles, yet M10 was actually less happy. Only M7 had
substantially lower negative affect scores after bleeding in both cycles. Negative affect
changed by >30% for M4 and M10 in both cycles, but in opposite directions on the two
occasions. Overall, positive affect did not change in the expected direction. In eight
out of fifteen cycles with >30% change, mood was less positive after bleeding than
before. On the other hand, in 11 out of 14 cases where negative affect changed, mood
was less negative after bleeding.
The women in this study were not selected for perimenstrual change, however, twelve
of the eighteen women whose data could be included in the analysis indicated that they
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definitely, or maybe had PMS. All of the 12 women who said 'yes' or 'maybe' they
experienced cycle related change, confirmed that experience to some degree according
to the 30% change rule showing at least some variability in affect. In the group of
women who said 'no' they did not have PMS, five out of six also showed a 30%
change in some variable. However, unlike the PMS reporters not all of them
'confirmed' on the mood variables. Three of these women did show evidence of
cyclical mood, but two only changed in physical state, and one had no changes.
B) Univariate analysis of variance (ANOVA). Two sets of univariate
ANOVA were carried out on the standardized phased data for all women for all diary
scales and z scores for PC's 1 and 2. In the first analysis the phases were compared
over the two cycles in an effort to uncover whether or not individual women showed
consistent symptom timing.
The variables for which individuals showed cyclicity varied considerably, and no trend
emerged for particular symptoms, or by pill type (see Table 3.05) There was also little
concordance with the woman's retrospectively reported worst 'symptom/s'.
Menstruation most often occurred in the same phase of the cycle, which is as one
would expect since the phases were generated around the time of bleeding. The one
woman for whom menstruation did not show a significant phase effect had a good deal
of breakthrough bleeding. It is also not surprising that there was a significant phase
effect for oestrone in many cases (n=8), as changes in oestrone levels are largely a
function of the 'liberating' effect of pill free interval, and the suppressive effect of the
resumption of pill taking. The cell means of those women in whom the phase effect of
oestrone did not achieve statistical significance indicate that either the magnitude of
change was not great, or its timing was not consistent in both cycles.
Only three women prospectively confirmed cyclicity on the variable which they
retrospectively reported to be their worst cyclical change in the MHRAQ-1. A further
eight failed to confirm on their reported variable, but showed cyclicity for others, and
five showed cyclicity when they had not previously reported experiencing any. Five of
the women who had reported mood cyclicity only showed variations in phase for
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ANOVA tests were also carried out using the phased data, adjusted so that phases were
centred around the time of the oestrogen peak. One cycle comprised the two phases
before the peak-phase, the peak-phase itself, and the four phases after it. The peak was
defined as the highest endogenous E-3-G value within eight days of a pfi: i.e.- phase
'Peakl-2', phase 'Peakl-1', phase 'Peak T, phase 'Peakl + 1', etc...., phase
'Peak 1+4', followed by phase 'Peak2-2', etc.. Because the peak in oestrone did not
occur in the same phase in both cycles, it was not a simple case of relabelling the
phases to denote their relationship to the timing of the E-3-G peak. For a proportion of
women the phases actually had to be redesignated, the effect of which was that some
phases are duplicated or omitted for this analysis. This means that the time continuum
has been broken, though for analytical purposes the two groups of 7 phases are
considered hormonally analogous cycles.
ANOVA tests were conducted for positive and negative affect, E-3-G, the physical
variables and the feeling sexually attractive scale. The results are summed up in Table
3.06 below in a similar manner to Table 3.05. Given that the data were aligned by
oestrogen one would have expected an artifactually high frequency of significant phase
effects for oestrogen. Curiously, only six women showed a significant phase effect of
oestrogen, while eight did so in the bleed-centred analysis. On inspection of the cell
means it is clear that in all but one case E-3-G is highest in the third phase, but the
degree of change from one phase to the next does not necessarily achieve statistical
significance.
Once again two women showed a significant phase effect for negative affect, but they
were not the same women who showed an effect in the bleed-centred analysis. Only
M7, who had a significant phase effect of negative affect, confirmed her reported worst
change6, and neither she nor T10 showed statistically significant change in E-3-G. On
the physical side, no one showed a phase effect for food craving and only one woman
each showed cyclicity by oestrogen phase in bloating and sexual attractiveness relative
to the oestrogen peak. Three women had significant variation in breast tenderness and
five in period pain.
6
M7 was also one of the few women who had a greater than 30% reduction in PC2
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3.6.4.4 Detection of cyclical change in groups
A) Repeated measures ANOVA using PC's. Analysis of Variance for
repeated measures was carried out on the six principle components for all women taken
together (no phase transformation or standardization). There was no significant effect
of daily mean E-3-G for the mood, sexuality or energy components (PCI- X2=22.930,
p=0.689; PC2- X2=23.218, p=0.673, PC3- X2=36.436, p=0.106; PC6- X2=25.734,
p=0.533). The physical components, however, did show a significant relationship to
E-3-G level (PC4- X2=160.105, p=0.000; PC5- X2=89.345, p=0.000).
In addition to looking at the effect of the level of E-3-G, the influence of bleeding on
the components was considered. Days when bleeding occurred were compared with
days when it did not, also using E-3-G as a covariate in order to examine changes
which could not be explained as a linear function of endogenous oestrogen
concentration. Once again PCs 1, 2 and 6 did not show significant differences on the
basis of bleeding (PCI- X2=0.007, p=0.936; PC2- X2=1.155, p=0.282; PC6-
X2=0.980, p=0.322), while PCs 3, 4 and 5 did (PC3- X2=4.647, p=0.031; PC4-
X2=l 14.992, p=0.00; PC5- X2=13.760, p=0.00). In other words, for all women
taken together sexuality, bloating, period type pain, cravings, and breast tenderness
seemed to be influenced by the presence or absence of bleeding.
Differences in component scores were also examined for the effects of pill type, pill
day, self designated PMS status, and gynaecological age (no.yrs.from menarche).
Only components 4 and 5 varied significantly by pill day (PC4- X2= 176.091, p=0.00;
PC5- X2=95.807, p=0.00), and no components differed significantly by pill type. This
result is consistent with the previous finding for PCs 4 and 5, as the presence of
bleeding is strongly influenced by day of the pill cycle. Analyses were carried out
twice for the effect of retrospective PMS status: once where "maybe" was taken to
mean "yes", and once where it was taken to mean "no". None of the components were
statistically significant by PMS status; however, PC2, the negative affect component,
had a value of X2=3.368, p=0.052 when "maybe" was taken as "yes". This is the
component that one would expect to be the best distinguisher of PMS status.
Finally an ANOVA was carried out to assess the effect of gynaecological age on the
principle components. There is some evidence that reporting of PMS type changes is
maximal in women who have been experiencing cycles uninterrupted by pregnancy or
steroid hormone use for between three and six years (Warner and Bancroft, 1990). It
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was hypothesized that gynaecologically older women would have more cyclicity.
Although seven years is the suggested time taken to achieve gynaecological maturity
(Metcalf & MacKenzie, 1980), five years created a better split in the data set. The
results were very similar to those for PMS status. No component was significantly
different between the two groups, but again the statistic for PC2 was approaching
significance (X2=3.123, p=0.066), with more negative affect in the gynaecologically
"immature" group (less than 5 yrs. from menarche).
B) Multivariate analysis of variance (MANOVA). There is an overall
suggestion in the above analyses that the volunteers tended to experience cyclical
changes in their physical well being, and may in a few cases have experienced cyclical
changes in their emotional well being as summarized in the negative affect variable. In
order to test further this possibility, and to equate the likelihood of such experience with
parameters of endogenous oestrogen change individual data were grouped in a number
of ways. Four different groupings were generated on the basis of distinct aspects of
oestrogen dynamics. The profiles of E-3-G are described in section 3.6.4 above.
There are a number of ways in which the hormone data can be divided into groupings
with potential biological meaning. In order to test the hypothesis that there is a
relationship between residual ovarian function and subjective state one must question
which aspects of oestrogen dynamics are indicative of function.
Since both the level of oestrogen and the speed of it's rise are potentially important
indicators of function, four groupings for the MANOVA were designated by the
following: 1) The peak level of E-3-G reached in the eight days following the onset of
withdrawal bleeding for both cycles. The high group had peaks of >30ng/gr (n=7),
while the low group had <30ng/gr (n=10). M9 was excluded because her two cycles
were different. 2) The baseline level of E-3-G, which was determined by taking the
mean of pill days 15 to 21. There were low, intermediate, and high baseline groups,
with mean levels of 8.8ng/gr (n=5), 12.3ng/gr (n=8), and 16.1ng/gr (n=5)
respectively. 3) The rise in the level of E-3-G from baseline to peak, or whether or not
the peak was at least double the baseline level. In the doubling group E-3-G changed
by at least two times from the baseline to the peak in both cycles (n=ll), whereas it
was less than double in one or both cycles in the non-doubling group. And 4) The
symmetry of the E-3-G profiles for the two cycles, or whether or not the rise from
baseline to peak was equal in the two cycles. If the ratio of change between the
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baseline and peak for both cycles was >1 they were symmetrical (n=8), but if it was <1
they were not symmetrical (n=10).
'Group' was a two level variable, except for the 'baseline' group which had three
levels. 'Cycle' was a two, and 'phase' a seven level variable. The phases were
oestrogen-peak-centred. The variables studied included breast tenderness, bloating,
period type pain, food cravings, feeling sexually attractive, and positive and negative
affect. These met the symmetry conditions in some instances and not others. Breast
tenderness, bloating, and period pain were not homogeneous. Food craving was not
homogeneous in three groupings, but was in the 'symmetry' groups. Feeling sexually
attractive, and positive and negative affect were all homogeneous at the 1% level of the
test. Only negative affect was always spherical. Breast tenderness, bloating, and
period pain were never spherical, and food craving and feeling sexually attractive
sometimes.
Four post hoc contrasts were carried out on each variable in each hormone grouping to
examine the nature of the phase relationships. They were as follows: 1) a comparison
of the phase when E-3-G peaked (Phase 3) with all the others phases; 2) a comparison
of the phase when E-3-G peaked (Phase 3) with all the others, excluding the main
menstrual phase (Phase 1); 3) a comparison of the three phases in which E-3-G rose
(Phase 2), peaked (Phase 3), and fell (Phase 4), and was therefore changing, with the
other four "baseline" phases; 4) a comparison of the two menstrual phases (Phase 1&2)
with the peak E-3-G phase (Phase 3), excluding all other phases. The results are
summarized in Tables 3.07 to 3.10, and each variable is considered in turn.
i) Breast tenderness. There was no effect of group on breast tenderness for any
of the hormone parameters. This initial, univariate, between-subject test is an overall
measure of group differences, but does not take account of any interactions. In the
'baseline' and the 'rise' groups the cycles were significantly different, (p=.03, and
p=.04), and in the 'rise' group, the group by cycle interaction approached significance
(p=.07). Neither of these groupings were based on similarity between cycles, while
the 'peak' and 'symmetry' groups were, so this result is not surprising.
The multivariate tests for the effects of phase, and group by phase were significant for
the 'peak' group only (p=.04, .03). This suggests that the phases were different from
each other overall, and also between groups for breast tenderness. Indeed, this was the
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Table 3.07 MANOVA Results for "Peak" Oestrogen Grouping
Test Statistic Br Bit Ptp Crv Atr PCI PC2
Sphericity tests 0.00 0.00 0.00 0.00 0.00 0.83 0.85
0.00 0.00 0.00 0.15 0.28 0.17 0.49
Homogeneity test N N N Y Y Y Y
Between subjects effects
Constant 12.99** 23.08** 13.83** 9.28** 71.39** 0.05 0.03
Peak 1.21 4.28 1.24 0.54 0.51 0.18 1.53
Within subject effects
Cycle 3.22 0.63 0.03 5.27* 0.93 0.09 0.92
Peak x cycle 0.00 0.01 1.83 1.34 1.92 0.00 1.06
Multivariate tests
Peak x phase 3.88* 0.23 1.31 1.10 0.74 2.01 0.53
Phase 3.68* 1.84 2.11 0.63 0.91 0.42 1.79
Average tests
Phase 6.81** 5.86** 4.55** 1.60 0.53 0.50 2.55*
Peak x phase 2.03 0.41 0.98 0.77 0.26 0.64 0.26
P.h. test 1: Phase t= -1.78 0.36 1.32 -1.00 -0.14 -0.43 -1.28
P.h. test 1: Pk x Phs t= 1.20 0.32 -0.32 2.11 0.09 -0.51 0.69
P.h. test 2: Phase t= 2.96* 3.15** 3.44** 0.38 -1.43 -0.99 2.11
P.h. test 2: Pk x Phs t= -1.44 -0.74 -0.80 -1.01 -0.10 -0.51 -0.52
P.h. test 3: Phase t= -2.57* -2.27* 0.55 -0.67 0.25 0.07 -1.35
P.h. test 3: Pk x Phs t= 0.61 0.98 -0.51 1.57 0.24 -0.14 -0.24
P.h. lest 4: Phase l= -2.45* -1.15 -0.71 -1.47 0.55 0.24 -1.15
P.h. lest 4: Pk x Phs t= 0.44 0.37 -0.51 0.19 -0.93 -0.40 0.01
Multivariate tests
Peak x cycle x phase 1.01 1.01 1.92 0.24 0.51 0.53 0.55
Cycle x phase 2.07 1.01 0.50 0.69 0.44 1.63 0.84
Average tests
Cycle x phase 1.37 0.71 1.44 1.40 0.73 1.63 0.95
Peak x cycle x phase 1.14 2.91* 0.78 0.12 0.93 0.69 0.68
P.h. test 1: Cy x Phs t= 1.24 -1.20 1.25 1.55 -0.91 0.53 -0.15
P.h. test 1: PkxCxPh t= 0.00 -1.51 -1.30 0.04 -1.03 -0.54 0.24
P.h. test 2: Cy x Phs t= 0.25 -0.54 -0.69 1.54 1.41 0.60 -0.39
P.h. test 2: PkxCxPh t= -1.04 0.36 -0.45 -0.03 1.46 0.45 0.47
P.h. test 3: Cy x Phs t= 0.22 -0.42 1.28 -1.04 0.65 - 2.00 -1.53
P.h. test 3: PkxCxPh t= -0.58 -1.12 -1.04 0.55 1.02 1.19 -1.76
P.h. test 4: Cy x Phs t= -1.83 1.33 -0.09 -0.46 -0.06 -1.72 2.10
P.h. test 4: PkxCxPh t= 0.74 2.16 0.03 0.37 -0.36 -1.15 0.92
Key: Br- Breast tenderness, Bit- Bloating, Ptp- Period type pain, Crv- Food craving,
Atr- Feeling sexually attractive, PCI - Positive affect, PC2- Negative affect,
P.h.- Post hoc test, C/y- Cycle, Ph/s- Phase, Pk- Peak
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Table 3.08 MANOVA Results for Oestrogen "Rise" Grouping
Test Statistic Br Bit Ptp Crv Atr PCI PC2
Sphericity tests 0.00 0.00 0.00 0.00 0.02 0.00 0.15
0.00 0.00 0.00 0.14 0.27 0.06 0.46
Homogeneity test N N N Y Y Y Y
Between subjects ejjects
Constant 11.71** 21.71** 13.32** 9.29** 75.75** 0.04 0.11
Rise 0.53 0.21 0.02 0.04 0.47 0.07 0.22
Within subject ejfects
Cycle 5.35* 0.03 0.66 3.73* 0.09 0.44 1.42
Rise x cycle 3.78 0.02 0.22 0.60 0.56 1.01 0.21
Multivariate tests
Rise x phase 0.53 1.18 0.57 0.24 0.81 1.03 2.46
Phase 1.81 1.95 1.55 0.64 1.01 0.58 1.39
A verage tests
Phase 6.24** 4.43** 3.19** 1.47 0.52 0.44 1.93
Rise x phase 1.48 0.71 1.42 0.27 0.89 2.07 2.84*
P.h. test 1: Phase t= -1.71 -0.40 1.00 -0.99 -0.19 -1.02 -0.44
P.h. test 1: Rise x Phs t= -1.18 -1.09 -1.63 -0.74 0.40 1.21 -0.92
P.h. test 2: Phase t= 2.82* 2.11 1.09 0.40 -0.95 -0.17 1.15
P.h. test 2: Rise x Phs t= 1.49 -0.58 -0.78 0.49 1.21 1.48 -2.23*
P.h. test 3: Phase t= -2.49* -2.53* 0.24 -0.82 0.38 0.23 -1.57
P.h. test 3: Rise x Phs t= -1.12 -0.49 -1.74 0.15 -1.14 -1.82 0.56
P.h. test 4: Phase t= -2.37* -1.40 -0.71 -1.46 0.49 0.15 -1.75
P.h. test 4: Rise x Phs t= -1.51 -0.69 -1.01 -0.10 -0.89 -1.66 2.04
Multivariate tests
Rise x cycle x phase 0.91 1.73 0.92 0.53 0.62 0.90 0.24
Cycle x phase 1.85 1.04 0.64 0.64 0.34 1.67 0.98
Average tests
Cycle x phase 1.67 1.05 1.31 1.13 0.58 1.04 1.19
Rise x cycle x phase 1.75 0.81 1.33 1.17 1.04 0.77 0.26
P.h. test 1: Cy x Phs t= 1.05 -1.37 0.95 1.37 -0.43 0.27 -0.04
P.h. test 1: RisexCxPh t= 1.81 -0.02 -1.12 2.07 0.25 0.12 0.19
P.h. test 2: Cy x Phs t= 0.51 -0.99 -0.95 1.40 1.09 0.68 -1.03
P.h. test 2: RisexCxPh t= -0.85 -1.00 -1.03 1.16 1.53 0.37 -0.11
P.h. test 3: Cy x Phs t= -0.06 -0.96 0.81 -1.11 0.54 - 2.01 -1.63
P.h. test 3: RisexCxPh t= 2.32* 1.40 -0.58 0.11 -0.60 0.56 0.38
P.h. test 4: Cy x Phs t= -2.64* 0.50 -0.59 -0.47 0.57 -0.74 1.72
P.h. test 4: RisexCxPh t= 2.50* 0.44 1.73 -0.21 -1.23 -0.77 -0.63
Key: Br- Breast tenderness, Bit- Bloating, Ptp- Period type pain, Crv- Food craving,
Atr- Feeling sexually attractive, PCI - Positive affect, PC2- Negative affect,
P.h.- Post hoc test, C/y- Cycle, Ph/s- Phase
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Table 3.09 MANOVA Results for Oestrogen "Baseline" Grouping
Test Statistic Br Bit Ptp Crv Atr PCI PC2
Sphericity tests 0.00 0.00 0.00 0.00 0.03 0.00 0.08
0.00 0.00 0.00 0.05 0.21 0.05 0.10
Homogeneity test N N N Y Y Y Y
Between subjects effects
Constant 13.78** 22.19** 12.71** 14.69** 79.66** 0.01 0.72
Baseline 1.22 0.18 0.01 3.20 1.03 0.29 6.63**
Within subject effects
Cycle 5.53* 0.12 1.42 4.54 0.22 0.20 1.10
Baseline x cycle 2.70 0.85 1.86 0.30 0.21 0.40 0.86
Multivariate tests
Baseline x phase 0.79 0.54 1.55 1.34 1.38 1.72 0.97
Phase 0.19 1.44 2.08 0.62 1.74 0.71 1.57
Average tests
Phase 6.50** 4.33** 2.83* 1.99 0.53 0.52 1.29
Baseline x phase 0.78 0.67 1.75 1.03 1.43 0.91 0.96
P.h. test 1: Phase t= -1.68 -0.84 0.71 -1.43 0.00 -0.99 -0.55
P.h. test 1: Bsln x Phs t= -1.18 1.29 0.14 1.37 -0.96 1.27 -0.24
P.h. test 1: Bsln x Phs t= 0.36 0.99 1.87 -1.98 -1.39 -0.32 -0.84
P.h. test 2: Phase t= 3.02** 1.94 0.85 0.59 -0.67 0.23 0.62
P.h. test 2: Bsln x Phs t= 0.34 0.05 1.22 -0.37 -0.13 -0.97 0.27
P.h. test 2: Bsln x Phs t= 1.37 0.50 1.02 1.86 -0.51 -0.14 1.00
P.h. test 3: Phase t= -2.43* -2.67* -0.04 -0.72 0.31 -0.18 -1.59
P.h. test 3: Bsln x Phs t= -0.76 0.17 -0.13 -0.67 -0.76 0.66 0.38
P.h. test 3: Bsln x Phs t= 0.38 0.94 1.52 -0.89 1.74 0.94 -1.52
P.h. test 4: Phase t= -2.35* -1.51 -0.67 -1.66 0.21 -0.27 -1.27
P.h. lest 4: Bsln x Phs t= -0.46 0.01 -1.72 1.05 0.86 0.91 0.47
P.h. test 4: Bsln x Phs fc= -0.24 0.83 1.64 -0.95 0.79 0.38 -0.13
Multivariate tests
Baseline x cycle x phase 1.42 0.99 1.11 0.69 0.39 0.68 1.42
Cycle x phase 3.24 0.82 0.60 0.79 0.32 1.49 1.58
Average tests
Cycle x phase 2.28* 1.41 1.22 1.41 0.69 1.08 1.35
Baseline x cycle x phase 1.78 0.87 0.89 0.39 0.33 0.40 1.22
P.h. test 1: Cy x Phs t= 1.11 -1.62 0.61 1.58 -0.22 0.40 0.01
P.h. test 1: BslnxCxPh t= 0.87 0.87 0.92 -0.36 -1.06 -0.69 -0.15
P.h. test 1: BslnxCxPh t= 0.01 0.99 0.61 0.88 0.00 0.48 0.28
P.h. test 2: Cy x Phs t= 0.57 -1.35 -1.18 1.59 1.15 ' 0.70 -1.08
P.h. test 2: BslnxCxPh t= -1.32 1.24 0.30 -0.21 0.79 0.10 0.10
P.h. test 2: BslnxCxPh t= 0.81 -0.46 1.06 1.09 -0.94 0.05 1.00
P.h. test 3: Cy x Phs t= 0.10 -0.83 0.52 -1.21 0.39 1.99 -1.49
P.h. test 3: BslnxCxPh t= 1.42 0.36 1.40 0.77 0.16 0.39 -0.11
P.h. test 3: BslnxCxPh t= 0.50 1.96 -0.07 0.07 0.22 -0.65 0.23
P.h. test 4: Cy x Phs t= -2.46* 0.41 -0.32 -0.45 0.33 -0.83 1.51
P.h. test 4: BslnxCxPh t= 2.27* 1.09 0.39 -0.25 0.03 -0.09 0.27
P.h. test 4: BslnxCxPh t= -1.38 -0.14 0.42 -0.25 0.29 -0.43 0.05
Key: Br- Breast tenderness, Bit- Bloating, Ptp- Period type pain, Crv- Food craving,
Atr- Feeling sexually attractive, PCI- Positive affect, PC2- Negative affect,
P.h.- Post hoc test, C/y- Cycle, Ph/s- Phase, Bsln- Baseline
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Table 3.10 MANOVA Results for Oestrogen "Symmetry" Grouping
Test Statistic Br Bit Ptp Crv Atr PCI PC2
Sphericity tests 0.00 0.00 0.00 0.00 0.02 0.00 0.06
0.00 0.00 0.00 0.04 0.22 0.04 0.37
Homogeneity test N N N Y Y Y Y
Between subjects ejfects
Constant 12.24** 21.72** 13.00** 8.72** 101.19** 0.14 0.01
Symmclry 2.66 0.48 0.45 2.03 7.01* 1.50 0.97
Within subject ejfects
Cycle 3.23 0.27 1.33 3.93 0.39 0.15 0.19
Symmetry x cycle 0.04 2.85 1.54 0.08 1.14 0.21 0.25
Multivariate tests
Symmetry x phase 1.28 2.31 1.01 1.54 0.65 0.66 1.54
Phase 2.38 1.46 1.36 0.58 1.29 0.60 1.41
Average tests
Phase 6.09** 4.16** 2.37* 1.28 0.53 0.57 1.10
Symmetry x phase 1.34 1.46 2.61* 1.83 0.84 0.75 1.19
P.h. test 1: Phase t= -1.76 -0.93 0.41 -1.01 0.07 -0.96 -0.40
P.h. test 1: Sym x Phs t= 0.46 -1.75 -1.70 0.57 1.15 -0.94 1.21
P.h. test 2: Phase t= 2.79* 1.87 0.69 0.29 -0.69 0.21 0.52
P.h. test 2: Sym x Phs t= -1.07 -1.11 -2.07 -1.27 0.08 0.73 -0.81
P.h. test 3: Phase t= -2.49* -2.67* -0.26 -0.76 0.42 0.09 -1.40
P.h. test 3: Sym x Phs t= 1.02 -0.35 -1.13 0.16 1.34 1.00 0.36
P.h. test 4: Phase 1= -2.36* -1.34 -0.78 -1.32 0.42 -0.25 -1.14
P.h. lest 4: Sym x Phs t= 0.86 1.67 0.51 1.44 0.52 -0.71 0.50
Multivariate tests
Symmetry x cycle x phase 1.26 0.25 1.38 2.16 1.33 1.32 0.54
Cycle x phase 1.65 1.00 0.64 0.71 0.79 2.53 0.96
Average tests
Cycle x phase 1.33 1.36 1.39 1.25 1.08 1.47 1.26
Symmetry x cycle x phase 0.40 0.39 0.80 1.49 1.53 0.90 0.37
P.h. test 1: Cy x Phs t= 1.14 -1.50 0.58 1.37 -0.29 0.43 -0.12
P.h. test 1: SymxCxPh t= -0.67 -0.60 -0.89 -2.16 0.54 0.72 -0.63
P.h. test 2: Cy x Phs t= 0.67 -1.13 -1.34 1.59 1.65 1.03 -1.17
P.h. test 2: SymxCxPh t= 1.62 0.01 -1.13 0.27 1.59 1.37 -0.60
P.h. test 3: Cy x Phs t= 0.24 -0.91 0.59 -0.91 0.52 - 2.41 -1.67
P.h. test 3: SymxCxPh t= -0.29 -1.17 -0.72 1.36 0.49 1.23 -0.56
P.h. test 4: Cy x Phs t= -1.80 0.46 -0.46 -0.65 0.34 -0.73 1.47
P.h. test 4: SymxCxPh t= 0.31 -0.65 -1.07 -0.74 0.00 0.85 -0.92
Key: Br- Breast tenderness, Bit- Bloating, Ptp- Period type pain, Crv- Food craving,
Atr- Feeling sexually attractive, PCI - Positive affect, PC2- Negative affect,
P.h.- Post hoc test, C/y- Cycle, Ph/s- Phase, Sym- Symmetry
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only instance, for any variable, for any grouping of women in which the multivariate
tests were significant. Multivariate tests that were performed for cycle by phase, and
group by cycle by phase interactions were never significant. Inspection of the epsilon
adjusted univariate statistics revealed that the phases were significantly different at the
1% level in all four hormonal groupings, but there is no group by phase, cycle by
phase, or group by cycle by phase interaction.
For breast tenderness, the second, third, and fourth post hoc tests were all significant
(at the p=.05 level or less) in all four hormone determined groupings. Indicating that
no matter which parameter was used to classify groups of women breast tenderness still
showed significant differences over the phases of the cycle in relation to E-3-G.
The amount of breast tenderness was different in the two 'peak' groups. Women
whose endogenous oestrogen was more suppressed and in whom E-3-G levels never
reached peaks of >30|ig/gr crt. had more breast tenderness than the high oestrogen
group. In both groups breast tenderness appeared to be inversely related to the level of
E-3-G, with least breast tenderness when oestrogen was highest. So, the phase
relationship to the oestrogen peak was similar, but the low oestrogen group were more
severely affected. Figure 3.10 shows the difference in mean breast tenderness scores
for the two groups over the oestrogen centred phases.
ii) Bloating. In the 'peak' group there was a near significant effect of group in the
between-subject univariate test (p=.06) for bloating, but there was no significant effect
of any other hormonal grouping. The cycles were not significantly different in any of
the groupings, nor was there any interaction between group and cycle. As stated above
none of the multivariate tests were significant for any group.
The epsilon adjusted univariate test of phase effect, however, was significant in all
groupings; at the 1% level in the 'peak', 'baseline', and 'rise' groups, and at the 5%
level in the symmetry groups. In all hormonal four groupings, the third post hoc test,
which estimated the difference between the phases of changing oestrogen with the
baseline level, was significant ('peak'- p=.04, 'baseline', 'rise', 'symmetry'- p=.02).
In the 'peak' groups the second test was also significant (p=.01), but only approached
significance in the other three groupings.
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Standardized oestrogen-centred cycle phase
Figure 3.10 Oestrogen-centred phase means for the high and low oestrogen
"peak" groups for breast tenderness.
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Further, the 'peak' by cycle by phase interaction was significant at the 5% level. So
when cycle and phase are both taken into account, the high and low oestrogen groups
seem to experience different amounts of bloating. As was the case for breast
tenderness, the cell means indicate that women with lower peak levels of E-3-G had
more pronounced bloating (see Figure 3.11). None of the other oestrogen parameters
distinguished between groups.
iii) Period Pain. The between-subject univariate test for the effect of group was not
significant for any hormonal grouping, nor were there any significant within subject
effects. The multivariate tests were not significant. The only significant results for
period pain were the epsilon-adjusted, univariate tests of phase effect. In the 'peak',
'baseline', and 'rise' groups this test was significant at the 5% level, but it only
approached significance in the 'symmetry' group. The only post hoc test that was
significant for period pain was the second one, in the 'peak' grouping: i.e. the highest
oestrogen phase was different from all the others (p=.01) when the first "menstrual"
phase was excluded.
iv) Food Craving, There was a significant, or nearly significant within-subject
effect of cycle for food craving in all the groupings: 'peak' p=.04, 'baseline' p=.05,
'rise' p=.07, 'symmetry' p=.07. Thus the first and second cycle of the study were
different from each other, no matter which oestrogen parameter was used to group the
data. This presumably obscured any potential phase effect in the data and none of the
other tests carried out achieved significance.
v) Feeling Sexually Attractive. Only one test was significant for this variable.
In the 'symmetry' grouping the initial between-subject univariate test was significant
(p=.02). This group difference was not confirmed, however, by the more powerful
multivariate, or epsilon-adjusted univariate tests. An inspection of the cell means
reveals that the group of women whose cycles were more symmetrical had higher self-
reported feelings of sexual attractiveness. That is, the women in whom E-3-G changed
by an equivalent amount between the baseline and peak levels in both study cycles,
reported feeling more sexually attractive (see Figure 3.12).
vi) Positive Affect. No tests were significant for positive affect, the measure of
positive affect. So, there were no differences between phases, cycles, or groups for
any of the hormone parameters investigated (see Tables 3.07-3.10).
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High E-3-G "peak" group (n=7)
Low E-3-G "peak group (n=9)
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Standardized oestrogen-centred cycle phase
Figure 3.11 Oestrogen-centred phase means for the high and low oestrogen
"peak" groups for bloating






















































Standardized oestrogen-centred cycle phase
Figure 3.12 Comparison of oestrogen-centred phase means for sexual
attractiveness in those women who had similar oestrogen
profiles in two consecutive cycles and those who did not.
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vii) Negative affect. The results for negative affect were not as consistent as for
the other variables. Results seemed to differ according to the hormonal parameter
under investigation. No test was significant for the 'symmetry' grouping. In the
'peak' group, only the univariate test of phase effect was significant (p=.03). (No
adjustment by the epsilon value was needed in the case of univariate tests for negative
affect, as data were spherical in all the groupings, due to the use of standard z scores.)
The 'peak' groups and cycles did not differ, and none of the post hoc tests were
significant.
In the 'rise' group, the univariate test of phase effect was not significant at p=.09, but
the group by phase test was, at p=.02, indicating that the groups were different when
the interaction effect of phase was accounted for. Only the second post hoc test, was
significant (p=.05), indicating that phase 3 was different from all the others when the
menstrual phase was excluded.
Finally, in the 'baseline' grouping there was a significant difference between the groups
in the between-subjects univariate test (p=.01). The cell means show that the
intermediate 'baseline' group had lower scores for negative affect in all phases than
either the high or low groups. The intermediate 'baseline' group tended to show more
clearly cyclical patterns of E-3-G, rising and falling in response to the pill free
interval,than the other two groups. In the univariate ANOVA aligned by bleeding
discussed above, the individuals in the high and low 'baseline' groups had less cyclical
profiles of E-3-G, with only two out of ten showing a significant phase effect for
oestrogen, versus five out of eight in the intermediate group. The 'baseline' group
differences in negative affect are shown in Figure 3.13.
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Standardized oestrogen-centred cycle phase
Figure 3.13 Comparison of oestrogen-centred phase means for negative affect
in women with high, intermediate, and low baseline levels of
oestrogen.
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3.7 Summary and Conclusions
This study was concerned with relating cyclical change in subjectively reported well
being to residual ovarian steroid production in two different groups of pill users. The
observational, correlational design was directed at accounting for one possible
mechanism which might explain the persistence of such experience in pill takers.
3.7.1 The Representativeness of the Sample
All those who completed the study were white, middle class, employed, highly
motivated, and well educated. All women were in relationships, the majority
permanent, and were largely non-religious, nulliparous, and well established on the
pill. They are therefore a homogeneous and non-representative sample of the
population at large. Nevertheless, they are similar to the majority of FPC attenders (see
Chapter Four).
3.7.2 Evidence of Residual Ovarian Function
The first aim of this investigation was to establish whether or not there is continued
ovarian function during OC cycles. All 20 women showed some evidence of residual
ovarian function determined by urinary hormone analysis7. As expected from previous
reports the majority of endogenous oestrogen change was concentrated during and
immediately after the pfi, while progesterone levels remained basal at all times. E-3-G
profiles were largely consistent within women over time8. Contrary to expectation
women established on monophasic and triphasic pills showed similar amounts and
dynamics of oestrone production9.
7
There was also evidence of folliculogenesis from ultrasound scanning and serum
hormone measures of half of the monophasic takers.
8
Serum levels were equivalent in a subsequent scanning cycle.
9
Gonadotrophin levels during a scanning cycle seemed to return to normal and produce
follicle growth in a subgroup ofmonophasic takers, in agreement with previous reports
(van der Spuy et al., 1990). Unfortunately, it was not possible to compare follicular
growth in triphasic and monophasic takers. In fact, a disproportionate number of
triphasic takers had stopped taking the pill by the time scanning was carried out (7 out
of 10 vs. 3 out of 10 monos.). In such a small sample of women it is difficult to know
if this reflects some adverse effect of the formulation or difference in the sort of woman
who uses triphasics, or is simply a function of the particular women who took part. It
has been suggested, but not shown definitively that triphasic takers may experience
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The picture of ovarian function found in this study is similar to previous reports which
indicate that for most women oestrogen levels are very low and may show a transient
rise beginning in the pfi, but are still generally lower than at the equivalent phase of the
normal cycle (early follicular). It is difficult to know if the subtle alterations in steroid
levels which most women showed are of any clinical consequence. It is more likely
that observed differences in endogenous steroid levels actually reflect differences in the
rate of pill metabolism. The implications of inter-individual differences in steroid
metabolism are not known, and there was wide variation in the degree of release from
pill suppression across women. One woman on each pill type showed a sustained and
marked rise in E-3-G during monitoring, and one woman who showed only moderate
E-3-G became pregnant while regularly taking Trinordiol a few months after the end of
the study. There was even more marked evidence of residual ovarian function amongst
women taking the monophasic formulation, Marvelon, in a subsequent study which is
described fully in Chapter Six.
3.7.3 Evidence of Cyclical Change in Subjective State
The second aim of this investigation was to determine whether or not the sample
experienced cyclical change in their emotional and physical well being. A variety of
methods were used to establish the presence of cyclicity in individuals and they
produced complex and inconsistent results. Retrospectively, 13 out of 20 (65%) of the
women said that they thought they had or might have PMS. Elowever, using the '30%
change' rule very few women in this sample confirmed the existence of PMS. Only
four women met the NIMH criterion for PMS for at least one physical change over two
prospectively monitored cycles (M6, T7, T8 & T10), while two other women met it for
mood changes (M7 & Til).
Few women had consistent experiences during both cycles. However, 15 out of 18
women had a significant reduction in one or more physical 'symptom/s' during at least
one cycle. More than half of these individuals had used less than 30% of the range of
the VAS. Fifteen women also had at least a 30% change in their standard score z for
more adverse mood reactions when commencing the pill than monophasic takers
(Bancroft et al., 1987a). Another possibility is that women chose to take part in this
investigation because they already had reservations about the pill and used the study as
an opportunity for a close reading of cycle-related events in order to confirm pre-
existent attributions.
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for positive and negative affect. These were not necessarily the same women who had
shown physical change, and the change in mood was not necessarily in the expected
direction. For example in 8 of the 15 cycles where positive affect changed women
were less happy after the bleed. In the majority of cases negative mood was lower after
bleeding, although in 3 cycles out of 14 women were still unhappy after a bleed.
Women were somewhat more likely to experience two physically similar cycles, and all
physical symptoms appeared prior to bleeding and remitted or improved after bleeding
finished. The low level of symptom experience in this sample is not particularly
surprising as volunteers were not selected on the basis of PMS reporting. Pill use may
also be reducing cyclicity for at least a portion (eg. Woods, et al., 1982).
ANOVA was carried out to determine whether or not individuals showed significant
change in well being over all of the cycles phases with consistent uming in relation to
either bleeding or the peak level of E-3-G. More women showed significant phase
effects for individual mood variables, or PC's 1 and 2 in relation to bleeding than peak
oestrogen. Physical variables changed in relation to oestrogen, but more often in
reladon to bleeding. Cyclicity in well being was generally subtle and varied a great deal
both across and within individuals.
Triphasic pills are meant to produce fewer "side effects" than monophasics via lower
dosage and perhaps because they emulate the menstrual cycle (eg. Hale, 1987). The
concept that triphasics are "more natural" or "healthier" (Guillebaud, 1984) may mean
that they are more often prescribed to women who are anxious about side effects, have
experienced them on other formulations, or are otherwise ambivalent about taking the
pill. These factors are likely to predispose them to discontinue. There was some broad
support for the idea that triphasic takers are more anxious than monophasic takers in
this investigation since they tended to report more PMS and to have higher neuroticism
scores on the EPI. However, there was no indication that triphasic takers had different
amounts or patterns of cyclical change.
3.7.4 Evidence of a Relationship Between Endogenous Oestrogen and
Subjective State
The final aim of this research was to explore the link, if any, between the dynamics of
endogenous steroids and subjective state over the OC cycle. When the rotated principle
components were entered into 1-way ANOVA the physical variables were more closely
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associated with levels of oestrogen than the mood variables. There was significant
change in physical and sexuality components over the pill cycle in the whole sample
which co-varied with E-3-G. It is likely that sexual feelings and activity are influenced
by the timing of bleeding, with sexual activity considerably less likely to occur on
bleeding days. Yet once bleeding has finished, the likelihood of sexual activity is
probably not influenced by the day of the pill cycle. Equally it is not surprising to find
an effect of cycle day and bleeding on the experience of bloating, breast tenderness,
food craving and period type pain, as physical symptoms are not likely to occur at times
distant from bleeding (Metcalf et al., 1990). It is also more likely that physical
symptoms have a mechanistic relationship to physiological events than mood states
(Bancroft & Backstrom, 1985). Perhaps, the absence of endogenous oestrogen which
presumably reflects the potency of exogenous steroids at the end of the pill cycle, is
responsible for physical symptoms at this time.
This analysis showed a near significant difference between women who retrospectively
reported PMS and those who did not for negative affect which is to be expected.
Gynaecologically immature women also had more negative affect. The reason for this
is not clear, and such a relationship would require confirmation in a larger sample.
There is other evidence in support of the idea that endogenous oestrogen levels
achieved during pill cycles may be related to subjective state, or to trait variables like
personality. In this sample women who retrospectively reported PMS were
significantly more likely to have high N scores on the EPI. And they also tended to be
the same women who had higher overall oestrogen levels with maximums above
30(ig/gr., entering the early follicular phase range. Perhaps ovarian production of
oestrogen has to exceed a certain level before it is detected by the brain, and alters the
brain environment sufficiently to produce subjective state change, or more particularly
heightened perception of physiological changes which are interpreted as PMS. On the
other hand, endogenous oestrogen may simply reflect the underlying pattern of
exogenous steroid metabolism which is primarily responsible for subjective outcomes.
It is likely that N scores and retrospective PMS reporting are confounded which would
explain why they are correlated. This does not explain the association of these traits
with high E-3-G, however even high oestrogen levels were relatively conservative in
comparison with the normal menstrual cycle.
The multivariate analysis which was performed on the data set was designed to test the
effects of various specific oestrogen parameters on well being. Very few of these tests
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were significant, but those that were suggest that there is a relationship between the
absolute levels of endogenous oestrogen and well being, and that the relationship is
stronger for physical changes than moods. At the end of the cycle when endogenous
oestrogen was well suppressed bloating and breast tenderness were high, and when
oestrogen recovered they declined. One possible explanations for this is that
endogenous oestrogen suppression directly causes breast pain and distension.
Alternatively the low oestrogen group may have had higher circulating or bioactive
levels of exogenous (pill) steroids which were causing the breast tenderness, etc..
through more potent target tissue effects.
Because multiple statistical tests have been performed on a small data set, and the
results arc not highly significant, these findings must be interpreted as trends which
require corroboration with a larger number of volunteers, preferably over a longer
timespan. The important possibility that individuals have different patterns of mood
and physical well being over the OC cycle because of different patterns of exogenous or
endogenous steroids deserves further research attention in a sample of women who are
experiencing marked cycle-related change.
Chapter 4 Assessment of Women's Menstrual Health
Experience and Attitudes Towards Vaginal
Bleeding
4.1 Introduction
In the previous chapter, the possible relationship between residual ovarian function and
persistent variation in well being over the combined pill cycle was considered. This
study showed that the amount of endogenous oestrogen released is not systematically
related to fluctuations in well being (except possibly certain physical variables), nor
could it explain fully the presence of these changes. There must be alternative
explanations for the experience of cyclical change, and in particular the perception of
about two-thirds of the women in the folliculogenesis sample that they had PMS. One
very important possibility is that women's attitudes, and those of the society at large,
about bleeding and related experience influence the way in which individuals process
and report this experience. The idea which was considered in Chapter Two that vaginal
bleeding and its sequelae are culturally symbolic is fundamental to our understanding of
cycle-related changes in subjective well being.
It has been noted that attitudes to bleeding were relatively uninvestigated in Western
industrialized societies before the 1980's (Brooks-Gunn & Ruble, 1980). One
explanation for this is that a false dichotomy has been created in which women in
Western societies are questioned about cycle-related symptoms and changes, while
women in non-Western settings are questioned about their beliefs and practices
pertaining to menstruation itself, i.e.- taboos (Paige-Ericksen, 1987). It is likely that
symbolic experience is 'translated' in each culture, in a culturally appropriate way via
the predominant thematic institutions of that society. Birke & Best (1982) suggest that
in our society 'science' has replaced the 'mythology and religion' of so-called
'primitive' cultures as the generative source of menstrual negativism and tabooing.
Thus in our society where biological phenomena are dealt with almost entirely in terms
of the medical model the prominent issue is cycle-related change, and in non-
medicalized cultures behavioural proscriptions and ritual actions are the norm. At least
this is the dichotomy which has been created. Yet there is evidence that "the beliefs
about menstruating women in our own society share important similarities with thebeliefs
held in other cultures" (p.175, Paige-Ericksen, 1987), suggesting that we have more in
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common with other cultures attitudinally than we are prepared to acknowledge. Equally
women in non-urban, non-Westernized societies report experiencing psycho¬
physiological changes of a similar nature and magnitude to those reported in our society
(Snowden &Christian, 1983). In this chapter semi-structured interviews and a
questionnaire survey have been employed in a reflexive manner to obtain information
about what women experience over their cycles and how they view this experience in
order to broaden our understanding of women's menstruation-related beliefs and
expectations.
4.2 Aims
The purpose of the research reported in this chapter is to broadly address if and why
women attending an Edinburgh family planning clinic consider vaginal bleeding to be
important. It is not possible in one chapter of this thesis to address all the complex
questions surrounding the acquisition, expression, and meaning of attitudes and beliefs
about menstruation. Thus, this chapter aims to describe some of these beliefs in
relation to certain demographic characteristics of the Clinic population, such as
contraceptive use. Finally this questionnaire survey provides a practical link with the
rest of the thesis. Respondents were questionned about their willingness to undergo
manipulations of their cycle length and the timing of bleeding, and at the same time
given the opportunity to volunteer for the experimental investigadon reported in Chapter
Six which involves cycle length manipuladon.
4.3 Methods of Assessment and Analysis
The findings in this chapter were derived from two different samples of women, all of
whom were recruited from the main Family Planning Clinic (FPC) in Dean Terrace,
Edinburgh. The first sample of twenty women who are described in the previous
chapter, provided information through both a questionnaire (MHRAQ-1, see Chapter
Three), and a semi-structured interview, and will be referred to as the folliculogenesis
study volunteers. The second sample was comprised of approximately seven hundred
consecutive FPC attenders, who completed a modified version of the MHRAQ-1.
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4.3.1 The Semi-Structured Interview
The final meeting with the folliculogenesis study volunteers took the form of a semi-
structured interview. This part of the study was seen as exploratory, and not
hypothesis testing as such. It was intended to generate information in an open-ended
way about women's beliefs. The interview schedule included questions about a
number of topics related to a woman's reproductive attitudes and menstrual health
experience: the pill, hormonal control, and contraception in general; pregnancy and
childbirth experience; attitude, experience, and behaviour relating to menstruation;
gender identity; personal relationships and sexuality. The qualitative interview method
known as discourse analysis was used. The technique involves conducting a semi-
structured or themed interview in which informants are encouraged to describe their
own views and experience in their own language with limited leading and prompting by
the interviewer (Lindzey & Elliot, 1985; Bogdan & Taylor, 1975; Lofland, 1971). A
series of pre-set questions are covered during the course of the meeting, but not
necessarily in a proscribed order.
The questions about menstruation1 were derived from the common themes reported in
the literature (eg.- Martin, 1989; Matlin, 1987; Birke & Best, 1982; Brooks-Gunn,
1985; Snowden & Christian, 1983), and covered menarchial experience, taboo,
concealment, avoidances, positive aspects, equipment use, naming, cyclicity, and the
desire to alter the cycle. The interview schedule was piloted with seven volunteers
from the Centre for Reproductive Biology in Edinburgh, before it was used with the
study sample. Questions that seemed to have little meaning or were too abstract were
dropped or modified. Redundancies were omitted, and the order of questions was
altered to be as logical and conversational as possible. The final schedule took
approximately one hour to complete. The questions pertaining to vaginal bleeding
experience are extracted below, while the complete interview schedule can be found in
Appendix 4.01.
l
Since all of the women interviewed were taking the pill, they were not menstruating in
the true sense. Where possible hormone withdrawal bleeds were discussed as 'bleeds',
but occasionally 'menstruation' was used in a generic sense to mean vaginal bleeding.
As will become apparent, most women do not make a distinction between menses and
hormone withdrawal bleeds.
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Menstruation
Let's move on now to some questions about menstruation. In the questionnaire I asked
you about your first period, and the way yourfamily reacted to it- could you just tell me
about that again.
Attitude, Experience, and Behaviour
Is menstruation something you feel able to speak openly about?
Who do you talk to about it? Other women ? Yourparmer? Other men ?
Why or why not?
Do you think menstruation is still a taboo subject? Why?
Do you mind ifpeople know you are bleeding? Why? Who?
Ifno- So why doesn't a woman who's at work or in the pub just walk to the
toilet with a tampax in her hand.
So, what's the difference between having a cold and having a period?
People tend to show offa cold and talk a lot about it, but women hide the fact
that they have their period when all of us bleed regularly?
What do you think is positive about menstruation?
Do you think you are perhaps more aware ofyour surroundings, or more
sensitive before or during yourperiod?
Is there anything that you avoid doing while you are bleeding?
Do you have sex? Ifnot- Why not? Who decides that? You, your partner,
both ofyou ?
Do you feel differently about yourselfon the days that you are bleeding from the
days when you are not?
What about at other times in the month ? (Pre- post-menstrually)
Do otherpeople notice the differences?
Do you think about menstruation when you are not bleeding?
What name do you use for menstruation?
Do you use pads or tampons?
Would you change your cycle ifyou could? (Either the pattern ofbleeding or your
physical and emotional experiences of it.) Why or why not? In what way?
The interviews with the study sample were audio-taped for later transcription. Four of
the 20 interviews were recorded using an old model Sony tape recorder, but the sound
quality on these tapes was poor, and a Sony Professional Walkman was purchased to
carry out the remaining interviews. One of the twenty tapes was too indistinct to
transcribe verbatim (M3). General points could be discerned from this tape, but quotes
are not taken from it for the analysis. Full transcriptions were made of the other 19
tapes, and these were used in the analysis.
The interview transcripts provided a rich source of information on women's attitudes to
vaginal bleeding and other aspects of reproductive health. It is beyond the scope of this
thesis, however, to fully explore these findings here. Nevertheless, the interview
transcripts were used as source material in the development of the Menstrual Health and
Reproductive Attitudes questionnaire- version two.
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4.3.2 Menstrual Health and Reproductive Attitudes Questionnaires
There is no single questionnaire in the published literature which comprehensively
gathers information about bleeding experience, contraceptive use, experience of cyclical
change, attitudes and practices relating to bleeding and contraceptive use, willingness to
alter the cycle, and demographic variables which may be related to all of these factors.
Several questionnaires and research projects have separately addressed these different
aspects including the Menstrual Attitudes Questionnaire (Brooks-Gunn & Ruble, 1980)
and the Menstrual Elimination Questionnaire (Miller & Smith, 1975) amongst others
(Jarvis & McCabe, 1991; [Ruder & Finn, 1981 in] Paige-Ericksen, 1987; Brooks-
Gunn, 1985; Snowden & Christian, 1983; Spencer-Gardner, et al., 1983; Paige, 1973;
Berry & McGuire, 1972; Moos, 1968). Aspects of many of these have been
incorporated into the Menstrual Health and Reproductive Attitudes questionnaire used
in this chapter (MHRAQ-2).
The development of version one of the MHRAQ was described in Chapter Three.
MHRAQ-2 had three purposes: 1) it offered a means to gather demographic
information about the clinic population; 2) it provided a tool to test the generalizability
of the menstrual attitudes derived from MHRAQ-1 and the semi-structured interviews;
and 3) it functioned as a recruitment device for the pill cycle length manipulation study
which is reported in Chapter Six.
MHRAQ-2 was based on MHRAQ-1, but was modified to accommodate the broad
scope of ideas generated by the semi-structured interviews. The order and wording of
questions was changed, and in some cases simplified, to make it possible for women to
complete the questionnaire without assistance while waiting in the FPC for a
consultation. A copy of MHRAQ-2 is contained in the Appendix 4.02. A special
"supplement" was added to the basic questionnaire comprised of quoted statements
made by women in the open interviews, or precis of views held by more than one
woman. The supplement consisted of a list of 37 statements with which respondents
could agree or disagree.
The supplement included statements relating to the nature of bleeding, embarrassment
linked with bleeding, neutral, positive, and negative views, awareness of other
women's bleeds, perceptions of men's views, and thoughts about menstrual education
and the use of menstrual equipment. It was intended that the supplement should cover
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a wide range of ideas and possess a balanced tone with some statements phrased
positively and some negatively, some with a feminist slant and some without. The
objective was to force women to consider each question in turn, and not produce a
response set.
The questionnaire was piloted with 20 Clinic attenders. Each woman was asked to
complete the questionnaire without assistance. I then went through it with her item by
item to determine what she understood each question to mean and how she thought it
could be improved. The questionnaire was refined in consideration of these
discussions, however, it was not formally validated.
In December 1989 and January 1990 the MHRAQ-2 was offered to every woman who
attended the FPC over the course of fourteen Clinic days, covering a total of thirty-eight
Clinic sessions. Attenders at the FPC are made up predominantly of women coming
for routine family planning consultations. A much smaller proportion attend for
colposcopy treatment, well woman services, or accompany partners to vasectomy
counselling and surgery. Women also attend for Menopause Clinics on Wednesday
afternoons, but they were not asked to take part. The numbers of women passing
through the clinic during these three weeks are summarized below.
Weekly subtotals of FPC attendance-Week: 11th to 15th Dec., 1989 437
8th to 12th Jan., 1990 560
15th to 18th Jan., 1990 493
Total numbers attending FPC 11th Dec. to 18th Jan. 1490
One thousand and eighteen (1018) questionnaires were handed out to consecutive clinic
attenders and 698 were satisfactorily completed and returned. Of those completed, a
random sample of five hundred (500) were coded and the data were entered into the
University of Edinburgh main frame computer. The data were verified using fortran
programmes written by Dilys Rennie and analysed using SPSS-x.
The analysis which is reported below addresses the following questions: 1) What are
the demographic characteristics of Clinic attenders? 2) Does this population consider
vaginal bleeding important and why? 3) Were the women who took part in the
folliculogenesis study demographically and attitudinally representative of this larger
cross-section of Clinic attenders? 4) Do women using the pill experience or perceive
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their vaginal bleeding or other cycle related experiences differently to women not using
the pill? And 5) Are those women who volunteered to take part in the cycle length
manipulation study different from those women who did not volunteer? An assessment
was made of the frequencies of responses of the whole sample to each question.
Comparisons of the response frequencies of pill versus non-pill users, and volunteers
versus non-volunteers were made using Chi-square (%2) tests, with Yates correction for
small cell size where appropriate.
4.4 Characteristics of the Family Planning Clinic Population
4.4.1 Demographic and Contraceptive Features
Estimations of the frequency distributions of demographic characteristics of the random
sample of 500 hundred FPC attenders shows them to be largely homogeneous. Clinic
attenders tend to be highly educated, non-religious, working women who are in
relationships with equally non-religious, largely professional, working men. As one
might expect, the age distribution of the sample, shown in Table 4.01, covers the entire
reproductive span, with almost three-quarters aged between 20 and 34 years.
Approximately two-thirds of respondents possess degrees or post-graduate
qualifications, and more than 70% are in full time employment. Most women also
work in professional, managerial, or support and trained traditional white collar jobs
including: doctors, lawyers, corporate executives, nurses, teachers, social workers, lab
technicians, bookkeepers, personal assistants, etc.. Further almost 40% of partners are
professionals or managers. Therefore, the vast majority of respondents may be
classified as belonging to social classes I and II and to a smaller extent, III according to
the indices provided by OPCS (1980) (see Table 4.01).
More than 90% of women report that they are presumptively fertile, and 86% (of the
90% who replied to the question) are in a sexual relationship. Only about 30% of the
sample have ever been pregnant, and 9% of first pregnancies were terminated. Of
women reporting that they have a religion, 60% are Protestant and 12% Catholic. The
remainder report no religion or did not reply to the question. Less than a third consider
themselves to be religious people, and only 14% say that they are currently active in
their religion. The distribution of partner's religions is similar, and even fewer partners
are reported to be religiously active (see Figures 4.01 and 4.02).
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Table 4.01 Biographical Details of Questionnaire Respondents:
Comparisons by pill use and volunteering
Variable Classification n = % X2 for pill X2 f°r
vs. non volunteers
pill users vs. non
volunteers






Missing data 8 1.6
Relationship In a relationship 429 85.8 0.00 0.00
status Not in a relationship 25 5.0
Missing data 46 9.2
Highest School leaver 90 18.0 3.85 3.96
educational Highers 90 18.0
attainment University/Poly./College 239 47.8
Postgraduate/Profession 75 15.0
Missing data 6 1.2
Employment Full time job 353 70.6 27.43** 8.33
status Part time job 43 8.6
No paid job 39 7.8
Student 54 10.8
Missing data 11 2.2
Respondents' Prof./Manag./Self-empl. 95 19.0 15.87* 10.56
social Support/Trained Traditnl 258 51.8
group Service/Manual 46 9.2
Home/Student/Unempl. 89 17.8
'
Missing data 12 2.4
Partners' Prof./Manag./Self-empl. 194 38.8 Not tested Not tested
social Support/Trained Traditnl 128 25.6
group Service/Manual 83 16.6
Student/Unemployed 44 8.8
Missing data 51 10.2
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Table 4.01 Continued
Variable Classification n = % %2 for pill X2 for
vs. non volunteers
pill users vs. non
volunteers
Fertility Presumptively fertile 462 92.4 Not tested Not tested
status Sterilized 7 1.4
Partner sterilized 4 0.8
Menopausal 1 0.2
No sexual realtionship 18 3.6
Trying to conceive 8 1.6
Parity Nulliparous 321 64.2 69.87** 4.21
1 pregnancy 64 12.8
2 pregnancies 47 9.4
3 pregnancies 25 5.0
>4 pregnancies 12 2.4
Missing data 31 6.2
Key: *p<0.05, **p<0.00, volunteers- those women who agreed in principle to take
part in the cycle manipulation study reported in Chapter Six.
More than two-thirds of these women are currently using the pill as their method of
contraception, and the majority have used their current method for more than one year.
The other commonly used methods include the intrauterine contraceptive device
(IUCD), female barrier methods, and condoms. More than half of the sample has also
used the pill at some time in the past, and 36% report condom, 12% female barrier
method, and 7% IUCD use in the past (see Figures 4.03 and 4.05).
Of current pill takers approximately 70% have used the pill for at least one year. Figure
4.06 shows that about 40% of those who could specify which type of pill they use are
taking monophasic combined pills, while only about 12% of women use triphasic
combined pills, and about 10% use progesterone only contraception. Thus pill takers at
the FPC are predominantly established users of low dose pills. The distribution of ages
at first pill use are shown in Figure 4.07. Two-thirds of women started the pill
between the ages of 16 and 20, and only 9% of the 500 have never used this method.
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Figure 4.02 Strength of religious beliefs and participation in religious
activities of respondents and their partners.
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Figure 4.04 Duration of present contraceptive method use.
Chapter 4 Attitudes to Vaginal Bleeding 162




HI Spermicide alone n=4
H Withdrawal n=29
S3 Rhythm method n=8
□ Vaginal ring n=1
Figure 4.05 Previous contraceptive method usage. Totals greater than 100%
due to past use of more than one method.
Hi Monophasic n=191
□ Triphasic n=62
□ Progesterone only n=48




Figure 4.06 Current use of different pill formuiations.
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Figure 4.07 Age at first pill use.
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4.4.2 Current Bleeding Experience
Approximately one-fifth of respondents report that they have light bleeds, three-fifths
moderate, and one-fifth heavy to very heavy. The duration of the bleed was similarly
distributed between 2 to 3, 4 to 5, and 6 to 7 days. Further about two-fifths each of the
sample noted that full bleeding lasts for 1 to 2, or 3 to 4 days (see Table 4.02). Table
4.02 shows the incidence of breakthrough bleeding, and the variability of cycle length.
The majority of women surveyed use only tampons to collect their menstrual blood.
This is split about evenly between tampons with applicators and those without. The
other third of women use pads some or all of the time, with or without tampons.
Table 4.02 Details of Bleeding for Questionnaire Respondents:
Comparisons by pill use and volunteering
Variable Classification n = % X2 for pill X2 for
vs. non volunteers
pill users vs. non
volunteers
Reported Light 103 20.6 33.67** 2.04
volume of Moderate 288 57.6
blood loss Heavy 78 15.6
Very heavy 22 4.4
Missing data 9 1.8
Duration of 2-3 days 64 12.8 Not tested Not tested
bleeding 4-5 days 303 60.6
6-7 days 103 20.6
8-9 days 5 1.0
>10 days 8 1.6
Missing data 17 3.4
Number of 1-2 days 229 45.8 Not tested Not tested
days of full 3-4 days 205 41.0
bleeding 5-6 days 27 5.4
7-8 days 2 0.4
Missing data 37 7.4
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Table 4.02 Continued
Variable Classification n = % X2 for pill X2 for
vs. non volunteers
pill users vs. non
volunteers
Variability in Always the same 218 43.6 Not tested Not tested
cycle length 2-3 days variation 170 34.0
5-6 days varaition 53 10.6
>10 days varaition 34 6.8
Missing data 25 5.0
Incidence of Never 266 53.2 Not tested Not tested
breakthrough Some cycles 128 25.6
bleeding All cycles 18 3.6
In the past 75 15.0
Missing data 13 2.6
Menstrual Tampons w/ applicator 183 36.6 9.23* 5.41
equipment Tampons w/out applictr. 152 30.4
used Pads only 56 11.2
Pads with tampons 53 10.6
Pads or tampons 47 9.4
Missing data 9 1.8
Reported Yes PMS 147 29.4 5.09 8.36*
PMS status Maybe PMS 126 25.2
No PMS 161 32.2
Past PMS 42 8.4
Missing 24 4.8
Key: *p<0.05, **p<0.00, volunteers- those women who agreed in principle to take
part in the cycle manipulation study reported in Chapter Six.
4.4.3 Cycle-Related Changes in Well Being
Approximately 55% of women surveyed said that they did have, or might have PMS.
About one-third said that they did not have it, and 8% felt they had had it sometime in
the past (see Table 4.02). Respondents were presented with a large number of aspects
of well being which might change with a regular pattern over their cycle. Figure 4.08
shows the percentages of women who indicated that they experience a particular
sensation/feeling cyclically. Bloating (60%), breast tenderness (58%), and period type

























Figure 4.08 Incidence of self-reported cycle-related "symptoms".
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pain (47%) are the most commonly reported physical symptoms. Tension (56%) and
tearfulness (54%) are the moods which were most frequently reported to cycle2.
Generally positive moods and cognitive/behavioural variables (lower 9 bars on figure)
were reported by fewer women to vary cyclically than negative moods and physical
states (upper 12 bars).
4.5 Attitudes and Behaviours of the FPC Population in
Relation to Bleeding
Almost three-quarters of the 500 respondents believe that it is important for women to
have periods (see Figure 4.09). The reasons which women gave on MHRAQ-1 and in
the interviews for finding bleeding important were incorporated into question 29 on
MHRAQ-2. Figure 4.10 summarizes respondents' characterization of the importance
of bleeding. Namely, the majority agreed that bleeding is natural, a good indication of
non-pregnancy, normal, shows that one is using contraception properly, a sign of good
health, a nuisance, a sign of fertility, and a habit. On the other hand, they disagreed
that it was unnecessary when using reliable contraception, a waste of bodily energy and
nutrients, emotionally cleansing, womanly, and physically cleansing. These later
statements also seemed to hold more limited meaning for women which is indicated by
the fact that 34% or more of women answered that it was not a belief they hold.
However, the fact that only 2 to 7% of women failed to respond to any part of this
question indicated that it was generally easily intelligible and meaningful.
Those activities which women avoid during vaginal bleeding are summarized in Figure
4.11. The only things avoided to a significant degree seem to be sexual intercourse,
and swimming. Over half of respondents observe the "sex taboo". More complex
aspects of women's beliefs about and attitudes to bleeding were explored using the 37-
statement "supplement" described above. Like the other Likert-type scales used in this
questionnaire the 'meaningfulness' of the statement was revealed by how polarized
responses were into agree/disagree categories versus 'neither agree nor disagree' or
missing entries. All responses are summarized in Appendix 4.03.
2
Irritability and depression, which are possibly the most commonly reported PMS-type
'symptoms' (eg.- Warner, et al., 1991) were unfortunately overlooked in this list.
Depression could be indicated by cyclical 'happiness', and 'anger' might be interpreted
by some as analogous to irritable. However, the relatively limited reporting of
'happiness' and 'anger' suggest that 'irritability' and 'depression' ought to have been
specified.
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H Important n=359
□ Not important n=113
□ Missing n=28
Figure 4.09 Respondents beliefs about whether or not it is important for
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Figure 4.11 Incidence of menstrual taboo observance.
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Statements which related to the instruction which should be given to children regarding
menstruation, the provision of equipment, bleeds as something embarrassing, and
bleeds as a neutral experience produced the most definitive responses. From 63 to 86%
of women agreed or strongly agreed that both boys and girls should be taught at school
and home about periods, and that girls should be shown how to use menstrual
equipment. About 50% of respondents believe that most people are embarrassed to talk
about periods, however, an equal proportion do not believe that tampons are
embarrassing to others. Because of the way in which the statement was phrased, their
replies do not preclude the possibility that they do hide menstrual equipment because
they themselves find its use embarrassing. More than three-quarters of women agreed
that although they are less embarrassed by bleeding than they were when they were
younger, they would be embarrassed if they bled onto their clothing.
A marked majority of women agreed that bleeding does not affect them a great deal, and
is not positive or negative, but "just there". While 38% disagreed that for them
menstruating is just another toilet habit, 32% agreed that it is. In contrast to the
response to neutral statements the majority of women disagreed with specifically
positive and negative statements about bleeding. Overall women do not find that
bleeding makes them feel relaxed, proud of being a woman, or is mainly a positive
experience. On the other hand, they also do not believe that bleeding "gets rid of their
rottenness", is a curse when it is painful, or makes them feel dirty. Women also tended
to disagree that the men they are in contact with view bleeding negatively, as painful
and traumatic, do not want to discuss it, or use it to stigmatize women. In contrast,
about three-quarters agreed that their own partners are sensitive and understanding
when a bleed affects them badly.
The reasons that more than half of women avoid sexual intercourse during bleeding
seem to be complex from their response to statements relating to menstrual sexuality.
Most women do not think tampon use is interpreted as being sexual, nor do they think
that it is morally wrong to have sex during a bleed. Equally, they do not avoid sex for
fear of getting blood on their partner. However, most do not feel especially sexually
receptive during a bleed and agree that they prefer not to have sex then because it is
messy.
The statements which seemed to possess the least meaning for women were those
relating to the nature of menstrual bleeding, and women's awareness of and solidarity
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with other women who are menstruating. These produced 'neither agree nor disagree'
responses between 22 and 48% of the time. About a third to one half of women agreed
that periods are to do with sex and babies, that they are private and personal, and that
the more a woman bleeds the more she is affected by it. More than half of respondents
are unaware that other women are bleeding, and while a quarter of women believe that
they notice menstrual blood's distinct smell, more than a third do not. The majority of
women could not relate to statements which indicated that bleeding made them feel
closer to other women, to their own mortality, or physically unique.
In spite of the importance with which most women view bleeding 52% have altered
their pill cycle length in the past (see Figure 4.12). The question relating to why the
cycle was altered and in what manner was not answered by the majority of women.
Nevertheless, of those responses given the most common practice seems to have been
to take 2 packets of pills in a row (20%) in order to avoid a bleed while on holiday
(23%). When women were asked if they would eliminate bleeding for a time if there
were no harmful consequences and they could be sure that they were not pregnant
almost four out of five said they would possibly or very likely do so (see Figure 4.13).
Less than one third of respondents said they were not likely to, or would definitely not
do so.
4.6 Representativeness of the Folliculogenesis Sample
The folliculogenesis study sample of Clinic attenders was highly representative of FPC
attenders at large. They were selected for established pill use, so are in this way similar
to two-thirds of Clinic attenders. Their educational attainments and employment
status, religion, relationship status, and parity are all similar to the general FPC sample.
The distribution of volume and duration of vaginal bleeding reported by the 500 FPC
attenders is also very similar in this sample.
Equally the beliefs of the larger sample about the importance of bleeding are similar to
those of the small sample of pill takers from which the questions are derived. Thus,
vaginal bleeding was seen as a sign of health, naturalness, and potential fertility, in
spite of the fact that bleeding on the pill is an artificial consequence of hormone
withdrawal and ovulation is not taking place. Several folliculogenesis volunteers said
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H Altered cycle n=258
□ Not altered cycle n=189
□ Missing n=53
Figure 4.12 Incidence of previous pill cycle length alteration.
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H Very likely / Possibly n=389
□ Not likely / Definitely not n=92
□ Missing n=19
Figure 4.13 Hypothetical willingness to eliminate vaginal bleeding for a time.
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that regular bleeding was a sign that their bodies were "working normally". Another
women said it was important to bleed because you are "supposed to"; another that it
gives a "feeling of routine". Others said women bleed to "clear the womb" or for
"cleansing once a month". And although withdrawal bleeding may still occur in the pill
cycle if a woman is pregnant, these women felt that their bleeds reassured them that the
pill was working properly, that they were using it correctly, and that they were not
pregnant.
Three women did not believe that bleeding on the pill was important. One, who is a
botanist, said that it is a "waste of energy" to bleed, and another who is a biochemist,
said it was not important if you were taking the pill, but was an important sign of non-
pregnancy during a "normal cycle".
Ten of these volunteers had altered the length of their pill cycle at some time in the past.
In eight cases the number of active tablets taken was extended beyond the usual twenty-
one. Most often a woman simply took two packets of pills in a row, usually because
she wanted to avoid a period on holiday. One woman takes several packets in a row
routinely (the "tricycle regime"). Two women shortened the number of active pills to
advance bleeding. One wanted a 'period' before she went on holiday, and one stopped
her pills early when she had breakthrough bleeding brought about by vomiting.
Women were asked how they would feel about eliminating withdrawal bleeding for a
time if there were no harmful physical consequences. Curiously, although ten women
had altered bleeding in the past, only eight said they would be very likely to do so in
future. Of the women who had previously taken extra pills to avoid bleeding while on
holiday, one said she would "definitely not" alter her cycle, and another said she was
"not likely" to do so, yet neither had had any problems with the manipulation. In spite
of these apparent contradictions, the majority of women expressed a willingness to alter
the cycle. The four possible responses were selected in precisely the same proportions
as the general FPC sample: "very likely" 8, "possibly" 8, "not likely" 3', and "definitely
not" 1.
The proportions of women retrospectively reporting PMS were similar in the study
sample to the larger sample. The prospective findings of the investigation seem to
support the reports made by the larger sample that bloating, breast tenderness, and
period type pain are the most frequently experienced cycle-related changes.
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4.7 Differences Between Pill and Non-pill Users
The fact that a sample of 20 separately recruited pill takers were so similar in
demographic, experiential, and attitudinal variables to a random sample of 500 Clinic
attenders who were using the full range of contraceptives begins to suggest that pill and
non-pill takers attending the FPC are not materially different. A direct comparison
between those taking the pill and all those using other methods of contraception within
the MHRAQ-2 sample shows that the two groups are generally quite similar. They
differ in the ways that are to be expected given the contraception which they are using.
The first way in which the groups differ is by age. The Chi-square test showed that pill
takers were significantly younger than non-pill takers (p<0.00; see Table 4.01 for X2
statistics). Eighty per cent of pill takers are between 20 and 34, while a quarter of other
method users are 35 or older, the time after which pill use is discouraged, especially in
smokers. Non-pill takers were also significantly less likely to be in full time
employment (79% pill vs. non-pill 58%) and more likely to be unemployed (7% pill vs.
non-pill 11%), in part time work (5% pill vs. non-pill 17%), or a student (10% pill vs.
non-pill 14%; p<0.00). In parallel to this, significantly fewer non-pill women were in
the professional/managerial bracket (22% pill vs. non-pill 15%), while significantly
more classed themselves as homeworker/ student/ unemployed, (15% pill vs. non-pill
27%; p<0.05). Some of these differences may be attributable to the fact that the non-
pill group had significantly higher parity (p<0.00). While 80% of pill takers had never
had a pregnancy only 44% of non-pill takers were nulliparous. Nineteen per cent of
pill takers have had between one and four pregnancies, versus 56% of non-pill takers.
The two groups did not differ in their relationship status or their level of education,
however (see Table 3.01).
As one would expect, pill and non-pill users differed on almost all aspects of their
attitude to current contraceptive use in ways which seem to relate directly to the effects
of the various methods. The amount of blood loss which women reported was also
strongly related to method use. While similar proportions of both groups report
moderate bleeding (59% pill vs. 58% non-pill), many more pill users indicate light
bleeding (27% pill vs. 8% non-pill), and many more non-pill users heavy to very heavy
bleeding (14% pill vs. 34% non-pill; p<0.00). Pill users are significantly more likely
Chapter 4 Attitudes to Vaginal Bleeding 111
to use tampons (72% pill vs. 58% non-pill), than pads with or without tampons (28%
pill vs. 42% non-pill; p<0.05). See Table 4.02 for X2 statistics.
In spite of the fact that non-pill users tend to bleed more heavily than pill users, the two
groups do not differ in the degree to which they consider bleeding important (X2=0.00,
p=0.98), nor in the reasons they cite for its importance. The groups did not differ in
their willingness to eliminate bleeding if they could (X2=1.36, p=0.71). However,
significantly more pill takers have altered their cycle length in the past (48% pill vs.
non-pill 30%; X2=8.99, p<0.01).
There were significant differences between the groups on only 4 of the 37 statements
on the questionnaire supplement. These differences suggest slight and subtle
differences in the attitudes to their bleeds of women using different contraceptive
methods. The views of the non-pill group, who have higher parity, were significantly
more polarized on the statement suggesting that periods are experienced differently after
having children (X2=24.73, p<0.001). Their views on the nature of bleeding were
different to pill takers. In particular, they were more inclined to disagree that bleeding
is private and personal (% disagreeing- 13% pill vs. 24% non-pill; X2= 18.57,
p<0.001), and agree that it brings women closer to their "physicalness" (% agreeing-
22% pill vs. 38% non-pill; X2=17.13, p<0.01). Finally, non-pill takers are
significantly less likely to find their partner sensitive and understanding when their
period affects them badly (% disagreeing- 3% pill vs. 14% non-pill, X2= 17.86,
p<0.01).
Women who do and do not use the pill did not differ significantly in the frequencies
with which they report suffering from PMS (see Table 4.02). However, they do differ
in the incidence of some self-reported cyclical symptoms. Namely, non-pill takers
report a higher incidence of cyclical change in tension (X2=8.19, p<0.01), breast
tenderness (X2=5.35, p<0.05), and backache (X2=6.29, p<0.05). There is also a non¬
significant tendency for them to report more cyclical period type pain (X2=3.02,
p=0.08), anger (X2=3.18, p=0.07), energy (X2=2.40, p=0.12), and creativity
(X2=2.57, p=0.10). On the other hand, there are no group differences in the incidence
of cyclical happiness, self-esteem, attractiveness, coordination, concentration, bloating,
hot flushes, or food craving. Nor are there any difference in variables which may be
altered by pill use, namely: tearfulness (depression), headaches, nausea, sexual interest
and activity, and acne.
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Pill takers and other method users were not compared on measures of partner's status,
religion, duration of method use, menarcheal experience, bleed duration, cycle length,
breakthrough bleeding, or menstrual avoidances.
4.8 Differences Between Manipulation Study Volunteers and
Non-Volunteers
All women taking the pill were asked if they would like to volunteer to take part in a
further study relating pill cycle length to well being. This was the primary, but not the
only device used to recruit participants into the study described in Chapter Six. It is of
interest to explore whether or not there are any systematic biographical or attitudinal
differences between pill takers who did and did not volunteer to take part in a study of
cycle length manipulation. The comparisons reported here do not describe the
differences between the actual participants and non-participants. Many women
expressed a willingness to take part in the investigation but ultimately declined to join
the study for a variety of reasons. The statistical comparisons are made between
women who agreed in principle to the idea of taking part versus those who were
unwilling even to be contacted. One hundred and seven or 32% of pill takers in the
random sample of 500 offered their name and address to be contacted about the further
study. The remaining 228 pill takers (68%) did not give any contact information. Thus
these comparisons are made amongst the 335 "volunteers" and "non-volunteers" in the
sample who were taking the pill. The same variables were compared as for the
pill/non-pill groups above.
Overall there were relatively few differences between the groups. Notably, there were
no differences in demographic variables, but there were slight differences in attitudes.
Volunteering women indicated that they were "encouraged" to use the pill because it is
separate from intercourse (89% volunteers vs. 76% non-volunteers; X2=7.79, p<0.05),
and because it caused an improvement in their PMS (47% volunteers vs. 29% non-
volunteers; %2=11.04, p<0.05), while non-volunteering women were "put off" by the
effects which the pill has on their hormones and their system (42% volunteers vs. 37%
non-volunteers; X2=8.37 p<0.05). The views of women who volunteered were
significantly more polarized into agree and disagree catergories over the idea that
bleeding is a habit than the non-volunteers. Equally volunteers were significantly more
likely to disagree that their periods are not positive or negative, "just there" (20%
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volunteers vs. 12% non-volunteers; X2=9.95, p<0.05), and "just another toilet habit"
(49% volunteers vs. 35% non-volunteers; X2=9.24, p<0.05). Volunteers agreed more
strongly than non-volunteers that instruction about periods (40% volunteers strongly
agree vs. 26% non-volunteers; X2=9.02, p<0.05) and equipment (68% volunteers
strongly agree vs. 66% non-volunteers; X2=10.08, p<0.05) should be more freely
available. They also tended to agree that pain is "the curse" (42% volunteers vs. 29%
non-volunteers; X2=9.59, p<0.05), and that the more one bleeds the more one is
affected by it (64% volunteers vs. 52% non-volunteers; X2=9.94, p<0.05).
The only other ways in which the two groups differed according to Chi-square tests
were in the distribution of their PMS reporting, and one cyclical symptom. Those
volunteering were more likely to report that they do have PMS, or have had in the past,
and less likely to say that they might or do not have it (Yes PMS 33% volunteers vs.
26% non-volunteers, No PMS 30% volunteers vs. 36% non-volunteers, Maybe PMS
22% volunteers vs. 30% non-volunteers, Past PMS 15% volunteers vs. 7% non-
volunteers; X2=8.36, p<0.05). They were also more likely to report cyclical food
craving (37% volunteers vs. 27% non-volunteers; X2=3.55, p<0.05). The two groups
did not differ in their willingness to eliminate bleeding if possible, however, there was
a slight tendency for more volunteers to say that they would be likely to do so (85%
volunteers vs 80% non-volunteers; X2=7.13, p=0.06).
4.9 Discussion of Findings
The aims of this chapter were to describe the characteristics of the samples studied in
this thesis, to assess the importance of bleeding experience to them, and to consider the
cultural filtering of attitudes and beliefs which may influence the reporting of cycle-
related experience.
4.9.1 Demographic Factors and Mlenstrual Health in the Whole Sample
The sampling for the studies reported in this thesis is population based, and thus has an
advantage over many other studies of attitudes and cycle-related change which have
used students or nurses as a sample pool (Dan, et al., 1980). However, the results of
MHRAQ-2 indicate that Edinburgh Family Planning Clinic attenders are not
representative of the whole range of Scottish women of reproductive age. There is a
strong bias in favour of higher social class, working women in their 20's who are
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nulliparous and take the pill. Given that the experimental studies in this thesis are
entirely concerned with established pill takers, however, this would seem to be an
appropriate recruitment centre. The volume and duration of bleeding reported by
women in this sample is similar to other samples, eg. moderate bleeds lasting for four
to five days, and consistent with the high incidence of pill use.
Choice of menstrual equipment has been related to the degree of traditionalism in
menstrual attitudes, with tampon use being associated with more liberal beliefs.
Snowden & Christian (1983) note that tampons tend to be used by urban, middle class
women, and in support of this most of this sample use tampons. Paige (1973)
interprets the rejection of tampons as "an indirect measure of anxiety about the invasion
of one's body, and about the sexual overtones of menstruation". This precept is partly
borne out by the fact that FPC attenders not using the pill were somewhat more likely
than pill takers to use pads. This may either be a function of apparently, slightly more
conservative attitudes to their bodies and bleeding (see below) or due to the fact that
their bleeds are heavier. An interesting dichotomy emerged from the semi-structured
interviews. Almost all women in the folliculogenesis sample used tampons. The
liberal / conservative divide seemed to be reflected more strongly in the attitudinal
differences between women who used tampons with or without applicators, than
between those choosing tampons over pads. Tampons with applicators were favoured
by those women who did not wish to touch their genetalia. The attitudinal differences
between the women using the two sorts of tampon were not investigated here, but this
apparent dichotomy might fruitfully be pursued in future.
More than half of women surveyed said that they did have or might have PMS. PMS
was not defined for them, and no measure of severity was made, however, the rate of
retrospective PMS reporting is within the variable range of incidence estimates given in
the literature (eg. Asso, 1983). Women were asked if they experienced any of a large
number of possible cyclic symptoms. The most commonly reported symptoms were
physical, though tension and tearfulness were noted by more than half of the sample
too. Bloating, breast tenderness, and period type pain were also the symptoms which
showed the clearest evidence of cyclicity prospectively in the folliculogenesis sample.
In this sample women who do and do not take the pill reported experiencing PMS with
a similar frequency. Yet there was a slight tendency for non-pill takers to indicate
specific symptoms more frequently, suggesting that oral contraceptives may reduce the
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severity or number of symptoms which a woman experiences. An alternative
explanation is that more symptomatic women do not choose, or do not tolerate the pill
(eg. Bancroft & Sartorius, 1991). Some sort of self-selection process of this kind may
explain why pill takers do not report higher incidences of those symptoms which the
combined pill has been traditionally linked such as depression, nausea, and headaches
(eg. Mears, 1966).
4.9.2 Characteristics and Differences of Sub-samples
In addition to the general finding that this sample of FPC attenders has similar
characteristics to population samples reported in other studies, it was clear that the
sample of women who took part in the folliculogenesis study were representative of the
larger population on all aspects measured. Equally women using different methods of
contraception were also similar for the majority of factors, with a few notable
exceptions.
Predictably, women using methods other than the pill were older, of higher parity, and
not so often employed as pill takers. There may be a variety of reasons for these
differences such as: the pill is less widely prescribed to women over thirty, age and
parity are likely to be confounded, parous women have access to methods like the
IUCD which are not generally offered to nulliparous women, barrier methods may be
more likely than hormonal methods to be used post-partum or to space children,
women with children may be less likely to be in paid work or have opportunities for
advancement to top level jobs, etc.. Further, the decision not to use the pill may be
linked to greater acceptance of a more traditional female role which has led some of
these women to choose to be homeworkers and mothers.
The not surprising fact that more women using non-hormonal methods have heavy
bleeding has been mentioned above. In spite of differences in bleeding experience,
however, the two groups do not differ in their views of the importance and reasons for
having bleeds. Between three and four out of five women, regardless of method used,
seem to view bleeding in normative and practical terms. It is seen as a monitor of
continuing good health and normality. While acting as a measure of contraceptive
performance, it is nevertheless seen as a nuisance. The reasons given for the
importance of bleeding by women in this sample are similar to the WHO survey
(Snowden & Christian, 1983) which reported that a majority of women world-wide
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consider bleeding " a natural, vital, physiological episode" which is "a sign of
continuing youth, fertility and femininity", of non-pregnancy, and a cleansing of "bad
blood". In this sample there was a tendency for women to relate more to the cognitive
than the emotional concepts about bleeding (eg.-womanliness, cleansing) which may
reflect a greater emphasis in Western culture on mechanistic, medical explanations of
physical experience.
It is of considerable interest and importance to the interpretation of the findings in this
thesis that women view their bleeding experience in a similar way, and endow it with
the same meaning whether or not they use oral contraception. Withdrawal bleeding
during pill cycles is physiologically different from menstruation. Yet a significant
proportion of women wrongly believe that withdrawal bleeding is an accurate assurance
that they are not pregnant, and even continue to see it as a sign of fertility when the
express purpose of oral contraception is to suspend one's fertility. This belief structure
undoubtedly influences women's willingness to undergo manipulations of their pill
cycle length. Having said this, the fact that more pill takers have altered the length of
their cycle in the past may reflect greater flexibility in their beliefs. Alternatively, it may
simply indicate greater opportunity, since non-pill takers cannot exercise the control
over the timing of their bleeds that pill takers may.
4.9.3 Attitudes to Bleeding
The most notable information to emerge from the semi-structured interviews was that
women's beliefs about bleeding and their cycles are highly complex and characterized
by ambivalence. The broad outline of women's beliefs about whether and why they
consider bleeding important were discussed in relation to question 29 above. The
questionnaire supplement offered more insight into the nuances of attitudes.
Brooks-Gunn & Ruble (1980) used a similar approach to the supplement in the
Menstrual Attitudes Questionnaire which included 33 statements with which women
could agree or disagree. The factors they derived from their investigation are similar
to the themes which emerged from the interviews and were incorporated into the
MHRAQ-2. These include the ideas that bleeding is natural and womanly, and it is
probably wrong or dangerous to interfere with it. On the other hand, it is
embarrassing, a source of shame, should be concealed, is messy, and is troublesome
when it causes symptoms.
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A majority of women surveyed conformed to the idea that bleeding is an embarrassing
event which ought to be concealed, and were particularly worried by the idea of
"excretory soiling". However, they did not seem eager to maintain the status quo, as
most believe that both male and female children should be taught more openly about
bleeding than they currently are. Otherwise most women in this sample subscribe to
the view that bleeding does not affect them a great deal, and is generally a neutral
experience. The men in their immediate environments are generally supportive, or at
least not derogatory about their cycles.
One of the most deeply rooted menstrual behavioural restrictions is the taboo on sexual
intercourse during bleeding. More than half of this sample reported abstaining from
sex during bleeding, in spite of their apparently relaxed attitudes. This figure is
consistent with other reports for "Western" women (eg. Paige-Eriksen, 1987; Matlin,
1987), while the sex taboo is reportedly observed by almost 100% of men and women
outside the US and UK (Snowden & Christian, 1983). It is not clear why this
behaviour persists. Women had great difficulty during interviews in offering plausible
reasons for it. Many replies related to the stated "unclean" nature of menstrual blood
and an implied fear of its dangerous, almost supernatural ability to defile those who
come into contact with it. Interviewees were not able to articulate this concept directly,
and questionnaire respondents gave the "mess" as their reason for abstaining. This
deeply sublimated pollution belief may help to maintain the "traditional hierarchical
relations between the sexes" (p. 185, Paige-Eriksen, 1987). Equally in some cases sex
may be avoided because of physical discomfort and cycle-related loss of well-being
during bleeding.
4.9.4 Attitudinal Differences in Sub-samples
It is somewhat surprising that pill and non-pill users, and volunteers and non-
volunteers only differ subtly on measures of attitudes to bleeding. In the pill/ non-pill
comparison the differences may be explicable in terms of higher parity and heavier
bleeding amongst non-pill takers. If women on the pill have lighter, more predictable,
and possibly less painful bleeds then they are likely to be less affected by them.
Equally, the relative ease of their bleeds may mean that they require less support from
their partners, while the non-pill user has had more opportunity to challenge the level of
her partner's sympathy. Several authors note that heavier bleeding is related to greater
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symptom experience, both before and during bleeding (Brooks-Gunn, 1985; Snowden
& Christian, 1983; Paige, 1973). This fact would be consistent with the tendency for
non-pill users to report more cycle-related changes. The pill and non-pill groups
differed in age, and it is possible that a future age-matched comparison of pill and non-
pill users might reveal more marked differences in bleeding-related attitudes than those
found in this survey.
The ways in which those women who did and did not volunteer to take part in a study
of altered cycle length differed seem to reflect differences in the strength, as opposed to
the direction, of certain beliefs. In particular, volunteering women held less neutral
views of bleeding, and were more inclined to link the effects of bleeding to greater pain
and volume. Yet the groups did not differ in terms of these parameters. The only
difference in symptom reporting was the incidence of food craving.
In addition, though all potential volunteers were similar demographically, there was a
tendency for women who did volunteer to report more frequently that they experience
PMS, and also to indicate that the pill had improved their PMS. Equally those women
not volunteering were slightly more likely to suggest that they disliked the hormonal
effects of the pill. Thus they may be put off a study in which cycle length is altered
because they tend to have adverse reactions to hormonal interventions, or because they
are less comfortable with the idea of such interventions.
These differences in current and past PMS experience have important implications for
the further study of the effects of cycle manipulation on well being. It would be
valuable if volunteers were inclined to have cyclical change in a study relating it to cycle
length, however, if the sample has already experienced a hormonally mediated
improvement in their PMS, then the potency of any manipulation effects will be
proportionally diluted. The differences between the groups may reflect underlying
personality differences which would also influence the data volunteers would generate
in a future study. For example, the greater strength of their views may reflect greater
extroversion, and an inclination to take part in a study in which they can further voice
these opinions. PMS reporting, particularly retrospectively, has recently been linked to
high neuroticism with a failure to confirm cyclical symptoms prospectively (Taylor,
Fordyce & Alexander, 1991). If the study sample were more neurotic, and less likely
to confirm this would have clear effects on findings.
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It is interesting that the two groups of women did not differ in their past experience of
cycle manipulation and that volunteers were only slightly more likely to express a
willingness to do so in future. One would have expected this measure above all others
to be predictive of volunteering. Indeed it is not clear from their responses to questions
about attitudes why none of the 80% of non-volunteers who "would alter" their cycles
failed to offer to do so.
4.9.5 Attitudes to Cycle Manipulation
Miller & Smith (1975) found that 79% of women in their white, unmarried,
nulliparous, lower to middle class sample would very likely or possibly eliminate
bleeding if it could be done safely for a time. The same question on the MHRAQ-2
more than 15 years later produced an almost identical distribution of responses, with
about 4 out of 5 women saying they might alter their cycle. Jarvis & McCabe (1991)
also found that 79% of their sample "would like to have their menstruation reduced".
When one women was asked in the semi-structured interviews if she would alter her
cycle if she could. Her reply may explain some of the inconsistency in women's stated
views:
"I think I tend to think when you take it normally and have the pill free
week you're actually having a normal period. I think in my mind it is as
it was before, and will be the same when I come off it. Whereas if you
kept taking it all the time that would be taking a drug to stop having
periods [My emphasis]." (T8)
The overarching theme which emerges from the literature on attitudes, desire for cycle
manipulation and the findings of the interviews and MHRAQ-2 is that both pill and
non-pill taking women wish their vaginal bleeding experience to be regular and
"normal". Instead of increasing the flexibility of women's concept of bleeding in fact,
oral contraception has actually reinforced the false belief that the 28-day cycle is the
norm. Because so many women take the pill, and the length of the cycle, at least with
combined pills is so invariate, the "average" cycle length across all women is probably
indeed nearer to 28 than it was before the pill was introduced. Further, the convenient
predictability of the pill, sometimes foreseeable to a particular time on a given day in
established users, seems to have made women intolerant of what are genuinely normal
deviations in cycle length. Ironically, the recent history of hormonal contraception may
be in large measure responsible for the lack of willingness on the part of women to pay
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more than lip-service to the idea of extending their cycles. With hindsight it might have
been better for women if the oral contraceptive pill regime had been completely different
from the menstrual cycle from its inception, thus the belief structure that grew up
around it might too have been more flexible.
4.10 Summary and Conclusions
This chapter indicates that the Family Planning Clinic sample from which all volunteers
in this thesis were drawn is fairly representative of well educated, working women of
reproductive age, and particularly of oral contraceptive pill users. It has also shown
that women's beliefs about vaginal bleeding are complex, and not necessarily uni¬
directional. Cultural attitudes inform both how questions about beliefs and experience
are posed and how they are responded to. While many women express a willingness to
manipulate the timing of their bleeds, it is possible that they may not be so prepared to
do so in practice because they are influenced by a desire to have "normal periods".
Women who take the pill view their bleeds and their cycle-related experience very
similarly to women who do not use hormonal methods.
Finally, the interview quote below highlights the danger of researching the menstrual or
pill cycle without considering the social context in which it is experienced:
I think there's a certain stigma attached to it still. It was just the reacdon
I had of a guy in the pub, and I didn't know him. I was with a friend
and he knew my friend quite well. And he'd had a lot to drink, like he
was pretty 'fou', and he turned round to my friend and he said, "Are
you bleeding this week?!" and I thought 'Oh no, I'm going to punch
this guy in the nose'. And she turned around and sort of looked at me
and she said, "We'll go somewhere else". And I says, "Yeah, come on-
let's get out of here." You know. Like it was just so silly, and it was
obviously something that he thought 'Yeah, this is going to strike a
chord, so I'll say to...', like it really was. (Was that to be aggressive
or...? ) Like everything you would associate with being bad. Like he
was just doing this to hurt us. There is still a stigma attached to it.
{Taboo? ) Yeah, unfortunately, which is a little disappointing. Come
on it is 1989!... {So what did that guy mean? ) Well there is a sentiment
attached to the fact that you're not clean. And people aren't so keen to
have intercourse then- and certainly that he was better as us because he
didn't bleed and we didL.Nastv. vicious, little man. You forget when
you've got quite an informed attitude what the rest of the population is
like. And to me that was the rest of the population rearing its ugly head
in the worst possible form, to say something like that. (T9)
Chapter 5 The Development of an Experimental Model
to Detect a Biological Rhythm of Well Being
Using Clinical Case Studies
5.1 Introduction
In Chapter Three a possible aetiological explanation was considered for the persistence
of cyclical change in emotional and physical well being during OC cycles. That study
showed that if there is a relationship between changes in well being and fluctuating
endogenous steroids it is probably weak, and is not adequate to explain the presence of
cyclicity in low dose monophasic or triphasic pill cycles. Chapter Four dealt with
women's attitudes to contraception and vaginal bleeding, and addressed the potential
acceptability of a contraceptive regime that alters the frequency of vaginal bleeding.
The interviews and questionnaire survey revealed that women's perceptions of their
bleeding experience are complex. While 80% of questionnaire respondents expressed a
willingness, in principle, to use a contraceptive that reduced the frequency of vaginal
bleeding, the majority of women using OCs and other methods consider vaginal
bleeding to be a sign of fertility, normality, good health and non-pregnancy, and
disagree that it it unnecessary when using reliable contraception.
These investigations provide the background for the research reported in this chapter
and the next by discounting one explanatory hypothesis and by elaborating the social
context in which these questions must at all times be considered. This chapter focuses
on the important temporal relationship between the steroid cycle and well being, and
offers a new theoretical model to explain it, an infradian rhythm of well being. The
nature of the purported rhythm was explored in the clinical setting of the Royal
Infirmary of Edinburgh Premenstrual Syndrome Clinic.
Because the aetiology of PMS is so poorly understood and women's experience of the
syndrome is so varied, effective treatment is difficult. The treatment strategy adopted in
a clinical setting may have to be individualized and experimental to achieve the best
result for a particular woman (Nader, 1991). From the Spring of 1988 until the Spring
of 1991, Dr. John Bancroft and I saw a number of PMS Clinic patients with who were
taking the pill. For many of these women Dr. Bancroft had chosen oral contraception
as the first line of treatment for their PMS, while the others were already using the pill
for contraception or PMS treatment at the time of referral to the Clinic. When I initially
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became involved with the Clinic, Dr. Bancroft had just begun to explore the possibility
that manipulating the length of the pill cycle, and in particular altering the timing of
withdrawal bleeding, might have a therapeutic effect on adverse cyclical symptoms.
Over the course of the next three years pill cycle length manipulations were attempted
with about a dozen women in an effort to manage symptoms. These explorations
helped to refine the theory and experimental model for an infradian oscillator. The
outcomes of these single case studies and some features of the theoretical model are
reported in this chapter.
5.2 Theoretical Background to Cycle Manipulation
in the PMS Clinic
As with cyclical change experienced during the menstrual cycle, some women who take
the pill feel worst prior to bleeding, while others have negative changes during
bleeding. Some pill takers have symptoms which remit gradually over the bleed, while
others experience an abrupt and dramatic improvement in well being coincident with the
onset of vaginal bleeding. Many women experience the onset of symptoms during
active tablet taking, therefore cyclical symptoms cannot be explained simply in terms of
steroid withdrawal.
Figure 5.01 shows the profile of daily diary ratings for depression and bloating with
bleeding, during two pill cycles for a PMS patient (code no. 8986) established on
Microgynon. It is clear that both mood and physical symptoms have their onset before
the pill steroids are withdrawn. It is also clear that the timing of symptom onset differs
from one cycle to the next; both symptoms occur earlier in the second cycle than in the
first. The occurrence of mood and physical changes and their remission during
withdrawal bleeding, along with variable timing from one cycle to the next cannot be
readily explained during the apparently constant hormonal conditions of the
monophasic pill cycle.
The variety of temporal arrangements of symptoms which one sees in pill takers led Dr.
Bancroft and me to postulate that there may be a number of specific ways in which
altering the timing of pill taking may have a therapeutic effect on cycle-related change.
We considered four potential causal mechanisms to explain the sort of responses
observed which may be known as: 1) a 'menstrual release' factor, 2) an exogenous
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Depression Onset During Active Pills








Day of Pill Cycle
Figure 5.01 Profile of daily diary ratings for depression and bloating in
relation to bleeding during two consecutive pill cycles in a PMS
Clinic patient showing the onset of symptoms during active tablet
taking, and the variable timing of symptom onset from one cycle
to the next.
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steroid withdrawal factor, 3) an endogenous steroid recovery effect, and 4) an
endogenous infradian rhythm.
1) In the first case, "menstrual release", we hypothesized that those women who
experience relief from symptoms with the onset of bleeding would benefit from a
shorter cycle in which vaginal bleeding was advanced, as this might cut short
symptoms. 2) In the second group of women, the withdrawal of pill steroids seems to
be associated with symptom onset. The most obvious example of this is the case of
'menstrual' headaches. The normal clinical solution to 'menstrual' headaches is to
extend pill taking beyond the conventional four week cycle (Guillebaud, 1991). This is
usually effective in reducing the number of steroid withdrawal headaches which the
woman has. Other symptoms may also occur predominantly during withdrawal
bleeding. This led us to hypothesize that extended pill taking could have therapeutic
potential by deferring symptoms in those women vulnerable to a steroid withdrawal
effect.
3) We also considered the possibility that the symptoms which pill takers experience
might be a consequence of the endogenous steroid recovery which occurs as a result of
the pill free interval, low steroid dose and/or poor pill absorption. We hypothesized
that if the subtle changes in endogenous steroids typically seen over the pill cycle were
responsible for symptoms extended pill taking might relieve symptoms by abolishing
all steroid cyclicity.
4) A final explanation for persistent cyclicity during pill cycles, which is not necessarily
incompatible with other mechanisms described above, is that it is a function of an
endogenous rhythm of mood and physical well being, allied to the steroid cycle. The
pill cycle provides a model system in which it is possible to manipulate the timing of
both the steroid cycle and vaginal bleeding. Therefore, by altering the length of the pill
cycle one may attempt to disrupt the temporal relationship between the well being,
bleeding and the steroid cycle.
5.3 Hypothesized Features of an Infradian Well Being
Rhythm
We may make reasoned guesses about the characteristic duration, amplitude, etc. of the
proposed rhythm which will help us to interpret it. First of all, it may be reasonable to
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postulate that the length of the rhythm will approximate the length of the menstrual or
pill cycle. Hypothetically, the length of the endogenous mood rhythm will be similar to
the length of each woman's own central trend in cycle length (Treloar, et ah, 1967), or
perhaps entrained to the length of the pill cycle in long term users. One might also
expect the freerunning period length of the infradian mood rhythm to show a good deal
of inter, and intra-individual variability, as the length of a biological rhythm is "seldom
very accurate" (p. 191) and "[i]t is inherent in the variability of biological rhythms that
the duration of a rhythm may differ from cycle to cycle" (Sollberger, 1965, p.203).
Another feature of this rhythm which might be expected to show large differences
across individuals, is its amplitude. There is certainly no uniformity over women in the
severity, nor even the features of cycle-related change. Therefore, one should expect
equal variability in free running conditions. Given this, a further probable aspect of
this rhythm is that it is a weak, and subdominant oscillator. If it were of prime
functional significance to show circa-monthly cyclicity in subjective state and behaviour
then the pattern would be more consistent across all women.
We hypothesize that the prime zeitgeber is the steroid cycle itself. While the feedback
mechanisms involved in the sequential events of the menstrual cycle are now well
understood, we do not possess an equal understanding of the mechanisms which time
the system. Since cycles of well being persist during pill taking it is unlikely that the
ovary is responsible for their timing. Yet their presence during pill cycles, with a
timing and severity equal to the menstrual cycle (eg. Walker and Bancroft 1990; Yuk,
Cumming, & Cumming, 1991) does imply that cycling steroids of either artificial or
natural origin, may express some form of control over the infradian rhythm.
Further evidence of the infradian rhythm's "dependence" on the steroid cycle is the fact
that it is largely absent before puberty, after the menopause, and during pregnancy1.
This may imply that it is only partially endogenous. The severity of change in well
being over the steroid cycle may depend on the close phase relationship of the two
rhythms. Sollberger (1965) outlines a number of technical features of rhythms that
may be of relevance here. He describes many components of the menstrual cycle as
being of the relaxation oscillator type. A variety of common rhythm models, including
l
There are anecdotal reports of continued cyclicity in well being after menopause and
during pregnancy (eg, Walker personal communication; Dalton, 1983; Kyger & Webb,
1972).
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the relaxation oscillator, are reproduced in Figure 5.02.. The concept of a relaxation
oscillator comes from van der Pol who described certain biological rhythms, such as
the heart beat, as characterized by a slow accumulation of energy which is suddenly
released when that energy is large enough to overcome a certain resistance in the
system. After this release of energy there is a 'refractory period' during which energy
is re-accumulated. The outcome is what Sollberger terms a characteristic "saw tooth
pattern" over time.
Examples of relaxation oscillators in the menstrual cycle are the gradual development of
a dominant follicle which suddenly ovulates in response to a transient LH surge, and
the slow build-up of the endometrium which rapidly sloughs off at menstruation. The
cyclic change in well being which many women experience over the steroid cycle may
fit this type of oscillator model. Negative affect and physical changes may develop
gradually over the second half of the cycle reaching peak severity a few days before or
immediately prior to menstruation. Some women then experience immediate relief from
symptoms with the onset of bleeding, while for others it is more gradual over the
course of bleeding.
The idea that biological rhythms may be hierarchical was discussed in Chapter Two.
Rhythms may simply be superimposed on one another, or may actually modulate one
another's behaviour (see for example combined impulse and sine wave model, Figure
5.02). In wave theory, "superposition" is a phenomenon whereby waveforms that are
superimposed on one another become mathematically additive. Sollberger (1965)
argues that when relaxation oscillators are 'lined up', or coupled this synergy is
particularly pronounced. Thus an infradian rhythm of well being which is relatively
innocuous on its own may only become noticeable, or troublesome when it is coupled
with the steroid cycle.
Two rhythms which are internal to the organism, the steroid and well being cycles here,
may interact with one another to establish a coupled oscillator condition. If one is
dominant to the other, the "leading" oscillator, (the steroid cycle) then it is called the
"pacemaker", as it gives 'time' to all its subordinate oscillators (the mood rhythm).
When the system is disrupted and the coupling disappears, the rhythms then begin to
oscillate at their respective characteristic frequencies (Sollberger, p. 180). If the
SineWav :CosinousFunction"DifferentialZeitgeber" ImpulseSineWav :witchFunction"Proport nalZeitgeber"(Dawn-DuskTyp ) Figure5.02Schematicofanumberfco monmod lsbiologi alrhythms takenfromSollb rger(1965),p.4
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coupling is "multidirectional" then the relationship between rhythm phases is much
more complex.2
5.4 Methods of Assessment
Women are referred to the PMS Clinic at the Royal Infirmary of Edinburgh by their
General Practitioner, their Gynaecologist, other clinics, or by themselves. At the time
that a woman is enrolled at the Clinic she is required to keep a daily diary record of her
mood and physical well being for two complete menstrual or pill cycles. She is usually
also requested to collect thrice weekly early morning urine samples for hormone assay.
These samples are assayed for oestrone-3-glucuronide and pregnanediol-3-glucuronide
to relate the timing of symptoms to ovulation and the luteal phase, for example, to
detect anovulation or luteal insufficiency. Pill takers are not generally required to
collect urine samples. However, a number of the women whom I followed through the
Clinic did collect urine given my interest in endogenous steroid production during pill
cycles.
The Clinic diary contains twelve, six-point ordinal scales of mood and physical states
commonly experienced over the menstrual cycle (see Appendix 5.01). Some print runs
of the diary also include a thirteenth scale: "craving for sweet foods". Like the visual
analogue diary described in chapter three, this diary also provides two spaces for
additional scales to be added by the woman herself. Diaries are presented in the form
of weekly booklets. This form of the daily diary has been used successfully in the
PMS Clinic for a number of years (5+). It is shorter and simpler to complete than the
diaries described elsewhere in this thesis, and therefore appropriate for clinical use.
Urinary steroid assays were carried out using the ELISA techniques described in
Chapter Three.
As far as possible, women were requested to maintain diary and urine collection during
pill cycle manipulations. However, in practice diary keeping tended to be somewhat
patchy. So where diary data and hormone results are available they are included to
illustrate women's responses to particular cycle alterations.
2
If the coupling between the steroid cycle and an infradian rhythm were multidirectional
then this might explain how the timing and therefore function of the steroid cycle is
disrupted during extreme psychic stress.
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Women were seen at the PMS Clinic at approximately one to six month intervals. The
interval between appointments depended on the course of treatment. During the times
that women were undertaking pill cycle manipulations, especially when these were first
being established, visits tended to be monthly. Once established on a helpful cycle
length, women were seen less frequently, particularly if doing well on extended cycles.
5.5 Results: Case Histories from an Edinburgh PMS Clinic
With no prior experience of the effects which cycle manipulations would have on well
being, but with a number of hypothesized mechanisms, Dr. Bancroft and I
systematically altered the length of the pill cycle in eleven PMS Clinic attenders. A
detailed case report for each woman is contained in Appendix 5.02, and Tables 5.01
and 5.02 summarize their experience.
The three sorts of change made to the conventional pill cycle were: 1) long extensions
of three or more additional weeks of active pills (n=6); 2) brief extensions of one to two
additional weeks of active pills (n=2); and 3) shortening active pill taking by up to six
days, with or without shortening of the pill free interval (n=3)3. Some examples of
these manipulations are shown in Figure 5.03.
3
Short cycles are less versatile than long cycles as one may only shorten the active pill
phase by a limited number of days and still achieve adequate suppression of
gonadotrophin and steroid production. It is therefore more risky to use these
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8735 Ovran 30 1) 9wks+7dy pfi
(twice)
2) 6wks +7dy pfi
(once)
general improvement of symptoms
in cycle 1, but negative mood &
bloating from wk 6 chronically until
pfi in cycle 2
mood declined in wks 3-4 and wk 6
prior to the pfi
8804 Microgynon 6wks+7dy pfi
(once)
breast tenderness, period pain, &
irritability chronically from wk 4
until the pfi
8843 Microgynon 12wks+7 dy pfi
(once)
moods generally improved, but still
had 'bad times', breakthrough
bleeding from wks 10-12
8846 Microgynon 9wks+7dy pfi
(once)
migraine wk 4; chronic breast
tenderness from wk 4; migraine,
depressed and tearful wk 6; stopped
pill early-wk 7; migraine 3 days
later, migraine 15 days after
stopping pill
8986 Microgynon 6wks+7dy pfi
(6 cycles, ongoing)
general improvement in symptoms,
but transient tension, anxiety, etc.
mid long cycle
9017 Marvelon 9wks+7dy pfi
(4 cycles, ongoing)
general improvement in symptoms,
PMS less marked, but symptomatic
at times of would-be bleeds in wks
4 & 8, main symptoms for ten days
prior to withdrawal bleed
8868 Ovran 30 4wks+6dy pfi
(once)
reduced severity of symptoms
premenstrually, but depressed in wk
1 of next cycle after pfi
8927 Marvelon 1) 4wks+ 7dy pfi
(once)
2) 5wks+ 7dy pfi
(once)
slightly improved; more irritable,
but less depressed
severe period pain and very irritable
in wk 5, but no bleeding
Legend- pfi= pill free interval in days, No.) = refers to the different sorts of
manipulated cycles which a woman consecutively underwent. For those women who
only experienced one type of manipulation the duration of treatment is noted in
parentheses. Comments on the outcomes of manipulations are based on retrospective
reports recorded in the Clinic notes.
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Table 5.02 PMS Patients in whom Pill Cycles were
Shortened for Treatment
Code Pill Cycle Outcome of
No. Formulation Manipulation/s Manipulation/s
8870 Microgynon 1) 15dys+7dy pfi PMS symptoms of anger and
(for 18 mos.) tension reduced from 3mos. to 2-3
days
2) 4wks+7dy pFi symptoms gradually returned to
(ongoing) longer duration of 10 days pre-
bleed, so she returned to
conventional cycle
8959 Brevinor 1) 6wks+7dy pfi symptomatic at time of would-be
(once) bleed in wk 4
2) 17dys+5dy pfi 2-3 days depression and anger
(3 cycles) before bleed
8972 Marvelon 17dys+4dy pfi symptoms relieved in cycle 1, 1 day
(3 cycles) depression and tearfulness before
bleed in 2nd cycle, but severe anger
and depression after 2nd pfi
Legend- pfi= pill free interval in days, No.) = refers to the different sorts of
manipulated cycles which a woman consecutively underwent. For those women who
only experienced one type of manipulation the duration of treatment is noted in
parentheses. Comments on the outcomes of manipulations are based on retrospective
reports recorded in the Clinic notes.
5.6 Discussion of Trends
Women's responses to these manipulations have been varied. Similar regimens have
not necessarily produced the same effects across women. There were two predominant
sorts of responses to the lengthened cycles. Some women found that all or certain
symptoms became chronic with protracted pill taking. In particular, breast tenderness,
bloating, period pain, and irritability were noted to begin at the time of the first
"missed" premenstrual or menstrual phase and then continue until relief was finally
gained from steroid withdrawal bleeding in the pill free interval (eg- 8804). Other
women found that negative moods and physical changes continued to occur at roughly
monthly intervals, or when they otherwise would have appeared during the
conventional four week cycle, and that these spontaneously resolved without the need
for a bleed (8843, 8986 and 9017). In some cases the same women experienced both
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the chronic and the cyclic patterns with different symptoms (eg. 8735 and see breast
tenderness vs. depression for 8846 in Figure 5.05). Thus, both subjective mood and
physical well being tended to continue to oscillate cyclically at roughly monthly
intervals, or to become chronic in this group of women undergoing much lengthened
cycles.
How do the outcomes fit in with the models described above for those cases who
underwent prolonged pill taking? All those women in whom pill taking was extended
had previously been experiencing their worst moods and physical changes after active
tablets had been stopped, and during withdrawal bleeding. Therefore, it seemed
superficially that they were responding to the withdrawal of exogenous steroids, and
we would have expected them to benefit from less frequent steroid withdrawal. Yet, in
the face of chronic steroid administration at a constant dose, they became symptomatic.
One might propose that this resulted from the effects of chronic steroid administration,
were it not for the fact that some symptoms spontaneously resolved in a number of
women with no apparent change in the steroid environment.
Figure 5.04 shows the diary ratings for selected variables over 28 weeks for patient
number 9017. She believed that an extended ten-week cycle vastly improved her
moods, but that she still experienced some symptoms in mid cycle. This pattern is not
very clearly reinforced by her diary ratings, although there does seem to be a peak in
tension soon after her first 'missed bleed' in the first long cycle.
Patient number 8846 illustrates the complexity of women's reactions. She was started
on the pill to control menstrual migraine headaches which she had experienced with
menstrual bleeding since puberty. Dr. Bancroft reasoned that if her pill cycle was made
longer than her fairly regular, approximately monthly menstrual cycle, then she would
experience the headaches less frequently. However, while attempting a ten week
regime she continued to have migraines at regular intervals during the pill cycle,
although her endogenous steroids were well suppressed and she was taking the pill
continuously (see Figure 5.05). Meanwhile, in the same steroid environment other
symptoms reacted differently. Her breast tenderness instead of occurring cyclically
was chronic from about the fourth week of pills, while depression and tearfulness,
which were not changes she typically experienced, coincided with her second migraine
attack during pill taking. And indeed, once she stopped taking the pill altogether she
experienced two further migraines in rapid succession.





















Figure 5.04 Four day mean phases for selected daily diary ratings of patient
9017 over two conventional pill cycles and two lengthened ten
week cycles. Dotted lines represent the beginning of withdrawal
bleeding episodes.
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Figure 5.05 Four day mean phases for selected daily diary ratings of patient
8846 over one lengthened pill cycle. Arrows indicate the timing
of migraine headaches. The dotted line indicates the onset of
withdrawal bleeding when the patient stopped taking OCs.
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In some way the disruption of the length of the steroid cycle, or of the steroid
environment produced by this extended pill cycle, induced more frequent migraine.
The pattern of her experience cannot be explained by "menstrual" release or by the
withdrawal of exogenous steroids, as she was taking the pill constantly when she
became symptomatic; nor can it be explained by the presence of endogenous steroids as
they were basal in her case. From the four models, this leaves only the possibility that
her migraine cycle was showing some endogenous rhythmicity, which had formerly
been linked to the menstrual cycle, but which continued to oscillate when the length of
the steroid cycle was artificially extended. Indeed five out of six of the women with
protracted pill taking returned to the Clinic reporting the cyclical experience of at least
some symptoms in the presence of constant pill taking. Four of these five women
reported that the extended regime had reduced the severity of their 'PMS' although it
had not abolished cyclicity altogether. Some evidence for this is given in Figure 5.06
which shows a slight rise in irritability and depression around the time of a 'would-be'
bleed for patient number 8986.
In both women, who underwent slightly lengthened cycles, symptoms occurred at their
usual premenstrual time, but were less severe, and then occurred again in about the fifth
week since the last bleed. It is difficult to explain these effects in terms of any of the
four models we have outlined. In one case (8868) the woman was depressed after a
delayed six day withdrawal phase, while the other woman (8927) had her PMS-type
symptoms in the fifth consecutive week of pills without a break. The two women were
in hormonally distinct phases of their cycle, yet both became symptomatic at the same
interval since the previous bleed. Both women had previously experienced their
symptoms for about two weeks premenstrually and during bleeding. For 8868 the
week when symptoms occurred would have been the early premenstrual phase of the
next cycle, while for 8927 the symptomatic phase would have been the immediate post-
bleeding week. Neither menstrual release, endogenous steroid effects, nor exogenous
steroid withdrawal can explain their responses over time. Perhaps under differently
timed entraining influences the endogenous pattern is emerging in these two women.
The reactions of the three women who underwent shortened pill cycles seem more
clear. Similar to the group undergoing extended cycles, they showed two sorts of
response. In two women bringing bleeding forward produced early symptom relief in
the manner we had anticipated with a 'menstrual release' factor. Figure 5.07 shows
regular oscillations in mood and physical changes over repeated short cycles for patient
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Figure 5.06 Four day mean phases for selected daily diary ratings of patient
8986 over two conventional pill cycles and the first six weeks of
one lengthened pill cycle. Dotted lines represent the beginning of
withdrawal bleeding episodes.
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Figure 5.07 Four day mean phases for selected daily diary ratings of patient
8870 over two conventional pill cycles and four consecudve 22
day pill cycles. Dotted lines represent the beginning of
withdrawal bleeding episodes.
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number 8870. She seems to experience the overall pattern of symptoms, but for less
time. The third woman reported experiencing 'post menstrual PMS'. The response
she described was similar to that of women in whom luteal regression was prematurely
induced with RU486 (Schmidt et al., 1991), and may indicate the effect of an
endogenous rhythm of well being. Her diaries show less clear evidence of cyclicity
than 8870's, but Figure 5.08 suggests that she feels anger after her first and third short-
cycle bleeds.
5.7 Limitations of the Clinic Data
The reactions of women to manipulations of their pill cycle length have been varied.
Yet a number of trends in response have emerged from the small number of
manipulations which we have tried in the PMS Clinic. While these trends are
suggestive, it is difficult to draw any firm conclusions about the mechanisms which
might be responsible
This anecdotal clinical data set has a number of limitations. Cases were accumulated
slowly over a long period of time. A trial-and-error approach had to be adopted
because we had no prior experience of the indications or outcomes of these temporal
regimes. Thus the protocol followed with each woman was individualized. As we
gained in experience, we refined our procedures and the gradual evolution in our
thinking about these treatments meant that no single protocol was rigourously followed
over time.
These treatments were also not blind, nor were they controlled. Most treatments for
PMS show a significant placebo effect (e.g Hamilton et al., 1988), and yet it is
impossible to quantify the contribution made by womens' expectation that the
manipulations would make them feel better. Indeed, we cannot discount the possibility
that those women who showed continued evidence of cyclicity did so because they
expected symptoms to occur at particular time intervals.
These women were also using a variety of different pill formulations, which seem de
facto to produce different patterns ofwell being in different individuals, even during the
conventional cycle. Finally, women could not be required to collect diaries and
samples indefinitely. They were attending the Clinic foremost as patients requesting





Figure 5.08 Four day mean phases for selected daily diary ratings of patient
8972 over two conventional pill cycles, two consecutive 21
day pill cycles, and two more conventional cycles. Dotted lines
represent the beginning of withdrawal bleeding episodes.
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treatment, and not to provide data for a research project. Therefore, the diary data is
incomplete and cannot be entered into rigourous mathematical analyses.
5.8 Implications for a Controlled Study to Test the
Existence of an Infradian Rhythm
Albeit suggestive, there is evidence from the PMS Clinic treatment case studies that
both mood and physical well being have the power to continue to oscillate in a constant
or truncated steroid environment. An endogenous infradian rhythm is an appealing
concept since it offers a plausible aetiology of cyclical change, and can also account for
inter and intra-individual variation in its expression.
Five of the 11 women who underwent manipulations in the Clinic reported some degree
of improvement as a result. However, this was only sustained for two women. One
(9017) pursued 10 week cycles, and the other (8870) short 22 day cycles. Many of the
remaining women actually discontinued the pill soon after trying an altered cycle length.
All of the women who had lengthened cycles reported the persistence of either cyclical
or chronic symptoms. It is interesting that the therapeutic lifespan of beneficial effects
seemed to be finite. One of the few women undergoing shortened cycles illustrates this
phenomenon clearly.
8870 was oligomenorrheic and experiencing three to five months cycles when she first
came to the Clinic. Her symptoms tended to build-up from about two weeks after a
period until relief finally came with the onset of the next period. So she was started on
the pill in an effort to increase the frequency of bleeding and improve her PMS through
a menstrual release mechanism. Twenty-eight day cycles did cut short prolonged
negative moods and physical changes, yet she remained symptomatic for about two
weeks prior to bleeding. She started short cycles because she wanted to relieve her
negative mood early before a holiday, and asked if she could stop the pill on day 15 to
see if this would help.4 The 22 day cycle further abbreviated her 'bad phase'. She
continued with short cycles, having only about 3 days of negative mood and physical
discomfort before the withdrawal week in each cycle. She followed this regime for 18
months, over which time the duration of the "bad phase" gradually increased to about
10 days. She therefore returned to a conventional pill cycle.
4
She was sterilized, so did not need OCs for contraception.
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There is good evidence in biological rhythm research that humans adapt differently to
phase advances and phase delays (Desir, van Cauter, Refetoff, Fang, Goldstein, Fevre-
Montage, L'Hermite, Robyn, Jadot, Szyper, Spire, Noel & Copinschi, 1983).
Aschoff called this phenomenon "reentrainment by partition". In his pioneering
research on human circadian rhythms he determined that phase delay, or rhythm
postponement (eg.- lengthened pill cycles) is much easier to adjust to than phase-
advance (eg.- shortened pill cycles) (Edlund 1987). When the phase of a rhythm is
brought forward it is more difficult for the organism to maintain the synchronization of
its internal rhythms. For example, westbound air travel (eg. UK to USA) is associated
with more rapid adjustment to the new time zone and less jet lag than eastbound. Pt.
8870 effectively underwent a radical phase-advance when she began a 22 day pill cycle
after normally having about four month long menstrual cycles. The slow return of a
longer 'bad phase' seems to reflect retarded reentrainment after a profound disruption.
"Reentrainment by partition" may also explain how it is possible that pt. 8972, and the
women in Schmidt et al.'s (1991) RU486 study apparently show 'postmenstrual'
PMS. The difference in individual responses may reflect the fact that for 8870 vaginal
bleeding encourages entrainment in a way which it does not for 8972. Thus more than
one entraining influence may be at work with variable potency in different individuals.
It would be very interesting to monitor a large number of women in whom menstrual or
withdrawal bleeding was phase advanced over numerous cycles to assess the degree
and speed of entrainment to the new cycle length.
Women who seek medical help for PMS may be different from other women who have
cyclical changes, but do not consult a doctor. Clinic patients may have greater faith in
medical remedies and thus may be more susceptible than a study population to placebo
effects (Warner, 1989- personal communication). However, this does not seem to be
borne out by these data, because only a small proportion of the 11 found the
manipulations helpful. From this data, the usefulness of cycle manipulations for
treating PMS appears to be limited. Much more research is required before treatment
strategies can be rigourously implemented.
A controlled, blind investigation is required in order to verify the existence of a
proposed endogenous rhythm of well being and characterize its features. This study
might explore a number of questions. If there is such a rhythm will it emerge under
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"free running conditions"? How robust is it over time? What is its average phase
length? Will it retain a consistent amplitude over time or will it become damped down?
How much individual variation is there? Will different women show different phases
and amplitudes? Does a woman's free running rhythm approximate her own
underlying central trend in menstrual cycle length? How susceptible would such a
rhythm be to the disruption, and re-timing of its primary zeitgeber? Is the steroid cycle
its primary zeitgeber, or a coupled oscillator? Are there therapeutic gains to be made by
"aligning" pill cycle length with "underlying cycle length"? And do parameters of
physical and emotional well being show similar or different rhythmic characteristics?
5.9 Hypotheses to be Tested in the Controlled Study
The low dose combined oral contraceptive pill was chosen as a tool to pursue these
research questions for a number of reasons. OCs eliminate ovulation and, to a large
extent, the cyclic variation of endogenous steroids and gonadotrophins. Exogenous
steroids are re-introduced in a controlled and easily manipulated way providing a
simple, cheap, readily available, safe, and non-invasive means of changing the duration
of the steroid cycle. Further, changing the length of the pill cycle is a familiar concept
to many women. As discussed in the previous chapter, many women alter their own
cycle length for reasons of convenience, which may include the control of cycle-related
change in well being. Thus, the effects that cycle manipulations have on vaginal
bleeding experience, and the acceptability of such changes to women may be
considered concurrently.
The study described in the Chapter Six was designed to test three specific hypotheses
relating to: 1) the existence of a purported endogenous mood oscillator, 2) the
relationship of said rhythm to the steroid cycle, and 3) the symptomatic features of the
rhythm.
1) If there is an endogenous infradian rhythm of mood which is normally entrained to
the cycle of ovarian hormones it will continue to show periodicity if the temporal and
hormonal inputs are held constant by continuous pill administration. Therefore:
HI: A group of women who undergo constant pill administration will show a regular
oscillation of mood during the manipulation period which represents the free-running
phase of their infradian mood rhythm.
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2) If there is an endogenous infradian rhythm of mood which is normally entrained to
the cycle of ovarian hormones then by lengthening one pill cycle we may achieve a
"phase advance" or forward shift in the mood cycle relative to the steroid cycle. We
will call this the "jet lag effect" because it should mimic the internal desynchronization
of the various circadian period rhythms which one sees after long distance air travel.
First there will be a disruption of the rhythms' relationship to one another, and
gradually over subsequent pill cycles, the mood rhythm will become re-entrained to the
hormonal cycle. Therefore:
H2: A phase-shift in pill taking will demonstrate that the hormonal cycle is a primary
zeitgeber for the endogenous mood rhythm, as a temporary lengthening of the pill cycle
in turn disrupts and re-entrains the mood rhythm to it.
3) If the driving force for changes in bodily state over the pill cycle is hormonal, and
the driving force for changes in mood state is an endogenous period rhythm, then
physical changes should vary in direct relation to fluctuations in endogenous and
exogenous reproductive hormones, while mood changes should persist regardless of
hormonal status. Therefore:
H3: Physical state will vary in direct relation to the specific hormonal changes induced
by different pill taking regimes, while variations in mood state may occur independently
of hormonal changes over time.
The rational behind the first two hypotheses was thoroughly discussed at the beginning
of this chapter, but the third hypothesis has not been so explicitly considered. There is
evidence that seems to suggest that the emotional and physical correlates of the
menstrual or pill cycle are not controlled by the same mechanism. Bancroft &
Backstrom (1985) propose a "systems model" to describe the probable causes behind
PMS. They suggest that physical changes like breast tenderness and bloating are a
function of the peripheral effects of cyclical steroids, while mood changes are produced
by the central regulatory system.
In their 1987 study of the effectiveness of the LHRH agonist, Buserelin, for the
treatment of PMS, Bancroft et al. found that for women who underwent extended
agonist administration, but still had bleeds, physical symptoms continued to precede
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bleeding, while the timing of mood symptoms became dissociated from the pattern of
bleeding. And in light of the fact that physical changes associated with the menstrual
cycle have widespread prevalence in both PMS and non-PMS sufferers (Metcalf et al.,
1990) it seems plausible to expect that they are more likely than emotional changes to be
a straightforward function of mechanistic hormonal drive. In fact, the evidence from
this thesis so far is contradictory on this point. The folliculogenesis study suggested
that physical changes in breast tenderness and bloating over the pill cycle were related
to subtle variations in endogenous oestrogen. The reports from PMS patients of
cyclical symptoms during extended pill taking from this chapter, however, indicate that
both moods and physical symptoms oscillate under constant steroid conditions. The
shortcomings of the Clinic data have already been elaborated.
These three hypotheses are tested in the study described in Chapter Six in which a low
dose combined monophasic pill was administered in a double-blind, controlled fashion
for 25 weeks to volunteers previously well established on a number of different low
dose pill formulations. The design of the study is summarized by the schematic
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Chapter 6 Characterizing an Infradian Rhythm through
the Manipulation of Oral Contraceptive Cycle
Length: A Double-Blind Controlled Study
6.1 Introduction
This chapter details the findings of a study in which the low dose monophasic OC,
Marvelon was taken in three different regimes over more than six months in order to
test the hypotheses which were described in the previous chapter. Withdrawal bleeding
weeks were built into continuous pill taking using placebos to achieve a double-blind
design. The theoretical background to this investigation was considered in detail in
Chapter Five.
Ethical approval for all of the methods and procedures employed in this study was
obtained prior to its implimentation. Approval was granted in writing by the
Paediatric/Reproductive Medicine Ethics of Medical Research sub-committee of the
Lothian Health Board on 23rd November, 1989.
6.2 Study Design and Randomization Procedure
6.2.1 The Control Group
A control group was included which underwent conventional four week pill cycles
throughout the study. They had a sequence of three weeks of active capsules followed
by a week of placebos for six cycles, with active capsules in the 25th and final week of
the study. They began a normal packet of Marvelon immediately after finishing the
study pill, so the final cycle was therefore 5 weeks long. This group was intended to
control for volunteers' expectations of their cycles, and their attribution of changes in
well being to the visible occurance of vaginal bleeding. In seeking an endogenous
oscillation it was also essential to have a comparison group who remained "entrained"
in the usual way. The control group could provide baseline information about the
nature, degree, and timing of cyclicity in moods and physical well being over the
conventional cycle against which the responses of women undergoing manipulations
could be compared.
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Another important reason to include a control group was to measure the impact of the
study itself on women's assessments of subjective state. In addition to the obvious
demands of maintaining daily monitoring for six months, the women in this study had
the added stress of double-blindness. While women experiencing menstrual cycles
never know for certain when their periods will occur, most women who are well
established on OCs know precisely when to expect a bleed. Some women even know
at what time of day it is likely to occur. Thus it is rather odd for a woman to be in a
situation where she does not know if her cycle will last four weeks or four months. A
lack of menstrual bleeding is often a source of anxiety for fear of pregnancy or some
physical abnormality. So although the volunteers had consented to undergo
manipulated cycles in a blind fashion they might still experience anxiety as a function of
the regime.
6.2.2 The Continuous Group
The second group, like the control group, also had two conventional four week cycles
at the beginning of the study. This group, which shall be called continuous, went on to
have constant active tablet administration for sixteen weeks, followed by a withdrawal
bleed in the final study week, 25. They had a conventional 4 week pill cycle
immediately after the study. This regime was intended to create freerunning conditions
by holding the steroid environment constant thus allowing the hypothesised infradian
oscillator to expose itself (HI).
6.2.3 The Phase Shifted Group
The so-called phase shifted group was included to test the second hypothesis (H2)
relating to the entraining influence of the steroid cycle on the endogenous mood
oscillator. With this model the sytem would be exposed to a transient disruption, and
then entrainement returned to its usual pattern. This group also underwent two
conventional four week cycles at the start. The third cycle was extended by two weeks
of active capsules to create a phase delay equivalent to adding one half of the usual
cycle length. After this six week cycle they then returned to conventional cycles for the
remainder of the study.
This regime left the group with three weeks of active capsules at the end of the study.
They were "due" for a withdrawal bleed, yet they immediately began a packet of
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Marvelon and in effect underwent a second phase shift through the consequent seven
weeks long cycle. This was longer than the oringinal phase-shift. Although formally
the protcol for this study only included 25 weeks of monitoring, most women
continued their diary keeping for two to three further weeks. Thus, there are data
covering the second phase shift for most women.
For both the phase shifted and continuous groups the first two months served as a
baseline. This offered an internal control that would show if a woman tended to
experience cyclicty of mood or physical well being during conventional pill use against
which the reactions to subsequent manipulations could be compared. Women also had
a chance to adjust to the Marvelon if they had switched from another pill formulation.
This baseline ought to have ensured that in the final four months of the study when the
manipulations actually took place, women's subjective state recording was not clouded
by anxiety about the study, by difficulties in adjusting to Marvelon, or by trouble
getting used to the diary scales.
6.2.4 Randomization
It was originally intended that sixty women should complete this investigation. This
was to be achieved by generating a total of 75 volunteers, and replacing drop-outs from
the residual pool of 15. If a woman's own underlying cycle length might be mirrored
in her freerunning phase length, then it was desirable to attempt to distribute women
with short, intermediate, and long cycles evenly over the three groups. The intention
was to take groups of 15 women as they entered the trial and stratify them based on
their own central trend, and then randomize them to one of the three groups.
This approach was not possible in practice because of the difficulty in recruiting large
numbers. In order to be able to test the experimental hypotheses adequately it was felt
that group allocation should be weighted in favour of the two manipulated groups in the
following ratio: 12 Controls, 24 Continuous, and 24 Phase shifted. But when it
became apparent that recruitment was proceeding slowly and the desired number might
not be reached, the distribution was altered so that one-sixth of participants would be in
the control group, two-sixths in the phase shifted group, three-sixths in the continuous
group.
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The numbers were largest in the continuous group to ensure that the primary question
under test, whether or not there is an infradian oscillator, could be satisfactorily
addressed even if the full number desired was not achieved. It was also anticipated that
more women might drop out of the continuous group than the other two because they
would be experiencing a much greater disruption to their usual cycle length, and might
experience more problems, particularly bleeding abnormalities as a result.
The original randomization blocks of 15 were generated using a random number
sequence taken from Fisher & Yates Statistical Tables for Biological. Agricultural and
Medical Research (1957). Four blocks and one reserve were generated with three
controls, and six phase-shifted and continuous allocations in each. I generated the
randomization sequences and passed then to Pamela Warner (PW) who was acting as
the blinder. PW randomly allocated a letter to each block from A to E. Group
allocations were to be taken from the E group to replace drop-outs.
I became aware of the problem with inadequate numbers early in enrollment, therefore,
PW created an algorhythm with which to combine blocks A and B, and blocks C and
D into two blocks of thirty and render one control and two phase shifts, continuous.
This produced the final 1/6, 2/6, 3/6 distribution. Had sixty women completed the
study there would have been ten controls, twenty phase shifted, and thirty continuous.
It proved to be impractical to stratify women based on central trend in cycle length, and
this procedure was abandoned. In fact, many women had difficulty recalling their
usual cycle length with any accuracy, possibly due to prolonged pill use in some cases,
and therefore such a stratification device would probably have been of limited
usefulness.
6.3 Recruitment Procedures and Selection Criteria
A number of different recruitment procedures were used to interest volunteers in the
study. Ultimately the number of women that took part was about two thirds of the
projected number. All of the of the volunteers for this study were recruited from
amongst women attending the Lothian Health Board Family Planning Centre (FPC) at
Dean Terrace, Edinburgh. Three separate recruitment drives were carried out. Those
women who volunteered to take part in the study were expected to meet the following
inclusion criteria.
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6.3.1 Inclusion Criteria for Volunteers
1) Age between 20 and 40 years, or 35 if a smoker. Twenty was taken as a lower age
limit for the same reason as in the folliculogenesis study, to try and ensure
gynaecological maturity. Younger women are also more likely to be living at home,
with parents who may not know that they are using contraception or are in a sexual
relationship. The regular telephone and postal contact required in a prospective study
make it difficult to conceal participation form other members of the household, which
may cause difficulties. Older women may also be better equiped to deal with the heavy
demands of long term diary keeping and urine collection. The upper age limits were
chosen to reflect the current wisdom about age/smoking related risk and pill use. We
exploited the fact that the FPC doctors had already made an assessment of the woman's
age and smoking related risk for combined pill use to avoid the need to make an
additional assessment.
2) Nulliparity or low parity. Repeated pregnancies may effect cycle length, bleeding
experience, or the response to exogenous steroids (eg. Treloar et al., 1967, Anderson,
1989). They may also influence the hypothesized infradian mood rhythm. Differences
in parity simply add another source of variance, which we felt was best excluded. In
practice the majority of women who attend the FPC are of low parity, so this criterion
did not alter the recruitment pool.
3) No manipulation of her pill cycle in the last calendar year. Clearly, it was desirable
only to accept women into the study who were "entrained" to a similar degree by the
conventional 28 day pill cycle in a study designed to test the existence of an infradian
rhythm. This might help to control another, large source of inter-individual variance.
4) Use of the present combined oral contraceptive formulation for at least three cycles.
Women needed to be moderately well established on their current pill formulation, and
not taking a progesterone only preparation. This way if they did have to switch from
another formulation to the study pill the effects would be minimized.
5) No contraindication to the use of combined oral contraception in general, and no
past history of mallignancy, serious metabolic, haematological, liver, or renal disease.
These are absolute contraindications to OC use. It is unlikely that any woman with
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these risk factors would be attending the FPC taking the pill, nevertheless, the
possibility was discounted based on the Clinic notes and initial interviews
6) No intention to start a pregnancy within three months of completing the study.
Some disruption to cycle length and bleeding patterns might be expected to occur after
completion of the study given its nature. For example, were extended pill taking to
cause any degree of endometrial hyper- or hypoplasia, it might be best for a woman to
experience several pill-free cycles before trying to conceive to permit the endometrium
to repair itself fully.
7) Living within five miles of Edinburgh, or able to come into the city for sample
collections and interviews. All meetings were scheduled to take place in the centre of
town, and volunteers were reimbursed their travel expenses.
8) Report of some degree of cyclical physical or mood experience over the pill cycle.
Obviously, it was desirable for women to show a degree of cyclicity, otherwise
detecting an infradian oscillator becomes an irrelevance. In practice, some of the
women ultimately enrolled did not report significant cyclical change, but the difficulty
in recruiting adequate numbers for the study militated against excluding them.
6.3.2 First Recruitment Drive
The MHRAQ-2 which was used as the main recruitment device for this study was
described in Chapter Four. The final page of MHRAQ-2 briefly outlined the nature of
the cycle manipulation study and invited women who were taking the pill to provide
their name, address, and telephone number if they wished to be contacted with further
information. (See Appendix 4.02) This self-administered questionnaire was a good
tool for conveying information and arousing interest that might encourage women to
take part in further research without "putting them on the spot" with a face-to-face
request to join a study. Those women who did not wish to take part'simply left this
page of the questionnaire blank. This technique had the further advantage that those
women who did volunteer were probably highly motivated. It was noted there how the
questionnaire sample of women may over-represent certain sub-groups of the general
population. Nevertheless, it is probably one of the best places from which to recruit
established OC users given the very high prescription rate in the Clinic1.
l
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Twenty-two per cent (22%, n=151) of the almost 700 women who completed the
questionnaire gave their name and address to be contacted. Twenty-five of the 151
were deemed not to fulfill the selection criteria on the basis of their questionnaire
responses. They were either too old, too young, or not currently using the pill.
Permission was granted by Dr. Elizabeth Barden, then acting director of the FPC, to
inspect the Clinic notes of those women expressing interest in the study to assess their
eligibility. A further twenty-three women were considered unsuitable because they
were using a progesterone-only pill due to contraindications for the combined pill such
as high blood pressure or migraine, or because they had had a previous adverse
reaction to Marvelon.
After the clinic notes had been examined for contraindications the remaining women
offering their names were contacted by telephone, or by letter if they had not provided a
phone number (See Appendix 6.01). The aim of the study was loosely described as "a
study of how women feel when they are using oral contraceptives". At the time of
telephone contact, it was first ensured that a woman met the slection criteria, and then
more precise details were offered about the nature of the investigation and the demands
that would be made on her time (diaries, urines, etc.). Women were told that the study
concerned finding out how cycle length relates to well being. Women were reassured
over the phone that the alterations that would be made in their pill cycle would not be
harmful in any way, and that there was no greater risk of pregnancy than when using
the pill normally.
Of the remaining 103, seventeen proved uncontactable as they did not provide a phone
number and did not respond to letters. A further fifty-four women did not respond to
repeated telephone calls and messages, or declined to take part at the first telephone
contact. Women gave a number of reasons for not wishing to take part, few of which
were medical. Most reasons were social and revealed a lack of understanding of the
pill's mode of action, and a great deal of fear surrounding the risks associated with pill
use. The list below includes reasons women gave for not wishing to take part.
* "I can't be bothered with it"- apathy, a feeling that it would involve too much effort
One reason why such a large proportion of women at the FPC are pill takers may be
that pill takers specifically attend Dean Terrace because they know that they will have
their pills prescribed, and dispensed to them on the spot. The large number of evening
clinics also make it convenient for working women.
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* Fears and unwillingness expressed by partner.
* Fear of side effects or the risk of pregnancy.
* Unhappy that she would not know when bleeds would occur,
"changing my routine".
* "I don't want to muck about with my hormones"-
fear of the unfamiliar, 'experimental' nature of the study.
* Not willing to switch pill types, settled on current pill and
had difficulties with other formulations.
* Under a great deal of stress at home or at work.
* Relationship difficulties, break-up.
* Lack of time.
* Lack of transport or too great a distance to travel.
* About to get married.
* Planning to come off the pill.
* Planning a pregnancy.
* Having other hormonal treatment.
* Menstrual migraine or withdrawal headaches.
Ultimately only thirty (30) of the original one hundred and fifty-one women actually
volunteered to enroll in the study, which is less than 20% and well below the desired
number of participants. Other steps were taken to recruit more women.
6.3.3 Second Recruitment Drive
The second recruitment drive took the form of a poster placed in the waiting room at the
FPC during July 1990. The text of the poster is contained in Appendix 6.02. This
poster did not generate any interest at all, and no one left her name or tried to contact me
during the approximately four weeks in June and July that it was in place. We had
originally thought that a poster would make it easier for women to express their
interest, and offer a better tool for pre-selection of appropriate volunteers, but this
proved not to be the case.
The poster seemed to lack an important element present in the questionnaire. Namely,
the questionnaire awakened thought and comment about novel or previously silent
subjects like attitudes to vaginal bleeding. In accustoming women to the idea of such
questions it perhaps went some way to persuading them that they personnally could
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play an active part in investigations designed to answer those questions. Some support
for this theory is offered by the nature of the comments women made on the first
questionnaire: comments applauding research efforts in this area.
6.3.4 Third Recruitment Drive
I decided to re-issue the original MHRAQ-2 with modifications so that it was quicker to
complete, and was specifically directed at women using the pill. The result was
MHRAQ-3. It contained 31 questions, some requiring multiple responses to Likert-
type scales, in one, four-page questionnaire derived from the first part of MHRAQ-2
(See Appendix 6.03). The procedure for administration was also simplified. Stacks of
questionnaires, pens, clipboards, and freepost envelopes were left in the FPC waiting
room under a sign that read: "Ifyou are on the pill would you please fill in one of the
questionnaires below." This was done primarily because the staff at reception were not
happy about asking women if they were taking the pill or not, as they felt it breached
their confidentiality. This also made it easier for those women who did not wish to fill
in a questionnaire to avoid doing so, again preferentially selecting those women who
were more highly motivated.
One hundred and fifty-seven (157) modified questionnaires were filled-in over the
course of nine weeks from August to October, 1990. Sixty-four women (64), or over
40% expressed a willingness to be contacted. Fifteen (15) of these were unsuitable
based on their questionnaire responses. Thirty-two (32) declined to take part at the first
telephone contact for the same sorts of reasons outlined above. The remaining 17 were
enrolled in the study, representing 11% of all respondants and 26% of those who had
specifically expressed interest.
6.3.5 Summary of Recruitment Efforts for Cycle
Manipulation Study
It took approximately one calendar year to recruit and enroll the volunteers for this
study. During this time approximately 1175 women were asked to take part. Of this
number 47 (4%) enrolled in the study and 36 (3%) completed it. I believe that there
were three primary factors contributing to the low response rate. 1) The concept of
systematically altering the length of one's cycle and not knowing when bleeds are going
to occur is seen as threatening and alien to many women. 2) The study was to be quite
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demanding, requiring consistant daily inputs over six months. 3) There was a long
and unforeseen delay between the administration of the first questionnaire and initial
contacts with women due to difficulties in securing a supply of oral contraceptives and
matched placebos for the study.
6.4 Methods
This study was conducted in a similar manner to the folliculogenesis investigation using
daily diaries prospectively to obtain information about subjective state, while at the
same time monitoring steroid levels with urinary hormone tracking. Equally
demographic details were gathered at the time of enrollment and volunteers were
required to complete a number of psychometric tests. The protocol was designed to last
for 25 weeks, but in practice many women continued monitoring for as much as seven
months. Full descriptions of the pill formulation, design, interview instruments, and
prospective monitoring procedures are contained in the sections that follow.
6.4.1 Pill Formulation and Presentation
6.4.1.1 The pursuit of double-blindness
There is a good deal of evidence that women have expectations about their menstrual or
pill cycles, and that sensations and changes may be wrongly or stereotypically
attributed to the events of the cycle (eg. Bains & Slade, 1988; Ruble, 1977; Parlee,
1974). In order to minimize these effects, and to ensure that knowledge of group
allocation did not bias the researcher in the conduct of the study, all efforts were made
to achieve a double-blind design. The intention of the original study design was to use
one of the new-generation gestagen containing monophasic pills (Femodene, Minulet,
or Marvelon) for which matched placebo tablets had been obtained, and generate
continuous strip-packs of pills with withdrawal bleeding weeks built in at the desired
intervals.
Achieving this proved to be a substantial obstacle to the rapid implementation of this
study. The three major pharmaceutical manufacturers who produce monophasic pills of
this type were approached, namely- Schering Health Care Limited (Femodene), Wyeth
Laboratories (Minulet), and Organon International (Marvelon). It was theoretically
possible for any of these firms to produce the special matched placebo pills required,
but there were two insurmountable problems: one practical and economic and the other
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ethico-legal. In order to make matched placebos the machines that are normally devoted
to the manufacture of pills would have to be stopped, the active ingedients removed and
set going again with an adjusted 'dose' of filler on its own. Under normal
circumstances these machines produce over one hundred thousand active tablets a
minute. But only about two thousand placebos were required for this trial. An
interuption to the manufacturing process ofmany minutes, even hours, to make a small
number of placebos would have cost the drug company a considerable sum in lost
profits. Special strip packaging would apparently have proved even more costly and
difficult.
The second difficulty was that it is illegal in Britain to produce a drug preparation which
looks exactly like a marketed product, but does not contain the active ingredient. This
is even the case for matched placebos in clinical trials. The reason for this is to protect
against the risk, however remote, that someone might take the placebo believing it were
the active, and suffer whatever medical consequences as a result (in this case, of
course, pregnancy). Therefore, it appeared that to achieve double-blindness with an
oral contraceptive one would have to specially produce not only the placebos, but the
actives as well. OCs are generally very small and unusual shapes, and the tooling
equipment to make, for example, a 6mm, white, bi-convex, sugar coated tablet is not
readily available outside the drug companies that make pills.
The option of an open study without matched placebos, but in which packaging was
used to obscure cycle phase, was considered. Possibilities were explored with
pharmacy departments in Edinburgh, Glasgow, and London to package active tablets
and unmatched placebos in opaque weekly bottles so that volunteers would only know
at the beginning of a given week if they would be having a withdrawal bleed.
Ultimately double-blindness was achieved. Prof. J. M. Newton at the School of
Pharmacy of the University of London proposed that active pills be packed inside
opaque gelatine capsules surrounded by lactose powder as filler. Placebos could then
be created using capsules packed with lactose powder alone.
6.4.1.2 Formulation, encapsulation, packaging and labelling
In the end the monophasic pill, Marvelon, was provided for the trial by Organon UK.
Marvelon contains 30(ig of Ethinyl Estradiol (EE) and 150(ig of the third generation
gestagen, Desogestrel (DSG), and is manufactured in Holland by Organon
International. Organon kindly agreed to supply ten thousand (10,000) ordinary,
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unpackaged Marvelon tablets for the study. These were sent to St. Bartholomew's
Hospital, London where the encapsulation took place.
Prof. Newton organised for the Marvelon tablets to be packed in lactose powder in size
0, opaque, white, gelatine capsules. The work was carried out by a registered
pharmacist, under the supervision of Prof. Newton and Dr Michael Lillywhite of St.
Bartholomew's Hospital. The precise protocol for encapsulation, and reconciliation
and checking is described in Appendix 6.04 in a statement supplied by John Young,
Bart's Production Pharmacist. An assessment was made of whether or not it would be
necessary to enclose an unmarked, 6mm, white, biconvex, placebo tablet in the placebo
capsules. The pharmacy determined that the placebo capsules looked and felt
sufficiently similar to encapsulated actives to use lactose powder alone in the placebos.
Bottles which contained either seven days' supply of Marvelon or placebo sported two
labels: a peelable content label and a study label. I placed the bottles in appropriate 25
week sequences according to the three regimes described above. The content label was
peeled off and placed on a reconcillition sheet, while the study label and bottle lid were
marked with the study week number. Pam Warner then acted as "blinder". She added
the volunteer code number to the prepared study labels according to the random-number
generated, master list for group allocation.
A Department of Health Doctors and Dentists exemption certificate was obtained to
permit the use Marvelon in this altered presentation, and in the manner outlined above.
Any deviation from the strict prescription guidelines laid down in the datasheet for this
pill requires that exemption be obtained. We were advised by Organon U.K. that the
lactose would delay pill absorption by approximately one hour. This would be
equivalent to injesting the pill just after eating a bar of chocolate or drinking a glass of
milk (David Hollingworth, 1990, personnal communication). Study participants were
advised of this and requested to take their study capsules one hour earlier than usual.
Individuals were switched to Marvelon, if they were not already taking it, from their
existing low dose combined formulation after a seven day pfi (i.e. capsules begun on
the eighth pill free day). Women who were already using Marvelon began the study
pills after a seven day pill free interval as always. I was assured by the Ex-Director of
Family Planning and Well Woman Services for Lothian Region, Dr. Nancy Loudon,
that there was no need to have a shorter pfi, or take extra precautions when switching
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pill formulations unless a woman was changing from a higher to a lower dose of
oestrogen (Nancy Loudon, 1989, personnal communication).
At the end of the twenty-five weeks of encapsulated tablet taking, volunteers were
given an ordinary packet of Marvelon in a sealed envelope and instructed to begin
taking the enclosed pills the day after they finished the last bottled capsule. The regular
strip packs of Marvelon were also generously provided by Organon U.K.. This
procedure was followed because all the participants in this study were using the pill for
contraception (see section 6.2 above).
6.4.2 Prospective Monitoring of Hormones and Subjective State
The women taking part in this study were required to complete a daily form diary rating
mood and physical well being. They were also requested to collect an early morning
urine sample three times a week at approximately even intervals. If a woman did not
wish to, or was unable to make the urine collection, she was not excluded from the
study.
6.4.2.1 Ordinal scale daily diary
In this study a 16-item ordinal scale diary form was used. It was intermediate between
the visual analogue diary described in Chapter Three and the PMS Clinic instument
described in Chapter Five (See Appendix 6.05).
Visual analogue scales (VAS) were abandoned in this study for three reasons. First of
all, it was apparent from the folliculogenesis study that some women found the concept
of a scale that assesses ones own internal state from best ever to worst ever difficult to
understand. Secondly, VAS's should be transformed by the range which a woman
used before they can be compared across women. Even if the scale is adjusted to take
account of the way the woman filled it in, it is impossible to know whether or not her
variance is comparable to that of another woman, or whether some women simply
experience less variation in their well being. The third drawback is a practical one.
VAS must be coded prior to data entry which is very time-consuming if they are used in
large numbers. Given that the current study monitored twice as many women for two
and a half times as long as the first study, the use of VAS's was prohibited by time
constraints.
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Ordinal scales have the advantage over VAS's that they can be compared across women
when the extremes are pre-defined. Because it was felt that the nought to five scale of
the Clinic diary did not allow a broad or subtle enough range, this scale ran from zero
to ten. "Not at all" was printed over the zero, "moderate" above five, and "extreme"
over ten. The ordinal scale diary seemed more intelligible to the volunteers, and was
easier to score than the VAS.
This diary contained fewer scales than the VAS diary. The questions about day length,
caffeine intake and smoking were all removed. A number of scales were removed
based on the factor analysis of VAS diary results from Chapter Three to eliminate
repitition. Three variables were dropped from PCI: "creative" because it seemed to
hold limited meaning for women, and was generally scored very low, and "relaxed"
and "getting on well with others" because they seemed to be highly correlated with the
"feeling good about youself" and "cheerful and happy" scales. Equally "mood up and
down" and "lacking self control" were removed, as negative affect was adequately
covered by "depressed and unhappy", "irritable", "aggressive / angry", and "tense and
anxious". "Feeling sexually attractive" was removed as it was very highly correlated
with "sexual interest" and "sexual activity".
One scale was added to this diary which was not included in the VAS diary:
"headache". I felt it was important to include this scale in a study which invovled
prolonging pill cycle length in order to see if it would increase the frequency or severity
of headaches, as there is evidence that headaches tend to cluster around the time of
vaginal bleeding (Dalton, 1983). Another factor which this study was particularly
concerned to monitor was vaginal bleeding experience. Therefore, a statement
requesting women to qualify the type of bleeding they experienced was included. It
was hoped that by asking women whether or not they believed they were experiencing
a period or spotting, one might be able to assess the significance that they were
attaching to concurrent moods and physical sensations. Like both other diaries, this
one contained two blank scales for women to monitor any additional symptom which
was meaningful to them.
As with both previous diaries, volunteers were instructed to complete one form last
thing each night, and to relate their ratings to the feelings that they had experienced over
the previous 24 hours. The daily diary instruction sheet is contained in Appendix 6.06.
Because of the sheer volume of daily diaries to be generated by this investigation (about
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10,000) their presentation was changed from the usual 7-day booklet. Twenty-eight
diaries were fixed together in A5 size booklets, printed on both sides of the page.
Strictly speaking volunteers should be prevented from retaining large numbers of
contiguous daily ratings to prevent them looking back at their scores as this may alter
subsequent scoring (Gift, 1989). However, it was felt that monthly booklets would
make administation easier, and volunteers were urged not to go back through their
previous ratings. Again, to spare expense and undue complexity the order of the scales
did not vary from day to day. Ideally the order of scales should vary to prevent
response sets (Gift, 1989). Some women who appeared to become bored with the
scales around mid-study were encouraged to fill the form in from bottom to top, or vary
the order in which they considered the scales.
6.4.2.2 Hormonal assessments
Given the extremely low levels of urinary progesterone found in low dose pill takers in
the folliculogenesis study, only oestrone-3-glucuronide was measured in all samples in
this investigation. In a few women who showed oestrone levels within the ovulatory
range "spot" pregnanediol levels were assessed to determine if ovulation might have
occurred. One urine sample per month was entered for a pregnancy test as a way of
reassuring women that they were not pregnant in the absence of monthly withdrawal
bleeds.
Oestrone was tracked in urine in the same manner as described in Chapter Three, except
that samples were collected three times a week rather than daily. The oestrone ELISA's
for this study were preformed in the MRC Reproductive Biology Unit by Irene Cooper
and Gillian Sutherland. The protocol for the assay was altered slightly to improve its
performance. It was determined that the assay was unable to come to equilibrium
binding in a one hour incubation, and that use of this short incubation time was
increasing the variablity of sample replicates. Therefore, the incubation was changed to
overnight at 4° C. The dilution of the reagents was adjusted to take account of this
change. The antibody was made up to a 1 in 100,000 dilution in assay buffer, and the
label to a 1 in 10,000 dilution. This change in protocol also allowed a larger number of
samples to be included in each assay without jepordizing the accuracy of the readings.
The inter- and intra-assay coefficients of variation (C.V.) were calculated from the
quality controls of 16 assays. They were as follows: between assay C.V.- low QC
20.2% (8.2 ng/ml) , medium QC 11.9% (16.5 ng/ml), high QC 9.4% (51.2 ng/ml);
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within assay C.V.- low QC 10.2%, medium QC 5.5%, high 5.9%. This calculation
includes drift from the middle of the first plate to the end of the second in a two plate
assay. These C.V.'s compare favourably with the previous performance of the assay
used at a one hour incubation.
If an individual's oestrone profile showed values steadily increasing over a withdrawal
bleeding interval and into active pill taking at levels that would indicate peri-ovulation in
a normal menstrual cycle then ovulation was supected. In the normal menstrual cycle
the peak level of progesterone is normally obtained approximately eight days after
oestrogen peaks. With no prior information about endogenous progesterone dynamics
in an ovulatory pill cycle, I used the menstrual cycle as a guide. If ovulation has
occured pregnanediol levels should be elevated for the remainder of the cycle above
about 0.5|imol/mmol.
Thus the urine sample that was nearest to eight days after the peak measured level of
oestrone was entered into a pregnanediol ELISA for each cycle in which a woman
showed evelated oestrogen. Assays were preformed by the staff of the NHS
Reproductive Endocrinology Laboratories (REL) at the Centre for Reproductive
Biology. This is the routine ELISA assay and is preformed according to the same
protocol outlined in Chapter Three.
One urine sample each month was also submitted for a pregnancy test which was
assayed for the presence of human chorionic gonadotrophin (BhCG) by REL. A
common source of anxiety and dissatisfaction in the "tricycle study" participants
(Loudon, et. al., 1977) was the lack of a regular monthly bleed to reassure them that
they were not pregnant. While the chance of conception was quite remote, I wished to
ensure that an individual's prospective daily diary ratings were not clouded by a
repeated or a chronic anxiety that she might be pregnant because she was not bleeding
every fourth week. The assay is sensitive enough to detect pregnancy two weeks after
conception, therefore, regular testing acted as a safeguard that a pregnancy would be
detected in very early gestation.
6.4.3 Enrollment Interview
Volunteers were enrolled in the study during a pill free interval a few days before they
were due to begin a new packet of pills. Every woman came to an interview scheduled
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to last for approximately one hour in the Research Ward (54) of the Royal Infirmary of
Edinburgh. Enrollment took place in two groups because of the two waves of
recruitment. The first two-thirds of participants entered the study between June and
August 1990. and the final third between October and December 1990. All volunteers
had completed the study by eary May, 1991. At the time of enrollment each volunteer
was given a comprehensive information sheet to read. A copy can be found in
Appendix 6.06.
6.4.3.1 Informed consent
After reading the information sheet, the volunteer provided informed consent in writing
on a consent form and offered her G.P.'s address so that s/he could be informed of her
patient's participation (see Appendices 6.07 and 6.08 for consent form and G.P.'s
letter). She was then taken through the interview schedule contained in the Appendix
(6.09) and was requested to complete a number of psychometric tests.
6.4.3.2 Interview schedule
The interview schedule obtained information about age, smoking, parity, pill taking
history, PMS status, a retrospective summary of cyclical experience, pill effects on
cycle experience, usual menstrual cycle length, pregnancy and post-partum experience,
and recent life events and psychiatric history. All of these factors were thought to be of
potential relevance to the manner in which women would experience this investigation.
The chart for recording retrospective cyclical experience is based loosely on the
retrospective PMS assessment contained in MHRAQ-1. The questions on life events
are derived from previous interview schedules used in research studies by John
Bancroft's group (see for example Walker, 1987). Pill, menstrual cycle, and PMS
history all may have obvious relevance to a study of this kind. Recent adverse life
events, psychiatric history, and experience of low mood after pregnancy are important
as they might be predictive of negative reactions to the study, or of a high background
level of stress which would make it difficult to interpret an individual's prospective
ratings.
6.4.3.3 Psychometric tests
Three different self-administered psychometric tests were used to assess parameters that
might be prognostic of women's reactions to manipulation of their cycle length. Copies
of these are contained in Appendices 6.10 to 6.12. The Eysenck Personality Inventory
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(EPI) Form B was used to assess personality. (See discussion of EPI, Form A in
Chapter Three).
Current clinical depression was screened for using the Beck Depression Inventory
(BDI). If a woman was severely depressed when she entered the study then daily diary
ratings would probably be invalid, and therefore she ought to be excluded. The degree
of subclinical depression might relate to the way in which a woman scored diary scales
reflecting negative affect, both around the time of bleeds and during other cycle phases.
A review of the research uses of the Beck Depression Inventory (BDI) over the last 25
years has recently been made (Beck, Steer, & Garbin, 1988). Although the Beck was
originally devised for use with psychiatric patients, it has been widely used in non-
psychiatric populations.
Finally, Locus of Control as it relates to health was measured by the Multidimensional
Health Locus of Control Scale (MHLCS), developed by Wallston, Wallston &
DeVellis, 1978. This scale measures three constructs of locus of control. The first,
Internal Health Locus of Control, is a measure of how strongly an individual feels she
is in control of her own health status. The other two parameters are different aspects of
external locus of control, or to what extent one believes ones health is controlled by
external forces. The Powerful Others dimension relates to the influence of doctors,
nurses, family members, etc., while the Chance dimension measures the extent to
which one believes one's health is fated.
I hypothesized that those women who were more externally controlled would be more
willing to tolerate manipulations of their cycle, because they would accept the control of
the researcher over their experience (as a powerful other), or would simply attribute the
experience to "the luck of the draw". Internally controlled women, on the other hand,
would be frustrated by not knowing when their bleeds were scheduled to occur. They
might report more adverse effects or dissatisfaction with the study as they were not able
to control their health experience as they normally do. Severity of women's cycle-
related symptoms has been associated with locus of control using this instrument
(Harding, 1987), and external LOC has been shown to rise premenstrually in women
with prospectively confirmed PMS (O'Boyle, Severino & Hurt, 1988).
After completing the interview schedule and psychometric tests, volunteers were
instructed in the method of completing daily diaries and collecting urine samples
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(described in Instruction sheet, Appendix 6.06). They were given a five week supply
of capsules at this time, and instructed to begin pill taking on the usual day that they
would begin a new packet.
6.4.4 Volunteer Monitoring and Case Notes
Approximately every four weeks volunteers returned to the Royal Infirmary for brief
meetings. These were devised to keep a careful check on how women were feeling,
and as an important way of maintaining motivation over the six to seven months that
each woman kept up monitoring. Diaries and samples were collected at this time, and
new supplies provided to last until the time of the next meeting. At every visit a woman
was asked "how she had been getting on since the last visit?". These meetings offered
a form of monthly retrospective in which volunteers could assess how they felt the
study was effecting them- its demands, the formulation, or the cycle manipulations.
They could also raise issues in their lives that were influencing thier feelings, and diary
ratings. The case notes provided quite a lot of information about women's perceptions
of the manipulations they were undergoing, and offer anecdotal information not
contained in the diary.
6.4.5 Final Structured Interview
Once a woman had completed all 25 weeks of the study, and had begun to take the
ordinary packet of Marvelon, she was scheduled for an hour long final interview. A
copy of the final interview schedule is contained in the Appendix (6.13). The volunteer
was asked a number of questions pertaining to how positively she had viewed the
experience, what changes she had noticed in her physical and emotional well being
while taking part, how her actual experience related to her prior expectations, any
dislikes, thoughts about irregular bleeding and fear of pregnancy. Her comments were
written down in summary, or verbatim if of particular relevance to the study objectives.
After this discussion, she was asked to complete a written assessment of her experience
which particularly concentrated on cyclical symptoms and potential side effects (see
Appendix 6.14). After this was completed and discussed, her group allocation was
revealled.
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6.4.6 Methods Used to Analyse Prospective Ratings
This investigation approached novel hypotheses in a novel manner. It was not clear
how the analysis of prospective measures should be carried out. The features of the
rhythm, if present, were not yet know, and it was part of the objective of the study to
describe those features. Therefore, when the protocol was originally developed it was
planned to carry out a descriptive analysis on a single case basis. However, a number
of more sophistocated analytic techniques were considered.
6.4.6.1 Mathematical techniques of rhythm analysis
Minors & Waterhouse (1989) provide a very useful summary of the available
techniques of analysis for biological rhythm data and the constraints placed on their
use. They begin by acknowledging the complexity of the problem, and the fact that
most techniques were developed for use with data from "physical systems" in fields
like engineering or physics, or for economic forecasting "where numerous cycles of
periodic phenomena are frequently available with a high rate of equidistant sampling"
(p.272). The rigid conditions for their use are almost never met with biological data,
which is inherently variable, vulnerable to a variety of internal and external influences,
and difficult to collect over a protracted timespan.
Frequent equidistant sampling has been carried out in this study. Minors &
Waterhouse (1989) recommend that if nothing is known about a rhythm, samples be
made at least six times during its anticipated period. They note that if sampling
frequency is too high measures will not be independent, which influences the utility and
validity of some statistical techniques. It is very likely that sucessive daily ratings of
well being are not indepentent of one another. However, it remains important to have
daily data because well being is not likely to show an even profile over time; indeed, if
it constitutes the sort of 'relaxation oscillator' proposed earlier it is vital to have frequent
measurements in order to best characterize its features over time. Nevertheless,
frequently sampled biological time series data will contain noise that may obscure the
biologically meaningful aspects of the rhythm, and smoothing is generally required.
One potential method is ANOVA. ANOVA can be used to detect whether or not there
is significant variation between several time points in a biological time series, and with
data of known period, any length of oscillation can be analysed (Minors & Waterhouse,
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1989). But this technique does not give any information about the characteristics of a
rhythm, nor can it detect a rhythm if the period is unknown, as it is in this case
Time Series Analysis (TSA) is also often used to analyse rhythm data. Cosinor-
rhythmometry was first described by Halberg et al. in 1972 and invovles fitting a
cosine function to the rhythm in question (Minors & Waterhouse, 1989). But this
technique requires that the period be known or can be assumed a priori. It also
assumes that the rhythm can be approximated by a cosine curve, and that the residual
errors are independent, and normally distributed. Cosinor is also not able to cope with
changes in rhythm parameters with time. So for example, it would not be appropriate
to use with the continuous group's diary data if cyclicity damps out over time due to
weak endogenicity and/or lack of reinforcement from the primary zeitgeber/dominant
oscillator (cycling steroid hormones).
There are ways to use cosinor analysis if one assumes the period of an unknown
rhythm. More complex, but still essentially sinusoidal oscillations can be described by
elaborations of cosinor in which harmonics are added to a basic cosine curve. This
involves Fourier's theorem for spectral analysis which says that any waveform can be
reproduced by a combination of sine and cosine terms (Minors & Waterhouse, 1989).
The risk is that biologically meaningless noise will be included along with the
fundamental rhythm. One can fit a curve to any time series dataset- even if it has been
generated randomly- using a sufficiently complex function, but it will be meaningless.
Several computer packages exist to perform such analyses but they were either
unavailable, or inappropriate for use in this thesis2.
A third technique is autocorrelation. Autocorrelation invovles correlating the time series
in question with a duplicate of itself after the introduction of various time lags. If there
is a rhythm present it will be revealled by a high correlation between duplicated
segments of the time series after the appropriate shift in phase. More simply stated it is
a means of seeing if sections of a time series overlap, or repeat themselves. It is
unlikely that a long string of sequential values will precisely repeat their form by chance
alone. This technique, like the others has drawbacks. The data need to be "stationary"
2
For example, in 1990 Teicher & Barber described an easy-to-use package written for
Macintosh computers which is specifically designed to deal with biological rhythm
data, and performs "multioscillator cosinor analysis" on rhythms of known or
unknown period. It seemed that this programme would be ideal to analyse this dataset,
but it was unfortunately unobtainable.
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with no tendency for the amplitude, period, etc. of the rhythm to change over time, and
one must have data for at least four cycles of the period which is being sought (Minors
& Waterhouse, 1989). As described above for cosinor analysis, there is no reason to
assume in this investigation that the data will meet these constraints. For example, in
the continuous group four months may be insufficient time to observe four repetitions
of the infradian rhythm if the free running period is 35 to 40 days.
After considering these matematical techniques to detect and describe the hypothesized
rhythm I returned to the simplest method: plotting the data over time, "eyeballing" it,
and describing its features within and across individuals. Minors & Waterhouse (1989)
summarize the utility of descriptive techniques:
"[A] description of the raw data will remain an important part of rhythm
analysis.... Even though it may not be possible to quantify the rhythm
mathematically, it may be sufficient to show that the form of the rhythm
is reproducible in many individuals or may be changed in a reproducible
way with some (fixed) experimental manipulation." (p.291)
Sollberger (1965) provides a good synopsis of the relationship of biological rhythm
research to statistical proof:
"In the earlier days of biological rhythm research, it was important to
convince the sceptics that rhythms really exist, and statistics was the
way to do it [T]his achieved more convincing than proving.
Fortunately, the rhythms have become accepted and the real proofs have
been obtained by the simplest statistical method possible, sheer
repetition (my emphasis). This is actually an effective test. If we have
only three or four individuals, congruent curves are proof enough since
it would require quite a lot of chance to arrange all the values in the
correct timing and sequences, if they were really random." (p.20)
Thus, after an inspection of the distribution of daily diary ratings over time, judgements
were made about both the presence of a rhythm and the clinical relevance of specific
women's experience over the course of the study. Individuals were dealt with on a
single-case basis in the first instance, and then similar patterns of experience were
grouped where appropriate. For example, individuals may be grouped if they have
been subjected to the same environmental circumstances and the same entraining
influences or zeitgebers, as they were in the phase shifted group.
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6.4.6.2 Data Reduction and Smoothing
The results of the descriptive analyses are detailed in the sections below. Certain
variables were isolated for close inspection, and the noise in the data was reduced to
improve the clarity of longitudinal profiles and to aid interpretation. For every woman
in each group Student t-tests were used to make a gross asessment of the change in
severity of symptoms over time by comparing the mean diary ratings for each symptom
during the first eight weeks (baseline) of the study with the mean for the subsequent 17
weeks (manipulation). These means were derived from the raw daily data. Selected
variables for each individual were also plotted. The data were examined for evidence of
a regular oscillation over time and trends across women in the three groups.
In order to reduce the amount of noise in biological time series data it is usual to smooth
it in some way. Normally one relates a given measurement to the points that surround
it using a moving average, which may be unweighted or weighted to emphasize the
point in question. This technique will systematically reduce the number of data points,
and allow general trends to emerge from background noise. It can, however, produce
spurious oscillations if adjacent or nearly adjacent points are fluctuating randomly in the
same direction. (Sollberger, 1965; Minors & Waterhouse, 1989). Instead of using a
moving average with this data set, the data was condensed by dividing it up into
discontinuous 4-day phases. The reason that four day blocks were taken is because the
conventional 28 day pill cycle can be divided evenly into seven blocks of four days. A
4-day block is large enough to incorporate the odd missed day of ratings, yet small
enough not to obscure rapid variations in the data which may occur from one day to the
next. Four-day phases are also consistent with the previous methods used in this
thesis.
It was clear that certain diary variables were highly intercorrelated. This is to be
expected when multiple scales are measuring features of the same thing, for example,
negative affect. Some women may distinguish little between such features, while
others may interpret these scales to be quite discrete emotions. On inspection of
individual's data it became evident that "cheerful and happy", "feeling good about self",
and "energetic and active" co-vary to a large extent; as do "irritable", "aggressive and
angry", "tense and anxious", and "depressed and unhappy". Furthermore, there
seemed to be a particularly close association between "irritable" and "aggressive and
angry", and between "tense and anxious" and "depressed and unhappy". These were
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interpreted as two distinct components of negative affect: an active, outwardly directed
component on one hand, and a passive, inwardly directed component on the other.
Positive affect seemed to show little predictable oscillation in the raw data. While
changes in happiness, energy, etc. are undoubtably neglected covariates of the steroid
cycle (eg. Stewart, 1989; Asso, 1991), it is the cyclical negative changes which women
tend to emphasize. Therefore the two components of negative affect described above,
and the most commonly reported physical symptoms were isolated for analysis. The
six variables were: 1) either "irritable" or "aggressive and angry", 2) either "tense and
anxious" or "depressed and unhappy", 3) breast tenderness, 4) bloating, 5) period type
pain, and 6) bleeding. Irritability and depression are two of the most frequently
discussed cyclical symptoms in the PMS literature. But as they correlated strongly with
other scales in this data set, only one of the two covariates in each mood dyad was
chosen to measure the active and passive dimensions of negative affect. The choice of
variables was based on the woman's own retrospectively reported worst symptoms, or
if she did not indicate which symptoms were worst, the variable with the greatest range
of variation over the diary scale was taken.
6.5 Results
6.5.1 Discontinuation Rate
Forty-seven women enroled in the study, and thrity-six completed it. This represents a
discontinuation rate of 23%. One might expect a high drop out rate in a study with
such great demands, yet only about one third of women stopped the study due to what
may be considered study side effects. Table 6.01 below summarizes the reasons for
discontinuation.
Chapter 6 Controlled Study ofPill Cycle Manipulation 237
Table 6.01 Reasons for Discontinuation from Cycle Manipulation Study
Reasons for drop out / discontinuation n =
Study "side effects" - worse PMS on Marvelon1 1
- weight gain and ambivolence about study
manipulations6 1
- worsening of persistent nausea4 1
- development of chronic breast tenderness
and depression5 1
Subtotal 4
Personnal factors or circumstances - demands of study too great 1
- break up of relationship, stopped pill3 3
- house destroyed by fire2 1
- family demands: ill health of father 1
- delayed start therefore too late to finish 1
Subtotal 7
Seven of these women dropped out of the study within the two month baseline period.
All but one did so due to changes in personal circumstances which made it impossible
to continue. One of the seven preceived her PMS to have worsened within the first
month of taking Marvelon and discontinued as a result (*).
Five women persisted in the study for twelve weeks or more. One woman had to stop
because her house was destroyed by fire 121, and another because her relationship ended
and she wished to stop the pill 0). This second woman may also have been depressed
(see discussion of BDI below). Three of the five who attemped to complete the study
stopped due to effects that may either be attributed to the pill formulation or to adverse
effects of cycle manipulations. One woman who had experienced nausea during the
first week of the cycle on previous formulations, developed persistent nausea while
taking Marvelon (4). She had been allocated to the continuous group. As a steroid
sensitive person, prolonged pill taking probably contributed to her discomfort. I
discontinued her from the study in week 14 as it seemed unethical to ask her to
continue. She stopped using oral contraception and her nausea resolved.
Only two of the 11 drop outs stopped the study due to adverse effects that may be
attributable to cycle manipulations. One woman was randomized to the continuous
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group and the other was phase shifted. The first woman was a very busy travelling
sales representative She found it difficult to maintain the diaries and sample
collection, and to keep appointments. The fact that she had very infrequent return visits
probably contributed to her anxieties when she found that she did not have a bleed for a
long interval. She reported that after the first "missed bleed" in week twelve she
became progressively more unhappy and depressed, and she also had continuous breast
discomfort and bloating. She had not been at all depressed previously. As will be
shown below, this pattern is similar to a number of other women in the continuous
group. The combined effect of these adverse symptoms and no reassurance in the form
of "check ups" caused her to discontinue the study and stop taking the pill altogether.
The woman in the phase shifted group who dropped out did so because she had
substantial weight gain that she believed was attributable to the study (6). She was also
disconcerted by changes in the consistancy and volume of her bleeds, which she found
darker and "stringy". In addition, she reported that her PMS which had been quite
severe prior to entering the study was not coming at the normal time, and was lasting
longer. Her experience was similar to others in the phase shifted group. The changed
bleeds and disrupted mood cycles may be attributable to the cycle manipulation. She
was already taking Marvelon when she entered the study, yet reported weight gain from
the outset. The fact that she became 'symptomatic' without any change in pill
formulation or regime implies that some of her reactions must be interpreted cautiously,
as they may reflect false attributions.
6.5.2 Volunteer Characteristics
The demographic characteristics of the women who offered to be contacted for this
study were discussed in the Chapter Four. The subsample who actually enrolled did
not deviate markedly from those who did not. The mean age of continuing volunteers
was 28.7 years. (SD 5.2), median age 28 years and range 19 to 41 years. These
women had all used the pill for at least four months prior to entering'the study. The
mean length of pill use was 4.7 years (SD 3.9), the median 4 years, and the range 4
months to 15 years. Only eight women were smokers, and all of these were 33 years
old or less. All women were of low parity, and most had never had a pregnancy:
29=para 0(0), 4=para 0(1), l=para 1(0), l=para 1(1), l=para 2(1). The number of
terminations are noted in parentheses. Figures 6.01 and 6.02 show the rank ordered
distributions of age and duration of pill use respectively.
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Figure 6.01 Ranked distribution by age of those women who completed the
study.
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Volunteers ranked by duration prior pill use
Figure 6.02 Ranked distribution by duration of prior pill use of those women
who completed the study.
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Table 6.02 COC pill types in use prior to entering study (Total n=36).
Moriophasic Pill Name Steroid Constituents n = 24
Brevinor EE 35|ig + NET 500pg 1
Microgynon / Ovranette EE 30|ig + LNG 150jig 14
Marvelon EE 30|ig + DSG 150(ig 6
Mercilon EE 20(ig + DSG 150(ig 2
Femodene EE 30pg + GSD 75pg 1
Triphasic Pill Name Steroid Constituents n= 12
Logynon / Trinordiol EE 30(ig + LNG 50(ig (x5)
EE 40pg + LNG 75pg (x6)
EE 30|ig + LNG 125|ig (xlO)
7
Trinovum EE 35(ig + NET 500|ig (x7)
EE 35|ig + NET 750pg (x7)
EE 35|ig + NET lOOOpg (x7)
5
Key: EE-ethinyloestradiol, NET-norethisterone, LNG-levonorgestrel,
DSG-desogestrel, GSD-Gestodene.
Table 6.02 indicates that five-sixths of women had to switch to Marvelon from another
combined pill formulation. Two-thirds of the sample were previously using a
monophasic pill and one-third a triphasic. While the length of time that women had
been taking their current formulation varied widely, 68% had taken it for at least two
years, and over 80% for at least one year. This only describes the current pill used,
and if previous formulations are considered, the duration of pill taking was longer for
the majority of women. Thus, this sample of women can safely be considered
established pill takers.
The distribution of retrospectively reported non-pill cycle lengths across the three study
groups is summarized in Table 6.03. It is difficult to make a between group
comparison as the group size is small. However, it appears without the benefit of a
statistical test that the number of women showing short, regular, long, very long, and
irregular cycles is similar in all three groups. The validity of women's self reported
average cycle length has been called into question because of the difficulty many
women have in accurately recalling or predicting the time of menstrual bleeds. While
women are very good at anticipating the duration of the bleed itself, it seems that they
are poor at predicting the inter-bleed interval (eg. Snowden & Christian, 1983). Thus
important though information about usual menstrual cycle length is for testing the
hypotheses of this study, this information is likely to be of limited value.
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Table 6.03 Distribution of Previous Menstrual Cycle Lengths
By Group Allocation
Group x Short: Regular: Long: Very long: Irregular:
Cycle length median median median length 42+ range 14-
<28 days =28 days >28 days days 50 days
Control 2 2 1 - -
Continuous 2 9 3 1 1
Phase shift 1 7 4 2 1
Total 5 (14%) 18 (50%) 8 (22%) 3 (8%) 2 (5%)
6.5.3 Major and Minor Events: A Source of Potential
Confounding
Very few women who took part in this investigation had an entirely trouble or stress
free six months. A wide variety of events, major and minor, occured. Many of these
experiences could have influenced subjective well being, and thus diary ratings. A
number of women took a course of antibiotics at some stage which may have interfered
with pill absorpdon, and thus effected hormone results. The commonly reported events
are listed in Table 6.04. The total number is in excess of thirty-six because most
women reported more than one event. Only three reported nothing at all. In
subsequent analyses, note is made when a specific event was considered to have
influenced diary ratings.
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Table 6.04 Day to Day "Hassles" and Major Life Events
Occuring During Study
"Life Event" Number reporting
Minor ill health or operation 11
Course of antibiotics / corticosteroids 10
Foreign travel- including trans-continental 10
Relationship difficulties or break up 8
Work stressful 7
Moved house, bought or sold property 6
Started a new job 5
Got engaged or married 5
Death of a close relative 3
Partner or family member ill 3
Sister had baby 3
Self or partner made redundant 2
Started new relationship 2
Miscellaneous-alcohol abuse, death of aquaintance,
assaulted at work, working night shifts, burgled,
clinical depression and anxiety, pet died
1 each
Note: Some women reported more than one event.
6.5.4 The Effect of Cycle Length Manipulation on the Pattern of
Vaginal Bleeding
The impact that systematic alteration in the length of the OC cycle has on women's
experience of vaginal bleeding is of fundamental importance. Previous studies of the
effects of prolonged pill taking have predominantly concerned themselves with the
question of its acceptability to women. This acceptability is intimately linked to the
efficacy of these manipulations in postponing bleeds. Women who experience a great
deal of breakthrough bleeding (BTB) are less satisfied with manipulation, and have
been more likely to drop-out of studies (Loudon, et al., 1977; Hamerlynck, et al.,
1987; de Voogd, 1991; Kornaat, et al., 1992). Therefore, it is important to consider
the bleeding experience of these volunteers in order to interpret their other diary ratings,
and to ascertain the potential acceptability of very long cycles. If extended cycles were
to have a favourable effect on cyclical negative affect, for example, women still might
not choose this as a PMS treatment if it grossly altered their pattern of bleeding.
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The total number of breakthrough and withdrawal bleeding days by group was close to
that predicted given the pill taking regime. The mean number of days bleeding per
woman in each group is shown in Figure 6.03. Figure 6.04 is a periodogram of the
bleeding experience of all the women who completed the study. Unlike scheduled
withdrawal bleeding, the patterns of BTB were quite different in the three groups.
Overall 10 out of 36 women had BTB in the baseline months: control 1/5, continuous
group 2/16, phase shifted 7/15.
BTB was relatively consistant over time in the phase shifted group; seven of the eight
women who had it in the baseline had further BTB later in the study. The continuous
group however, who had virtually no BTB in the baseline had an exponential increase
in the number of bleeding days as the study progressed. Eleven out of sixteen women
in this group had BTB during the protracted cycle, and in the fouth month of
continuous pills, 9 women had more than 100 days of bleeding between them (see
Figures 6.05 and 6.06).
6.5.5 Hormonal Results
All of the BhCG tests conducted for this study were negative. There were no
pregnancies. There was considerable anxiety about pregnancy, but the tests reassured
women.
Twenty-five of the 36 women who completed the study collected urine samples: 5/5
controls, 8/16 continuous, 12/15 phase-shift. All samples were assayed for E-3-G in
the manner described above. The pattern of oestrogen that these women showed
during the first 11 weeks of the study was very similar to that of the
Microgynon/Ovranette and Logynon/Trinordiol takers in the folliculogenesis study.
Because samples were not collected on the same study days by all volunteers weekly
group means are reported. Figure 6.07 compares the E-3-G profiles for all three
groups in the baseline weeks. (Three women in the phase-shifted group have been
excluded- see below) All groups show a typical profile of rising E-3-G during the
withdrawal bleeding intervals in weeks 4 and 8, and peak levels in the first week of pill
taking in weeks 5 and 9. Oestrone levels return to the post-menopausal range by the
second consecutive week of pills where they remain until the next withdrawal week.
There was no significant difference between the three groups in the first 11 weeks
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Figure 6.05 Total number of days of breakthrough bleeding occurring during
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Figure 6.07 Comparison of weekly mean oestrone levels across all three
study groups during the 11 baseline weeks.
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(Control vs. Continuous t=-0.20, p=0.84; Control vs. Phase shifted t=-0.41, p=0.68;
Phase shifted vs. Continuous, t=0.20, p=0.84).
This pattern continues for the remainder of the study for the control group3. Those
women who collected samples in the continuous group showed quite homogeneous
profiles. When the withdrawal bleeding intervals were abolished so too was escape
ovarian function. After a low mean peak in week 9 there were no further notable rises
in E-3-G, and levels remained at a post-menopausal baseline for the remainder of the
study. (See Figure 6.08) Only half of the continuous group provided samples, and it
is possible that the other half would have shown a different degree of ovarian function.
The pattern of the phase shifted group, shown in Figure 6.09, is more complex than the
other two, and runs counter to expectation in a number of ways. In week 12, when a
bleed would have occurred had there not been a phase delay, E-3-G showed a transient
rise. Fevels returned to baseline in week 13, but rose again in the actual withdrawal
week, 14, and peaked in the first subsequent active week. The profile after the next
two withdrawals was similar to the baseline.
Student's t-tests comparing the oestrone profiles of the groups in the second half of the
study (weeks 9-25) showed that the control and phase-shifted groups were not
significantly different from one another (t=-0.53, p=0.59), while the control and
continuous (t=3.11, p<0.00), and continuous and phase shifted (t=-3.10, p<0.00)
were. These results are consistent with the visible differences between the mean
profiles of the three groups, and with the exogenous steroid regimes administered.
The oestrogen results of three women in the phase shifted group were excluded from
the group mean because they were markedly different from the remainder of the group.
Volunteers BIO, C7, and D4 each had peak E-3-G values which were ten-fold higher
than the mean of the other 9 women in this group. Figure 6.10 shows the daily E-3-G
measures for these women. The peak levels which they achieved were at least equal to,
if not substantially greater than, the E-3-G levels which one sees around ovulation in
the normal menstrual cycle. Furthermore, each woman showed a sustained rise in
E-3-G over many days during more than one cycle, over the six months. These
3
It becomes less distinct because one woman stopped collecting samples in week 13, a
second missed samples during the would-be peak weeks 24 and 25, and a third (CIO)
had raised E-3-G at unusual times relative to withdrawal weeks.
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Figure 6.09 Weekly mean oestrone levels during the entire study in the phase
shifted group.
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Figure 6.10 Individual oestrone profiles for three women in the phase shifted
group who showed markedly elevated levels of oestrone.
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extended and repeated rises in E-3-G within three separate individuals imply that this is
not an artifact of assay error or poor sampling technique4. The lowest values are
similar to the baseline levels shown by all the other pill takers in this thesis, reflecting
that the samples covered the whole range of the assay.
Pregnanediol levels were assayed in "spot" samples in the manner described above for
these three women, in each of the ten cycles in which E-3-G was raised. No
pregnanediol level was high enough to indicate that ovulation may have taken place,
and it was concluded that, although reflecting substantial folliculogenesis these cycles
were anovulatory.
6.5.6 Final Assessment
This section describes the self-reported retrospective experience of the study. Tables
6.05 to 6.09 summarize changes in emotional and physical well being and bleeding
parameters reported by the three groups of women on the study assessment form.
"Postive affect / energy" relates to the sentence completions for "happy" and "energy"
on the form. "Negative affect" includes "bad tempered", "mood swings", "depressed",
and "tense". If a woman reported at least one of these she was included in the
appropriate category. No individual's responses were divided- e.g. more depressed,
but less tense.
4
Isolated spikes are sometimes observed in urinary steroid profiles when a sample has
been taken late in the day, and is therefore very dilute. A "watery" sample will have a
very low creatinine reading. It will also have to be used at a lower than normal dilution
in the ELISA, possibly "neat", and will thus be susceptible to interference and an
inflated reading. This produces a distorted E-3-G/Crt ratio in "one off" samples, but
cannot explain the protracted rises seen here.
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Table 6.05 Retrospectively reported change in mood and




PMS 1(20) - 4M (80)
Positive Affect / Energy - - 5M (100)
Negative Affect 3M (60) - 2(40)
Sexual interest - 2M (40) 3 (60)
Breast tenderness - - 5M (100)
Bloating 2M (40) - 3(60)
Weight gain 2M (40) n/a** 3(60)
Headaches 1(20) - 4M (80)
Period type pain - 2M (40.0) 3(60)
One of those women who experienced symptoms was already taking Marvelon when
she began the study, and her experience of symptoms is denoted by the symbol - M.
** The questionnaire was not worded to allow women to indicate if they had lost
weight. Percentages are shown in parentheses.
The control group shows that certain effects may be attributed to the Marvelon itself, or
to the influence which simply taking part in the study had on well being. None of the
controls reported any increase in happiness or energy, but three noted more negative
affect. Two reported more tension (A 14 & C6) and one had more irritability and mood
swings (B14). One woman (A14) who described more tension along with weight gain,
more bloating, and less sexual interest was already taking Marvelon prior to entering
the study. She had changed neither OC formulation nor regime, therefore, the
symptoms she experienced must be attributable to other causes.
The woman who was more irritable (B14) indicated in her final interview that she had
only had these feelings initially, and attributed them to a fear of the unknown. She
believed that she was more anxious because she was blind to the timing of her bleeds.
Once she had had several bleeds at the "normal" intervals she decided that she was
probably a "control" and had no further negative mood. Both of these cases suggest
genuine study effects.
Changes in physical well being are less likely to result from anxiety about study effects
and more likely to be a consequence of the switch to a new pill. Yet the Marvelon taker
noted a number of physical changes too. It could be chance that some of the controls
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felt physically different during this six months. Alternatively, diary keeping might have
peaked awareness. The control groups experience dictates that caution should be used
in interpreting the cause of such changes in the other groups. Negative study effects
here may be a function of the unique nature of this investigation; notably that
concealling the time of bleeding from women seems to cause anxiety.
Table 6.06 Retrospectively reported change in mood and




PMS 1 (6) 6m (35) jQMMMm (59)
Positive Affect / Energy 4m (24) 4m (24) 9MMM (53)
Negative Affect 9M'n (53) 6m (35) 2mm (i2)
Sexual interest 4Mm (24) 4m (24) 9mm (53)
Breast tenderness 7Mm (41) 2M (12) 0023 22
Bloating JQMMMm (<^ 4m (24) 3(18)
Weight gain 11Mm (65) n/a** 6MMm (35)
Headaches 4m (24) 3m (18) Iqmmm (59)
Period type pain 2M (12) 4(24) 1 iMMMm (65)
* Note that this number includes one woman who dropped out of the study from this
group in week 18; she is not included in the assay or diary data analyses.
3 women in the continuous group were taking Marvelon when they began the study,
and their experience of symptoms is denoted by the symbol - M.
2 further women were taking Mercilon, which has 10|ig less EE than Marvelon; their
experience of symptoms is denoted by the symbol - m .
** The questionnaire was not worded to allow women to indicate if they had lost
weight. Rounded percentages are shown in parentheses.
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Table 6.07 Retrospectively reported change in mood and




PMS 3(20) 6M (40) 6M (40)
Positive Affect / Energy 3M (20) 2M (13) 10(67)
Negative Affect 4M (27) 5M (33) 6(40)
Sexual interest 1 (7) 2(13) 12MM (80)
Breast tenderness 4M (27) 2(13) 9M (60)
Bloating 3 (20) - 12MM (80)
Weight gain 4M (26) n/a** 11M (73)
Headaches 4M (27) 2M (13) 9(60)
Period type pain 5 (33) 3M (20) 7M (47)
2 women in the phase shifted group were taking Marvelon when they began the study,
and their experience of symptoms is denoted by the symbol - M.
** The questionnaire was not worded to allow women to indicate if they had lost
weight. Rounded percentages are shown in parentheses.
As one might expect, the two manipulated groups reported higher incidences of change
in their well being than the control group. Between 20 and 40% of women in these two
groups described feeling better during the study months with less PMS, happier/ more
energy, and less negative affect. About an equal proportion in the phase shifted group,
however, and over half of the women in the continuous group noted more negative
moods. The two manipulated groups also had substantial proportions of women who
seemed to be worse off physically. This was particularly marked in the continuous
group in which over 40% of women reported more breast tenderness, bloating and
weight gain, and about one quarter less sexual interest and more headaches.
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Table 6.08 Self-reported bleeding pattern.
Group Withdrawal Bleeding More Less Same
Control Volume 1(20) 1 (20) 3M (60)
(n=5) Duration - 3 (60) 2M (40)
Continuous Volume 6MM (35) 6M (35) 5mm (29)
(n=17*) Duration 4(24) 3m (17) |QMMMm (59)
Phase shifted Volume 4M (27) 3 (20) 8M (53)
(n=15) Duration 3 (20) 3 (20) 9MM (60)
* Note that this number includes one woman who dropped out of the study from this
group in week 18; she is not included in the assay or diary data analyses.
3 women in the continuous group were taking Marvelon when they began the study,
and their experience of symptoms is denoted by the symbol - M.
2 further women were taking Mercilon, which has 10(ig less EE than Marvelon; their
experience of symptoms is denoted by the symbol - m. Rounded percentages are
shown in parentheses.
Table 6.09 Comparison of the retrospectively reported incidence
of breakthrough bleeding.













* Note that this number includes one woman who dropped out of the study from this
group in week 18; she is not included in the assay or diary data analyses.
3 women in the continuous group were taking Marvelon when they began the study,
and their experience of symptoms is denoted by the symbol - M.
2 further women were taking Mercilon, which has 10(ig less EE than Marvelon; their
experience of symptoms is denoted by the symbol - m. Rounded percentages are
shown in parentheses.
Tables 6.08 and 6.09 summarize the retrospectively reported bleeding experience of the
study participants. Overall about half the women who completed the study reported
some change in the volume, duration, or pain associated with bleeding. A slight
majority of women noted that while their bleeding was heavier, it tended to be shorter
and less painful. Eighteen volunteers indicated that they had had BTB at some time
during the six months. Thus more than half the women taking part experienced
'irregular' bleeding or spotting. In fact, the completed diaries indicate that 20, rather
than 18 women had bleeding during active pill taking. The discrepancy may be due to
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poor recall, very minor amounts of BTB, or it may be because some women actually
believed their break-through-bleeds were "proper periods". At least two women did
report that they were having "periods" when they were in fact having BTBs.
6.5.7 Clinical Monitoring
The monthly interview notes gave the volunteer's perspective on the effects of the
manipulations. Four women in the continuous group who had previously experienced
cyclical well being over the pill cycle, with negative affect prior to bleeding, reported
relief from symptoms during the protracted cycle. One woman (B3) who suffers from
PMS and her fiance both noticed a marked improvement in her moods during the
protracted cycle. She described it as being more "level", "even", "less up and down".
Another woman (C3) reported more breast tenderness and weight gain, but although
she had expected to have PMS even if she were not bleeding monthly, she commented
that she had had "no PMS at all" during the study.
A third woman (C5) indicated that she had felt very well during the protracted cycle,
and that she enjoyed not having periods. Both she and her husband believed that the
study had helped to improve her moods substantially, and she had also had none of the
usual pain or bloating. She described "tremendous" chocolate craving before her Final
withdrawal bleed in week 25. The fourth woman (A5) was experiencing quite
profound PMS when she entered the study. Yet after the first baseline cycle she
reported that her moods were very steady and she did not feel "premenstrual" at all.
She described the improvement as "no' always beeing ready to swing for people."
A second group of three women in the continuous group continued to report having
cyclical symptoms at intervals although the hormone regime was constant. One woman
(B8) noted that she had "all the signs" of a coming period, including tearfulness, spots,
and bloating, during the first missed withdrawal bleed in week 12. These symptoms of
a period spontaneously resolved after a few days. She "was fine" in week 16, but she
"felt like" she was going to have a period in weeks 19 and 20, and an episode of
spotting followed. The second woman (C4) reported "feeling very premenstrual" in
weeks 15 and 24. Her symptoms included her usual pattern of moodiness,
constipation, and indigestion. These "premenstrual" episodes correspond to the fourth
would-be premenstruum, and the sixth would-be withdrawal bleeding phase. The third
woman (B12) found that her mood was very "up and down" from weeks 8 to 19 of the
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study. For example, in week 19, which was the fourth would-be premenstruum, she
was "very depressed", then felt "euphoric" for a few days before having a six day BTB
in week 20. She was one of the volunteers who believed that she was having regular
withdrawal bleeds, although it was actually BTB.
Over half of the women in the phase shifted group reported experiences which seemed
to indicate the presence of some sort of ghost cycle, and/or a general disruption in the
timing of cyclical changes brought about by the phase shift. The pattern of fluctuations
in subjective state after the phase shift often seemed to be different from what it had
been before, and in many cases physical and mood states became dissociated. One
woman (A8) who normally had severe negative mood change before bleeding, and who
dropped out of the study because of the effects which it had on her (see case 6 in Table
6.01 above) felt that she was "premenstrual for most of the month" during the 6-week
phase shifted cycle. She reported that after the bleed in week 14 her negative affect
peaked and dissipated several times without associated bleeds. She said that, "the
study has put me a week ahead of myself with PMT."
Another phase shifted woman (C9) felt bloated, and "had a discharge" during the
would-be bleeding week 12, and then felt irritable at irregular intervals throughout the
remainder of the study. She was already on Marvelon, and had formerly had her most
irritable phases premenstrually. One woman (CI) bled in both weeks 12 and 14, and
again at the would-be bleed time in week 26. She also had period pain, but no bleeding
in week 19.
Another woman (D2) was tired in week 12, but "had no PMS", yet became "moody
and irritable" a few days before the withdrawal bleed in week 14. She then had period
pain in week 16 but no bleed. In week 26 when a bleed was "due" but did not occur
because the packet of Marvelon had been added straight on, she felt like she should be
having a bleed as she "had period pain and headaches, and was grumpy."
Two more women who normally experience PMS symptoms before their bleeds found
the timing had changed. One (B15) had all the usual physical symptoms prior to bleeds
from the beginning of the study, but no "PMT day". Her "PMT day" previously fell
predictably on day 19 of a pill packet, about 7 or 8 days prior to bleeding, yet she did
not have one in the study until week 16, 12 days prior to the next bleed. She then had
another "PMT day" 11 days later, one day before the week 18 withdrawal bleed. She
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had still others for one day each in weeks 24 and 26. The second woman (B9) noted in
week 12 that she had had "all the signs that it was due", but only had spotting, and then
a "proper period" in week 14. Again in week 24, when a would-be bleed should have
been, she felt depressed and tense, but did not have another actual withdrawal week for
a further four weeks.
The data provided here are retrospective and anecdotal. However, they give some
suggestive evidence that certain women experienced persistent cyclicity in subjective
state during continuous pill administration. In others, cyclical changes were damped
down or disappeared. Reports from the phase shifted group indicate that the timing of
cyclical changes in relation to withdrawal bleeding can be successful altered by
"moving the period". For a number of women changes that formerly only happened
before a withdrawal bleed began to happen at other times of the cycle after the phase
shift.
Contrary to the initial hypothesis, physical changes did not appear to be more closely
bound to variations in exogenous steroid levels than mood changes. This is reflected
by the fact that a number of women experienced period pain in the absence of any
bleeding or of a placebo week. Breast tenderness seemed to be more severe and
persistent in the extended groups, and may be more steroid dependant than other
physical changes.
6.5.8 Results of Prospective Daily Diaries
The daily diary data are summarized in this section according to the descriptive
techniques which were outlined in section 6.4.6.2 above.
6.5.8.1 The severity and timing/cyclicity of selected diary variables
in the control group
Six women were allocated to the control group. However, one woman had to be
single-blindly switched to the continuous group in mid-study (her case will be
discussed later), so ultimately there were only 5 controls. At the beginning of the study
two of these women reported that they did not have PMS or any notable cyclical change
in their well being. A further two reported mild emotional and physical changes, while
one presented as a PMS sufferer. Yet on inspection of the plots of selected diary
variables over time, the only symptoms which showed any marked regularity for the
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four women who had retrospectively reported no changes or mild PMS were period
pain and bleeding itself.
Theoretically, no symptom should have changed in severity at all over the study in this
group since they underwent no manipulation of their cycle. Table 6.10 below
summarizes the number of women in the control group who showed either a
statistically significant increase, decrease, or no change in the mean severity of each
variable in a Student t-test between the two baseline months and the four "treatment"
months. This table shows that there were changes in the control group over time. One
control each showed a decrease in the 4 physical symptoms. Three of these four
women had switched to Marvelon for the study, but the woman whose diaries showed
less marked bloating over time was already taking Marvelon before she entered the
study. Curiously this was the same woman who noted on her final assessment form
that she had been more bloated during the study. So there is a contradiction between
her retrospective and prospective assessments of this symptom. We must therefore be
cautious when interpreting the cause for changes in symptom severity in the two
manipulated groups.
The most notable finding is that all the controls were less irritable after the first two
months. This would seem to confirm that taking part in the study, initially had a
negative effect on volunteers, but over time with regular bleeds this effect wore off.
This could be due to anxiety and hightened awareness due to diary keeping, double-
blindness, or it could reflect the settling-in period on a new pill formulation. The
profile for irritability for four of the controls in Figure 6.11 shows the tendency for
scores to be higher in the first two months of the study.
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Figure 6.11 Individual phased profiles of irritability for four women in the
control group. Dotted lines indicate the position of the pill free
interval.
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Table 6.10 Control Group: Number of women showing significant













no change 4 4 - 2 4 3
more - - - 1 - 1
less 1 1 5 2 1 1
The fifth woman who considered herself a PMS sufferer, was the only one in the
control group who showed a predictable relationship between her well being and her
endogenous steroid and bleeding patterns. Both her pattern of bleeding and her
oestrogen profile were irregular for a pill taker. Rather than showing consistent
withdrawal bleeds within a few days of starting a dummy pill week, her bleeds started
while still taking active pills or did not occur during the dummy pill week at all. Her
oestrone levels were also relatively high and do not show the classical post-menstrual
rise and rapid return to baseline demonstrated in Chapter Three.
Figure 6.12 shows the profile of a number of her symptoms. Note the relationship of
peaks in irritability and breast tenderness to subsequent bleeds whether scheduled or
breakthrough. Note also the elevation in the baseline level of bloating, which though
higher still oscillates in time with bleeds. The profile for depression which is not
shown was similar to irritability.
None of the controls showed a robust cyclical pattern, therefore their usefulness as a
baseline for steroid cycle linked cyclical change is limited. This problem was probably
produced by small numbers and by the fact that women were not chosen to take part in
this study because they reported cyclical changes, but recruited on the basis of their pill
taking and willingness to undergo cycle manipulations. Fortunately, the women in the
"experimental" groups may serve as their own control because they experienced two
conventional four week cycles prior to manipulation.
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Figure 6.12 Profiles of selected mood and physical variables in relation to
bleeding for control CIO. Dotted lines indicate the position of the
pill free interval.
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6.5.8.2 The severity and timing/cyclicity of selected diary variables
in the continuous group
The responses of women to constant pill taking were not uniform. A number of
patterns of symptoms emerged from the diary ratings. When the diary data of the 16
members of this group were examined a number of idealized models were kept in mind
that might describe the patterns in the data. These models were developed based on
various potential aeitiolgical theories for the existence of cyclical change in well being.
They were designed to categorize similar responses to the manipulation, but in practice
proved too inflexible and arbitrary to be of practical use. However, for their theoretical
interest they are reproduced in Appendix 6.15.
A number of patterns did in fact emerge from the data itself. If this group were to show
persistent oscillation in well being with constant pill administration in precisely the
same manner that they do during conventional cycles then one would expect no change
in overall mean symptom severity. Alternatively if symptoms occurred only around the
time of withdrawal bleeding then one would expect all of the means to be significantly
lower in the second half of the study, since there is only one scheduled bleed. The
table below demonstrates that neither is the case.
If bleeding and period type pain were purely a function of steroid withdrawal then one
would expect lower mean levels in the second half of the study However many women
did not show a change in the mean amount of these variables. This may reflect the fact
that a large proportion of women in the group had significant amounts of breakthrough
bleeding. But an even larger number have no change in period pain, which suggests
that period pain occurred in the absence of bleeding for some women.
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Table 6.11 Continuous Group: Number of women showing significant













no change 7 11 11 8 7 8
more - - 1 5 6 5
less 9 5 4 3 3 3
The mood symptoms are more difficult to interpret. But it is clear that a much smaller
percentage of this group than the controls had improved mood as the study progressed.
And quite a number of women actually became more irritable or depressed. The
distribution of significant changes in breast tenderness and bloating were very similar to
depression, with about a third of women scoring higher breast tenderness and bloating
in the second half of the study.
On examination, the diary data of 4 of the 16 women was deemed to be of limited
interest because symptom levels were too low or too erratic to interpret, or data were
missing. For the remaining 12 it became evident that a number of women showed
similar patterns of symptoms. There were four groups of three women each who
showed consistent patterns of symptoms to one another. The probability that different
women will experience one symptom in a similar way over six months is remote, but it
is even more unlikely that they will be similar for more than one symptom concurrently.
So although conventional statistics connot be readily applied to this data, the repetition
across women implies a genuine effect.
A) Symptom subgroup one. The first group is made up of volunteers A7, B4,
and B12. Figures 6.13 to 6.15 show their symptom profiles over the entire study. In
these and subsequent figures one mood variable is shown as an illustration, along with
the four physical variables. In this subgroup negative mood, notably depression
seemed to become chronic as the study progressed. One woman (A7) described it as
being like an endogenous depression. The three physical symptoms, breast tenderness,












































Symptom subgroup 1. Profiles of selected mood and physical
variables for condnuous group member A7. Dotted lines indicate
the position of pill free intervals. Closed arrows indicate the
position of "would-be" withdrawal bleeds. Open arrows indicate
thp. nnsifinn nf mipTninp. hp.nrlar.hp.s
Chapter 6 Controlled Study ofPill Cycle Manipulation 267
depression >jr V y y
Study week
Figure 6.14 Symptom subgroup 1. Profiles of selected mood and physical
variables for continuous group member B4. Dotted lines indicate
the position of pill free intervals. Closed arrows indicate the
position of "would-be" withdrawal bleeds.
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Figure 6.15 Symptom subgroup 1. Profiles of selected mood and physical
variables for continuous group member B12. Dotted lines
indicate the position of pill free intervals. Closed arrows indicate
the position of "would-be" withdrawal bleeds.
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bloating, and period pain also worsened and became chronic over the long cycle. Two
women eventually gained relief from breast tenderness at the time of the final dummy
pill withdrawal bleed in week 25. The third woman whose breast tenderness remains
high, was already taking Marvelon when she entered the study, so this effect seems to
be attributable to constant steroid administration rather than the formulation per se.
Bloating does not return to basal levels for any of the three by the end of the study.
Period pain does not show the same chronic elevation of the other two symptoms, but
tends to become more frequent as the cycle progresses. Although it always occurs with
bleeding whether this is scheduled or breakthrough, it also occurs at other, random
times. Pain is resolved by the end of the study for the two women whose week 25
bleed was complete, and for the third who was still bleeding, it was waning.
Although the predominant effect in this subgroup seems to be chronic sympotmatology,
there is also evidence of persistent cyclicity. A7 and B12 seem to experience an
exacerbation of depression and bloating around the times when withdrawal bleeds
would have occurred in weeks 12, 16, and 20. The effect is more marked for Bi2. B4
also has an oscillatory pattern superimposed on a raised baseline of breast tenderness
and bloating, but the period seems to be greater than four weeks.
A7 also had more migraine headaches during the study which appeared at regular 5 to 6
week intervals5. She noted that before starting on the study pill she had infrequent
migraines, perhaps once a year. Within two months on Marvelon she had a migraine
(week 8), and had three further attacks in weeks 13/14, 20 and 25 (see Figure 6.13).
She felt that these headaches were more profound and lasted longer than those in her
previous experience. These were not consistently withdrawal headaches as two of the
four occurred during active pill taking. Before the study she was taking Mercilon
which is identical to Marvelon except that it contains 10|ig less EE each day. All three
women in this subgroup reported that they usually had some PMS-type experience. A7
reported mild cyclicity, while B4 and B12 reported marked PMS.
B) Symptom subgroup two. The second group of three women, which includes
Al, A3, and C8, is in some respects similar to the first. (See Figures 6.16 to 6.18)
Their negative mood, particularly irritability either remains apparently cyclical (Al), or
actually improves6. Breast tenderness and bloating, however, become more severe and
5
Her experience is similar to that of PMS patient 8846. See figure 5.05.
6
Volunteer Al was going through a difficult relationship break-up during the study,
which seems to be markedly reflected in her depression scores, but not irritability. The
other two women had minimal tension/depression.



















i j ■■ ■■—»-»
20 24 25
Figure 6.16 Symptom subgroup 2. Profiles of selected mood and physica
variables for continuous group member A1 in. Dotted line:
indicate the position of pill free intervals. Closed arrows indicate
the position of "would-be" withdrawal bleeds.
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Figure 6.17 Symptom subgroup 2. Profiles of selected mood and physical
variables for continuous group member A3. Dotted lines
indicate the position of pill free intervals. Closed arrows indicate
the position of "would-be" withdrawal bleeds.
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Figure 6.18 Symptom subgroup 2. Profiles of selected mood and physical
variables for continuous group member C8. Dotted lines
indicate the position of pill free intervals. Closed arrows indicate
the position of "would-be" withdrawal bleeds.
Chapter 6 Controlled Study ofPill Cycle Manipulation 273
more variable after the baseline, during the extended cycle. There is some suggestion
that while these symptoms are generally elevated they show exacerbation at the time of
would-be bleeds at roughly monthly intervals, viz- breast tenderness for A3 and
bloating for C8. The Marvelon taker in this group (A3) shows very similar patterns of
breast tenderness and bloating to the Marvelon taker in group one (B4). The profiles of
period pain in this group are distinct from the previous group. Pain seems
predominantly to occur at the time of bleeding, whether scheduled or breakthrough, but
not at other times.
The severity of mood symptoms in this subgroup is consistent with the women's
retrospective report of PMS-type changes. Al, who showed the most substantial mood
change in her diaries reported having marked cyclical changes at the beginning of the
study. A3 and C8, on the other hand, both indicated that they only ever experienced
physical changes. Their retrospective report is confirmed by the almost complete
absence of moods in their prospective ratings.
C) Symptom subgroup three. The third group of women, including A5, B3, and
C3, are distinct from the previous two because they record a resolution of negative
moods as a result of the prolonged cycle. This effect is particularly marked for
irritability. (See Figures 6.19 to 6.21) One woman, B3, consistently reported during
the study that her mood was improved by prolonged pill taking, however, she actually
shows some worsening of mood early in the manipulated cycle7. While no one in this
group was an established Marvelon taker, B3 had been taking Mercilon. All three of
these women reported experiencing PMS prior to the study, marked for A5 and B3,
and mild for C3, but none showed clear evidence of cyclicity in the two baseline cycles.
A5 who showed the most marked mood change in the baseline had been so distressed
by her PMS symptoms when she first entered the study that it almost caused her
relationship to break down and her to discontinue the study. She stopped taking the pill
for five days in the first control cycle. Instead of dropping-out, she was encouraged to
start the pill again, and to re-start the study the following month, thus her first control
cycle is actually her second month on encapsulated Marvelon. So the absence of mood
change in her second (actually third) cycle may demonstrate that she had already
7
This corresponds to a time when she was having physiotherapy on her Achilles tendons
which prevented her from exercising, and was preparing for her up-coming wedding,
both of which affected her mood.
Chapter 6 Controlled Study ofPill Cycle Manipulation 21A
breast tenderness
Study week
Figure 6.19 Symptom subgroup 3. Profiles of selected mood and physical
variables for continuous group member A5. Dotted lines
indicate the position of pill free intervals. Closed arrows indicate
the position of "would-be" withdrawal bleeds.




Figure 6.20 Symptom subgroup 3. Profiles of selected mood and physical
variables for continuous group member B3. Dotted lines
indicate the position of pill free intervals. Closed arrows indicate
the position of "would-be" withdrawal bleeds.

































Figure 6.21 Symptom subgroup 3. Profiles of selected mood and physical
variables for continuous group member C3. Dotted lines
indicate the position of pill free intervals. Closed arrows indicate
the position of "would-be" withdrawal bleeds.
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adjusted to the Marvelon, and that it was contributing to her improved mood.
The physical symptoms were consistent across all the women. Initially, all three
women showed chronic breast tenderness during the extended cycle at levels similar to
those seen during the baseline. Unlike the previous six women whose breast
tenderness continued until the end of the extended cycle, breast tenderness resolved in
these women before the end of the long cycle, prior to any change in the exogenous
steroid environment. It lasted longest in B3, but no woman had any breast tenderness
after study week 23. Bloating also continued in the long cycle, again at similar or
slightly reduced levels to the baseline. Yet instead of becoming chronic, bloating
continued to oscillate at approximately monthly intervals with peak levels typically
occurring at the times of would-be bleeds. The effect is most marked for B3. Period
pain was confined predominantly to the times of scheduled and breakthrough bleeds
which were uncommon in this subgroup.
D) Symptom subgroup four. The final group of three women, which includes
A4, All, and B8 are distinctive because all of their symptoms seem to show a degree
of sustained oscillation from the baseline through the extended cycle. Their profiles are
shown in Figures 6.22 to 6.24.
This group includes the woman, All, who had to be switched from the control group
into the continuous group, late in the study. She was experiencing withdrawal
migraine headaches during dummy pill weeks. Rather than loose her to the
investigation, she was re-allocated single-blindly to the continuous group. While she
was undergoing the conventional four week control cycles she had migraines during
each withdrawal bleeding week (4, 8 and 12). She had experienced headaches during
bleeding while on Brevinor, but they were less severe and shorter. Her pill sequence
was adjusted so that she would have no more dummy pill weeks until week 25. Thus
she entered the continuous group after three, rather than two, baseline cycles, and only
took active pills continuously for 12, rather than 16 weeks. She had no further
migraines until dummy pill week 25, when she had a less severe migraine than she had
had previously. This woman's migraines were alleviated by extended pill taking, while
A7, described in subgroup one, had the opposite experience.
























ure 6.22 Symptom subgroup 4. Profiles of selected mood and physical
variables for continuous group member A4. Dotted lines
indicate the position of pill free intervals. Closed arrows indicate
the position of "would-be" withdrawal bleeds.
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Figure 6.23 Symptom subgroup 4. Profiles of selected mood and physical
variables for continuous group member All. Dotted lines
indicate the position of pill free intervals. Closed arrows indicate
the position of "would-be" withdrawal bleeds.




Figure 6.24 Symptom subgroup 4. Profiles of selected mood and physical
variables for continuous group member B8. Dotted lines
indicate the position of pill free intervals. Closed arrows indicate
the position of "would-be" withdrawal bleeds.
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The pattern of symptoms in this group is, as previously, not as clear for moods as for
physical symptoms. There is roughly monthly oscillation in irritability in all three
women, which is most marked during the three months of continuous pills for All.
The pattern of breast tenderness is quite similar across the women. B8 shows the most
consistent pattern with breast tenderness rising to a peak just before the would-be
bleeds in weeks 12, 16, 20, and 24. Bloating also shows a marked and regular
oscillation, again with a very clear pattern for B8, but quite pronounced oscillation for
A4 and All. Finally period pain occurs predominantly at the times of scheduled or
breakthrough bleeds, but does show a slight tendency to occur at approximately the
times of would-be bleeds, though it is not marked in any of the three women.
These three women all gave different retrospective accounts of PMS experience. A4
believed she had only slight changes in moods and physical symptoms. A11 reported
having mild PMS-type changes, and B8 noted marked cyclicity.
6.5.8.3 The severity and timing/cyclicity of selected diary
variables in the phase shifted group
The gross difference in the severity of mood and physical scores between the baseline
and manipulation phase was determined as before using t-tests. Like the continuous
group, all the volunteers in this group should have had significantly less bleeding, yet
only 1 out of 15 recorded a reduction in the second four months Again this is probably
due to breakthrough bleeding. Women also continued to experience the same mean
daily amount of period pain while having fewer scheduled bleeds. The distribution of
change in mood symptoms is virtually identical to that for the continuous group. And
the reasons for this may be similar. Not quite so many women in this group had more
breast tenderness, but many were more bloated.
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Table 6.12 Phase Shifted Group: Number of women showing
significant difference (p<0.05) in mean diary score from baseline to












no change 14 12 10 8 10 5
more - 1 1 5 2 6
less 1 2 4 2 3 4
This group was similar to the other study groups in that the physical variables showed a
much clearer pattern than the mood variables. Fifteen women completed the study in
this group; the diary data for two was of limited interest because they were virtually
asymptomatic. For the thirteen women remaining one pattern of symptom timing
predominated. In 8 women the pattern of variation over time in breast tenderness,
bloating and period pain was sufficiently clear and consistent to merit producing the
mean symptom profiles, which are shown in Figure 6.25.
In the majority of these women the three symptoms occurred before or during
withdrawal bleeding in the two baseline cycles. During the phase shifted cycle,
however, physical symptoms showed a tendency to begin early, with significant
symptoms occurring just before or during the would-be bleeding time in week 12.
Breast tenderness peaked in week 11 and was falling during week 12, but it began to
rise again in the absence of a bleed. It only fell as a result of the withdrawal bleed in
week 14, reaching the baseline in the next week. Almost immediately it began to
increase once again, but this time the peak in week 17 was closer to the actual bleed in
week 18. By the third bleed after the phase-shift the pattern looked very similar to the
baseline. In the next cycle the pattern is the same, with breast tenderness falling in
week 26 in spite of the fact that there is no withdrawal bleed in this week.
The pattern is similar for bloating except instead of regressing spontaneously in week
12 it continues to be raised until the withdrawal in week 14. The mean does not return
to baseline levels immediately after this bleed but continues irratically until it peaks in
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Period Type Pain n=8
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Figure 6.25 Mean profiles of three typical physical symptoms from 8 women
in the phase shifted group. Dotted lines indicate the position of
pill free intervals. Closed arrows indicate the position of
"would-be" withdrawal bleeds.
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the next withdrawal week, 18. The profile in the third "cycle" looks more like the
baseline than the previous one, and once again bloating increases and peaks just before
the newly entrained would-be bleed in week 26. It would seem that the phase shift had
a greater disoganizing effect on bloating than it did on breast tenderness, nevertheless,
there does seem to be a gradual re-entrainment to the new cycle after the transient
disruption.
Period pain is more closely tied to the immediate pre-bleeding and bleeding phases
during the baseline than the other two symptoms. The response of period pain to the
phase change is much the same, with a rise beginning in week 11 that is sustained until
week 14, followed by a fairly chaotic cycle. The third cycle after the shifted one is like
the baseline, and pain appears in week 24, peaks in 25, and is declining in week 26.
It was serendipitous that the ordinary packet ofMarvelon given at the end of the study
produced a cycle that lasted seven weeks. This was in fact longer than the originally
planned phase-shift. Because the majority of women continued to fill in diaries for a
few weeks into the packet of Marvelon, there are data for the would-be bleed in week
26. It appears that after the first disruption, the physical symptoms have gradually re-
entrained to the new cycle timing. The rise of symptoms in week 26, when there is no
steroid withdrawal, reflects the effectiveness of the re-entrainment.
There is unfortunately no similarly clear picture of disruption followed by re-
entrainment for mood variables. None of the mood scales for the women in this group
showed any marked cyclicity, although 5 women reported mild and 6 marked cyclical
change retrospectively. The worst symptoms which women reported retospectively do
tend to agree with those scored most severely in the diaries. Notably, the 8 women
who showed marked cyclicity of physical symptoms had generally reported these
retrospectively. Equally, without having based the decision about how to group
women's diary patterns on a prior knowledge of retrospective PMS reporting, the
groups do follow these lines. The 8 women with cyclicity in all of their physical
symptoms all reported either mild or marked PMS retrospectively. Three women were
not included in the mean, but did report PMS experience. The one who noted mild
PMS was free of physical symptoms. The two who noted marked PMS (A 15 and
BIO) did show cyclical bloating, and A15 may also have had the prevailing pattern of
breast tenderness and period pain.8
8
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It is important to note that within the sub-group of eight women there were equal
numbers with and without breakthrough bleeding. The sub-group also includes two
women who had very substantial oestrone peaks, yet five for whom they were very
slight or only moderate. Thus there does not seem to be any consistent relationship
between bleeding patterns or residual ovarian oestrogen and the pattern of physical
symptoms seen.
6.5.9 The Influence of Psychometric Variables on Response to
Cycle Manipulation
The distribution of the EPI scale scores relative to the published total population norms
are summarized in Figure 6.26. It is acknowledged that women tend to score higher
than men on neuroticism, and lower on extroversion (Eysenck & Eysenck, 1964). In
this sample however, 78% of scores fall within one standard deviation of the
population mean for neuroticism. This population also shows a strong tendency to
greater extroversion, with 83% of scores at or above the mean. The lie scores were
also relatively conservative. Only 4 women had lie scores >/= 4, with the maximum at
6. Five is taken to be the maximum score at which the test can be reliably accepted
(Eysenck & Eysenck, 1964).
Internal versus Powerful Others LOC is shown in Figure 6.27, and versus Chance
LOC in Figure 6.28. The majority of women scored within the normal range for
Internal LOC (81% within 1SD), yet only 39% did so for Powerful Others and 61% for
Chance. All of the outliers scored low for Powerful Others, and all but one high for
Chance. The indication is that for this sample chance is a more meaningful external
determinant of health than are people like doctors, nurses, etc..
Based on the cut-off scores described in Beck et al. (1988), 75% of this sample report
no orminimal depression. And in the remaining 25% only mild to moderate depression
is indicated. No one was therefore excluded from the study due to depressed mood.9
The distribution of Beck scores across groups is summarized in Figure 6.29.
This is difficult to assess because A15 had missing data during both of the phase shifts.
9
The psychometric test scores of the five of the women who dropped out of the study
late were calculated and compared with the other study groups. The means scores for
the drop outs were similar to the continuing groups except for depression. The drop
outs were substantially more depressed. Two women had no depression, while one
had a moderate BDI score and two were severely depressed.




























Figure 6.26 Scatter of Eysenck Personality Inventory scores relative to the
published population norms. Thick dotted lines indicate
population means; thin dotted lines indicate population standard
deviations.
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Figure 6.27 Scatter of Internal versus Powerful Others Multidimensional
Locus of Control Scores reladve to population norms. Thick
dotted lines indicate population means; thin dotted lines indicate
population standard deviations.
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Figure 6.28 Scatter of Internal versus Chance Multidimensional Locus of
Control Scores relative to population norms. Thick dotted lines
indicate population means; thin dotted lines indicate population
standard deviations.
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□ Late Drop-outs n=5
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Severity of Beck Score
Figure 6.29 Distribution of Beck Depression Inventory scores across the
study groups and drop-outs.
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Comparisons were made between the three study groups using Student's t-tests and no
significant differences were found for Extroversion (Control vs. Continuous t=1.16,
p=0.26; Control vs. Phase shifted t=1.13, p=0.27; Continuous vs. Phase shifted t=-
0.17, p=0.86) or Neuroticism (Control vs. Continuous t=1.05, p=0.30; Control vs.
Phase shifted t=0.91, p=0.37; Continuous vs. Phase shifted t=-0.13, p=0.39). There
were also no group differences for Internal (Control vs. Continuous t=-0.68, p=0.50;
Control vs. Phase shifted t=-0.99, p=0.33; Continuous vs. Phase shifted t=—0.79,
p=0.43) or Chance LOC (Control vs. Continuous t=-0.95, p=0.35; Control vs. Phase
shifted t=-0.47, p=0.64; Continuous vs. Phase shifted t=-0.42. p=0.67). In keeping
with the general trend in the data towards low Powerful Others LOC, the phase shifted
group had significantly lower PLOC than the continuous group (t=3.31, p<0.01). The
three study groups did not differ in mean BDI score, yet the drop-outs had significantly
higher Beck scores than the phase shifted group (t=-2.35, p<0.05) and non
significantly higher scores than the control and continuous groups.
Further comparisons were made between "symptomatic" subgroups to discover
whether test results predicted study response. Within groups correlations were also
sought between test scores. Tests on subgroups were not made for the controls as
there were too few of them. For the continuous group, subgroups 1 and 4 (mood+)
were combined and compared with subgroups 2 and 3 (mood-). The resulting groups
reflect the presence or absence of notable diary ratings for mood respectively. The
mood+ group had chronic/cyclic moods and physical changes, while the mood- group
had irregular or resolved moods and chronic/cyclic physical changes. There were no
significant differences for these mood groups on neuroticism, LOC, or depression, nor
did any of the tests correlate significantly with one another within groups.
The phase shifted group was divided into two subgroups based on the presence of
cyclicity in the three physical variables. The 8 women who were included in the means
for physical variables above constitute the "cyclical" group and the remaining 7 women
who did not show a consistent pattern or were asymptomatic are "non-cyclical". There
was no significant difference between the two groups for LOC or depression.
However, the women in the cyclical group were significantly more neurotic than the
non-cyclical group [t=4.24, p<0.00, mean: 15.3 (4.1) vs. 6.6 (3.8)]. While there was
no significant correlation between Beck scores and neuroticism or LOC for the cyclical
and non-cyclical groups, neuroticism was significantly positively correlated with
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Chance LOC for the cyclcial women (r=0.79, p<0.05). ELOC and PLOC did not differ
between subgroups.
When all women in the phase shifted group were taken together this correlation
between neuroticism and CLOC was upheld (r=0.64, p<0.01). There was also a
significant inverse relationship between neuroticism and ILOC in the whole group (r=-
0.59, p<0.05). There was no significant relationship with PLOC.
There was a near significant relationship between neuroticism and Beck scores (r=0.50,
p=0.056) in the phase shifted group. Neuroticism was significantly correlated with
depression in the Continuous group as a whole (r=0.53, p<0.05). There was no
relationship between neuroticism and LOC in this group, however, the BDI correlated
with PLOC (r=0.57, p<0.05).
Because PMS is known to be related to neuroticism, the relationship between
retrospectively reported PMS status and N scores was examined. Over the whole
sample 15 women (42%) reported marked PMS, 11 mild (31%), and 10 none at all or
physical symptoms only (27%). Women with N scores of 16 or higher were
considered to have high neuroticism. Twelve women (33%) had high N scores and
their distribution by PMS status was relatively even: 6/15 marked (40%), 3/11 mild
(27%), 3/10 none/physical only (30%). Thus self-reported PMS status did not seem to
relate to a propensity to score highly on the EPI for neuroticism. And as demonstrated
above there was only a limited tendency for high N scores to be related to prospective
symptom reporting (phase shifted "cyclical" only).
6.5.10 The Acceptability of Manipulated Pill Cycles to Women
A final consideration of this chapter must be the acceptability of cycle manipulations to
women. It is clear that the manipulations influence bleeding experience and seem to
affect well being. The acceptability of the regimes were assessed in two ways:
informally during monitoring interviews, and formally by open questions during the
final interview, and on the study assessment form. These included: What did you
dislike about taking part in the study? Did you dislike not knowing when you were
going to bleed? Did you have any irregular bleeding? How did you feel about this?
Were you worried that you might become pregnant? What was positive for you about
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taking part in the study? Would you take part in a similar study again? Would you
recommend it to a friend?
These questions elicited a variety of statements from women that reflect certain
recurring themes. These themes are largely consistent with the ideas expressed in
previous chapters of this thesis, notably that regular vaginal bleeding is taken as an
indication of non-pregnancy, fertility, and good health. Women perceive a normal
range for acceptable bleeding experience, and scrutinize and question any experience
which deviates from it. This study was designed to produce just such deviations, albeit
in a controlled and supportive environment.
A) Fear of pregnancy. About half of the volunteers expressed a specific fear that
they might be pregnant: 0/5 controls, 7/16 continuous, 8/15 phase shifted. For the
majority the first "missed period" in week 12 produced considerable anxiety. A
number of women telephoned for reassurance at the time that this bleed was expected,
and most women were eager to know the result of their pregnancy test in this month.
Pregnancy fear was common in spite of the fact that it had been repeatedly emphasized
that the study might involve longer than normal cycles. Of those who had been
concerned, about half commented that their fear was transient. They were no longer
concerned after the first missed bleed in the two manipulated groups, and after the first
few months with regular cycles in the control group. Only one woman indicated that
she was increasingly concerned the longer she went without a bleed in the continuous
group (A6).
B) Other concerns about irregular bleeding. Amenorrhea was associated with
fear of future infertility or adverse health consequences for a few women. Curiously
those women with more information, the nurses and the parous women, expressed
more anxiety about the absence of bleeds. One nurse (C9) carried out a home
pregnancy test. All three parous women were particularly concerned about pregnancy.
Two (A5,C4) began to associate food cravings with possible pregnancy, and the third
(A3) who was not even sexually active during the study was nevertheless worried10.
A3 also queried whether or not her "periods" would return after the study. It seemed
that the fear of no-bleeding made BTB acceptable, as A3 experienced a 4 week long,
to
This apparently irrational fear seems to be connected with the experience of one of her
friends who was sterilized then subsequently conceived. This volunteer knew that
theoretically she could not be pregnant, yet "theoretically" nor could her friend.
Chapter 6 Controlled Study ofPill Cycle Manipulation 293
heavy BTB during the extended cycle, but she did not complain about it. Under other
circumstances protracted bleeding itself might cause alarm. However, A3 was
reassured by it and considering it a "period" said "I just sort of made up for the one that
I'd missed". Another nurse (B12) had BTB which she knew could have been a
consequence of study manipulations. But because she had never had it before, she
began to "get a bit twitched" since she knew medically that irregular bleeding occurs in
cancer of the cervix.
Two other women indicated that it was simply the novelty of not bleeding which
affected them, saying that it was strange "psychologically". The women in the sample
with very high internal LOC, as well as a few others, noted that they disliked not
knowing when they were going to bleed, because they disliked not being in control.
An additional common reason was social. At least a quarter of women were anxious
least they be "caught out" by unsuspected bleeding. There was a fear of "exposure"
and being without the equipment for concealment. Therefore, a number of people
carried pads and tampons with them at all times. Further, B12 perfered to have regular
bleeds so that she could "rationalize things in terms of the cycle".
Women gave several reasons why they did not fear pregnancy, or did not worry about
not knowing the planned time of bleeds. First of all, about a quarter of women
expressed faith in the technology. Either they felt secure of the pill's efficacy, they
relied on the accuracy of the hCG tests, or they were confident of the safety of the
study. One woman (CI4) simply said that she was "not at all bothered" about the
effects of the study on her bleeds. Another (B15) stated "I loved not knowing when I
was going to menstruate...every 4 weeks is a drag, even with these tiny little periods
on the pill." A10 said that she found it easier to take a pill every day. Many women
indicated that they did not worry about the arrival of bleeds because they had symptoms
as an early warning. Some women reported mood changes and some physical or both.
Pain was a particularly reliable indicator of impending bleeding.
C) Likes and dislikes of the actual experience. Women also commented
about their likes and dislikes of the actual experience of amenorrhoea or BTB. About 8
women noted that they liked not having the hassle, inconvenience or disruption
associated with monthly bleeds. A7 stated that she "would be delighted to take the pill
all the time", and have no further 'periods'. A11 said, "I don't think you need a period
every month. It doesn't make them any different. I think 2 times a year would be Fine-
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3 times a year." Three women (A5, B3, B8) liked not bleeding because they associated
it with a lack of PMS-type symptoms. B8 (who did in fact appear to have persistent
cyclicty) said, "I really did enjoy not having the periods- it really made a big
difference." And B3 was "very disapointed" when she finally did have a bleed.
A few women recorded being aggrevated by BTB. B11 felt that BTB affected her
mood because it put her "out of sorts", and A4 found spotting annoying and ill timed.
Some women were annoyed when surprise bleeding stained underclothing. C4 did not
like BTB at all: "I just feel dirty; I don't like wearing a tampon every day." Several
women in the manipulated groups were eager to bleed by the end of the study, not due
to pregnancy fear, but to relieve a build-up of symptoms. B9 had bad PMS in the
second phase shift, and "never wanted a period so much in [her] life." A1 wanted a
period to relieve her substantial bloating and breast tenderness, while C4 felt her
'period' could not be withheld any longer: "Only just holding a period at bay; like a
dyke holding this period back."
6.6 Conclusions and Discussion
No single biological phenomenon or substance is able to explain the apparently regular
variation in well being that a proportion of women experience in association with the
steroid cycle. This chapter has explored the alternative possibility that cyclical change
may be the result of a long term endogenous rhythm which becomes entrained to the
steroid cycle.
Although this investigation was quite demanding, only 3 out of the original 47 dropped
out due to possible effects of the cycle manipulations. The fact that one of these
women felt she gained weight, etc. due to the study pill although she was already
taking Marvelon when she entered the study implies that some adverse reactions may
not have arisen from changes in formulation or cycle length, but constitute false
attribution. The age range of volunteers was broad and women were well established
on the pill with over 80% having taken it for at least 1 year. Of the 36 women who
completed the study, 6 were current Marvelon and 2 Mercilon takers. Almost all
women had significant experiences and hassles over the study which might have
effected their daily ratings or oestrone levels. These were mainly minor ill health,
antibiotic use, and relationship changes.
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6.6.1 Breakthrough Bleeding: Endometrial Atrophy or
Receptor Fatigue?
In the UK clinical trials of Marvelon (Wiseman, et al., 1984) the incidence of
breakthrough bleeding was found to be about 5%, and spotting 7%. During the first 11
weeks of this trial over 27% of volunteers recorded bleeding during active tablet taking,
making the frequency of unscheduled bleeding in the baseline months greater than
double the UK incidence. There is no obvious explanation for this finding, save that
women prone to BTB were more inclined to volunteer to take part, perhaps because
they would be less concerned about the potential for the study to disrupt bleeding.
Another alternative is that the discrepancy comes from a methodological difference.
The participants in the UK trial were seen three times over a six month period at 1,3,
and 6 months. At these visits they were asked how they had felt over the last month,
and "no leading questions were asked about specific complaints". This could easily
result in an under reporting of BTB. Wiseman, et al. (1984) nevertheless state that the
incidence of BTB which they report is higher than that seen in larger treatment trials.
More important than the baseline levels of BTB, however, is the way that bleeding
dynamics were effected by prolonged cycles. There was an exponential increase in
BTB over the extended cycle in the continuous group, with a substantial rise after the
12th week. One possible explanation for this is poor progesterone receptor function.
In order for progesterone receptors in the endometrium to function normally during the
menstrual cycle they require priming by unopposed oestrogen. Without this
progesterone from the corpus luteum cannot act adequately on the receptors to produce
a secretory epithelium. One effect of having combined steroid administration from the
beginning of the pill cycle is that the proliferative phase lasts only a few days, and the
remainder of the cycle is comprised of an extended secretory phase, followed by a few
days of relative endometrial atrophy just before withdrawal bleeding (Pincus, 1965).
Baird & Glasier (1991) have argued that unscheduled bleeding on the pill may occur
because the endometrium is not exposed to unopposed oestrogen for long enough to
give it the capacity to respond to the progestagen. Indeed, the only time during the pill
cycle when unopposed oestrogen is present is when endogenous oestrogen is secreted
during the pill free interval. Presumably, the consequence of this is that although there
is adequate progestagen present, the tissue, unable to "read" it at the receptor level,
behaves as if steroid had been withdrawn and bleeds.
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In addition to its effects on receptors unopposed oestrogen is also responsible for
endometrial repair. It is possible that a poorly repaired endometrium would become
increasingly atrophied during extended pill taking. Over the 16 week cycle patches of
tissue may have begun to necrose causing more frequent and prolonged bleeding as the
cycle progressed. Notably, all three of the Marvelon takers in the continuous group
had quite prolonged BTB while those in the other two groups had only a bit of
spotting. Perhaps receptor damping occurs more readily in women already accustomed
to desogestrel.
BTB did not seem to relate to the amount of endogenous E-3-G that women produced.
The association was not considered on a cycle to cycle basis to determine whether or
not those women showing marked oestrogen recovery during a pfi avoided BTB during
the subsequent cycle. However, substantial endogenous oestrogen has been
documented during Marvelon use, which did not correlate consistently with
breakthrough bleeding (Kuhl, Gahn, Romberg, Miirz & Taubert, 1985). The cause of
BTB during pill cycles remains unclear, but it is apparent that it is impractical to attempt
to withhold vaginal bleeding for more than 3 months using a low dose combined pill.
6.6.2 Residual Ovarian Oestrogen
Generally speaking the endogenous oestrogen levels seen in the study volunteers
reflected the expected degree of pill induced steroid suppression, and were consistent
with the pill regimes. There were a few oddities however, that require explanation.
One woman in the control group showed peak levels of E-3-G at unexpected times, out
of association with withdrawal bleeding intervals. She reported a strange experience in
the middle of the study in which she passed a "blob" of tissue transvaginally. She
believed it may have been a miscarriage, but her G.P. did not and all of her monthly
GhCG tests were negative. After this episode she had an irregular bleeding pattern
including only scant bleeding in week 16, and a missed withdrawal bleed in week 20.
She did, however, have breakthrough bleeding in weeks 18 and 22. Her diary keeping
was also erratic. It is possible that she was taking her pills irregularly, which would
account for unusual hormonal profiles and bleeding patterns. This is unfortunately
impossible to verify.
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The continuous group showed oestrogen profiles which one would have expected.
Only half of this group collected samples, however, which makes it difficult to
conclude that all were well suppressed during extended pill taking. Yet, there was no
consistent difference in bleeding or subjective state for those with and without samples.
For example, the women with low E-3-G levels in this groups were evenly distributed
across the four symptom subgroups described in section 6.5.8.2.
The phase shifted group, on the other hand, included three women with very high
E-3-G levels, which exceed those normally seen during ovulatory menstrual cycles. It
has been noted that missed pills were probably not responsible. In all of the ten cycles
E-3-G began to rise during the pill free interval, but for some reason was not
suppressed during the first week of active tablet taking as is usual. Kuhl, et al. (1985)
measured endogenous steroids and gonadotrophins over three cycles of Marvelon use
in 22 women. They found that LH and FSH levels were not significantly different to
control and washout cycles, except on pill day 21. Gonadotrophins had recovered fully
by the end of the pfi, and oestradiol remained high in 4 out of 22 women. Oestradiol at
mid cycle (pill day 11) was substantially higher in these women than it had been in
control cycles.
Perhaps for some women in this sample the steroid dose was inadequate to shut down
fully pituitary function, and enough gonadotrophin was released to encourage follicular
growth. However, the feedback relationship between the ovary and hypothalamus was
distorted preventing an LH surge. Spot pregnanediol estimations indicated that
ovulation never occurred. Considering the absolute levels of E-3-G which were
achieved it is likely that multiple large follicles developed which luteinized, unruptured,
late in the cycle. "Follicular cysts" of >/= 30mm diameter have been observed on
ultrasound scans in 8% of triphasic pill cycles, with correspondingly high oestradiol
levels (van der Vange, et al., 1985). In spite of their uniformly high oestrone levels
these women in the phase shifted group had different amounts of BTB and quite
distinct symptom profiles, which suggests that although of interest for contraceptive
efficacy, endogenous steroids are not fundamentally responsible for the patterns of
mood and physical well being observed over the pill cycle.
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6.6.3 The Infradian Rhythm: Evidence and Aetiology
Three hypotheses were under test in this investigation using prospective daily ratings of
well being. The first stated that there would be continued evidence of regular
oscillations in well being during extended pill taking in the continuous group. This
cyclicity would constitute the free running period of an in-built rhythm of emotional
well being under constant steroid conditions. A proportion of women did indeed show
evidence of such a pattern for both moods and physical changes. The second
hypothesis, tested by the phase shifted group, proposed that the steroid cycle acts as the
primary zeitgeber for this endogenous rhythm, and thus after a phase delay of half a
cycle subjective state would re-entrain to the new phase length. Again this seems to be
borne out by the data.
The third hypothesis which argued that there would be different aetiologies for moods
and physical changes was not supported by the data. Physical symptoms were not
allied to steroids as was hypothesized. On the contrary, it was predominantly physical
symptoms which showed continued circa-monthly oscillation. None of the physical
variables responded in a sufficiently uniform manner across women to be wholly
steroid driven. The disproof of this hypothesis lends additional credibility to the notion
of endogenicity since one would expect physical changes to be less susceptible than
mood to the influence of attribution and expectation. This would seem especially likely
for breast tenderness and period type pain, as these do not generally occur at times
distant from menstruation and are also not readily confused with other physical
sensations, as bloating may be. A proportion of women in the continuous group did
show chronic breast tenderness and bloating, but also depression. Period type pain
usually occurred with bleeding whether scheduled or not.
There was an overall tendency in this dataset for mood profiles to be more difficult to
interpret than physical ones. Cyclical physical changes are commonly seen in both
women seeking help for PMS and those not reporting PMS (Metcalf, et al., 1990).
Therefore, one would expect physical symptoms to be prominent in a study population
which was not selected for PMS experience, and cyclical moods might be expected to
be less evident. In keeping with this, the PMS Clinic sample (Chapter Five) does seem
to show more robust patterns of mood during manipulated cycles, which share the
same dynamics as the physical changes in this controlled study sample. In both
samples, however, mood cyclicity shows greater variability in phase and amplitude
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than physical states over manipulated cycles. But since mood patterns show large
differences from one cycle to the next in conventional pill taking and the menstrual
cycle this finding is not surprising. What is surprising is that phenomena like period
pain were reported at times in the continuous and phase shifted regimes when bleeds
were "due" according to the conventional four weekly pill cycle.
The possibility that women had symptoms at particular times because they expected to
cannot be discounted, even for physical sensations. The control group show that there
was a tendency for the study to affect women badly. Their diaries reveal that all
controls were made more irritable by taking part, in the early part of the study, and then-
side effects lists include bloating, weight gain, headaches, and loss of sexual interest.
A woman already taking Marvelon noted all of these physical changes except
headaches. Volunteers were asked what had changed during the six months of the
study, but not if they felt the study had caused side effects. So the changes reported
may or may not have been attributed by women to the manipulations.
6.6.4 The "Marvelon Effect"
One possible reason for women's reactions, both positive and negative may be the
formulation. For example, volunteer A5 reported a substantial improvement in her
PMS over the study, but this began during the baseline suggesting that either a placebo
or formulation effect was at work. Breast tenderness, nausea, loss of libido, fatigue,
depression, and weight gain have all been reported in response to Marvelon (Kuhl, et
al., 1985; Wiseman, et al. 1984). But others indicate that the incidence of nausea,
headaches, breast tenderness, and depression is lower during Marvelon use (Wiseman,
et al., 1984; Massi, Ciardetti, Zucconi, Ottanelli, & Braccini, 1986), and that blood
loss and pain are reduced (Nabrink, Birgersson, Colling-Saltin, & Solum, 1980).
Different individuals show antithetical responses. The fact that the controls who had
switched to Marvelon from another pill became "symptomatic" implies that some of the
effect may be due to the formulation.
Some women in the two extended groups might also have been suffering from relative
steroid overdose. Chronic breast tenderness, bloating, depression, and loss of sexual
interest may be due to extended DSG administration. Desogestrel is a potent
progestagen with low affinity for androgen receptors (Wiseman, et al., 1984).
Progestagens are thought to contribute directly to these particular symptoms (Bancroft
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& Sartorius, 1990) through their effect on steroid sensitive target tissues. Although it
is only suggestive, one woman with prolonged depression (A7) did describe it as being
like an endogenous depression that was worse in the morning, etc.. As with BTB, the
three women in the continuous group already taking Marvelon showed a tendency to
have other adverse physical reactions like chronic breast tenderness and bloating, which
also suggests some sort of changed response to DSG over time.
Desogestrel raises SHBG and therefore di-hydrotestosterone binding capacity
(Cullberg, Knutsson, Lindstedt, Mattsson & Steffenson, 1982). Thus DSG may also
have anti-androgenic effects. The relationship between testosterone and sexual interest
in women is equivocal. It may be important in some women, and chronic DSG may
have contributed to loss of libido in the continuous group through this route. Further,
Marvelon's potent progestagenic effect on cervical mucous could contribute to a
perception of vaginal dryness, which is also libido inhibiting. Two women who
reported significant loss of sexual interest during the study indicated low sexual interest
at the initial interview, yet others seemed to undergo a genuine change. The factors
responsible for women's sexual interest are complex, and will not be elaborated further
here, save to note that there may have been a steroid component operadng in this study.
6.6.5 Endogenicity: How and Why?
Discounting potential study effects, Marvelon effects, and steroid overdose effects how
much evidence does this controlled investigation provide that an endogenous rhythm of
well being linked to the steroid cycle is present in women? An inspection of the
longitudinal plots of selected variables for the continuous group show evidence of the
regular cyclical oscillation of one or more symptoms in 10 out of 16 women. There
was a great deal of inter-individual variation in the expression of symptoms over time,
but three patterns predominate. Some women showed regular evenly spaced peaks of
symptoms, interspersed with basal values (eg. subgroup 4). Others experienced
continued cyclicity superimposed on a raised baseline (eg. subgroup 1), while others
experienced cyclicity with both changing phase and amplitude (eg. subgroups 2&3).
The lack of uniformity in women's responses is not particularly surprising since
cyclical subjective state is rarely highly consistent over time in even the most tightly
entrained circumstance. Furthermore, biological rhythms are known to differ markedly
across individuals, and would especially do so if the oscillator were only "partially
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entrained", or a weak or "slave" oscillation as was proposed in Chapter Five. The
patterns described above would be consistent with a model in which a weak
endogenous rhythm of well being existed which was entrained by or coupled to the
steroid cycle. In a freerunning condition it would show a tendency to loose amplitude
and frequency, or even "miss beats" without the stimulatory/reinforcing effects of
cyclical steroids. Equally, being steroid sensitive its parameters might show a tendency
to worsen in a chronic steroid environment like the one imposed upon it by this
experimental design. Further, if it conforms to a relaxation oscillator model, then
steroid withdrawal would be prerequisite for symptom relief, which might help to
explain the chronic symptom patterns that some women showed.
The reactions of women in the phase shifted group lend strong support to the idea of an
infradian well being oscillator. It was important to include this group because they
constitute a driven system in which the hypothesized entraining mechanism is
systematically altered. For this reason, it is not surprising that there was marked
similarity of response across individuals in this group. It was demonstrated that, at
least physical variables, showed a sustained rise during the phase shifted cycle, were
disturbed in the following cycle, and then restored to their original phase relationship to
bleeding/steroid withdrawal in the next. While this could be attributed to the transient
effects of chronic pill steroids, the rise in symptoms at the time of the would-be bleed in
week 26 is not so readily explained. It would seem that not only has re-entrainment
occurred, but that it has done so rapidly, and symptoms have thus "anticipated" the new
cycle length.
Progressive circadian dysregulation under the influence of progesterone, like that
described by Parry (1990), is not able to account for the persistence of moods and
physical symptoms seen during this controlled investigation in which steroids were
held constant. The study results seem to point to a longer term rhythm which has a
steroid independent time-keeping mechanism. Further research will clearly be required
to elucidate the properties of the purported oscillator and its causal mechanism.
6.6.6 Cycle Manipulation as a Treatment Tool
Given the evidence that altering the length of the oral contraceptive pill cycle improves
well being in a proportion of women how useful might it be as a therapeutic instrument
in the treatment of cycle related change? About 20-25% of women in the Clinic and the
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controlled study were significantly improved by the manipulations. None of the Clinic
patients experienced an absolute remission of their symptoms, but their severity and
duradon was reduced. One study participant seemed to be relieved of all negative mood
during extended pill taking, while others recorded substantial improvements. It is
possible that some of their improvement is attributable to the placebo effect, well
known for its potency in PMS treatments. Equally, some changes may be attributable
to the pill steroids.
Twenty per cent is a quite small proportion, and about an equal number of women were
actually made considerably worse by the regimes. Ideally one would like to be able to
detect factors which would accurately predict the quality of a woman's response. And
the problem of steroid precipitated effects still remains. The concept of improving PMS
by altering cycle length seems to be a useful one, but using OCs to do so would appear
to have limitations.
A number of women in both samples made anecdotal reports indicating that "tailoring"
the length of the pill cycle to their own underlying menstrual cycle length might be
beneficial. Two women in the Clinic (9017 & 8735), and one in the study (A15) found
that they were least "symptomatic" over long pill cycles which closely approximated the
length of their six to seven week menstrual cycles. There is no medical reason that all
women should have a 28 day pill cycle. Women certainly show greater variability in
cycle length when not using the pill. Doctors in Soviet Georgia have apparently been
successfully tailoring monophasic pill cycle length to women's underlying "sexual
cycle" for over twenty years now, with an 80% reduction in the so-called nuisance side
effects of the pill (Archil Khomariduze, 1991, personnal communication).
Unfortunately all of these findings are currently only published in Russian. The
implications of these reports are potentially far reaching. If pill related side effects
could be simply reduced, it would increase the pill's acceptability and improve
continuation rates.
6.6.7 The Acceptability of Cycle Manipulation to Women
The utility of any system which seeks a therapeutic effect on well being by altering the
timing of steroid changes, and thus of vaginal bleeding depends on its acceptability.
Fear about potential disruptions to the accustomed pattern of bleeding and well being,
and poor reactions to the actual effects of manipulations may both limit acceptability.
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Overall the acceptability of the study protocol was good. However, women were being
carefully monitored and knew they could seek reassurance or drop out if they had
difficulties. Many of them did note that they had faith in the efficacy of the pill, which
controlled their anxiety. Acceptability would probably have been even greater,
however, if women were undergoing changes in cycle length in a non-blind fashion,
because they would feel that they had more control over the experience and could plan
ahead.
There was a good deal of pregnancy fear. The first missed bleed was often the first
experience of amennorhoea for these largely nulliparous women. After the initial
failure to bleed, most volunteers tended to relax and accept the changes quite well. This
is of theoretical interest because some studies report that women would be unwilling to
accept a contraceptive regime which altered their pattern of bleeding, particularly one
which made it less frequent (eg. Snowden & Christian, 1983). This study seems to
show that without having had any experience of this kind, responses to this question
are invalid. Pill use itself tends to alter blood volume and controls its timing. So while
women guess that they will not like changes, experience tends to show that they will
accommodate them when they do occur. The very regularity of the pill cycle may make
the concept of unconventional cycle lengths even more remote. Having said that the
women in this study generally accommodated bleed changes, they were highly self-
selected by their willingness to take part in a study of this kind. Recruitment was very
difficult, and the large number who refused to take part may show that the majority of
women would not even try an altered pill regime once. It would, therefore, be
inappropriate to generalize from this study alone.
The implications are nevertheless important as this is perhaps the first time that oral
contraceptives have been used in a double-blind way to conceal the timing of vaginal
bleeding from women. It is vital for the uptake of new innovations in contraception to
understand how acceptable women find a method which alters the expected timing of
vaginal bleeding. Three new mechanical-steroid techniques of contraception now exist,
the vaginal ring, steroid bearing IUCD's, and Norplant®, all of which are likely to alter
the pattern of bleeding. Full use cannot be made of these new methods without a better
understanding of how to make their effects on bleeding acceptable to women, and this
study does provide empirical evidence for a steroidal contraceptive regime in which the
timing of bleeding is unknown, or irregular.
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6.6.8 The Drawbacks of the Controlled Study
There are a number of limitations of the data reported in this chapter, apart from those
already mentioned above, which make findings suggestive, but in no way conclusive.
The biggest problem was that only a small number of women took part, and those who
did were highly self-selected. In particular, the control group was too small to provide
adequate control data. In addition, although a double-blind design was used the pattern
of bleeding soon revealed a woman's group allocation to the investigator. Women
entered the study having taken a variety of pill formulations over different lengths of
time. Some women were already using Marvelon, while others had to switch to it.
Having the Marvelon users provided a useful internal control, but mixed pill histories
was nevertheless a source of potential confounding.
Other difficulties arise with methodology and analysis. The daily diary form may not
have allowed women to accurately describe their subjective state. Each scale possesses
a unique meaning to each woman, and the scales are doubtless used in different ways
by individuals. Ratings may be influenced by the length of time that one has been
keeping them, and one's subjective state when one is making them. It is also not clear
the best way in which to analyse the prospective data which they generate.
Ideally one would like to have a means of weighting constellations of symptoms into a
few concept variables, and of systematically and reliably removing noise. How, for
example, does one account for the influence of day to day hassles and life events in
rating scores? The analytic methods used in this chapter were entirely descriptive, and
as such lack the support of statistical proof. Without such mathematical parameters it
may be difficult to attest to the validity of observations about the data. It may be said in
support of these techniques, however, that they were appropriate in a preliminary and
exploratory study of this kind. In light of these factors the findings should certainly be
interpreted with caution, and not be generalized until confirmed in a larger sample,
perhaps using more sophisticated forms of analysis.
6.7 Chapter Summary
Changing the length of the oral contraceptive pill cycle has proved to be a useful and
effective experimental tool for studying the properties of an hypothesized endogenous
rhythm of well being. A proportion of women do experience persistent cycles of
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mood, and particularly physical well being under constant exogenous steroid
conditions. This suggests that an infradian rhythm exists with in-built momentum
which will freerun in the right conditions. The phase shifted group gave evidence that
the purported oscillator may be primarily entrained by cycling steroid hormones. The
period of the rhythm seems to be approximately one month in duration. There is
considerable inter- and intra-individual variation in both the frequency and amplitude of
cycling that women show. This implies that the oscillator is weak, and gains most of
its force from its entrainment with a dominant pacemaker like the steroid cycle. Much
more research needs to be done before its presence is confirmed, but in the meantime
minor alterations in the length of the combined OC cycle may be effective in relieving
oppressive cyclical changes or minor pill side effects in a proportion of women.
Chapter 7 General Discussion and Suggestions for
Further Research
Cyclical change in women's well being is a phenomenon worth explaining for social,
scientific, and therapeutic reasons. The research reported in this thesis has explored the
potential for a determinist effect of cycling steroids on the central nervous system,
described psychosocial factors and beliefs, and investigated the novel theory of a
biological clock mechanism in the aetiology of variations in subjective state.
The investigation of residual ovarian function and subjective state showed that all
volunteers had persistent ovarian oestrogen production at a low level, which was
independent of the variable doses of progestagen in their pill formulation. Twenty per
cent of this sample experienced more than 30% change in physical symptoms around
withdrawal bleeds, while only ten per cent had changes in mood of this magnitude.
However, 75% of women had mood and physical symptom cyclicity of lesser
magnitude. Low level change in subjective state with a preponderance of physical
symptoms is to be expected from a non-clinical sample of women.
The main finding of this study was that there may be a relationship between certain
physical symptoms, notably breast tenderness and bloating, and the level of
endogenous oestrogen. There are a number of possible explanations for this
relationship. Endogenous oestrogen may have a direct symptom mediating effect on
target tissues such that when oestrogen is high breast pain and bloating are low, and
vice versa. The overall degree of oestrogen suppression may determine the severity of
the symptom. Alternatively, the level of endogenous oestrogen is only a byproduct of
the potency of the exogenous steroids. If so, either the exogenous oestrogen or
progestagen, or the two in combination exert an adverse effect on target tissues. The
temporal pattern of symptoms may be explained by the cumulative effect of pill steroids
over the cycle. Symptoms do not appear until the pill hormones have achieved full
ovarian, and possibly hypothalamic and pituitary, suppression, or until exogenous
steroids have been in the system for a certain minimum length of time. The concept of
direct exogenous steroid effects or relative steroid overdose may help to explain those
women in the OC cycle length manipulation study who developed chronic symptoms
while taking the pill continuously.
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An alternative explanation is that the apparent temporal relationship of steroid levels to
physical symptoms is spurious. Perhaps symptoms only relate to the events
accompanying vaginal bleeding. Physical symptoms in this sample showed a stronger
relationship to the phase in which bleeding occurred than to the phase in which
oestrogen peaked. Since in the majority of cases the profile of endogenous oestrogen
was highly constrained by the day of the pill cycle, the apparent link between breast
tenderness and bloating and oestrone at the group level may have occurred by default.
The difficulty with a "menstrual" or uterine factor theory is that the mechanisms which
control spontaneous menstruation, and hormone withdrawal bleeding on the pill are
likely to be quite different. For example, in the absence of any entraining mechanism,
there is no endocrine signal, or change in the internal uterine environment during the
pill cycle which signals impending bleeding. Given that physical and mood symptoms
may appear during active tablet taking, a purely "menstrual mechanism" seems
unlikely.
The possibility remains that some threshold level of change in either endogenous or
exogenous steroids must be achieved before the CNS responds, and symptoms are
perceived. The women in this study whose levels of endogenous oestrogen passed the
arbitrary threshold of 30ftg/gr Crt. were more likely to retrospectively report that they
had PMS. Perhaps there is a phase or dose response curve in CNS sensitivity to
cycling steroids which determines whether or not a woman will become symptomatic.
However, three women in the phase shifted group of the cycle manipulation study had
levels of oestrogen which would exceed any limit for either the pill or menstrual cycle,
and their symptom experience did not differ from women who had extremely low levels
of endogenous steroid, throwing this hypothesis into question.
The theoretical basis for the investigation of the effects of pill cycle length manipulation
was that, rather than exerting mechanistic drive, the steroid cycle has a facilitatory effect
on cyclical well being. The hypothesis that cyclical fluctuations in mood and physical
change would persist during constant steroid conditions was supported'by the findings.
Equally, there was evidence that the steroid cycle acts as an entraining agent in the
timing of this infradian oscillation in well being. Mood and physical symptoms did not
appear to have different aetiologies. Indeed, physical changes were more robust than
mood changes in the controlled sample, in keeping with the notion that physical
symptoms are more prominent than moods in non-clinical samples, while as one would
expect, mood symptoms showed more marked cyclicity in the PMS Clinic patients.
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Overall the findings of the double-blind controlled investigation and the PMS Clinic
case studies give strong evidence that there is an infradian rhythm of well being which
is entrained to the steroid cycle. The large variation across and within individuals
however, suggests that this rhythm is weak. Indeed, four months of freerunning
conditions are probably not sufficient to conclude that the rhythm is truly endogenous.
A longer period of monitoring might reveal that the rhythmicity damps out to extinction
after many cycles. Nevertheless, there was no evidence for reduced amplitude or
frequency in the rhythm over the investigation in those women who showed clear
evidence of symptom periodicity.
There were a number of difficulties inherent in using oral contraceptives to generate
freerunning conditions. Firstly, the rate of breakthrough bleeding was very high,
particularly after twelve continuous weeks of pill administration. Irregular bleeding is
one of the most common reasons for OC discontinuation, and therefore not a tolerable
side effect, particularly if cycle length manipulation is to be used for therapeutic
purposes. Secondly, chronic steroids seem to induce chronic symptoms in a
proportion of women, notably breast tenderness and distension, bloating, depression,
and in a few cases migraine headaches. Thirdly, the experimental demands of a
double-blind study in which women did not know when bleeds would occur had a clear
negative effect on well being, which was evident in the control group. Women are
preconditioned by the negative popular image of the pill to be wary of its adverse
effects. Even women who decide to take the pill are likely to approach it with a certain
trepidation. Finally, the very regularity of the pill cycle may reduced women's
willingness to tolerate hormonal cycles of unusual length. While the continuation rate
of women in this study was good and was not strongly influenced by the manipulations
themselves, recruitment was very difficult and the volunteers were probably
exceptional.
In addition to the practical difficulties with the model, is the important problem that it is
impossible to remove the confounding effects of the exogenous pill steroids. There is
no way to create a steady endocrine state in a naturalistic way. The alternatives to the
OC model are likely to possess similar difficulties. For example, one could monitor
well being in women who have been ovariectomized, or pharmacologically castrated
using a GnRH agonist while giving replacement steroids in a controlled manner.
Freerunning could be assessed in both steroid free and constant steroid conditions. Yet
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further theoretical and ethical difficulties arise. It is more likely that such manipulations
will emulate transitional or pathological hormonal states in non-representative samples
of women, than replicate the dynamic endocrine environment of the normal menstrual
cycle. And no matter how "ideal" the hormonal manipulation is, it will never be ethical
to subject large numbers of healthy women to prolonged hormonal disruptions which
have known adverse effects (eg. loss of bone density, endometrial hypo-/hyperplasia)
and may have adverse health consequences which are not yet known. In the absence of
viable alternatives, the pill probably offers the safest, easiest, and most acceptable
model system, in spite of its limitations. It would be extremely desirable to repeat both
of the "experimental" studies in this thesis with much larger samples, over a longer time
course, in women with prospectively confirmed, marked mood fluctuation.
In addiuon to the practical difficulties in carrying out such research, the methodological
problems of gathering and analyzing time series data for subjective state remain.
Having confirmed that there probably is an infradian oscillator, it would be desirable to
model the parameters of the rhythm mathematically. The descriptive evidence would be
enhanced by statistical proof.
Different women experience their cycles differently. The nature of a woman's
subjective experience is undoubtedly influenced by her personality, her expectations of
the cycle, her social conditioning, her immediate environment, and her coping
mechanisms. It was not within the scope of this thesis to test any specific hypotheses
relating to psychosocial factors. Qualitative, reflexive techniques were used to gather
information about demographic variables and women's beliefs in order to take a holistic
approach to cycle-related experience. Quality research into the way that beliefs and
menstrual experience interact is urgently needed. It is very difficult to assess attitudes
in an unbiased way. Studies are required which compare different methods of eliciting
information, and which allow for complexity and contradiction in the structure of
women's beliefs about this complex area. Perhaps broader information will permit the
eventual development of typologies that may be used to predict the way in which
women respond to and interpret their cycle-related experience. It would be valuable to
compare women with different social and cultural backgrounds, demographic
characteristics, stress levels, and reproductive histories more rigourously than was
possible in this largely homogeneous Edinburgh sample.
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The relationship between subjective state and the steroid cycle is variable, individual,
and undoubtedly influenced by multiple causes. Given these facts it is, and will remain
a methodologically complex area of research. Describing well being in relation to the
menstrual or pill cycle is rather like reporting the weather. It can only ever be described
with a degree of accuracy, the influences upon it can be enumerated but the degree of
their effect at any given time, in any given place varies and is dynamic, and it is difficult
to forecast. The validity of the description depends at all times on the level of analysis.
Perhaps steroids are the local ambient temperature, the infradian oscillator is the
seasons, and societal attitudes and normative expectations about the cycle are global
warming. This research is the "weather" for today. The "forecast" will need to take
account of an even greater degree of research complexity.
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Abdominal Ultrasound Follow-Up to the Study of
Folliculogenesis Reported in Chapter Three
In Chapter Two it was noted that ultrasound scanning (USS) has become an
increasingly used and valuable tool in the assessment of ovarian follicular development,
both within and outside of pill cycles. Size is normally related directly to the amount of
oestrogen a follicle produces, and the dynamics of its growth over time to its functional
capacity. The risk of escape ovulation and consequent contraceptive failure was not the
primary concern of this thesis. It was, however, considered to be a theoretical interest
to compare endocrine and morphological indices of ovarian function. In particular no
previous study has examined folliculogenesis in women who were well established on
oral contraceptives, nor has the appearance of the ovaries of women taking triphasic
versus monophasic pills been systematically compared. The abdominal ultrasound
scanning (USS) carried out as part of the study of folliculogenesis reported in Chapter
Three aimed to address these deficits.
Training, Scanning Protocol and Equipment
It was originally intended that all 20 study participants would be scanned during their
second cycle in the study, however this proved impracticable because the equipment
was not routinely available at the time. Almost a full year passed before the scanning
was carried out. A large proportion of the volunteers were lost to follow-up because
they had stopped taking the pill, or for a variety of other reasons discussed in the
results section below. Before the study participants were assessed, I carried out a total
of 21 practice scans to learn the technique with the aid of 8 local volunteers attending
the Royal Infirmary of Edinburgh. Dr. E.L. Yong provide instruction and supervision.
Each study volunteer who was able to participate was monitored over one complete pill
cycle. The first scan was carried out within the first three days of the pfi. This was
intended to act as a baseline at which the ovaries were likely to be their most quiescent.
Scans were made as frequently as practically possible in order to establish the probable
pattern of follicular growth, development and regression. The intervals between scans
were determined by the observed growth rate of the follicles, and the amount of
endogenous oestradiol and gonadotropin present. Most follicular activity was expected
to occur during the pfi., and the first week of pill taking. But it was also desirable to
account for what Elstein & Killick (1985) call "autonomous follicular development" in
the face of declining steroids and gonadotophins late in the cycle. Queenen, et. al.
(1980), for example, document the sudden development of a 10 mm follicle on day
fourteen of pill taking which "disappeared during the next twenty-four hours". Each
woman underwent between 3 and 6 scans during the pfi, and 7 and 10 during active
tablet taking, with a total range of between 11 and 16.
Scans were conducted with a real-time sector scanning machine (Diasonics DSI-RF
BMS Scotland Ltd.). The machine had both trans-abdominal, and trans-vaginal
probes. The vaginal probe gives high resolution to follicles as small as 1-2 mm, thus
its use would be desirable in a study where one expects to see predominantly small
follicles. However, because vaginal scanning is a physically and psychologically
invasive procedure, probably best carried out by a gynaecologist, I was not prepared to
undertake it, and all scans were conducted with the abdominal probe.
Volunteers arrived for scanning with a full bladder, as the procedure works by
bouncing ultra-high frequency sound-waves off the barrier between tissues of different
densities. Aqueous liquids such as urine and follicular fluid appear on the scan as black
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areas, implying low echogenicity. A full bladder in effect creates a "window" through
the abdominal tissues to the uterus and ovaries below. Both ovaries were visualized in
lateral and transverse planes and the diameter of all follicular structures was measured
from top to bottom, and right to left using the electronic on-screen callipers. The
scanner was fitted with a camera to take instant freeze-frame pictures of the screen
image. Photographs were taken of the baseline state, and at intervals over the cycle.
The quality of pictures of small follicles is poor, therefore no photographs are
reproduced in the text.
Serum Sampling and Steroid and Gonadotropin Assay Techniques
Because the scanning was not concurrent with the diary keeping and urine sampling,
each woman was asked to provide a 10 ml. venous blood sample every day that she
attended for a scan. I was trained by the nursing staff of Ward 54 in the Royal
Infirmary of Edinburgh to carry out the venepuncture. Samples were centrifuged
immediately and plasma was assayed the same day by the staff of the Reproductive
Endocrine Laboratories (REL), Edinburgh in their routine assays for Oestradiol (E2),
and Lutienising Hormone (LH). Follicle Stimulating Hormone (FSH) was estimated in
all the samples in one 3-day assay carried out by Robin Sellers of the MRC
Reproductive Biology Unit, Edinburgh using an assay kit purchased from Serono
Laboratories.
Conventionally, serum hormones are related to USS. Because there is much more
published information about blood levels, urinary hormone levels were not estimated in
this phase of the investigation. The urinary E-3-G profile over the cycle closely
parallels E2 (WHO, 1982), and E-3-G like E2 has a linear relationship with follicular
size (Khatkhatay, et al., 1988). The results for plasma may therefore be compared with
the E-3-G profiles derived from urine samples during the main study months.
LH estimations were made using two different assays. The daily rapid-LH assay was
producing surprisingly high levels for pill takers, although still low relative to the
normal cycle, and it was thought that values were being inflated by interference of non-
gonadotrophin particulate matter. Thus at the end of each woman's cycle all of her
samples were entered into a 3-day assay. With the exception of one woman whose
levels were genuinely raised, LH levels in the 3-day assay were more than 2 times
lower than those of the rapid assay. The REL normal ranges were used for LH and
Oestradiol, and those supplied with the assay kit were used for FSH.
Results of the Ultrasound Scanning Follow-up and Associated Serum
Hormone Measures
Ultrasound scanning of the ovaries was carried out to provide a morphological index of
ovarian function. Because there was a long delay after the prospective monitoring,
scanning became a follow-up exercise. A number of women were difficult to contact,
and many of were no longer available to take part. Table 1 below summarizes reasons
for drop-out. Altogether, 4 monophasic and 9 triphasic takers were lost to the
investigation. One triphasic taker (T4) was eight months pregnant at the time she was
contacted having conceived while taking Trinordiol. She said that she had not missed
any pills. She was one of the most reliable study participants, and did not miss a single
sample or diary over the original two and a half month investigation. If this were a
genuine method failure it is difficult to explain in light of her low level, cyclic E-3-G
profile (See Figure below). The tenth triphasic taker (T6) attended for four scans but
did not continue because she lived outside Edinburgh and did not tolerate venepuncture
well, and her data are not reported here. A fifth monophasic taker (M3) was
hospitalized just before her scanning cycle for gastro-enteritis, and was not followed-
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up. Ultimately five monophasic takers were scanned over one cycle and no triphasic
takers, so unfortunately comparison of the two pill types was not possible.
The results for all the volunteers are summarized in the Table 2 below. Between 2 and
7 small follicles were visible on each ovary at each scan. There were usually about 4
follicles present. Only three of the five women had a follicle with a mean diameter of >
9mm: M4 (both sides), M8 (left), M10 (right). In no instance did a dominant follicle
appear to be recruited, although the largest follicle in M10 persisted from the fifth day
of the pfi until the ninth day of pills.
The oestradiol profiles were largely consistent with the patterns of urinary oestrogen
shown during the earlier phase of the study. For example, M10 had relatively high
levels of urinary oestrogen which oscillated around a baseline of about 35 ng/mg Crt.,
and also had the largest follicle on scan which remained for half of the cycle. The
Figure shows the E-3-G profiles of those women not illustrated in Chapter Three
(Figures 3.07-3.09). Oestradiol levels during the scanning cycle entered the early
follicular phase range in two of the women with large follicles (M4 and M10). The
overall impression was that oestrogen was low, yet gonadotrophins were surprisingly
high for women on the pill. The same two women with high E2 had early follicular
phase levels of LH (3-day assay). This was transient in M4, but persisted through
most of the cycle in M10. All five women had follicular phase levels of FSH for at
least part of the cycle: M4 all days, M5 days 27-8, M6 days 27-5, M8 days 27-6, M10
all days.
In summary all women showed multiple, small, slow-growing, low-oestrogen-
producing follicles on both ovaries throughout the cycle. Maximum follicular size
seemed to relate to gonadotrophin levels and no follicles over 9mm were seen after
about day ten of pill taking. The sort of ovarian response a woman shows over her pill
cycle seems to be consistent within women across time as ovarian morphology in a
scanning cycle was intelligible in terms of prior oestrone profiles.
Table 1. Original Volunteers Unable to Take Part in Follow-up
Reason for Drop-Out Monophasic Triphasic
Moved out of area 1 1*
Discontinued Pill- Partner sterilized - 2
Discontinued Pill- Age & Fear of side effects 1* -
Discontinued Pill- Physical side effects - 1
Discontinued Pill- Mood / Sexual side effects 1 1
Discontinued Pill- Relationship ended 1 2
Method Failure- Pregnancy - 1
No time available at present to take part 1 2
Total** 4 9
* Indicates individuals who's relationships have also ended. **Totals reflect that some
women could not take part for more than one reason.
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Table 2. Ultrasound and Gonadotropin Results for
Five Monophasic Pill Takers
Volunteer Pill Day Oestradlol Rapid LH 3 day LH 3 day FSH No. Foils. No. Foils. Max. Foil. Max. Foil.
code no. ('bid davs) Dtnol/I I.UVI I.UjI I.IM >2mm left >2mm rlqht on left on rlqfrt
M4 22 (pfi) 69 4.5 2.03 2.29 no scan no scan no scan no scan
23 (pfi) 53 5.0 2.24 3.25 3 3 4x4 4x4
24 (pfi)* 136 4.3 3.03 5.2 4 4 4x6 5x6
26 (pfi)* 106 7.4 2.87 6.11 4 4 9x10 6x9
28 (pfi)* 100 8.9 4.14 7.53 5 5 7x7 10X12
3 42 8.7 3.30 5.42 5 4 7x14 3x8
5 54 10.2 5.55 7.08 5 5 6x9 7x8
3 91 9.9 4.71 6.25 5 4 6x11 8x10
10 3 4 5x9 6x9
12 42 7.9 3.27 3.25 3 4 6x10 6x7
15 <30 4.0 1.32 2.13 3 4 8x8 5x6
17 39 2.58 2.22 T 3 5x7 5x6
M5 24 (pfi) 42 2.2 0.13 <0.50 no scan no scan no scan no scan
25 (pfi)" 32 2.7 0.13 0.52 • • ■
27 (pfi)* 54 3.7 0.68 4.07 3 3 4x5 5x6
3 <30 3.4 1.54 5.18 4 3 7x10 4x8
4 46 5.0 1.31 5.25 4 3 7x8 5x7
6 33 0.3 0.19 2.76 4 5 6x7 4x6
3 33 1.6 0.09 2.07 5 5 6x7 6x10
11 39 4.0 0.24 0.78 4 5 6x6 3x5
13 <30 1.4 0.10 0.54 6 2 7x7 6x7
17 45 4.1 0.24 <0.50 4 3 7x7 5x6
20 32 2.9 0.12 <0.50 4 2 5x7 4x6
M6 23 (pfi) <30 3.2 0.13 <0.50 ■
24 (pfi) 37 2.0 0.13 <0.50 2 3 4x4 4x4
25 (pfi) 43 4.0 0.13 <0.50 3 - 5x5
25 (pfi) <30 3.1 0.24 0.74 - 3 5x5
27 (pfi)* <30 4.4 0.36 2.51 3 2 3x3 4x4
28 (pfi)* <30 5.5 1.02 6.83 3 • 4x4 -
1* 71 5.1 1.43 9.6 3 3 7x7 5x6
2* 55 4.8 0.74 5.5 3 3 8x8 5x7
3 39 6.4 1.42 4.97 - -
4 <30 4.7 0.65 3.24 3 2 5x7 5x5
5 34 5.1 1.02 2.63 3 2 4x5 3x4
7 <30 4.7 1.12 1.52 2 3 5x5 4x5
10 <30 3.6 0.31 0.76 2 3 5x5 5x6
14 <30 3.2 0.13 <0.50 2 3 5x5 5x6
16 37 4.1 0.13 <0.50 - - - -
21 32 3.3 0.13 <0.50 - - • -
M8 23 (pfi) <30 4.8 0.18 0.54 3 2 5x5 5x6
24 (pfi)* <30 4.2 0.13 0.65 3 • 4x6 -
27 (pfi)* 81 5.6 2.00 10.75 3 3 4x6 4x5
2 41 4.3 1.13 4.46 5 3 9x9 8x8
3 33 4.3 1.36 3.75 3 4 6x9 7x7
4 41 3.1 0.53 3.18 4 5 8x10 7x9
5 50 3.1 0.64 2.24 4 3 6x6 6x6
6 <30 4.4 0.44 2.06 4
'
4 . 5x6 5x6
9 <30 2.9 0.17 0.87 5 5 4x6 5x5
12 41 1.9 0.92 0.77 5 4 7x9 3x8
16 57 2.5 0.73 <0.50 5 4 6x7 6x7
18 45 2.8 0.62 0.51 3 3 7x7 6x8
20 42 2.9 0.53 <0.50 3 - 4x5 -
M10 23 (pfi) 46 4.5 2.72 2.45 4 3 3x7 5x6
24 (pfi)* 30 6.0 4.15 3.8 3 4 3x4 5x7
26 (pfi)* 84 5.1 3.67 4.75 4 4 5x6 9x13
27 (pfi)* 67 7.1 4.73 5.19 4 4 6x6 7x10
28 (pfi)* 165 8.8 5.00 5.82 4 4 6x10 9x10
2 65 10.7 6.79 3.92 4 5 4x9 6x11
3 99 13.3 10.66 5.58 4 5 7x8 9x15
5 90 10.6 8.84 4.29 4 5 6x8 5x10
6 34 5.5 5.39 3.98 4 5 7x8 8x9
9 67 4.1 3.12 2.88 5 7 5x8 7x12
10 45 10 3 7.13 3.37 ~ S 7x7 5x7
• T [ 52 1 58 -> V) I 2-" 3 4 5/3 5/7
-7
I
i 2.03 ] 2.22 3 I 4 4x5 1




OVER 50 MILLION WOMEN A YEAR TAKE "THE FILL"-
ARE YOU ONE OF THEM ?
Dear Clinic Attender:
Do you take the oral contraceptive pill? Have you been taking your pill for six
months cr more? If so you may be able to help us.
An enormous number of women worldwide take the pill each year. Its benefits as a
contraceptive, as well as, its desirable and undesirable sice effects are well known.
But there is stiil a great deal to be learned about hew the pill works and how
women's bodies respond to it. Not all pill types are the same, nor, cf course, are all
women.
We would like to know more about how women adjust physically and mentally to
the pill that they take, and how this adjustment locks after several months of pill use.
We feel that this information will broaden our understanding of women and their
individual contraceptive needs, and will help us to learn how to better and more
effectively use this very important form of contraception.
If you are taking one of the following brands of pill: Micrcgynon ©, Ovranette ®,
Logynon ®,or Trinordiol ®; are between the ages twenty and thirty-five; and have
been taking the same pill for at least six months, then you may be able to help us by
participating in our study. The advantage to you is that by the end of the research
we will be able to tell you how you individually have adjusted to the pill.
If you think that you might be interested in taking part please contact me before you
leave the Clinic and I will give you the full details of the investigation. If I am not in
the Clinic just now please write your name, address, and telephone number at the
botttom of this leaflet and leave it with the receptionist. I wiil contact you soon.
Thank you veny much.
Erin McNeill









A STUDY OF LONG TERM PILL USE
Thank you for ycur interest. Here is some more information about why we are doing
this study and what you would need to do if you decided to participate.
The study is aimed at women who have been taking the pill for some time. We
would like to find out what sort of physical and mental experiences ycu are having
while taking the pill, and how well your pill is suppressing the activity of your
ovaries. It may be that while your pill is effectively keeping you from getting
pregnant your ovaries are not completely 'shut off. This means that your body may
still be manufacturing its own hormones.
We wish to know if this has any effect on the way that you are feeling. The
information that we gather from this study may help us to know which pill is best
suited to which woman, which might benefit you as well as others.
We would like to monitor each woman for about two and a half months, over at
least two pill cycles. There will be some questionnaires for you to fill in at the
beginning, and one or two informal chats spaced over the time of the study. You
will need to collect daily urine samples first thing in the morning in small bottles
which we will provide. These must be stored in a freezer or the freezing
compartment of a fridge for periodic collection. You will also need to fill in a simple
'diary' form each night before you go to bed with scales that measure how you have
felt that day . These will be collected at the same time as the urines.
Neither of these last two procedures is time consuming. We hope that you will find
them quick and easy to carry out, and that they will not interfere with your daily
schedule.
Rest assured that all of the information you give us will be confidential, including
your name, address, and telephone number. No questionnaire or 'diary' which you
fill in will have your name on it; names and addresses will be kept separate.
Whether you take part or not will not influence the care that you receive at the
Family Planning Clinic. If you do finally decide you wish to take part we will ask for
your consent to send a brief letter to your general practitioner to let her/him know
that you are involved in the study.
If you think you would be interested in taking part, please contact me, and I will give
you more details about what the study involves and answer any questions that you
might have.
I look forward to hearing from you soon.
Erin McNeill
MRC Reproductive Biology Unit
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C6)Doy ueverforg ttakepills?Y sd
No□
Doy uevertakepilllatthann rmal?Y s□
No□
C7)Tninkingofyourlasttwopacketsfill ,havy ut nypilll te? (within12hrs.oft eimeyounormallytaki )?
Yes□ No□
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Howmany
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excited̂ pleased j proud frightenedqupsetg confusedqembarassed notbotheredr:
Idonotremember
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B15)Doy uthinkitsimp rtanttbleedreg larly?Y sO
No□
Why? Whatwouldy ufeelifyoudin tble ?.
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AfewcyclesCD AbouthalfthecyclesCD Many/allc cles
□
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What I would like to do is talk about some of your thoughts and feelings about birth
control and reproduction, and where possible examine how your arrived at your ideas-
what factors you feel have been important in influencing you.
So please take your time in answering if you need to, and stop me if you do not
understand what I am driving at. I apologize if I repeat some of the questions from the
questionnaire, but we have a chance now to talk about them more freely.
CONTRACEPTION AND HORMONAL CONTROL
O.K., perhaps the the easiest place to begin is with the Pill.
THE PILL
How did you choose to take the Pill in the first place?
How have you found taking it?
Do you think there is a particular sort of person who takes the Pill?
Does that describe you?
Some people think taking the Pill is "interfering with nature". What do you think?
Hormonal Control
Do you think that your hormones affect you? In what way?
Are their affects always the same or do they change over time?
Do you think that there is a "natural" or "right" hormonal state to be in?
What is it?
Some people feel that they control their bodies- others that their bodies control them.
What would you say you feel about yours? Does that feeling change over time?
Would you say you liked your body?
Contraception in General
What do you think a woman's rights are when it comes to being able to control getting
pregnant and having babies?
Where do you think your ideas about this come from.
Do you think that your partner's [husband's] attitude is the same as yours?
How is it different? If yes- Why is that?
Is he like other men in his attitudes? If no- Why is he different?
Do you think he has feelings about the pill in particular? Do other men you know?
PARITY AND GRAVITY




Let's move on now to some questions about menstruation. In the questionnaire I asked
you about your first period, and the way your family reacted to it- could you just tell me
about that again.
Attitude, experience, and behaviour
Is menstruation something you feel able to speak openly about? Who do you talk to
about it? Other women? Your partner? Other men? Why or why not?
Do you think menstruation is still a taboo subject? Why?
Do you mind if people know you are bleeding? Why? Who?
If no- So why doesn't a woman who's at work or in the pub just walk to the toilet
with a tampax in her hand.
So, what's the difference between having a cold and having a period? People tend to
show off a cold and talk a lot about it, but women hide the fact that they have their
period when all of us bleed regularly?
What do you think is positive about menstruation?
Do you think you are perhaps more aware of your surroundings, or more sensitive
before or during your period?
Is there anything that you avoid doing while you are bleeding?
Do you have sex? If not- Why not? Who decides that? You, your partner, both of
you?
Do you feel differently about yourself on the days that you are not bleeding from the
days when you are not? What about at other times in the month? (Pre- post-
menstrually)
Do other people notice the differences?
Do you think about menstruation when you are not bleeding?
What name do you use for menstruation?
Do you use pads or tampons?
Would you change your cycle if you could? (Either the pattern of bleeding or your
physical and emotional experiences of it.) Why or why not? In what way?
GENDER IDENTITY
All of these questions have to do with the specific reproductive potential of women. I
am interested in how you feel about yourself as a woman.
Do you like being a woman?
Do you think that the people around you expect certain things of you because you are
female? What do they expect? Who expects it?
Do you change the way you behave meet these expectations? Do you want to?
Do you think that women are expected to be constant in their mood and behaviour? Are
we? Is that a good or a bad thing?
Are men constant? Are they expected to be? Should they be?
PERSONAL EXPERIENCE
Relationships
What sort of relationship do you have with you partner/ husband?
Can you describe it to me? (What are the most important features of it?)
Do you feel you have particular roles that you follow?
Does that have anything to do with the sort of person you are?
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Optional: Sexuality
When did you start having sexual relationships?
How would you characterize yourself sexually?
How would you characterize your present sexual relationship?
WRAP UP
Is there anything I have not asked you about which you think is important, and will
help me to understand you better- Some specific experience or event in your life
perhaps that has influenced your attitudes?
One final question- What do you think really motivated you to take part in this study?
(Thanks, and remember to mention the ultrasound.)
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Results of the Supplemental section of the MHRAQ-2: results given for
a random consecutive sample of 500 Family Planning Clinic volunteers
% Agree Neutral Disagree % missing
The Nature of Bleeding
• "Basically, I think periods are to do with
sex and having babies." 32 30 30 8
• "I feel women's menstrual bleeding is unique.
It is not just the body's waste products like
urine-blood is life matter-what you're 19 4 8 25 8
made up of."
• "I think bleeding brings women an awful
lot closer to mortality or to physicalness than
men ever need to be. It's a constant reminder
that you're flesh and how your body works." 25 3 9 28 8
• "My menstrual bleeding is private and
personal." 4 4 36 15 6
• "I feel the more a woman bleeds the more 4 9 29 14 8
she is affected by it."
Bleeds are Embarassing
• "I think other people are embarrassed by 22 26 4 6 6
tampons and pads so I try to hide them."
• "I believe most people are embarrassed
to talk about periods." 4 5 17 31 6
• "I was more embarrassed about menstrual
bleeding when I was younger than I am 7 7 8 8 7
now I'm older."
• "I would be embarrassed if I bled onto my
clothing." 7 6 9 8 7
Bleeds as Neutral
• "My period doesn't tend to affect me,
after the first couple of days I tend to forget 5 7 11 27 5
it's happening."
• "My period is not positive, it's not negative, 62 19 13 6
it's just there."
• "For me menstrual bleeding is just another




• "I quite enjoy bleeding... it gives me a certain 6
relaxed feeling."
• "Having a period gives me a feeling of pride
in my womanhood." 10
• "Overall, I view my period as a positive 27
experience."
Bleeds as Negative
• "I am just glad to get rid of the blood. I feel
like it's all the rottenness in me coming with
it."
• "When I have a painful period it makes me
think of bleeding as 'the curse'."
• "I feel dirty when I'm bleeding."
Bleeding and Sex
• "I don't think it's morally right to have sex
during my period." 11
• "I prefer not to have sex when I have a 5 6
period because of the mess blood makes."
• "I think the act of putting in, and taking out
tampons is interpreted by some people 9
as being sexual."
• "I don't like to have sex when I'm bleeding
because I don't like to get blood on my 18
partner."
• "I particularly enjoy sex when I am bleeding, as
I am especially sensitive and responsive then 12
both physically and emotionally."
Awareness of other women's bleeds
• "Menstrual blood has a distinct smell which I
can detect on myself and other women." 28
• "I am aware when other women are bleeding 10
without them telling me."
• "I find that the shared experience of having periods




Neutral Disagree % missing
24 6 5 6
41 41 8
38 27 7
28 6 0 6
22 4 0 6
17 55 6
22 6 2 6
14 24 7
30 5 5 8
31 43 8





Perceptions of men's views
• "The men I know just want to forget
about that week in the month and talk
about the other three."
• "I think some of the men I know use the fact
that women bleed as proof of their inferiority.
• "In my experience, some men do not take
my views seriously when they think I
am having a period."
• "I think my partner believes periods must be
painful because he associates blood with
pain, injury, and trauma."
• "My partner is sensitive and understanding
when my period affects me badly."
Agree Neutral Disagree % missing
13 19 61 6
5 23 6 6 7
18 31 43 8
15 30 48 8
72 15 6 7
Instruction about periods and equipment
• "I think schools should teach more openly
about periods to girls."
• "I think it is up to parents to tell their
daughters about periods, and how to
deal with them."
• "I think girls ought to be taught or shown
how to use tampons."
• "I think women should get tampons and
pads on the NHS."
86 7 1 6
76 11 7 7
82 10 3 7
66 23 4 8
63 13 17 7
• "I think boys should be taught as openly about
periods as girls."
Legend:
Numbers in bold represent the majority view. In some case the majority of women
responded neutrally which may indicate a number of things: 1) the statement just
doesn't apply to most women- eg. a question about children, 2) women have never
considered the idea, 3) women are undecided in their opinion, or 4) the statement is too
escoteric and is meaningless to most women.
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Case Reports of Premenstrual Syndrome Clinic Patients
Receiving Oral Contraceptive Pill Cycle Length Manipulation
as Treatment for Premenstrual Syndrome
The following are case summaries for eleven women who attended the Premenstrual
Syndrome (PMS) Clinic at the Royal Infirmary of Edinburgh between May, 1988 and
May, 1991. Each woman underwent some manipulation of the length of her OC cycle
in an effort to moderate adverse cycle-related changes in mood or physical well being.
The case summaries are descriptive, retrospective reports derived from Clinic case
notes. A description of the individual's clinical experience is usually followed by a
consideration of the possible aetiological mechanisms responsible for her reactions to
the cycle manipulations. Further theoretical consideration can be found in Chapter
Five.
Case No. 8735:
Mrs. H. began attending the PMS Clinic in June of 1987, at age 30. She noted that her
worst cyclical symptoms were tearfulness and loss of control, as well as, nausea,
vomiting, and pain. She was taking Ovran 30 before she first came to the Clinic, for
contraception and to help "regularize" and manage her periods, which are about 42 days
when not on the pill. Her PMS was generally less severe on the pill, but symptoms
had shifted to the bleeding phase.
Dr. Bancroft decided to ask her to take three packets of pills in a row in an effort to
reduce the frequency of her adverse symptoms. For the first three months she was
relatively symptom free, but in the second extended cycle she developed mood
symptoms and a sensation of bloating after about six weeks of active pills. These
symptoms continued to "build-up" or worsen over the remaining three pill weeks.
After this Dr. Bancroft reduced her cycle to six weeks of active pills followed by a
week off. She found this satisfactory, though she reported a decline in mood ("a blip")
at the end of the first packet which gradually improved into the second packet. Her
mood began to decline again towards the end of the second packet, worsening until the
beginning of the withdrawal bleed, when she experienced relief.
It is interesting to note that the pill cycle length which best suited Mrs. H. was the one
which most closely approximated the length of her own non-pill cycle of about six
weeks. In this case the improvement may have been achieved by re-entraining her
mood rhythm to her underlying menstrual cycle. We do not know if Mrs. H.'s
improvement on this regime was sustained, as she was discharged from the Clinic in
July 1988 with the intention of stopping the pill to try to conceive.
Case No. 8804
Mrs. B. began attending the PMS Clinic in January 1988, at age 37. She presented at
the Clinic with premenstrual irritability and cyclical breast changes. She noted that she
had had PMS for about ten years; since the birth of her two children in 1977 and 1979.
She was very depressed after the birth of her second child, who is handicapped.
Dr. Bancroft started her on Microgynon as a PMS treatment in March 1988. She noted
a big improvement in her breast changes, but was still suffering from irritability which
had now shifted away from the premenstrual phase into the pill free interval. Dr.
Bancroft suggested trying two packets of pills in a row without a break, in an effort to
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eliminate some of the adverse symptom phases.
Mrs. B. reported that while she felt fine during the first three weeks of active pills, she
felt ill through the whole of the second three weeks. Her breasts and back were sore,
she had period type pain, and felt "uptight" from the fourth to the sixth weeks of pills.
After two seven-week cycles, she was returned to a conventional pill cycle. She
reported herself that the pill was most helpful with physical symptoms, but had little
impact on her emotional cycle.
In this case the most acceptable pill cycle length was also close to Mrs. B.'s non-pill
menstrual cycle length of about 27(±2) days, suggesting a similar mechanism was
operating as in 8735's case.
Case No. 8843
Ms. G., age 22, came to the Clinic in May 1988 complaining of depression,
weepiness, and an inability to cope in the premenstruum. Dr. Bancroft started her on
Microgynon as a treatment for her PMS. After one month of pills she returned
reporting breast tenderness that lasted throughout pill taking, and weepiness during the
pill free interval, prior to bleeding. She had not experienced breast tenderness before
starting the pill.
Once again Dr. Bancroft wished to use a protracted pill cycle to eliminate the adverse
symptoms which seemed to be clustered in the pill free interval. Ms. G. was planning
a two month trip to East Africa over the summer, and therefore it was doubly desirable
to reduce the number of bleeds. She was advised to take three packs of pills in a row
from June until August and then have a seven day break.
She returned to the Clinic in October, 1988. She had misunderstood our instructions
and taken four packs of pills in a row, intending to take a fifth. During the fourth pack
she began to have breakthrough bleeding that lasted for about three weeks. She had a
pill free interval after this pack, and experienced a heavier than normal bleed. Though
she felt somewhat physically drained by the prolonged bleeding, her mood was
improved by the regime. She reported that she still had bad times, but felt an overall
improvement on the pill in mood, and particularly in her acne. She decided to continue
with a conventional pill regime, and felt sufficiently improved to be discharged from the
Clinic.
Case No. 8846
Mrs. P. first came to the Clinic in April, 1988. She was thirty-eight years old and had
two small children. Her presenting complaint was a life long history of migraine
headaches during menstruation. Dr. Bancroft decided to prescribe Mi'crogynon to be
taken continuously for nine weeks in an effort to eliminate bleeding, and therefore the
associated headaches. Mrs. P. had not taken the pill for about thirteen years. She
recalled reacting differently to different formulations, but believed that Microgynon had
been an acceptable brand for her in the past.
Since childhood, Mrs. P.'s migraines had begun just prior to bleeding, peaking on the
second or third day of menstruation. Over the last year, however, they had been
coming at other times as well. Attacks were characterized by frequent vomiting and the
need to be bedridden for about 48 hours. She noted that both her mother and maternal
grandmother suffered similarly, and that she had experienced a total remission during
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both of her pregnancies.
Mrs. P.'s reaction to this regime was quite unfavourable, but the results are very
illuminating. She felt fine at the outset, but experienced a migraine and vomiting at the
end of the first pill packet, during the time when she would otherwise be having a
withdrawal bleed. The migraine ended after about two days, but she felt increasingly
unwell during the second three weeks of pills with a noticeable and steady increase in
breast discomfort and enlargement. On day nineteen of pack two (cycle day 40) she
had a second migraine with vomiting, and was very depressed and tearful which she
said was unlike her. She stopped taking the pill at the onset of this attack, and as a
consequence had a withdrawal bleed three days later (cycle day 43). On the second day
of this bleed she had a severe migraine attack with vomiting which lasted for three full
days. She had a fourth migraine twelve days later.
There are a number of possible explanations for Mrs. P.'s response to this regime. It is
likely that her migraines' relationship to menstruation is not as a direct result of
ovulation, but at least in part, a result of the hormone withdrawal that precedes a natural
or pill cycle bleed. This would explain the third migraine she had. Since her migraines
have come every thirty days for the last ten years, beginning just before a bleed,
expectation might be playing some part in their timing. Alternatively, the regularity of
her migraines could be explained by a rigid entrainment of the Migraine cycle to her
menstrual cycle. This may be why she had the first and second attacks even though she
did not bleed, because the migraine cycle had begun to free run.
Her E-3-G levels during the two months she was on the pill indicate that the pill had
taken rapid effect in suppressing ovarian function. Basal levels of endogenous steroids
may have been experienced by the body as hormone withdrawal and precipitated the
first two migraines by a physiological mechanism. They may also have acted as a
modulator which phase advanced the migraine cycle through an oscillator mechanism.
The final migraine may have been a result of the general disruption in the timing of the
hormonal zeitgeber, which if an infradian oscillator were present as hypothesized,
would be the expected outcome of a phase shift of aberrant length which was generated
by the seven week pill cycle. It is also possible that these headaches would have come
at these times irrespective of any changes that were made to her hormonal cycle, as she
had reported that attacks were beginning to come at times other than during menstrual
bleeding.
Code No. 8868
Mrs. N. first came to the Clinic in July, 1988 at the age of 32. She had been on the pill
since the age of thirteen to moderate painful periods. She came off it in 1986 and
conceived her only child within three months. Before the birth of the baby she had
experienced breast changes over the cycle, but never any mood changes. Her PMS
only really emerged after the birth of her son, and was characterized by depression,
irritability, anger, loss of control, and breast tenderness starting on about day seven of
pills and worsening until the onset of the withdrawal bleed. Dr. Bancroft considered
that the pregnancy had in some way altered her responsiveness to steroidal
contraception.
Mrs. N.'s case is complicated by the fact that in about 1983 she experienced the onset
of bipolar affective disorder. She had had about five manic episodes which required
hospitalization, and had been taking Lithium for about four years. During the time we
were seeing her she was also suffering from insomnia, frequent "dizzy turns" (anxiety
attacks and ulcerative collitis. The many powerful drugs that she was taking may have
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been interacting in some way that we did not fully understand. And her tendency to
severe episodes of depression may have clouded the picture of her premenstrual
experience, as she also began anti-depressants in January, 1989.
Like other patients attending the Clinic, Mrs. N. prospectively monitored her subjective
state by completing a self-rated daily diary, and collected daily urine samples for
hormone assay for several months. There seemed to be a close positive relationship
between her variations in ovarian oestrogen, and her well being. She showed evidence
of considerable liberation from pill suppression as a result of the seven day pill free
interval, with peak levels in the preovulatory range achieved by the end of the first pill
week. Rises in oestrogen were accompanied by improvement in subjective state, and
falls by a steady worsening of her well being.
We considered conflicting hypotheses about the cause of this woman's PMS: 1) that
symptoms were a result of oestrogen deficiency; 2) that her symptoms were a
consequence of the regular starting and stopping of the pill, a sort of phase delayed on-
off mechanism; and 3) perhaps in addition to one of the preceding theories, that she had
a mood rhythm rigidly entrained to her hormonal cycle by almost twenty years of
strictly dmed pill cycles.
Dr. Bancroft decided that lengthening Mrs. N.'s pill cycle might reveal whether or not
it was the regularity of cycle length, or fluctuations in steroid hormones which was the
most salient factor in her PMS. We decide to take a conservative approach at first and
add only one week on at the end of a pack. In addition, Mrs. N. was asked to have just
six days off before starting a new pack to try and reduce the degree of ovarian
recovery. Mrs. N. reported that while she had premenstrual symptoms during the
second and third weeks of pills as usual, she had felt better on the extended regime.
However, she was very depressed for about ten days after the end of the bleed, during
the time when she would otherwise have been feeling her best.
It was then decided that she should stop the pill. She attended two subsequent
appointments over the space of five months in which she showed a marked and
sustained improvement in her mood and self-presentation. Her entire manner seemed
to have changed from a woman who would barely lift her head at an appointment, to
someone who appeared relaxed, confident and happy, but not at all manic. She said
that she felt better than she could remember feeling in years, and that others had
commented. "They must be able to see it in your eyes", she said. Mrs. N.'s dramatic
improvement in affect after stopping the pill may have been due in part to the removal
of some interaction between the pill and the Lithium she was taking to treat her affective
disorder. Alternatively, she benefited from the restoration of high endogenous steroid
levels. She stated that she still experienced some PMS, but that it was much less severe
and prolonged, which along with her reaction to the attenuated pill cycle suggested to
us the presence of a mood oscillator. Perhaps her cycle-related depression was
successfully postponed (phase delayed) by the five week pill regime, but was of
exaggerated severity due to the combined effects of a phase-shift and prolonged ovarian
suppression. Mrs. N. was discharged from the Clinic in September, 1989.
Case No. 8870
Mrs. B. first attended the Clinic in December, 1989. She had one child and had since
been sterilized. Mrs. B.'s was oligomenorrheoic, with periods only once every four to
five months. She reported experiencing a two week phase of positive well being after a
period, followed by PMS symptoms which increased in severity until the onset of the
next bleed several months later. Her symptoms included breast tenderness, irritability,
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and a general dislike of others with increasing aggressive feelings, which in the final
premenstrual week would culminate in violence towards her husband.
Dr. Bancroft decided to see if the severity of her symptoms could be mitigated by
generating more frequent bleeds. She was started on Microgynon in December, 1989
which suppressed her steroid hormones to basal levels. After the first two pill cycles
she reported that she experienced one good week after the withdrawal bleed followed
by a build up of her usual symptoms during the next two weeks until the onset of the
next bleed. While the pill did not prevent symptoms occurring, it did seem to "reset the
clock" each month, producing proportionally more good weeks than before. She said
she was helped by the knowledge that her symptoms would remit with the onset of
bleeding.
At her March, 1989 Clinic appointment Mrs. B. indicated that she was going on
holiday for the next fortnight, and did not want to have a PMS episode while away.
Because she is sterilized and did not require the pill for contraception, we decided to
advance her bleed still further by cutting short the pill cycle. We wished to abolish her
PMS symptoms early by using this regime. She stopped active tablets on pill day
fifteen and had a seven day break, before resuming a twenty-eight day cycle. She
monitored her progress throughout this time with prospective daily self-ratings.
When Mrs. B. returned to the Clinic in June, 1989 she reported that the manipulation
had worked as desired, and prevented her symptoms from building up. We suggested
that she return to this regime of 15 days-on and 7 days-off, and see if it were possible
to eliminate her worst premenstrual week in subsequent pill cycles. I spoke to her on
the phone in August, 1989 and she said that she had had a "super month". By
November, 1989 she had had four months of twenty-two day cycles, and reported that
her PMS was now confined to about two or three days of the cycle. She felt "75%
better" and was calmer and "not so short with people".
At her return appointment in July, 1990 Mrs. B. was still feeling well on the twenty-
two day pill regime, but her premenstrual agitation and anxiety had returned to the
longer duration of about ten days. Nevertheless, she still gained relief as soon as the
bleed began. She said she was happier and more settled than she has been. My clinical
impression was that her affect had improved, she appeared less strained, more relaxed,
smiled more easily, and that her complexion was better. She is still being monitored in
the Clinic. It is likely that Dr. Bancroft will change her to a lower dose pill, such as
Mercilon, at her next visit because she is thirty-four, smokes fifteen cigarettes a day,
and has recently been having palpitations.
Because Mrs. B. did not require the pill for contraception, we were able to investigate
the potential benefits of a shortened cycle for her PMS. The manipulation was very
much an experimental one at the beginning, since we had no previous experience of its
effects. The outcome for this woman was most favourable, and the benefits have been
sustained for more than a year. In her case, there is a strong relationship between the
onset of bleeding and relief from symptoms. It could be that in this and other cases of
cyclical mood change, whatever is responsible for the onset of bleeding, is involved in
the control of symptoms. However, the mechanism which initiates menstrual and
withdrawal bleeding remains ill understood.
In attempting to explain how the regime might be affecting a centrally controlled mood
regulating system to confer its advantage, it is important to consider the fact that though
the overall change has been maintained, Mrs. B. has recently reported a bad phase of
greater duration, about ten days, compared with a bad phase of about three days when
the regime was introduced. This fact suggests that the short cycle improved her mood
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state by disrupting the phase relationship between the mood and steroid hormone
cycles. The short cycle was continually phase advancing a bleed, and consequently
also curtailing the negative mood cycle which had become entrained to her very long
natural cycles. The great discrepancy in length between the old and new cycles made it
very difficult for the mood cycle to reentrain itself to the pill cycle. Nevertheless, over
the course of a year of short cycles, the length of the "symptomatic" phase within the
short cycle increased suggesting that a gradual reentrainment took place.
Case No. 8927
This 23 year old woman first attended the Clinic in March, 1989. She began
experiencing PMS in the autumn of 1986. Ms. C. was sixteen years old at menarche
and started to take the pill when she was 17, so it is unlikely that she ever really had
well established menstrual cycles. The pill, which she takes for contraception, is
Marvelon.
Her PMS is characterized by mood swings and irritability beginning about ten days
before her bleed. Symptoms were worst in the three or four days immediately before a
bleed, during the pfi, and gradually improved over the course of bleeding. Prospective
diary ratings indicated that her symptoms were of clear premenstrual and menstrual
timing. Her "good phase" lasted for about two weeks after the end of a bleed.
Dr. Bancroft decided to extend pill taking by one week in an effort to attenuate the
phase of positive well being. Ms. C. reported feeling more irritable, but less depressed
on this regime. Her diary data indicated a slight overall improvement in her symptoms.
In March, 1989 Ms. C. asked if she could take two additional weeks of pills instead of
only one, as she wanted to avoid symptoms while on holiday.
The outcome of this five-week-on-one-week-off cycle was very interesting. During the
fifth week of pills, days thirty-one to thirty-five, she was very irritable, and had bad
period pain, although she did not bleed. She reported that the pain was more like what
she used to experience before she started the pill. Ms. C.'s diary data indicated an
overall improvement on the prolonged pill cycle, however, she was not satisfied with
the degree of improvement and stopped taking the pill.
It seemed that Ms. C. fared best on a five week pill cycle. Although, she still
experienced cyclical mood change during a four-week-on-one-week-off regime, the
extra week seemed to extend the number of good rather than bad days. It was also
interesting that when her pill cycle was extended by more than a week she experienced
her symptoms in the fifth pill taking week, or the would-be bleeding week, and they
were more severe than usual. The symptoms remitted at the end of that week.
This pattern suggests that she possessed an endogenous mood rhythm of five weeks
duration, linked to the hormonal cycle. When she was on a conventional pill cycle her
worst symptoms occurred during week four, bleeding seemed to modulate them, and
they disappeared about two days after the bleed finished. Four weeks of pills followed
by a withdrawal bleed seemed to be a good marriage of the mood and hormonal
rhythms. Perhaps the five-weeks-on cycle was not able to "reset" the timing of the




Mrs. M. first came to the Clinic in August, 1989. She had been taking Mercilon for
about four cycles for her PMS. She has two children and her husband has had a
vasectomy. She felt the pill had generally improved her symptoms. When not on the
pill, she had cycles of about twenty-two days. She reckoned the pill had lengthened
her good phase, and shortened the bad phase to about three days. In October, 1989 her
family doctor switched her to Brevinor because she was experiencing a lot of pain in
her calves and a loss of sexual interest on Mercilon. Mrs. M.'s case is somewhat
clouded by the fact that over the course of time that she was being monitored in the
Clinic she was having considerable marital difficulties with a number of separations
from her husband.
In January, 1990 Mrs. M. reported that she had tried to take two packs of pills in a
row, but that it did not really help, as she still had a "bad patch" when she would have
been bleeding. In March, 1990 she expressed doubt about whether the pill was really
helping since she was regularly having breakthrough bleeding at which time her
symptoms of depression and anger would begin. She told Dr. Bancroft that she had
had twenty-two day cycles before the pill, and it was as if her own underlying cycle
was "breaking through" in spite of the pill. Dr. Bancroft suggested that she try a short
pill cycle of 17-days-on-5-days-off
When she returned two months later she noted an improvement. The symptomatic
phase which had been lasting for ten days prior to a bleed on the old regime, was now
only a few days long. She reported feeling better able to cope, and noted that going on
the pill had seemed to help at first, but that the effect had "worn off" on the
conventional pill cycle.
In spite of the improvement generated by a twenty-two day cycle Mrs. M. stopped the
pill. After three months off it she reported that she was slightly worse. She is still
attending the Clinic, and Dr. Bancroft intends to review her situation in a few months
time.
Mrs. M.'s case shares some elements with others. It is notable that she, like others,
reported a symptomatic phase during an extended pill regime at the time of the would-
be withdrawal bleed. She also seemed to fare best on the pill cycle which most closely
approximated the length of her natural menstrual cycle, and stated in her own words
that her mood cycle seemed to have a periodicity of its own which was not controlled
by the length of the hormonal cycle.
Case No. 8972
Ms. D. first attended the Clinic in October, 1989 at the age of 28. She had been using
the pill for contraception on and off for years, and most recently, Marvelon since May,
1989. She noted that her PMS usually begins on about the seventeenth day of pills and
lasts until her bleed starts. It is characterized by anger, aggression, irritability, and
tearfulness. She has had PMS for five or six years.
Since Ms. D.'s symptoms begin on about day seventeen of pill taking, and remit with
bleeding Dr. Bancroft, and I decided to see if a shortened pill cycle was of any benefit.
Because she needed the pill for contraception we decided that she should take seventeen
active pills, and then have only four days off.
When Ms. D. returned to the Clinic in January she was in her third shortened cycle.
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She had noticed an improvement in the first cycle, and had only one day of feeling
depressed and tearful in the second cycle. However, she had four days of premenstrual
type symptoms, notably anger, after her bleed finished. She commented: "It's as if my
body has been tricked for a couple of months and then it woke up and realized that it
should be having PMS now." This post-menstrual episode was worse than she had
ever known it, and she remarked that she had never had her symptoms after a period
before.
Dr. Bancroft advised her to persevere with short cycles for two more months. He
anticipated that she would have another "post-menstrual episode", but that it would be
less severe as it was not being reinforced. When she returned in April, 1990, Ms. D.
reported that she was still getting severe PMS. She noted that the timing of her breast
tenderness remained very predictable with respect to the onset of bleeding. Her mood
symptoms, however, had adopted a quite unpredictable timing. She was having her
usual mood symptoms as severely as ever, but for a shorter time before her bleed. But
she was also having a second symptomatic phase after the bleed.
She was returned to a conventional pill cycle. Her symptoms arrived between the
seventeenth and nineteenth day of pills and seemed somewhat improved. However,
Ms. D. decided to stop taking the pill in July, 1990. After five months off the pill, she
reported that her PMS was noticeably worse. Her cycle length ranged from 24 to 27,
with a mean of 25 days. She questioned whether "any change (in cyclical hormones)
makes it (PMS) different for a while". Though her PMS is worse off the pill, she
would like to conceive soon, so will remain off it, and continue to be monitored in the
Clinic.
The occurrence of Ms. D.'s symptoms after the onset of bleeding in a truncated pill
cycle implies that her endogenous rhythm may have previously been entrained to the
conventional pill cycle, and was disrupted by the short cycle. It is difficult to know if
the subsequent conventional cycles were better or just the same as the cycles prior to the
manipulation. It is also curious that Ms. D.'s PMS was so much more severe after she
had stopped the pill, though the length of the cycle is shorter than the pill cycle.
Perhaps, her PMS is more powerfully entrained to a short natural or pill cycle, but is
unable to link itself so powerfully with the longer 28 day pill cycle which thus
modulates the severity of symptoms.
Case No. 8986
Mrs. M. first attended the Clinic in December, 1989 at the age of 30. Mrs. M.'s
symptoms include being "nervy", accident prone, bad tempered, tired, lethargic, and
having diarrhoea and carbohydrate cravings before a period. She has been on
Microgynon for about one year and a half, and says she was "quite suicidal" before the
pill. The pill has greatly improved, but not eradicated her PMS, which she considers to
be severe. On the pill her symptoms have tended to occur during the pill free interval.
Mrs. M. was very depressed after the birth of her only child nine years ago. She lost
her interest in sex then, and feels it has never really returned. Relations with her
husband are poor.
At her February, 1990 visit Dr. Bancroft suggested she take two packs of pill in a row
to try and eliminate the worst symptom phase that occurs during the pfi. Mrs. M. had
one seven week cycle, and then interrupted the two pack regime and had two
conventional pill cycles. She did this because she predicted that she would be
premenstrual before her final nursing exams, and wanted to eliminate this possibility.
When she came to the Clinic in August, 1990 she was at day 23 of her seven week pill
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cycle, and said she "felt lousy" and was "tempted to have a period to release the
tension."
She noted that she had been much improved by the seven week cycle at first, by after
the two conventional four week cycles, she was just as symptomatic on the seven week
cycle. It is possible that the initial improvement was due to the change in regime, but
her mood cycle is now too disrupted with respect to her pill cycle to accommodate the
further changes in regime.
Case No. 9017
Mrs. R. first came to the Clinic in May, 1990 reporting that she had had cyclical
symptoms since menarche. She had been taking Marvelon since 1987, but had recently
stopped for two months due to an operation and found that her PMS was worse. So,
she resumed Marvelon in June to control her PMS. Because like many others her
worst symptoms occur during the pill free interval, Dr. Bancroft advised her to try a ten
week pill cycle. But also in view of the experience of others, he advised that we see
her towards the end of the second pill packet, in case she was experiencing a build up
of symptoms.
When she came to the Clinic in September, she had had seven and a half consecutive
weeks of pills, and was feeling quite well. She noted that both her husband and her
mother had commented on the improvement in her mood. She did say that she had had
ups and downs, and that "you could probably see where I would have had a period, but
it (her diary ratings) was all one's and two's." Overall, her symptoms seemed to be
damped down by this regime. Her cycle when not on the pill tends to be fairly long,
varying from 31 to 42 days in length. The improvement in her moods was sustained
over two subsequent ten-week cycles. While monthly symptoms were diminishing,
PMS symptoms had begun to occur in week eight or nine of pills, prior to the
withdrawal bleed in week ten. This suggests that she was undergoing a gradual
reentrainment to the much longer cycle length.
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Thank you very much for completing our questionnaire at your recent Family Planning visit. I
am very grateful that you have expressed an interest in a further study of how women feel svhen
they are using oral contraceptives. We believe that this research may help us to take important
steps towards a better understanding of how the menstrual cycle, or in your case the pill cycle,
may effect a woman's moods, physical sensations, and reactions to events in her everyday life.
1 hope that you will be able to help us by taking part in the study.
My name is Erin McNeill, and I am the one who you will speak to and be in contact with during
the study if you decide to take part. As you can see from the above address, I am based in the
Medical Research Council's Reproductive Biology Unit in Chalmers Street.
Basically what the study involves is having a number of women take one type of combined oral
contraceptive pill for a period of six months and report in a systematic way on how they feel
over that time. What will be different about the way in which you take your pill is that the pills
will be specially packaged so that you just take one everyday without knowing when your
"week off" is going to happen. Some cycles may be more than 28 days, but this will have no
effect at all on the way your contraception works. 1 will explain everything that will happen in
the study when I first meet with you.
Before we go any further I would like to make sure of a few of your details. First of all it is a
lot easier and quicker for me to contact you by phone, especially in the day time. So could you
please let me have both your daytime and evening telephone numbers if you have not given
them to me already. Could you also tell me exactly how long (as far as you know) you have
been on your pill and what its brand name is. And if you happen to live outside Edinburgh,
could you let me know how easy it would be if you took part in the study for you to come in
for interviews and check-ups about once a month. Please Fill out these details on the enclosed
bit of paper and return it to me in the freepost envelope. I look forward to hearing from you




Do you take a Combined Oral Contraceptive Pill ?
Are you between the ages of 20 and 40
(35 if you smoke) ?
Do you notice predictable changes in either
your mood or your physical well-being
or both over your cycle ?
Would you be interested in having
periods less frequently ?
Or
Are you curious to know if a longer pill cycle
might improve some of the physical or mood
changes which you experience over your cycle ?
9
If the answer to all these questions is Yes, then you may be able to help me:
The people who invented the Pill believed that women consider it normal to bleed
every 4 weeks, and for this reason they decided all women should take the pill in a
standard way: 3 weeks on & 1 week off. But women who are not on the Pill do not all
have cycles of the same length. The length of the cycle can vary a great deal and still
be perfectly normal.
The truth is there is no medical reason why thePill should be taken in this rigid way.
Having a Pill cycle longer than 4 weeks will not reduce contraceptive cover or be
harmful medically, and it may even have some benefits for your health and well-being.
I am conducting a study on the way that Pill cycles of different lengths affect the
way women feel. It may be that individual women need to find a Pill cycle which suits
them best individually.
I need your help to answer this question, which may benefit you and other women
as well. If you think that you would like to take part in this study, or would like to talk
to me about what it involves please leave your name, address, work and home telephone
numbers with the staff at reception, and I will contact you.
Or you can phone me on 031-229-2575. Ask for Erin McNeill or leave a message
with the switchboard.
I look forward to hearingfrom you soon.
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Appendices 6.04 353
Encapsulation of "Marvelon" Tablets. For MRC Trial
To produce capsules suitable for a double blind trial Marvelon tablets were packed in
opaque gelatin capsules with lactose as filler. Strictly this does not achieve a true
"double blind" as the code may be broken by opening of the capsules. Co-operation of
investigator and patients to not break the code in this way must be ensured.
The empty capsules were placed in a "labocap" capsule filling machine which holds 100
capsules. These were first approximately half filled with lactose. 100 Marvelon tablets
were counted and checked. Using tweezers one tablet was placed in each capsule. The
plate of capsules was visually checked by a second person before the capsules were
filled with lactose and capped. This procedure was carried out in a cytotoxic cabinet
within the non-sterile production area to prevent exposure of the operators to the
steroids contained in the tablets.
The capsules were packed in 7s and 2 labels were attached to each bottle - the study
label and a peelable content label. The peelable content labels provided a method of
reconciliation when coding material.
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INFORMATION SHEET FOR VOLUNTEERS lhb Protocol 89/45
Welcome to our study of women on the pill.
Why we are doing this study
First let me explain why we are doing this study. The people who invented the oral
contraceptive pill decided that women should take it in such a way that they would bleed every
28 days. They decided this because they thought that most women had a cycle that was about
28 days long. The truth is that most women do not have a cycle of exactly 28 days, and for
most people the cycle changes in length a good deal from one to the next. Most women will
find that they have their own average cycle length, but for one person that may be 35 days
while for another it is 26.
The point is not all women who take the pill would be having 28 day cycles if they were not
taking it. We wonder if it is right for all women to take the pill in exactly the same way.
Maybe some women would feel better physically or emotionally if they took the pill in the way
that was most similar to their own average cycle.
How we would be changing your pill taking
You will be involved in the study for about six months (25 weeks of pills). During this time
we will give you your pills to take. You will be taking a common, low-dose (30pg oestrogen),
combined oral contraceptive pill. This study is what is called "double-blind". This means that
neither you nor I will know which study group you have been put in. We will both be 'blind'
to the sequence in which you are being given pills to take. A third person, who is helping me
to do this research, will know which group you are in. She will have a code to tell her exactly
how you are taking your pills.
We cannot tell you what sort of pill cycle you will experience because this might influence the
way you report how you feel. But we can say that no one will be taking fewer than 21 pills at
a time between weeks of dummy pills. So the minimum number of contraceptive pills that
you would take before having a week off would be 21 just like in the normal pill cycle. The
longest time that you would take contraceptive pills without a week of dummy pills would be
16 weeks. There is no medical reason why it is dangerous for a woman to take contraceptive
pills for this length of time without a break. The only thing that might happen is that she will
have irregular, or breakthrough bleeding.
The pills will be just like your normal contraceptive pill except they will be enclosed in
gelatine capsules filled with lactose powder, and packed in small bottles. You will take one pill
every day. Usually you will be taking a contraceptive pill, but at times when we are giving
you a week off you will take a 'dummy pill'. The 'dummy pills' will contain only lactose
powder which is the sugar that occurs naturally in milk. Because we do not wish you to know
which pills are dummy pills and which ones are active contraceptive pills it will be necessary
for you to take one capsule every day. The lactose in the capsules will delay the time it takes
for your body to absorb and start using the hormones in the pill by approximately one hour, so
you should try to take your pill one hour earlier than you normally do. It is also a good idea to
take the pill at the same time each day.
Each bottle will contain one week's supply of pills (7 capsules), and will be labelled with your
study code number, and the study week number. It is extremely important that you use the
bottles in the correct order, that is, you Finish all the capsules in the bottle labelled week
number one first, before you open week number two's supply. So, you should open bottle
"Wk.l" first and finish all the capsules in it, then you should open bottle "Wk.2" and finish
all the capsules in it, and so on like this until you finish "Wk.25", and come to the end of the
study. You will be given a five weeks supply of pills each time you come for an appointment
(every four weeks) to reduce the chance of bottles getting lost or muddled. You should bring
all empty bottles and the open one you are currently using with you when you come up to see
me each month.
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What else will you have to do
There are a number of things which we would like you to do, as well as taking the specially
packed pills, so that we can follow how you are feeling.
1) Meet with me (Erin McNeill) twice for a period of about one hour- once at the beginning and
once at the end of the study for an informal interview.
2) Record how you have felt each day on a 'diary form'. (Explained below)
3) Collect a sample of urine first thing in the morning, three times a week. (Explained below)
4) Come up to the Royal Infirmary once every four weeks to give a urine sample for a
pregnancy test (just as a safeguard!), and to get more diaries and pills.
Interviews
At the first interview I will explain what the study involves and fill in any gaps in the
information about periods and contraception that were not covered by the questionnaire. I will
also ask you to fill in a few other short questionniares. In the interview at the end we will talk
about your experience in the study. Both meetings should only take about one hour.
Daily Diaries: What they are and how to fill them in
You will be given a booklet each month that contains 28 diary forms, or a 4 week supply. One
diarv form is to be filled in each night just before vou go to bed throughout the study. The
answers you give should relate to the way you have felt over the last 24 hrs., since you last
filled in a diary. It is important that you do not go back and look at vour answers from
previous days, and you should fold the booklet in such a way that you can only see the diary
form that you are currently filling in. If vou forget to do a diarv do not try to fill it in the next
day: please just put a line through the page you have missed.
The scales cover a number of different emotions and physical states. You should circle or put
an 'X ' through one number between zero and ten for each scale. Zero is the least and ten is the
most that you have experienced that feeling. Please write your code number, the date, and the
number of the pill that you have taken that day in the spaces provided. There are 2 spaces at the
end of the scales in which you may include other things which you regularly experience, but
which are not on the list. If you do add something you should rate this emotion/sensation every
day just like the rest of the scales, even if it is often zero. Please answer the questions at the
bottom of the page as well.
There are two scales to do with sexual feelings. The first SXLINTR stands for sexual interest.
You should use this scale to record how interested in sex you were today. The other scale SXL
ACTV has to do with sexual activity. Please tick Y or N for yes or no if you have had sexual
activity today or not. Tick the boxes S if you masturbated, P if you had sexual activity with
your partner, and I if this involved intercourse. Circle a number on the scale for how satisfying
you found the sexual activity. If you are filling in your diary before you go to bed as you are
meant to then you should rate the scales for sexual feelings, and activity that has taken place in
the previous 24 hrs., including the previous night (since you last filled in a diary).
Obviously if you have not had any sexual activity then please leave this scale blank.
Arrangements can be made for you to return completed diary booklets by Freepost, or our van
driver can collect them, though you may find it easiest to just bring the finished booklet with
you when you come for your monthly visit.
Urine Samples
We would like you to collect urine samples so that we can measure the reproductive hormones
that your own body is producing. We will give you a supply of small bottles to collect your
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sample in. Three times each week you should fill one bottle first thing in the morning. Try to
collect samples at equal intervals over the week. (E.g.-monday, Wednesday, and friday, or
tuesday, thursday, and Saturday). Mark it in pencil (ink will run!) with your code number, the
date, and the pill number for that day, and place it in the freezing compartment of your fridge,
or deep freeze.
You should bring your frozen samples, completed diary booklets, and used pill bottles with
you when you come up to the hospital every four weeks. If you miss an appointment, or
cannot make it other arrangements can be made to ensure that we get your sample for pregnancy
testing, and that you have a constant supply of pills and diaries.
Additional urine samples for monthly Pregnancy Test
Every four weeks we would like you to come up to the Royal Infirmary to give an early
morning urine sample for that day. This should be collected even if you would not normally
collect a thrice weekly one that day. We need this sample in order to do a pregnancy test on it.
If vou are taking vour pills one each dav as vou should there is no risk that you will get
pregnant. The main reason we are doing this is to reassure you. As we have said, the
changes in the length of you cycle may mean that you do not bleed as often as every four
weeks. So if we can let you know that you are not pregnant then you should not worry about
the fact that you have not had a bleed for a while. We will reimburse you your travel expenses
to and from the hospital at the end of the study.
Arrangements for Collection of Diaries and Samples
It would work out quite well if you could bring each month's diaries and urine samples with
you when you come for your monthly repeat visits. We can have a chat about how you are
getting on and I will be able to give you another month's supply of pills, diaries and sample
bottles. If this is not feasible other arrangements can be made.
Medical Adviser
Although we do not expect you to have any problems we have built in a safeguard to deal with
any physical concerns that arise. There will always be a doctor available to help you if you
have a problem that you feel is related to the study. (Please see names below). This doctor will
know which pill cycle you are on, so she will know what to do if you miss a pill or are
concerned about your pattern of bleeding.
You must contact me or one of these doctors straight awav if vou miss more than one pill so
that we can advise vou of what to do. If you miss just one pill take it as soon as you
remember, or together with the next day's pill.
Please do not hesitate to contact me at any time if you have questions or concerns. I look
forward to working with you over the coming months.
Yours sincerely,
Erin McNeill
People to contact in case of a problem:
Ms. Erin McNeill





Centre for Reproductive Biology
031-229-2575 ext.2216
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Lothian Health Board Protocol 89/45
CONSENT FORM
I have read the information sheet provided, and spoken to the investigator (Erin
McNeill). I understand what is required of me, and I agree to take part in this study of
the oral contraceptive pill. It has been explained to me that I will not be taking my oral
contraceptive as I normally do, but that the changes made for the study will not effect
the contraceptive protection the pill gives me.
I know that I may withdraw from this study at any time, for any reason, and that I may
refuse to answer any question if I wish.
I agree that my G.P. be informed that I am taking part, and that Erin McNeill may look




Letter to General Practitioner
Dear Dr.
Your patient, , attended the Dean Terrace Family Planning
Clinic recently, and agreed to take part in an ongoing study into the possible benefits of different oral
contraceptive cycle lengths for mood and well being which is being conducted through the MRC
Reproductive Biology Unit.
The time course of involvment in the study for each individual is a period of about seven months
during which time her pill cycle will be altered in a controlled fashion for about four months. This is a
double-blind investigation, using placebo tablets during would be pill-free-intervals. Individuals will
be allocated to one of three groups: 1) a 'control group' which will have 21 active pills followed by 7
placebos throughout, 2) an 'extended group' who will have one six week pill cycle during the study, and
3) a 'continuous group' who will have a period of 16 weeks active pill administration during the study.
These manipulations of the cycle will have no effect on contraceptive efficacy.
We have provided Ms. with a six months supply of Marvelon which
Organon International have kindly supplied. The presentation of the tablets has had to be altered in
order to achieve blindness. Tablets have been placed in gelatine capsules packed in lactose powder.
The lactose does not interfere with pill absorption, but may delay steroid uptake by the gut wall by up
to one hour, and women have therefore been advised to take their pill one hour earlier than normal.
During withdawal bleed intervals women will be taking a capsule that contains lactose powder alone.
The women have been advised to contact us first in cases of missed pills. Drs. Glasier, West, and
Bancroft will be able to break the randomization code if necessary in order to advise a woman of the
degree of risk created by an error in pill taking and how to rectify it. The probability that an individual
will be late in taking, or miss one or more pills is very high over a six month study period. Therefore
we ask your cooperation in contacting us if your patient should attend your surgery for such a reason
and it is evident that we have not yet been contacted.
We will conduct a pregnancy test on urine every four weeks. This is not because we forsee any change
in the pregnancy risk from that in normal pill taking, but primarily to provide the reassurance of
nonpregnancy in lieu of a bleeding episode to those women who are on an extended pill regime (see 2
and 3 above). We felt you should know this to prevent causing you unnecessary alarm if a patient were
to mention it without explaining the justification.
If you have any queries do not hesitate to contact one of us at the above address. Erin McNeill will be
conducting the study and blind to the group to which a woman has been allocated. She will be
supervised by Dr. Bancroft. Drs. Glasier, and West will be informed and available at all times to advise
on medical issues. We thank you for your cooperation.
Your sincerely,
Erin McNeill Dr. Anna Glasier
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Final Interview of Pill Cycle Manipulation Study
Structured to take approximately one hour.
Volunteer Code Number.:
Date:
Study Week and Day:
A) Collect all remaining study materials
B) Briefly review how she has been since the last visit in the same
manner as in previous monthly meeting: So how have you been since I last
saw you?
C) Pose the following questions and note responses:














4) Do you think you were expecting to feel differently during the study?
5) Did you feel differently in the way you expected to?
6) What happened that you didn't expect?
7) What did you dislike about taking part in the study?
8) Did you dislike not knowing when you were going to bleed?
9) Did you have any irregular bleeding? How did you feel about this?
10) Were you worried that you might become pregnant?
11) What was positive for you about taking part in the study?
12) Would you take part in a similar study again? Why yes or no?
13) Would you recommend to a friend that she take part in this study? Why yes or no?
14) Overall how would you describe your experience?
D) Ask her to fill in a brief written assessment of the study.
E) Go through the assessment with her and explore the areas where
verbal and written responses are different.
F) Unblind her. Tell her which group she was in, and briefly explain
the reason why the study was carried out. Note her comments once she
is unblinded. Thank her for taking part. Explain that the results will be
written up, but that confidentiality will be maintained.
StudyAssessment
CodeNumber: Date:
1)Pleasecircleihcorr cteply. Iwas/anotw rriedabouttheff ctsthaterudvwouldvenmebeforeIsta t di .



















































Pleasenotnyoth rchangeswhichyouexperiencedwhi harnotlist d here:
3)Pleasecirclthcorrectreply. Duringdiestudy,Iwas/notw rriedbouttheffec sthatw havingonme.
Ifyes:Whichffectsworriedyoumo tanwhy? Theeffectsonmybl eding,because Theeff ctsonmyphysicalwelbeing,cause. Theeff ctsonmyood,b cau e. Other. 4)Pleasecompl tethfollowingsentence Iamverypleased/apl asedr g etv ryuch regretthaItookp rtinhstudy,b c use Anyothercommentsabouttstudy:
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Idealized Models for Detecting the Presence of an
Endogenous Infradian Rhythm of Well Being
The following five figures depict some possible patterns of respone to the
manipulations in pill cycle length made in the controlled study. Each model is idealized
to represent the manifestation of the rhythm based on one possible causal mechanism.
The effect that the particular mechanism might have on each study group is shown in
succession. The shape of the curve is meant to approximate the shape that one often
sees of diary ratings over time. It is an amalgamation of some of the models shown in
Figure 5.02. While the principle of the relaxation oscillator is useful, the saw-tooth
function is probably not the most accurate visualization of cycle-related change, nor is a
cosine curve or an impulse sine wave. The function drawn in these models aims to
reflect the speed at which symptoms tend to build up and be released in real time over
the cycle.
Model 1 shows the symptom pattern that might be expected if the endogenous rhythm
were approximately 28 days long, and would free run robustly in spite of disruptions to
the steroid cycle. For this to occur the oscillator would have to be very strongly
determined with the implication that under normal circumstances the infradian rhythm
and the steroid cycle were in coupling, but that the infradian rhythm is not driven by the
steroid cycle. Thus the phase changes in the phase shifted and continuous groups
would not modulate the timing of the purported rhythm. The rhythm is hypothesized to
be circa-monthly because of its apparent relationship to the timing of the pill/menstrual
cycle, but this need not be the correct period. Differences in period across individuals
may begin to explain the wide varaition one sees in the expression of cycle-related
symptoms.
Model 2 explores two ways in which cyclicity may be shown to be steroid dependent.
Strictly speaking in figure 2a the peak in symptoms should occur after the
withdrawal/fall of steroid hormones. This model implies that changes in well being
only posses the endogenous momentum which is given to them by changes in the
steroid environment. Therefore it is the sudden withdrawal of steroids in the pill cycle,
or the precipitating events and their rapid fall in the menstrual cycle which produce
symptoms. A variation on this sort of steroid dependency, shown in 2b, presumes that
after a certain duration of either endogenous or exogenous steroids the individual will
become symptomatic. This function encorporates the concept of "menstrual release" in
which the fall in steroids and/or the physiological events inherent in vaginal bleeding
produce a relief from adverse symptoms.
Model 3 also infers a degree of endogenicity. However, in the two variations of this
model, the pattern need not be terribly robust, but may be susceptible to a variety of
entraining, disruptive, or modulating influences. In this concept the rhythm may only
be "borrowing" its momentum from other internal or external rhythmic forces and not
posess real in-built drive. Alternatively, it may be a weak internal mechanism which is
a "slave oscillation" to a dominant pacemaker. There may even be variation in the
amplitude or period of the rhythm from one cycle to the next based on slight variations
in the temporal relationship of the infradian rhythm to the forces that are driving it.
And, for example, in the continuous group which is experiencing no reinforcement
from cycling steroids, the well being oscillator may become damped down over time or
show larger than usual changes in its period. Equally one would expect the period and
amplitude of the rhythm to be disturbed following the smaller phase disruption in the
phase shifted group.
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These models are ideals. The actual experience of individual women shows nothing
like the uniformity shown in Models 1 and 2 for the control group. There are abundant
examples throughout this thesis to demonstrate that. What is more likely than that one
model will fully describe the reactions women show to cycle manipulations, is that their
responses will be a of compilation of all of these. The only principle that is exclusive
would be that steroid hormones determine subjective state in a mechanistic way.
However, there is no conclusive evidence to support this idea, and abundant evidence
to suggest that it offers inadequate explanation. Further if any one model provided the
best fit it should do so consistently within a symptom, and probably across symptoms.
A tracing of each function was over-laid on the profiles of selected symptoms for all
women who took part in the cycle manipulation study. No one symptom was
uniformly described by a specific model. Only the physical symptoms, breast
tenderness, bloating, and period pain showed a slight tendency to be best described by
the steroid dependent model 2b. Both mood and physical variables were loosely
approximated by other models particularly 3b which describes changes in the frequency
of peaks in symptom levels. This is plausible within biological rhythm theory which
indicates that weak oscillations may "miss beats" when the timing of the dominant
oscillator is interupted. A further possibility which was observed in the dataset is that
both steroid determining and endogenous rhythm effects may be operating
concurrently. For example, there were instances in the continuous and phase shifted
groups when peak levels of symptoms occuring at regular intervals, seemed to be
superimposed upon a raised baseline (eg. B12-depression and bloating, A3-breast
tenderness). Thus, some of the principles underlying these models do seem to posess a
degree of explanatory value, but no one model is adequate on its own. The features of



























Model 3b - Weak endogenous rhythm with variable period
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